data_2g0l_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2g0l _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.403 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.629 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.402 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.402 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.556 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.556 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.42 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.439 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.415 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.456 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.502 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.416 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.502 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.416 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.629 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.59 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.421 ' O ' HG11 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.432 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.432 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.423 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.683 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.533 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.479 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.533 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.417 ' N ' HD23 ' A' ' 67' ' ' LEU . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.49 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.53 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.59 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.495 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.51 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.526 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.649 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' HD22 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.475 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.449 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.649 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.532 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.532 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.466 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.46 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.51 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.46 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.455 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.426 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.425 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.425 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.455 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.426 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.486 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.655 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.402 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.438 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.668 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.455 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.668 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.425 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.411 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.411 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.425 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.455 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.577 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.3 p30 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.526 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.404 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.422 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.572 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.502 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.443 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.572 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.478 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.423 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.49 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.486 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.475 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.481 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.487 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.409 ' O ' ' HG ' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.486 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.453 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.453 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.469 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.566 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.427 HG13 ' O ' ' A' ' 69' ' ' VAL . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.417 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.469 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.405 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.405 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.409 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.489 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.446 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.446 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.427 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.425 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.425 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.511 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.504 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.426 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.467 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.447 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.447 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.431 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.524 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.504 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.408 HD23 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.524 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.431 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.431 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.418 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.418 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.447 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.426 HG11 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.638 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.638 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.494 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.494 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.426 ' HB3' HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.473 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.499 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.499 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.536 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.469 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.469 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.493 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.473 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.552 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.493 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.552 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.536 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.409 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.45 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.413 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.527 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.413 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.429 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.45 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.463 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.404 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.423 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.544 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.425 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.544 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.425 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.534 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.534 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.509 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.4 HD12 ' CE3' ' A' ' 83' ' ' TRP . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.4 ' CE3' HD12 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.527 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.558 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.405 ' O ' HG11 ' A' ' 69' ' ' VAL . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.457 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.457 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.441 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.454 HG11 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.645 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.566 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.506 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.45 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.506 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 81' ' ' THR . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.432 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.489 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.454 ' HB3' HG11 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.558 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.517 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.54 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.526 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.526 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.439 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.573 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.422 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.415 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.491 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.43 ' C ' ' HG ' ' A' ' 98' ' ' SER . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.43 ' HG ' ' C ' ' A' ' 97' ' ' LEU . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.491 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.41 ' O ' HG12 ' A' ' 19' ' ' VAL . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.565 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 8' ' ' THR . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 64' ' ' SER . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.537 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.565 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.459 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.452 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.452 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.459 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.537 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.451 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.415 ' O ' HG11 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.424 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.424 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.419 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.472 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.441 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.411 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.411 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.596 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.525 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.596 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.525 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.401 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.404 HG23 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.549 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.509 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.549 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.533 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.475 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.404 ' HB3' HG23 ' A' ' 40' ' ' VAL . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.549 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.408 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.413 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.413 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.549 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 69' ' ' VAL . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.43 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.411 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.411 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.464 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.43 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.455 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.524 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.468 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.468 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.415 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.415 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.535 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.401 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.445 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.524 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 p30 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.607 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.573 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.488 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.488 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.418 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.443 ' O ' HG13 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.478 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.472 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.402 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.581 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.478 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.448 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.472 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.446 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.587 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.558 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.46 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.558 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.496 HD13 ' N ' ' A' ' 68' ' ' THR . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.496 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.412 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.412 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.438 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.438 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.49 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.595 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.431 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.517 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.431 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.628 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.63 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.414 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.446 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.446 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.456 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.456 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.403 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.403 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.414 HG12 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.63 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.595 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB2' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.401 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.424 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.46 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.422 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.424 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.428 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.428 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.419 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.65 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.65 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.539 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.5 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.527 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.405 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 69' ' ' VAL . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.479 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.539 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 81' ' ' THR . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.491 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.614 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.402 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.402 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.43 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.624 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.484 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.559 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.424 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.424 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.403 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.624 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' HG11 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.469 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.469 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.627 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.627 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.486 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.47 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.52 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.436 HG11 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.486 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.415 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.5 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.5 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.553 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.408 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.702 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' HG12 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.453 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.527 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.553 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' HB2' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.491 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.702 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.407 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.407 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 66' ' ' SER . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.455 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.455 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.416 HG12 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.582 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.582 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.418 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.469 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.418 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.435 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.435 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.498 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.439 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.416 ' HB3' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.439 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.418 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.473 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.597 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.441 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.441 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.473 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.519 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.407 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.539 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.409 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.48 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.413 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.435 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.589 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.433 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.467 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.467 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.589 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.418 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.521 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.439 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.448 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.506 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.466 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.506 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HA ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.559 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.402 ' H ' ' HD3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.4 HD12 HG22 ' A' ' 110' ' ' ILE . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.458 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.6 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.486 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.616 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.572 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.458 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.616 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.486 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.479 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.479 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.427 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.6 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.593 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.412 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.403 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.412 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.403 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.475 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.505 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.447 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.41 HG21 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.44 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.481 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.461 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.593 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.481 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 041 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.485 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.435 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.435 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.417 HG12 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.59 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.59 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.585 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.485 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.516 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.427 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.427 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.503 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.434 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.434 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG12 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 042 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.421 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.436 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.421 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.666 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.701 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.436 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.409 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.424 HD12 ' CE3' ' A' ' 83' ' ' TRP . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.409 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.424 ' CE3' HD12 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.409 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.415 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.417 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.701 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.666 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.443 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.417 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 043 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.504 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.449 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.435 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.417 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.488 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.488 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.546 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.422 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.455 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.425 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.453 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.453 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 044 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.429 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.542 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.474 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 045 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.452 ' O ' HG11 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.515 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.425 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.504 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.54 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.412 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.515 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.452 HG11 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.54 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.421 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.504 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.473 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 0 0 . 1 . 046 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.433 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.438 HG11 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.427 ' CG ' ' H ' ' A' ' 42' ' ' THR . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.427 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.433 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.44 ' N ' HD23 ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.438 ' HB3' HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 047 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.609 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.608 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.608 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.678 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.495 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.678 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.415 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.415 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.609 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.449 ' N ' HD21 ' A' ' 67' ' ' LEU . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.495 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.409 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 048 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.409 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.454 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.48 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.422 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.407 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.409 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.455 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.588 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.451 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.447 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.447 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.451 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.429 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.429 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.455 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.447 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.447 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 050 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.411 ' H ' HG22 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' HD13 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.567 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.402 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.51 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.585 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.44 HD13 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.416 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.424 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.424 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.567 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.438 HG22 HD13 ' A' ' 110' ' ' ILE . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 051 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.539 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.539 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.411 ' O ' HG12 ' A' ' 19' ' ' VAL . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.489 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.411 HG12 ' O ' ' A' ' 8' ' ' THR . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.481 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.521 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.489 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.422 ' N ' HD23 ' A' ' 67' ' ' LEU . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.481 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.521 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.458 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.458 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.437 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.497 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 052 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.522 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.412 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.412 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.632 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.589 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.411 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.458 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.408 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.408 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.496 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.423 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.496 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.455 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.632 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 053 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.548 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.468 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.416 ' HB3' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.457 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.451 HD22 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.404 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.451 ' HB2' HD22 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.548 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.457 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.469 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.469 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.468 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 054 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.612 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.441 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.42 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.612 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.42 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.446 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.446 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 055 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.406 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.434 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.485 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.515 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.441 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.443 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.515 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.42 ' C ' ' HG ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.42 ' HG ' ' C ' ' A' ' 97' ' ' LEU . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 10' ' ' SER . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 056 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.409 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.506 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.409 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.685 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.519 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.519 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.403 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.506 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.417 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.418 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.418 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.425 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.425 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.685 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 057 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.558 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.537 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.41 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.537 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.558 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.446 HD13 ' O ' ' A' ' 34' ' ' VAL . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 058 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.417 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.402 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.402 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.408 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.656 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.44 HG13 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.551 HD22 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.429 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HB2' HD22 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.417 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.407 HD21 ' O ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.533 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.429 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.44 ' CZ3' HG13 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.439 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.439 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.656 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.412 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.438 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.403 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.629 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.42 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.402 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.402 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.556 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.556 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.594 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.42 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.439 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.415 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.456 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.502 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.416 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.502 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.416 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.629 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.594 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.59 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.421 ' O ' HG11 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.432 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.432 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.423 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.683 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.604 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.533 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.479 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.533 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.417 ' N ' HD23 ' A' ' 67' ' ' LEU . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.49 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.624 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.53 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.59 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.624 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.495 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.51 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.807 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.649 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' HD22 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.475 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.449 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.649 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.532 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.619 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.532 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.466 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.46 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.51 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.46 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.807 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.455 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.426 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.745 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.425 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.425 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.455 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.426 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.568 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.486 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.655 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.402 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.745 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.438 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.668 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.455 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.668 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.645 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.425 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.411 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.425 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.502 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.455 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.577 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.3 p30 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.645 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.526 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.404 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.422 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.825 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.572 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.502 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.443 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.572 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.478 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.423 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.49 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.825 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.486 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.454 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.505 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.475 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.481 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.487 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.409 ' O ' ' HG ' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.486 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.505 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.453 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.453 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.469 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.86 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.566 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.427 HG13 ' O ' ' A' ' 69' ' ' VAL . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.417 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.469 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.403 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.405 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.458 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.86 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.405 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.405 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.409 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.524 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.473 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.446 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.446 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.557 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.427 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.425 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.425 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.511 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.557 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.504 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.426 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.467 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.447 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.447 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.431 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.849 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.524 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.504 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.408 HD23 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.524 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.431 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.431 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.418 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.418 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.543 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.849 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.426 HG11 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.494 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.534 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.638 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.638 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.494 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.63 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.494 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.426 ' HB3' HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.63 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.473 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.499 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.499 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.536 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.469 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.469 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.493 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.76 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.473 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.552 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.493 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.495 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.552 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.536 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.502 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.409 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.76 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.45 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.654 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.413 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.527 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.413 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.429 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.654 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.796 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.45 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.463 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.443 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.404 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.796 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.423 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.544 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.425 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.544 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.425 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.712 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.534 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.534 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.509 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.457 HD23 ' H5 ' ' A' ' 114' ' ' FLN . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.4 ' CE3' HD12 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.527 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.712 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.558 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.405 ' O ' HG11 ' A' ' 69' ' ' VAL . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.457 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.457 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.441 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.454 HG11 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.442 HD23 " H2'" ' A' ' 114' ' ' FLN . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.645 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.655 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.566 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.506 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.45 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.506 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.463 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.432 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.489 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.454 ' HB3' HG11 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.558 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.655 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.517 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.54 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.526 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.726 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.526 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.522 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.726 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.439 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.803 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.573 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.422 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.415 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.491 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.43 ' C ' ' HG ' ' A' ' 98' ' ' SER . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.43 ' HG ' ' C ' ' A' ' 97' ' ' LEU . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.446 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.491 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.803 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.41 ' O ' HG12 ' A' ' 19' ' ' VAL . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.565 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 8' ' ' THR . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 64' ' ' SER . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.537 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.836 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.565 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.459 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.452 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.452 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.459 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.537 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.451 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.836 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.415 ' O ' HG11 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.424 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.424 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.812 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.419 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.472 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.441 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.411 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.411 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.812 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.596 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.525 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.854 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.596 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.424 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.525 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.854 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.401 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.404 HG23 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.659 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.549 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.509 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.549 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.533 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.475 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.527 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.404 ' HB3' HG23 ' A' ' 40' ' ' VAL . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.659 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.549 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.408 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.637 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.413 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.413 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.549 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 69' ' ' VAL . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.43 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.411 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.411 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.464 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.43 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.455 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.637 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.524 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.468 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.468 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.482 ' HB3' " H6'" ' A' ' 114' ' ' FLN . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.452 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.415 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.415 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.535 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.401 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.445 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.532 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.524 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 p30 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.532 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.607 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.573 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.488 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.813 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.488 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.527 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.418 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.813 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.443 ' O ' HG13 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.478 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.472 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.402 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.814 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.581 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.478 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.486 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.448 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.576 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.446 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.462 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.814 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.587 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.558 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.46 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.485 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.558 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.496 HD13 ' N ' ' A' ' 68' ' ' THR . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.496 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.575 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.412 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.412 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.438 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.438 ' HB1' ' O ' ' A' ' 87' ' ' ASP . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.49 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.49 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.575 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.595 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.431 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.517 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.431 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.628 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.63 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.414 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.446 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.446 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.779 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.456 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.456 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.403 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.403 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.414 HG12 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.492 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.63 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.595 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.779 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB2' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.401 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.424 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.819 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.46 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.422 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.424 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.401 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.428 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.428 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.819 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.419 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.65 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.65 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.62 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.539 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.527 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.405 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 69' ' ' VAL . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.479 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.539 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.429 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.491 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.614 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.62 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.402 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.402 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.43 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.624 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.818 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.484 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.559 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.424 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.424 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.453 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.624 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.548 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.818 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' HG11 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.469 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.469 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.627 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.627 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.714 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.486 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.47 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.52 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.436 HG11 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.486 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.515 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.415 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.5 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.5 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.714 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.553 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.408 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.702 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' HG12 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.851 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.453 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.527 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.553 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' HB2' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.491 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.702 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.407 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.407 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.497 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.851 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 66' ' ' SER . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.455 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.455 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.416 HG12 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.582 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.582 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.427 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.483 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.418 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.469 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.461 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.435 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.435 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.498 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.439 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.416 ' HB3' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.439 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.483 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.418 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.473 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.597 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.653 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.441 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.441 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.473 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.519 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.46 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.412 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.407 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.653 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.729 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.539 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.409 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.527 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.48 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.729 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.413 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.435 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.589 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.767 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.433 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.467 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.467 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.589 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.403 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.767 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.418 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.521 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.439 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.448 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.506 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.466 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.506 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.814 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HA ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.559 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.402 ' H ' ' HD3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.539 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.4 HD12 HG22 ' A' ' 110' ' ' ILE . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.814 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.458 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.6 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.486 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.456 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.616 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.572 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.458 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.616 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.486 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.502 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.479 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.479 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.427 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.6 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.502 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.593 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.412 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.403 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.412 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.403 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.8 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.475 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.505 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.447 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.41 HG21 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.44 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.481 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.461 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.593 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.481 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.8 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.485 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.435 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.435 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.417 HG12 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.59 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.59 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.67 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.585 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.485 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.516 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.455 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.427 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.503 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.434 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.434 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG12 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 041 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.67 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.421 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.436 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.421 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.666 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.701 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.409 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.774 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.436 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.415 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.409 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.409 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.424 ' CE3' HD12 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.409 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.415 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.417 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.701 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.666 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.443 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.417 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 042 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.774 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.504 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.449 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.435 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.417 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.793 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.488 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.488 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.546 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.422 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.455 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.425 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.445 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.453 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.453 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.5 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 043 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.793 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.429 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.542 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.428 HD13 " H6'" ' A' ' 114' ' ' FLN . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.746 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.474 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.576 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 044 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.746 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.452 ' O ' HG11 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.515 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.425 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.504 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.817 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.54 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.412 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.515 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.452 HG11 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.54 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.421 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.598 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.504 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.473 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.401 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 0 0 . 1 . 045 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.817 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.433 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.438 HG11 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.427 ' CG ' ' H ' ' A' ' 42' ' ' THR . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.427 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.698 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.433 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.44 ' N ' HD23 ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.526 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.438 ' HB3' HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.435 ' HG ' " H6'" ' A' ' 114' ' ' FLN . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 046 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.698 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.609 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.608 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.608 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.651 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.678 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.495 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.678 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.415 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.415 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.609 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.449 ' N ' HD21 ' A' ' 67' ' ' LEU . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.464 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.495 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.409 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 047 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.651 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.409 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.454 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.534 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.48 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.422 ' N ' HD23 ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.407 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.657 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.402 ' N ' " H5'" ' A' ' 114' ' ' FLN . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.409 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.657 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.455 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.739 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.588 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.451 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.423 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.447 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.447 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.451 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.429 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.429 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.455 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.447 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.447 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 049 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.739 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.411 ' H ' HG22 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' HD13 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.567 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.402 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.865 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.585 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.44 HD13 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.58 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.416 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.424 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.424 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.567 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.438 HG22 HD13 ' A' ' 110' ' ' ILE . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 050 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.865 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.539 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.539 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.411 ' O ' HG12 ' A' ' 19' ' ' VAL . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.489 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.411 HG12 ' O ' ' A' ' 8' ' ' THR . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.846 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.481 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.521 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.489 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.422 ' N ' HD23 ' A' ' 67' ' ' LEU . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.481 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.521 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.455 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.406 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.458 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.458 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.437 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.497 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 051 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.846 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.522 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.412 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.412 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.632 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.589 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.411 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.458 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.408 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.408 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.496 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.423 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.496 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.455 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.632 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 052 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.816 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.548 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.468 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.416 ' HB3' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.457 ' HB3' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.786 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.451 HD22 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.404 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.451 ' HB2' HD22 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.548 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.457 ' N ' ' HB3' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.469 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.469 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.494 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.468 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 053 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.786 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.612 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.441 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.798 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.42 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.612 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.42 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.446 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.446 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 054 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.798 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.406 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.434 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.443 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.485 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.515 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.755 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.441 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.443 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.515 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.42 ' C ' ' HG ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.42 ' HG ' ' C ' ' A' ' 97' ' ' LEU . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 10' ' ' SER . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 055 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.755 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.409 ' HB ' ' HB1' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.506 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.409 ' HB1' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.685 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.838 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.519 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.519 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.403 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.506 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.417 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.403 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.418 ' CG ' ' HG1' ' A' ' 81' ' ' THR . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.418 ' HG1' ' CG ' ' A' ' 79' ' ' ASP . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.425 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.425 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.685 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.434 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 056 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.838 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.558 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.537 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.705 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.41 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.537 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.558 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.446 HD13 ' O ' ' A' ' 34' ' ' VAL . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.481 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.409 HE21 " H5'" ' A' ' 114' ' ' FLN . 17.5 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 057 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.705 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.417 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.402 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.402 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.408 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.656 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.44 HG13 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.762 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.551 HD22 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.429 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HB2' HD22 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.417 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.407 HD21 ' O ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.533 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.429 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.437 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.44 ' CZ3' HG13 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.439 ' CG ' ' HG1' ' A' ' 89' ' ' THR . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.439 ' HG1' ' CG ' ' A' ' 87' ' ' ASP . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.656 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.407 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.412 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.438 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 058 nuclear orig full ' A' A ' 114' ' ' FLN . . . . . 0.762 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.641 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.688 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.571 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.571 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.568 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.568 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.53 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.457 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.512 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.442 ' HA ' HD12 ' A' ' 13' ' ' LEU . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 95' ' ' VAL . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.446 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.687 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.489 HG12 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.419 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.489 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.439 HD12 ' HB ' ' A' ' 81' ' ' THR . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 77' ' ' LEU . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.419 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.54 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.451 HG21 HG11 ' A' ' 19' ' ' VAL . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.611 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.428 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.556 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.511 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.658 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.485 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.406 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.658 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.504 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.466 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.506 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.411 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.4 HG21 HD13 ' A' ' 13' ' ' LEU . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.516 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.5 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.471 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.439 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.499 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.499 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.516 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.897 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 69' ' ' VAL . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.897 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.447 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.447 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.682 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.411 ' H ' ' HA ' ' A' ' 45' ' ' LEU . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 40' ' ' VAL . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.682 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.438 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.4 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 17' ' ' THR . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 ' HB ' ' A' ' 81' ' ' THR . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.438 ' HB ' HD12 ' A' ' 77' ' ' LEU . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.476 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.58 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.424 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.456 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.425 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.545 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.578 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.519 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.456 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.471 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.504 HD12 ' HB ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.4 ' HB3' HG21 ' A' ' 40' ' ' VAL . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.545 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.428 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.428 ' HG2' HD13 ' A' ' 97' ' ' LEU . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.485 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.48 HG21 HD13 ' A' ' 13' ' ' LEU . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.423 HG11 HG21 ' A' ' 95' ' ' VAL . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.711 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 45' ' ' LEU . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.463 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.408 ' HA ' ' O ' ' A' ' 38' ' ' ALA . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.489 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.489 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.494 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.494 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.549 ' HB3' HG21 ' A' ' 40' ' ' VAL . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.423 HG21 HG11 ' A' ' 19' ' ' VAL . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.711 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 97' ' ' LEU . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.485 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.474 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.456 ' O ' HG12 ' A' ' 69' ' ' VAL . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 HG23 ' A' ' 68' ' ' THR . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.638 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.486 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.481 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.577 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.469 HG23 HG22 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.416 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.481 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.638 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.567 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.578 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.416 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.416 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.536 ' HA ' HD12 ' A' ' 13' ' ' LEU . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 10' ' ' SER . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.416 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.416 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.435 HG22 ' HB2' ' A' ' 97' ' ' LEU . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.425 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.511 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.449 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.493 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.4 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.414 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.414 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB2' HG22 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.475 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 97' ' ' LEU . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.458 ' HB2' HE21 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.457 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.461 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.525 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.425 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.457 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 1.7 pt20 -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 21' ' ' VAL . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.404 HG21 HD13 ' A' ' 13' ' ' LEU . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 95' ' ' VAL . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' HA ' HG12 ' A' ' 7' ' ' VAL . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB3' ' HZ ' ' A' ' 73' ' ' PHE . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.44 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.688 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.402 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.415 ' HZ ' ' HB3' ' A' ' 38' ' ' ALA . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.511 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.44 ' HB3' HG21 ' A' ' 40' ' ' VAL . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.44 HG21 HG11 ' A' ' 19' ' ' VAL . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.495 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.51 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.51 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.495 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.414 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.551 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.525 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.449 ' HB3' HG21 ' A' ' 40' ' ' VAL . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.551 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.414 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.543 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.406 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.833 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 108' ' ' VAL . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.833 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.424 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.541 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 67' ' ' LEU . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.424 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.441 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.467 HG21 HG11 ' A' ' 19' ' ' VAL . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.408 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.401 ' HG2' HD11 ' A' ' 97' ' ' LEU . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.429 HG21 HG11 ' A' ' 34' ' ' VAL . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.429 HG11 HG21 ' A' ' 21' ' ' VAL . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.431 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.626 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.4 HD12 ' HB ' ' A' ' 81' ' ' THR . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD12 ' A' ' 77' ' ' LEU . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HB3' HG11 ' A' ' 108' ' ' VAL . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.499 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.499 HD12 ' HA ' ' A' ' 10' ' ' SER . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 13' ' ' LEU . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' HB3' ' A' ' 97' ' ' LEU . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.423 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.557 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.462 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.557 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.55 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.528 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.423 HD11 ' CE3' ' A' ' 83' ' ' TRP . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.423 ' CE3' HD11 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.543 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.492 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.408 HG11 ' HB3' ' A' ' 9' ' ' PRO . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.462 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.572 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.474 HG21 HD13 ' A' ' 13' ' ' LEU . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.451 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.451 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.743 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.45 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.661 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.466 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.588 HD21 ' HB ' ' A' ' 34' ' ' VAL . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.47 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.51 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 81' ' ' THR . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.44 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.743 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.572 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.588 HD13 HG21 ' A' ' 17' ' ' THR . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.588 HG21 HD13 ' A' ' 13' ' ' LEU . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.457 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.55 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.445 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.457 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.501 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.416 ' HB3' HG21 ' A' ' 40' ' ' VAL . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 108' ' ' VAL . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.461 HD13 HG21 ' A' ' 17' ' ' THR . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.461 HG21 HD13 ' A' ' 13' ' ' LEU . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 95' ' ' VAL . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.449 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.535 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.478 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.437 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 81' ' ' THR . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 77' ' ' LEU . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.535 ' HB3' HG21 ' A' ' 40' ' ' VAL . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.437 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 19' ' ' VAL . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.856 HD13 HG21 ' A' ' 17' ' ' THR . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.856 HG21 HD13 ' A' ' 13' ' ' LEU . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.579 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.613 HG21 HG11 ' A' ' 34' ' ' VAL . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.727 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.535 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.463 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.425 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.579 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.456 HD12 ' HB ' ' A' ' 81' ' ' THR . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.456 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.458 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.535 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.727 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.621 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.621 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.492 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.525 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.462 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.451 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.475 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 108' ' ' VAL . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.614 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.676 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.42 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.556 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.614 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.441 HD11 ' CE3' ' A' ' 83' ' ' TRP . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.441 ' CE3' HD11 ' A' ' 77' ' ' LEU . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.676 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.521 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 7' ' ' VAL . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.502 HG21 HG11 ' A' ' 34' ' ' VAL . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 21' ' ' VAL . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.4 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.521 HG23 HG22 ' A' ' 86' ' ' VAL . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.513 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.482 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.515 HD12 ' HB ' ' A' ' 81' ' ' THR . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.515 ' HB ' HD12 ' A' ' 77' ' ' LEU . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 40' ' ' VAL . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.4 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.5 HD13 HG21 ' A' ' 17' ' ' THR . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.5 HG21 HD13 ' A' ' 13' ' ' LEU . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.494 HG11 HG21 ' A' ' 95' ' ' VAL . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' CG ' ' A' ' 76' ' ' PHE . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.561 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.402 ' HA ' HD22 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.411 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.494 HG21 HG11 ' A' ' 19' ' ' VAL . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.5 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.531 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.479 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.595 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.551 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.479 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 82' ' ' ARG . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.4 HG11 ' HB3' ' A' ' 38' ' ' ALA . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 19' ' ' VAL . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.538 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' HD13 ' A' ' 97' ' ' LEU . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.609 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.413 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.58 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.546 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.404 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.411 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.514 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.421 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.451 ' O ' HG12 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.595 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.408 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.586 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.497 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.462 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.473 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.578 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.578 ' HG2' HD13 ' A' ' 97' ' ' LEU . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.416 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.406 HG21 HG21 ' A' ' 65' ' ' THR . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.403 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.431 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.406 HG21 HG21 ' A' ' 34' ' ' VAL . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.43 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 110' ' ' ILE . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.431 ' HB3' HG21 ' A' ' 40' ' ' VAL . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.495 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.557 HD11 HG21 ' A' ' 69' ' ' VAL . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.604 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.434 ' H ' HG21 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.61 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.436 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.524 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.524 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.631 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.635 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.455 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.446 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.467 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.406 ' H ' HD11 ' A' ' 67' ' ' LEU . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 60' ' ' ASN . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' H ' ' CG ' ' A' ' 58' ' ' ASP . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.406 HD11 ' H ' ' A' ' 53' ' ' SER . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.446 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.41 HG11 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.635 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.407 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.434 HG21 ' H ' ' A' ' 10' ' ' SER . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.61 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.496 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.446 HG23 HG22 ' A' ' 86' ' ' VAL . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.43 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.436 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.452 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.42 ' HB3' HG21 ' A' ' 40' ' ' VAL . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.446 HG22 HG23 ' A' ' 40' ' ' VAL . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.422 ' HB3' HG21 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.422 HG21 ' HB3' ' A' ' 10' ' ' SER . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG11 HG21 ' A' ' 95' ' ' VAL . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.615 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.508 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.528 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 52' ' ' PHE . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.487 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 81' ' ' THR . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.413 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.408 HG21 HG11 ' A' ' 19' ' ' VAL . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.616 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 108' ' ' VAL . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.412 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.412 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.572 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.628 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.408 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.457 HG21 ' HB3' ' A' ' 83' ' ' TRP . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 74' ' ' GLU . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.572 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.4 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.457 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.426 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.628 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.4 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.4 ' HG2' HD13 ' A' ' 97' ' ' LEU . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 7' ' ' VAL . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.476 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.477 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.477 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.441 HG23 HG22 ' A' ' 86' ' ' VAL . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.406 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.406 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.427 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.531 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.433 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.441 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.457 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.433 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.51 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.51 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.51 HD13 HG21 ' A' ' 17' ' ' THR . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.51 HG21 HD13 ' A' ' 13' ' ' LEU . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.569 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.4 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.707 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.59 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.453 ' HA ' HD12 ' A' ' 67' ' ' LEU . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.52 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.569 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.453 HD12 ' HA ' ' A' ' 52' ' ' PHE . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD11 ' A' ' 110' ' ' ILE . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.487 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.535 HD11 ' CE3' ' A' ' 83' ' ' TRP . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.535 ' CE3' HD11 ' A' ' 77' ' ' LEU . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.59 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.707 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 69' ' ' VAL . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.424 ' HA ' ' H ' ' A' ' 111' ' ' SER . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 66' ' ' SER . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 95' ' ' VAL . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.468 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HB2' HE21 ' A' ' 36' ' ' GLN . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.596 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.596 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.514 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.544 ' HB3' HG12 ' A' ' 18' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.544 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.43 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.544 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.521 HG21 HG11 ' A' ' 19' ' ' VAL . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.544 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.45 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.424 ' H ' ' HA ' ' A' ' 11' ' ' SER . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.65 HD13 HG21 ' A' ' 17' ' ' THR . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.65 HG21 HD13 ' A' ' 13' ' ' LEU . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 34' ' ' VAL . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.508 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.402 HG11 HG21 ' A' ' 21' ' ' VAL . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.454 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.482 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.522 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.41 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.49 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.486 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.417 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.552 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.417 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.487 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.404 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.463 HG13 ' HB3' ' A' ' 97' ' ' LEU . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.59 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.431 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.47 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.488 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.402 ' HB2' HD21 ' A' ' 48' ' ' ASN . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.488 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.405 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 ' HB3' ' A' ' 38' ' ' ALA . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.59 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.438 ' HA ' HD12 ' A' ' 13' ' ' LEU . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.644 HD13 HG21 ' A' ' 17' ' ' THR . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.644 HG21 HD13 ' A' ' 13' ' ' LEU . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.576 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.486 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.526 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.483 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.515 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.493 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.515 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.405 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' HD11 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.576 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.435 HD11 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.411 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.405 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.498 ' H ' ' HD3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.483 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.467 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.603 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.479 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.629 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.555 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.555 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.428 HG13 ' HB1' ' A' ' 63' ' ' ALA . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.428 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.467 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.629 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.501 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.437 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.603 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.595 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.648 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.421 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.421 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.487 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.542 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.45 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.648 HG11 ' HB3' ' A' ' 38' ' ' ALA . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.595 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 041 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 108' ' ' VAL . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.491 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.443 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.443 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.406 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.406 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.613 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.6 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.507 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.507 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.491 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.419 HD22 ' N ' ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.6 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.567 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.44 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.501 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.52 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 7' ' ' VAL . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.487 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 042 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 108' ' ' VAL . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.439 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.672 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.707 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.518 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.403 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.475 HG22 ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.475 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.403 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.435 HD11 ' CE3' ' A' ' 83' ' ' TRP . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.412 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.435 ' CE3' HD11 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.412 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.613 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.439 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.707 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.672 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.464 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 7' ' ' VAL . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 043 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.447 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.415 ' OG ' HG22 ' A' ' 19' ' ' VAL . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.55 HD13 HG21 ' A' ' 17' ' ' THR . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.55 HG21 HD13 ' A' ' 13' ' ' LEU . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.415 HG22 ' OG ' ' A' ' 10' ' ' SER . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.447 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.41 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.462 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.465 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.448 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.461 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.509 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.562 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.435 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.461 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.439 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB3' HG21 ' A' ' 40' ' ' VAL . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.471 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.542 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 044 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.438 HG11 HG21 ' A' ' 95' ' ' VAL . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.437 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.437 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.544 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.445 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.483 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.483 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.401 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.483 HD12 ' HB ' ' A' ' 81' ' ' THR . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.483 ' HB ' HD12 ' A' ' 77' ' ' LEU . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG11 ' A' ' 19' ' ' VAL . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 045 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.475 ' O ' HG12 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 66' ' ' SER . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.507 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.428 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.543 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.5 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.53 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.543 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.436 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.428 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.507 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.588 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.473 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.453 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.426 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB3' HG21 ' A' ' 40' ' ' VAL . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.516 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.622 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.516 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.509 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 047 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.617 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.427 HG21 HD13 ' A' ' 13' ' ' LEU . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.622 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 66' ' ' SER . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.617 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.496 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.618 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.694 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.497 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.694 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.423 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.622 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.497 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.493 ' HB3' HG21 ' A' ' 40' ' ' VAL . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 HG23 ' A' ' 40' ' ' VAL . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.435 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.496 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 048 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.58 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.405 ' H ' HG21 ' A' ' 110' ' ' ILE . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' VAL . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 95' ' ' VAL . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.697 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.511 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.424 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.511 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.424 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.697 HG11 ' HB3' ' A' ' 38' ' ' ALA . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 19' ' ' VAL . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.405 HG21 ' H ' ' A' ' 10' ' ' SER . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.406 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.601 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.437 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.601 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.413 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.406 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.406 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 050 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.495 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.479 ' H ' HG21 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.454 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.495 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.408 ' HA2' HD11 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.592 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.592 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.407 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.407 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.454 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.501 HD11 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.811 HD12 ' HB ' ' A' ' 81' ' ' THR . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.811 ' HB ' HD12 ' A' ' 77' ' ' LEU . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.431 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.434 ' HE3' HD11 ' A' ' 77' ' ' LEU . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 28.2 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.479 HG21 ' H ' ' A' ' 10' ' ' SER . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 051 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.433 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 108' ' ' VAL . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.458 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.507 HG11 HG21 ' A' ' 95' ' ' VAL . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.733 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' A' ' 83' ' ' TRP . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.5 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.52 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.454 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.5 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.52 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.439 HD11 ' CE3' ' A' ' 83' ' ' TRP . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.733 HG11 ' HB3' ' A' ' 38' ' ' ALA . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.438 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.507 HG21 HG11 ' A' ' 19' ' ' VAL . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.512 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.509 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.509 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 7' ' ' VAL . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 052 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.54 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.421 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.421 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.631 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.655 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.418 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.595 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.435 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.548 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.631 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.493 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 053 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG23 HG22 ' A' ' 86' ' ' VAL . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.46 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.5 HD21 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HB2' HD21 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.568 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.46 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 40' ' ' VAL . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.43 ' SG ' ' HB2' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.47 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 054 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.625 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.529 HG11 HG21 ' A' ' 95' ' ' VAL . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.421 ' HB2' HD21 ' A' ' 48' ' ' ASN . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.625 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.43 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.529 HG21 HG11 ' A' ' 19' ' ' VAL . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 055 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.555 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.439 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.67 HD13 HG21 ' A' ' 17' ' ' THR . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.67 HG21 HD13 ' A' ' 13' ' ' LEU . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.555 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.511 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.47 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.516 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.532 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.408 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.459 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.504 HG21 HD11 ' A' ' 110' ' ' ILE . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.532 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.504 HD11 HG21 ' A' ' 69' ' ' VAL . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 056 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.439 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.573 HD13 HG21 ' A' ' 17' ' ' THR . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.573 HG21 HD13 ' A' ' 13' ' ' LEU . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.69 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.536 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.405 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.518 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.428 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.69 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.425 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 057 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.685 HD13 HG21 ' A' ' 17' ' ' THR . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.685 HG21 HD13 ' A' ' 13' ' ' LEU . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.4 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 86' ' ' VAL . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.4 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.57 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.422 HG22 HG23 ' A' ' 40' ' ' VAL . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.407 ' HG ' HG13 ' A' ' 34' ' ' VAL . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 058 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.459 HD13 HG21 ' A' ' 17' ' ' THR . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.459 HG21 HD13 ' A' ' 13' ' ' LEU . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.431 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.415 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.415 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.662 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.481 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.465 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.584 HD21 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.584 ' HB2' HD21 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.431 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.548 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.427 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.481 HG11 ' HB3' ' A' ' 38' ' ' ALA . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.662 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.411 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.641 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.688 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.571 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.571 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.586 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.568 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.568 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.53 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.457 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.512 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.586 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.442 ' HA ' HD12 ' A' ' 13' ' ' LEU . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 95' ' ' VAL . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.446 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 " H2'" ' A' ' 114' ' ' FLN . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.687 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.594 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.489 HG12 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.419 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.489 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.642 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 77' ' ' LEU . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.419 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.54 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.451 HG21 HG11 ' A' ' 19' ' ' VAL . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.611 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.642 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.428 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.556 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.511 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.798 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.658 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.485 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.406 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.658 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.633 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.504 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.466 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.506 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.798 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.411 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.4 HG21 HD13 ' A' ' 13' ' ' LEU . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.516 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.737 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.5 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.471 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.439 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.588 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.499 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.499 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.516 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.737 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.897 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 69' ' ' VAL . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.897 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.447 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.447 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.682 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.411 ' H ' ' HA ' ' A' ' 45' ' ' LEU . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 40' ' ' VAL . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.682 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.633 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.438 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.4 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 17' ' ' THR . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.528 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.438 ' HB ' HD12 ' A' ' 77' ' ' LEU . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.476 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.58 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.633 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.424 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.456 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.425 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.545 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.578 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.519 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.456 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.471 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.504 HD12 ' HB ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.4 ' HB3' HG21 ' A' ' 40' ' ' VAL . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.545 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.428 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.428 ' HG2' HD13 ' A' ' 97' ' ' LEU . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.816 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.485 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.48 HG21 HD13 ' A' ' 13' ' ' LEU . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG11 HG21 ' A' ' 95' ' ' VAL . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.711 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 45' ' ' LEU . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.463 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.472 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.489 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.489 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.494 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.494 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.549 ' HB3' HG21 ' A' ' 40' ' ' VAL . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.423 HG21 HG11 ' A' ' 19' ' ' VAL . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.711 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 97' ' ' LEU . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.485 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.495 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.474 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.456 ' O ' HG12 ' A' ' 69' ' ' VAL . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 HG23 ' A' ' 68' ' ' THR . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.638 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.486 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.481 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.855 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.577 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.469 HG23 HG22 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.416 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.481 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.638 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.567 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.425 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.578 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.416 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.416 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.855 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.536 ' HA ' HD12 ' A' ' 13' ' ' LEU . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 10' ' ' SER . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.416 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.416 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.435 HG22 ' HB2' ' A' ' 97' ' ' LEU . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.425 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.464 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.449 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.493 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.4 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.571 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.414 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.414 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB2' HG22 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.571 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.475 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 97' ' ' LEU . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.458 ' HB2' HE21 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.457 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.461 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.844 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.525 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.425 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.554 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 1.7 pt20 -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.844 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 21' ' ' VAL . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.404 HG21 HD13 ' A' ' 13' ' ' LEU . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 95' ' ' VAL . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' HA ' HG12 ' A' ' 7' ' ' VAL . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB3' ' HZ ' ' A' ' 73' ' ' PHE . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.44 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.511 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.688 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.402 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.415 ' HZ ' ' HB3' ' A' ' 38' ' ' ALA . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.511 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.655 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.44 ' HB3' HG21 ' A' ' 40' ' ' VAL . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.44 HG21 HG11 ' A' ' 19' ' ' VAL . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.655 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.495 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.51 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.51 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.751 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.495 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.414 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.551 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.525 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.503 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.449 ' HB3' HG21 ' A' ' 40' ' ' VAL . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.551 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.414 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.543 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.513 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.406 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.751 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.833 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 108' ' ' VAL . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.833 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.649 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.424 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.541 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 67' ' ' LEU . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.424 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.441 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.467 HG21 HG11 ' A' ' 19' ' ' VAL . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.408 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.401 ' HG2' HD11 ' A' ' 97' ' ' LEU . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.649 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.429 HG21 HG11 ' A' ' 34' ' ' VAL . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.429 HG11 HG21 ' A' ' 21' ' ' VAL . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.788 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.431 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.626 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.477 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD12 ' A' ' 77' ' ' LEU . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.788 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HB3' HG11 ' A' ' 108' ' ' VAL . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.499 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.499 HD12 ' HA ' ' A' ' 10' ' ' SER . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 13' ' ' LEU . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' HB3' ' A' ' 97' ' ' LEU . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.423 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.557 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.462 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.557 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.704 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.55 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.528 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.423 HD11 ' CE3' ' A' ' 83' ' ' TRP . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.423 ' CE3' HD11 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.543 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.492 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.408 HG11 ' HB3' ' A' ' 9' ' ' PRO . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.462 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.704 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.572 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.474 HG21 HD13 ' A' ' 13' ' ' LEU . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.451 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.451 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.743 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.45 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.552 HD22 " H2'" ' A' ' 114' ' ' FLN . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.661 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.638 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.466 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.588 HD21 ' HB ' ' A' ' 34' ' ' VAL . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.47 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.51 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.493 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.44 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.743 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.572 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.638 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.588 HD13 HG21 ' A' ' 17' ' ' THR . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.588 HG21 HD13 ' A' ' 13' ' ' LEU . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.457 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.55 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.445 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.72 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.457 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.501 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.416 ' HB3' HG21 ' A' ' 40' ' ' VAL . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.446 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.542 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.72 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 108' ' ' VAL . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.461 HD13 HG21 ' A' ' 17' ' ' THR . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.461 HG21 HD13 ' A' ' 13' ' ' LEU . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 95' ' ' VAL . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.449 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.535 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.478 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.799 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.437 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 81' ' ' THR . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 77' ' ' LEU . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.535 ' HB3' HG21 ' A' ' 40' ' ' VAL . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.437 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 19' ' ' VAL . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.799 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.856 HD13 HG21 ' A' ' 17' ' ' THR . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.856 HG21 HD13 ' A' ' 13' ' ' LEU . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.579 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.613 HG21 HG11 ' A' ' 34' ' ' VAL . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.727 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.535 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.831 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.463 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.425 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.579 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.456 HD12 ' HB ' ' A' ' 81' ' ' THR . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.456 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.458 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.521 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.535 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.727 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.831 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.621 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.621 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.492 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.525 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.804 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.462 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.451 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.475 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.804 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 108' ' ' VAL . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.614 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.676 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.42 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.848 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.556 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.614 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.444 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.441 ' CE3' HD11 ' A' ' 77' ' ' LEU . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.676 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.521 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 7' ' ' VAL . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.848 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.502 HG21 HG11 ' A' ' 34' ' ' VAL . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 21' ' ' VAL . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.4 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.521 HG23 HG22 ' A' ' 86' ' ' VAL . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.649 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.513 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.482 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.552 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.515 ' HB ' HD12 ' A' ' 77' ' ' LEU . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 40' ' ' VAL . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.4 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.649 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.5 HD13 HG21 ' A' ' 17' ' ' THR . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.5 HG21 HD13 ' A' ' 13' ' ' LEU . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.494 HG11 HG21 ' A' ' 95' ' ' VAL . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.631 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' CG ' ' A' ' 76' ' ' PHE . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.561 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.402 ' HA ' HD22 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.411 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.494 HG21 HG11 ' A' ' 19' ' ' VAL . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.631 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.5 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.531 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.496 ' HB3' " H6'" ' A' ' 114' ' ' FLN . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.479 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.439 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.595 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.551 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.479 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.555 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 82' ' ' ARG . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.4 HG11 ' HB3' ' A' ' 38' ' ' ALA . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 19' ' ' VAL . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.538 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' HD13 ' A' ' 97' ' ' LEU . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.555 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.609 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.413 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.58 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.546 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.404 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.805 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.514 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.542 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.805 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.451 ' O ' HG12 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.595 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.408 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.808 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.586 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.497 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.462 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.496 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.591 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.578 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.578 ' HG2' HD13 ' A' ' 97' ' ' LEU . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.808 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.416 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.406 HG21 HG21 ' A' ' 65' ' ' THR . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.403 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.431 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.406 HG21 HG21 ' A' ' 34' ' ' VAL . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.43 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 110' ' ' ILE . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.584 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.431 ' HB3' HG21 ' A' ' 40' ' ' VAL . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.495 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.557 HD11 HG21 ' A' ' 69' ' ' VAL . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.604 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.584 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.434 ' H ' HG21 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.61 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.436 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.524 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.524 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.631 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.635 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.455 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.446 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.773 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.467 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.406 ' H ' HD11 ' A' ' 67' ' ' LEU . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 60' ' ' ASN . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' H ' ' CG ' ' A' ' 58' ' ' ASP . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.406 HD11 ' H ' ' A' ' 53' ' ' SER . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.446 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.41 HG11 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.515 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.635 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.407 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.434 HG21 ' H ' ' A' ' 10' ' ' SER . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.61 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.773 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.496 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.446 HG23 HG22 ' A' ' 86' ' ' VAL . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.43 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.81 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.436 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.452 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.419 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.42 ' HB3' HG21 ' A' ' 40' ' ' VAL . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.446 HG22 HG23 ' A' ' 40' ' ' VAL . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.81 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.422 ' HB3' HG21 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.422 HG21 ' HB3' ' A' ' 10' ' ' SER . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG11 HG21 ' A' ' 95' ' ' VAL . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.615 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.469 HD22 " H2'" ' A' ' 114' ' ' FLN . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.611 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.508 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.528 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 52' ' ' PHE . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.487 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.453 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.413 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.408 HG21 HG11 ' A' ' 19' ' ' VAL . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.616 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.611 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 108' ' ' VAL . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.412 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.412 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.572 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.628 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.408 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.457 HG21 ' HB3' ' A' ' 83' ' ' TRP . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.811 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 74' ' ' GLU . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.572 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.4 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.457 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.458 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.628 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.4 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.4 ' HG2' HD13 ' A' ' 97' ' ' LEU . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.568 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 7' ' ' VAL . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.811 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.476 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.477 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.477 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.406 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.406 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.704 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.427 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.531 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.433 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.541 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.441 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.457 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.433 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.51 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.51 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.704 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.51 HD13 HG21 ' A' ' 17' ' ' THR . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.51 HG21 HD13 ' A' ' 13' ' ' LEU . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.569 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.4 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.707 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.59 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.844 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.453 ' HA ' HD12 ' A' ' 67' ' ' LEU . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.52 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.569 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.453 HD12 ' HA ' ' A' ' 52' ' ' PHE . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD11 ' A' ' 110' ' ' ILE . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.487 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.535 HD11 ' CE3' ' A' ' 83' ' ' TRP . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.535 ' CE3' HD11 ' A' ' 77' ' ' LEU . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.59 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.707 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.517 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 69' ' ' VAL . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.844 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.424 ' HA ' ' H ' ' A' ' 111' ' ' SER . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 66' ' ' SER . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 95' ' ' VAL . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.468 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HB2' HE21 ' A' ' 36' ' ' GLN . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.596 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.596 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.445 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.475 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.514 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.544 ' HB3' HG12 ' A' ' 18' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.544 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.43 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.493 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.544 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.521 HG21 HG11 ' A' ' 19' ' ' VAL . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.544 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.45 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.424 ' H ' ' HA ' ' A' ' 11' ' ' SER . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.493 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.65 HD13 HG21 ' A' ' 17' ' ' THR . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.65 HG21 HD13 ' A' ' 13' ' ' LEU . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 34' ' ' VAL . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.508 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.402 HG11 HG21 ' A' ' 21' ' ' VAL . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.647 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.454 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.482 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.522 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.478 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.41 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.647 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.49 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.486 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.721 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.552 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.417 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.543 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.487 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.721 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.404 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.463 HG13 ' HB3' ' A' ' 97' ' ' LEU . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.59 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.431 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.47 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.758 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.488 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.402 ' HB2' HD21 ' A' ' 48' ' ' ASN . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.488 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.417 HD22 ' H5 ' ' A' ' 114' ' ' FLN . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.405 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 ' HB3' ' A' ' 38' ' ' ALA . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.59 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.415 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.758 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.438 ' HA ' HD12 ' A' ' 13' ' ' LEU . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.644 HD13 HG21 ' A' ' 17' ' ' THR . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.644 HG21 HD13 ' A' ' 13' ' ' LEU . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.576 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.486 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.526 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.483 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.515 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.493 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.515 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.405 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.806 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' HD11 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.576 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.435 HD11 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.411 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.405 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.498 ' H ' ' HD3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.483 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.56 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.806 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.467 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.603 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.479 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.449 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.629 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.555 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.555 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.428 HG13 ' HB1' ' A' ' 63' ' ' ALA . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.428 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.467 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.629 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.501 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.526 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.437 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.603 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.526 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.595 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.648 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.421 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.421 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.792 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.487 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.542 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.45 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.411 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.648 HG11 ' HB3' ' A' ' 38' ' ' ALA . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.595 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.792 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 108' ' ' VAL . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.491 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.443 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.443 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.406 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.406 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.613 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.66 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.6 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.507 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.507 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.491 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.419 HD22 ' N ' ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.6 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.567 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.477 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.501 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.52 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 7' ' ' VAL . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.487 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 041 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.66 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 108' ' ' VAL . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.439 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.672 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.707 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.518 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.403 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.767 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.475 HG22 ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.475 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.403 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.446 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.412 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.435 ' CE3' HD11 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.412 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.613 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.439 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.707 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.672 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.464 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 7' ' ' VAL . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 042 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.767 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.447 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.415 ' OG ' HG22 ' A' ' 19' ' ' VAL . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.55 HD13 HG21 ' A' ' 17' ' ' THR . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.55 HG21 HD13 ' A' ' 13' ' ' LEU . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.415 HG22 ' OG ' ' A' ' 10' ' ' SER . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.447 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.41 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.462 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.465 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.448 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.788 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.461 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.509 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.562 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.435 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.461 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.439 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.439 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB3' HG21 ' A' ' 40' ' ' VAL . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.471 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.542 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.517 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 043 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.788 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.438 HG11 HG21 ' A' ' 95' ' ' VAL . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.437 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.437 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.544 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.445 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.501 HD12 " H6'" ' A' ' 114' ' ' FLN . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.736 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.483 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.483 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.401 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.595 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.483 ' HB ' HD12 ' A' ' 77' ' ' LEU . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG11 ' A' ' 19' ' ' VAL . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 044 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.736 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.475 ' O ' HG12 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 66' ' ' SER . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.507 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.428 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.806 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.543 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.5 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.53 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.543 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.436 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.428 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.507 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.806 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.688 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.588 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.473 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.453 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.426 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB3' HG21 ' A' ' 40' ' ' VAL . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.516 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.622 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.516 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.509 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 046 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.688 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.617 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.427 HG21 HD13 ' A' ' 13' ' ' LEU . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.622 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 66' ' ' SER . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.617 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.496 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.618 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.645 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.694 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.497 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.694 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.423 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.622 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.497 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.493 ' HB3' HG21 ' A' ' 40' ' ' VAL . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 HG23 ' A' ' 40' ' ' VAL . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.435 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.496 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 047 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.645 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.58 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.405 ' H ' HG21 ' A' ' 110' ' ' ILE . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' VAL . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 95' ' ' VAL . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.697 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.541 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.511 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.424 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.511 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.424 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.686 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.697 HG11 ' HB3' ' A' ' 38' ' ' ALA . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 19' ' ' VAL . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.405 HG21 ' H ' ' A' ' 10' ' ' SER . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.406 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.686 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.601 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.437 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.734 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.601 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.407 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.413 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.406 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.406 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 049 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.734 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.495 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.479 ' H ' HG21 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.454 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.495 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.408 ' HA2' HD11 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.858 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.592 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.592 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.407 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.407 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.454 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.501 HD11 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.811 HD12 ' HB ' ' A' ' 81' ' ' THR . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.811 ' HB ' HD12 ' A' ' 77' ' ' LEU . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.431 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.434 ' HE3' HD11 ' A' ' 77' ' ' LEU . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 28.2 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.479 HG21 ' H ' ' A' ' 10' ' ' SER . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 050 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.858 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.433 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 108' ' ' VAL . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.458 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.507 HG11 HG21 ' A' ' 95' ' ' VAL . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.733 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' A' ' 83' ' ' TRP . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.839 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.5 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.52 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.454 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.5 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.52 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.469 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.733 HG11 ' HB3' ' A' ' 38' ' ' ALA . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.438 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.507 HG21 HG11 ' A' ' 19' ' ' VAL . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.512 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.509 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.509 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 7' ' ' VAL . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 051 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.839 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.54 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.421 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.421 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.631 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.655 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.418 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.81 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.595 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.435 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.548 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.631 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.493 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 052 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.81 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG23 HG22 ' A' ' 86' ' ' VAL . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.777 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.5 HD21 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HB2' HD21 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.568 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.46 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.559 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 40' ' ' VAL . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.43 ' SG ' ' HB2' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.51 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.47 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 053 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.777 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.625 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.529 HG11 HG21 ' A' ' 95' ' ' VAL . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.792 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.421 ' HB2' HD21 ' A' ' 48' ' ' ASN . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.625 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.43 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.529 HG21 HG11 ' A' ' 19' ' ' VAL . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 054 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.792 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.555 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.439 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.67 HD13 HG21 ' A' ' 17' ' ' THR . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.67 HG21 HD13 ' A' ' 13' ' ' LEU . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.555 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.511 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.47 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.516 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.532 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.408 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.75 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.459 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.504 HG21 HD11 ' A' ' 110' ' ' ILE . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.45 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.532 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.504 HD11 HG21 ' A' ' 69' ' ' VAL . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 055 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.75 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.439 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.573 HD13 HG21 ' A' ' 17' ' ' THR . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.573 HG21 HD13 ' A' ' 13' ' ' LEU . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.69 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.831 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.536 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.405 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.518 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.428 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.431 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.69 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.425 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 056 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.831 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.685 HD13 HG21 ' A' ' 17' ' ' THR . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.685 HG21 HD13 ' A' ' 13' ' ' LEU . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.4 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 86' ' ' VAL . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.4 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.698 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.57 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.506 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.422 HG22 HG23 ' A' ' 40' ' ' VAL . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.407 ' HG ' HG13 ' A' ' 34' ' ' VAL . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 057 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.698 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD13 HG21 ' A' ' 17' ' ' THR . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.459 HG21 HD13 ' A' ' 13' ' ' LEU . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.415 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.415 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.662 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.481 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.465 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.755 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.584 HD21 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.584 ' HB2' HD21 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.431 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.548 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.427 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.465 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.481 HG11 ' HB3' ' A' ' 38' ' ' ALA . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.662 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.423 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.411 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 058 nuclear build full ' A' A ' 114' ' ' FLN . . . . . 0.755 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.641 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.688 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.571 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.571 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.568 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.568 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.53 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.457 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.512 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.442 ' HA ' HD12 ' A' ' 13' ' ' LEU . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 95' ' ' VAL . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.446 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.687 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.489 HG12 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.419 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.489 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.439 HD12 ' HB ' ' A' ' 81' ' ' THR . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 77' ' ' LEU . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.419 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.54 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.451 HG21 HG11 ' A' ' 19' ' ' VAL . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.611 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.428 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.556 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.511 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.658 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.485 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.406 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.658 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.504 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.466 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.506 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.411 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.4 HG21 HD13 ' A' ' 13' ' ' LEU . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.516 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.5 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.471 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.439 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.499 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.499 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.516 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.897 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 69' ' ' VAL . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.897 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.447 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.447 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.682 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.411 ' H ' ' HA ' ' A' ' 45' ' ' LEU . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 40' ' ' VAL . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.682 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.438 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.4 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 17' ' ' THR . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 ' HB ' ' A' ' 81' ' ' THR . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.438 ' HB ' HD12 ' A' ' 77' ' ' LEU . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.476 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.58 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.3 p30 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.424 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.456 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.425 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.545 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.578 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.519 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.456 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.471 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.504 HD12 ' HB ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.4 ' HB3' HG21 ' A' ' 40' ' ' VAL . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.545 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.428 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.428 ' HG2' HD13 ' A' ' 97' ' ' LEU . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.485 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.48 HG21 HD13 ' A' ' 13' ' ' LEU . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.423 HG11 HG21 ' A' ' 95' ' ' VAL . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.711 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 45' ' ' LEU . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.463 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.408 ' HA ' ' O ' ' A' ' 38' ' ' ALA . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.489 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.489 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.494 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.494 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.549 ' HB3' HG21 ' A' ' 40' ' ' VAL . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.423 HG21 HG11 ' A' ' 19' ' ' VAL . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.711 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 97' ' ' LEU . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.485 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.474 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.456 ' O ' HG12 ' A' ' 69' ' ' VAL . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 HG23 ' A' ' 68' ' ' THR . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.638 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.486 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.481 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.577 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.469 HG23 HG22 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.416 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.481 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.638 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.567 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.578 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.416 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.416 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.536 ' HA ' HD12 ' A' ' 13' ' ' LEU . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 10' ' ' SER . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.416 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.416 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.435 HG22 ' HB2' ' A' ' 97' ' ' LEU . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.425 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.511 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.449 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.493 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.4 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.414 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.414 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB2' HG22 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.475 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 97' ' ' LEU . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.458 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.457 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.461 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.525 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.425 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.457 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 21' ' ' VAL . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.404 HG21 HD13 ' A' ' 13' ' ' LEU . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 95' ' ' VAL . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' HA ' HG12 ' A' ' 7' ' ' VAL . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB3' ' HZ ' ' A' ' 73' ' ' PHE . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.44 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.688 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.402 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.415 ' HZ ' ' HB3' ' A' ' 38' ' ' ALA . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.511 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.44 ' HB3' HG21 ' A' ' 40' ' ' VAL . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.44 HG21 HG11 ' A' ' 19' ' ' VAL . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.495 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.51 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.51 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.495 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.414 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.551 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.525 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.449 ' HB3' HG21 ' A' ' 40' ' ' VAL . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.551 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.414 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.543 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.406 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.833 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 108' ' ' VAL . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.833 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.424 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.541 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 67' ' ' LEU . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.424 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.441 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.467 HG21 HG11 ' A' ' 19' ' ' VAL . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.408 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.401 ' HG2' HD11 ' A' ' 97' ' ' LEU . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.429 HG21 HG11 ' A' ' 34' ' ' VAL . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.429 HG11 HG21 ' A' ' 21' ' ' VAL . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.431 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.626 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.4 HD12 ' HB ' ' A' ' 81' ' ' THR . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD12 ' A' ' 77' ' ' LEU . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HB3' HG11 ' A' ' 108' ' ' VAL . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.499 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.499 HD12 ' HA ' ' A' ' 10' ' ' SER . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 13' ' ' LEU . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' HB3' ' A' ' 97' ' ' LEU . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.423 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.557 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.462 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.557 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.55 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.528 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.423 HD11 ' CE3' ' A' ' 83' ' ' TRP . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.423 ' CE3' HD11 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.543 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.492 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.408 HG11 ' HB3' ' A' ' 9' ' ' PRO . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.462 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.572 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.474 HG21 HD13 ' A' ' 13' ' ' LEU . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.451 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.451 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.743 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.45 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.661 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.466 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.588 HD21 ' HB ' ' A' ' 34' ' ' VAL . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.47 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.51 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 81' ' ' THR . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.44 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.743 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.572 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.588 HD13 HG21 ' A' ' 17' ' ' THR . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.588 HG21 HD13 ' A' ' 13' ' ' LEU . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.457 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.55 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.536 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.445 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.457 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.501 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.416 ' HB3' HG21 ' A' ' 40' ' ' VAL . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.536 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 108' ' ' VAL . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.461 HD13 HG21 ' A' ' 17' ' ' THR . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.461 HG21 HD13 ' A' ' 13' ' ' LEU . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 95' ' ' VAL . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.449 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.535 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.478 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.437 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 81' ' ' THR . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 77' ' ' LEU . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.535 ' HB3' HG21 ' A' ' 40' ' ' VAL . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.437 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 19' ' ' VAL . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.856 HD13 HG21 ' A' ' 17' ' ' THR . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.856 HG21 HD13 ' A' ' 13' ' ' LEU . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.579 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.613 HG21 HG11 ' A' ' 34' ' ' VAL . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.727 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.535 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.463 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.425 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.579 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.456 HD12 ' HB ' ' A' ' 81' ' ' THR . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.456 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.458 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.535 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.727 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.621 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.621 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.492 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.525 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.43 ' HA ' HD13 ' A' ' 67' ' ' LEU . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.462 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.451 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.475 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 108' ' ' VAL . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.614 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.676 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.42 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.556 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.614 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.429 ' HA ' HD13 ' A' ' 67' ' ' LEU . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.441 HD11 ' CE3' ' A' ' 83' ' ' TRP . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.441 ' CE3' HD11 ' A' ' 77' ' ' LEU . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.676 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.521 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 7' ' ' VAL . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.502 HG21 HG11 ' A' ' 34' ' ' VAL . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 21' ' ' VAL . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.4 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.521 HG23 HG22 ' A' ' 86' ' ' VAL . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.513 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.482 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.515 HD12 ' HB ' ' A' ' 81' ' ' THR . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.515 ' HB ' HD12 ' A' ' 77' ' ' LEU . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 40' ' ' VAL . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.4 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.5 HD13 HG21 ' A' ' 17' ' ' THR . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.5 HG21 HD13 ' A' ' 13' ' ' LEU . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.494 HG11 HG21 ' A' ' 95' ' ' VAL . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' CG ' ' A' ' 76' ' ' PHE . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.561 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.402 ' HA ' HD22 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.411 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.494 HG21 HG11 ' A' ' 19' ' ' VAL . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.5 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.531 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.479 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.595 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.551 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.479 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 82' ' ' ARG . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.4 HG11 ' HB3' ' A' ' 38' ' ' ALA . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 19' ' ' VAL . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.538 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' HD13 ' A' ' 97' ' ' LEU . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 p30 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.609 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.413 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.58 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.546 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.404 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.411 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.454 ' HA ' HD13 ' A' ' 67' ' ' LEU . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.514 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.421 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.451 ' O ' HG12 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.595 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.408 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.586 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.497 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.462 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.473 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.578 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.578 ' HG2' HD13 ' A' ' 97' ' ' LEU . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.416 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.406 HG21 HG21 ' A' ' 65' ' ' THR . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.403 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.431 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.406 HG21 HG21 ' A' ' 34' ' ' VAL . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.43 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 110' ' ' ILE . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.431 ' HB3' HG21 ' A' ' 40' ' ' VAL . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.495 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.557 HD11 HG21 ' A' ' 69' ' ' VAL . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.604 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.434 ' H ' HG21 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.61 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.436 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.524 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.524 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.631 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.635 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.455 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.446 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.467 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.406 ' H ' HD11 ' A' ' 67' ' ' LEU . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 60' ' ' ASN . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' H ' ' CG ' ' A' ' 58' ' ' ASP . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.406 HD11 ' H ' ' A' ' 53' ' ' SER . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.446 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.41 HG11 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.635 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.407 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.434 HG21 ' H ' ' A' ' 10' ' ' SER . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.61 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.496 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.446 HG23 HG22 ' A' ' 86' ' ' VAL . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.43 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.436 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.452 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.42 ' HB3' HG21 ' A' ' 40' ' ' VAL . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.446 HG22 HG23 ' A' ' 40' ' ' VAL . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.422 ' HB3' HG21 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.422 HG21 ' HB3' ' A' ' 10' ' ' SER . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG11 HG21 ' A' ' 95' ' ' VAL . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.615 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.508 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.528 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 52' ' ' PHE . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.487 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 81' ' ' THR . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.413 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.408 HG21 HG11 ' A' ' 19' ' ' VAL . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.616 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 108' ' ' VAL . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.412 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.412 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.572 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.628 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.408 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.457 HG21 ' HB3' ' A' ' 83' ' ' TRP . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 74' ' ' GLU . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.572 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.4 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.457 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.426 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.628 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.4 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.4 ' HG2' HD13 ' A' ' 97' ' ' LEU . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 7' ' ' VAL . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.476 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.477 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.477 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.406 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.406 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.427 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.531 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.433 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.441 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.457 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.433 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.51 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.51 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.51 HD13 HG21 ' A' ' 17' ' ' THR . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.51 HG21 HD13 ' A' ' 13' ' ' LEU . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.569 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.4 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.707 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.59 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.453 ' HA ' HD12 ' A' ' 67' ' ' LEU . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.52 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.569 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.453 HD12 ' HA ' ' A' ' 52' ' ' PHE . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD11 ' A' ' 110' ' ' ILE . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.487 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.535 HD11 ' CE3' ' A' ' 83' ' ' TRP . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.535 ' CE3' HD11 ' A' ' 77' ' ' LEU . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.59 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.707 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 69' ' ' VAL . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.424 ' HA ' ' H ' ' A' ' 111' ' ' SER . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 66' ' ' SER . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 95' ' ' VAL . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.468 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HB2' HE21 ' A' ' 36' ' ' GLN . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.596 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.596 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.514 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.544 ' HB3' HG12 ' A' ' 18' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.544 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.43 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.544 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.521 HG21 HG11 ' A' ' 19' ' ' VAL . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.544 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.45 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.424 ' H ' ' HA ' ' A' ' 11' ' ' SER . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.65 HD13 HG21 ' A' ' 17' ' ' THR . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.65 HG21 HD13 ' A' ' 13' ' ' LEU . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 34' ' ' VAL . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.508 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.402 HG11 HG21 ' A' ' 21' ' ' VAL . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.454 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.482 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.522 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.41 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.49 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.486 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.417 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.552 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.417 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.487 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.404 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.463 HG13 ' HB3' ' A' ' 97' ' ' LEU . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.59 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.431 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.47 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.488 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.402 ' HB2' HD21 ' A' ' 48' ' ' ASN . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.488 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.405 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 ' HB3' ' A' ' 38' ' ' ALA . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.59 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.438 ' HA ' HD12 ' A' ' 13' ' ' LEU . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.644 HD13 HG21 ' A' ' 17' ' ' THR . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.644 HG21 HD13 ' A' ' 13' ' ' LEU . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.576 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.486 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.526 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.483 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.515 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.493 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.515 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.405 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' HD11 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.576 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.435 HD11 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.411 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.405 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.498 ' HD3' ' H ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.483 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.467 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.603 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.479 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.629 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.555 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.555 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.428 HG13 ' HB1' ' A' ' 63' ' ' ALA . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.428 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.467 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.629 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.501 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.437 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.603 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.595 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.648 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.421 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.421 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.487 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.542 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.45 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.648 HG11 ' HB3' ' A' ' 38' ' ' ALA . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.595 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 041 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 108' ' ' VAL . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.491 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.443 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.443 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.406 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.406 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.613 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.6 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.507 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.507 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.491 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.419 ' N ' HD22 ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.6 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.567 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.44 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.501 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.52 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 7' ' ' VAL . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.487 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 042 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 108' ' ' VAL . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.439 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.672 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.707 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.518 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.403 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.475 HG22 ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.475 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.403 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.435 HD11 ' CE3' ' A' ' 83' ' ' TRP . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.412 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.435 ' CE3' HD11 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.412 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.613 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.439 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.707 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.672 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.464 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 7' ' ' VAL . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 043 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.447 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.415 ' OG ' HG22 ' A' ' 19' ' ' VAL . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.55 HD13 HG21 ' A' ' 17' ' ' THR . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.55 HG21 HD13 ' A' ' 13' ' ' LEU . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.415 HG22 ' OG ' ' A' ' 10' ' ' SER . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.447 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.41 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.462 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.465 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.448 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.461 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.509 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.562 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.435 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.461 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.439 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB3' HG21 ' A' ' 40' ' ' VAL . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.471 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.542 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 044 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.438 HG11 HG21 ' A' ' 95' ' ' VAL . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.437 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.437 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.544 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.445 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.483 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.483 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.401 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.483 HD12 ' HB ' ' A' ' 81' ' ' THR . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.483 ' HB ' HD12 ' A' ' 77' ' ' LEU . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG11 ' A' ' 19' ' ' VAL . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 045 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.475 ' O ' HG12 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 66' ' ' SER . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.507 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.428 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.543 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.5 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.53 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.543 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.436 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.428 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.507 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 0 0 . 1 . 046 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.588 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.473 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.453 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.426 ' N ' HD22 ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB3' HG21 ' A' ' 40' ' ' VAL . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.516 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.622 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.516 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.509 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 047 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.617 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.427 HG21 HD13 ' A' ' 13' ' ' LEU . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.622 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 66' ' ' SER . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.617 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.496 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.618 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.694 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.497 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.694 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.423 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.622 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.497 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.493 ' HB3' HG21 ' A' ' 40' ' ' VAL . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 HG23 ' A' ' 40' ' ' VAL . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.435 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.496 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 048 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.58 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.405 ' H ' HG21 ' A' ' 110' ' ' ILE . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' VAL . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 95' ' ' VAL . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.697 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.511 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.424 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.511 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.424 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.697 HG11 ' HB3' ' A' ' 38' ' ' ALA . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 19' ' ' VAL . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.405 HG21 ' H ' ' A' ' 10' ' ' SER . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.406 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.601 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.437 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.601 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.413 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.406 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.406 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 050 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.495 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.479 ' H ' HG21 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.454 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.495 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.408 ' HA2' HD11 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.592 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.592 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.407 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.407 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.454 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.501 HD11 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.811 HD12 ' HB ' ' A' ' 81' ' ' THR . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.811 ' HB ' HD12 ' A' ' 77' ' ' LEU . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.431 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.434 ' HE3' HD11 ' A' ' 77' ' ' LEU . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.479 HG21 ' H ' ' A' ' 10' ' ' SER . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 051 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.433 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 108' ' ' VAL . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.458 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.507 HG11 HG21 ' A' ' 95' ' ' VAL . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.733 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' A' ' 83' ' ' TRP . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.5 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.52 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.454 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.5 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.52 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.439 HD11 ' CE3' ' A' ' 83' ' ' TRP . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.733 HG11 ' HB3' ' A' ' 38' ' ' ALA . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.438 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.507 HG21 HG11 ' A' ' 19' ' ' VAL . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.512 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.509 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.509 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 7' ' ' VAL . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 052 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.54 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.421 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.421 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.631 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.655 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.418 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.595 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.435 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.548 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.631 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.493 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 053 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG23 HG22 ' A' ' 86' ' ' VAL . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.46 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 37' ' ' CYS . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.5 HD21 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HB2' HD21 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.568 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.46 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 40' ' ' VAL . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.43 ' SG ' ' HB2' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.47 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 054 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.625 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.529 HG11 HG21 ' A' ' 95' ' ' VAL . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.421 ' HB2' HD21 ' A' ' 48' ' ' ASN . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.625 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.43 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.529 HG21 HG11 ' A' ' 19' ' ' VAL . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 055 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.555 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.439 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.67 HD13 HG21 ' A' ' 17' ' ' THR . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.67 HG21 HD13 ' A' ' 13' ' ' LEU . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.555 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.511 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.47 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.516 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.532 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.408 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.459 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.504 HG21 HD11 ' A' ' 110' ' ' ILE . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.532 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.504 HD11 HG21 ' A' ' 69' ' ' VAL . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 056 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.439 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.573 HD13 HG21 ' A' ' 17' ' ' THR . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.573 HG21 HD13 ' A' ' 13' ' ' LEU . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.69 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.536 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.405 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.518 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.428 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.69 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.425 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 057 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.685 HD13 HG21 ' A' ' 17' ' ' THR . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.685 HG21 HD13 ' A' ' 13' ' ' LEU . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.4 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 86' ' ' VAL . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.4 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.57 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.422 HG22 HG23 ' A' ' 40' ' ' VAL . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.407 ' HG ' HG13 ' A' ' 34' ' ' VAL . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 058 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.459 HD13 HG21 ' A' ' 17' ' ' THR . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.459 HG21 HD13 ' A' ' 13' ' ' LEU . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.431 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.415 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.415 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.416 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.662 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.481 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.465 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 36' ' ' GLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.584 HD21 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.584 ' HB2' HD21 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.431 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.548 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.427 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.481 HG11 ' HB3' ' A' ' 38' ' ' ALA . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.662 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.411 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.966 0 CA-C-O 120.614 0.245 . . . . 0.0 110.439 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.81 112.62 57.73 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.561 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_endo -76.85 171.43 18.0 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.853 2.369 . . . . 0.0 111.972 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.15 81.4 1.96 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.261 0.553 . . . . 0.0 111.236 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.38 106.14 18.28 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.052 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.04 99.29 7.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.6 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -115.94 160.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.009 0.433 . . . . 0.0 111.457 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -120.96 95.69 48.83 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.5 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.67 147.69 40.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.627 2.218 . . . . 0.0 112.385 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 4.2 m -81.7 89.82 6.29 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.09 0.471 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 m -104.58 113.01 26.3 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.689 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.15 25.51 40.12 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.318 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.641 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 55.0 mt -119.86 162.29 19.38 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.1 m -86.48 -177.29 6.15 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.724 0.297 . . . . 0.0 111.024 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -76.59 155.82 33.25 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.88 69.79 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.5 m -73.53 146.95 44.43 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 122.63 0.372 . . . . 0.0 110.761 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.7 t -95.01 112.18 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.966 0.412 . . . . 0.0 110.472 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.8 t -80.26 127.52 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.974 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 29.9 ttmt -92.96 123.14 36.01 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.566 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.1 t -126.17 124.24 65.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.258 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.07 105.7 5.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.111 0.481 . . . . 0.0 110.834 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 122.7 6.71 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.116 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.99 150.76 38.73 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.761 0.315 . . . . 0.0 110.742 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.72 34.19 19.68 Favored Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.7 mt -103.61 -169.25 1.61 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.239 -0.48 . . . . 0.0 110.458 -179.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.8 tp60 -88.96 107.45 19.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.261 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 118.99 6.68 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.217 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.26 -19.95 19.47 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.212 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 80.1 m -81.68 140.58 34.26 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.789 0.328 . . . . 0.0 110.827 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.85 122.57 35.36 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 98.8 m-85 -107.39 122.07 45.87 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.894 0.378 . . . . 0.0 110.716 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -89.49 129.76 35.93 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.8 t -132.74 130.21 58.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.631 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.13 -175.58 27.28 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -84.51 52.38 2.35 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.688 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -63.1 104.89 0.62 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.497 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.86 178.41 4.29 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.571 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -67.1 126.58 29.64 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.156 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -115.96 -28.46 2.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.995 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -152.48 177.12 10.96 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.571 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 1.9 m -63.07 96.5 0.1 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.153 0.501 . . . . 0.0 111.438 -179.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.9 2.04 81.71 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.11 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -115.67 134.31 59.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.012 0.434 . . . . 0.0 110.5 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.06 167.22 11.99 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -152.04 138.34 18.44 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.95 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.586 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 60.2 m -95.5 170.72 9.16 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.784 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.568 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 24.0 p-10 -105.14 121.61 45.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 0.0 110.599 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 92.8 Cg_endo -83.2 -7.1 11.07 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.504 2.136 . . . . 0.0 112.445 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.36 -70.87 0.42 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.32 59.44 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.538 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.568 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.0 p90 -111.25 151.92 27.75 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.2 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m -147.29 83.0 1.55 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.37 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 p -65.05 133.66 52.13 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -118.55 137.12 53.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.098 0.475 . . . . 0.0 111.246 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.0 t -92.31 148.44 22.13 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 136.99 46.37 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.809 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.1 p30 -82.67 -173.64 4.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.377 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.84 -13.33 61.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.766 -179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 -95.05 -4.8 45.78 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.191 0.519 . . . . 0.0 109.667 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.42 29.39 55.96 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.627 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -119.8 153.58 35.53 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 111.151 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.53 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -141.91 112.5 7.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.827 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.0 m -111.74 131.53 55.25 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.541 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -148.97 172.33 14.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.945 0.402 . . . . 0.0 110.819 -179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.2 m -143.54 131.12 21.18 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -122.19 150.46 42.22 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.233 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -102.58 113.31 26.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.262 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.7 p -75.26 114.8 15.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.218 0.532 . . . . 0.0 111.272 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -94.28 164.15 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.518 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 9.7 tpp180 -77.0 -41.86 41.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.009 0.433 . . . . 0.0 110.021 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -129.26 129.54 45.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.89 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.5 p90 -142.72 159.12 42.84 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.101 0.476 . . . . 0.0 111.557 -178.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -79.33 117.21 20.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.21 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.71 124.58 6.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.632 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.457 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 14.3 m-85 -129.69 145.09 51.54 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.778 0.323 . . . . 0.0 110.615 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.512 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 20.3 mt -83.9 -178.86 7.12 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 12.0 m-85 -82.64 -17.01 46.15 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.161 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 8.2 p-10 -78.43 -35.54 46.78 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.246 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.82 -6.9 5.81 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.103 -0.57 . . . . 0.0 112.02 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 12.9 m -85.97 142.45 28.79 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.669 0.271 . . . . 0.0 110.598 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.08 159.14 15.84 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.618 -0.265 . . . . 0.0 110.301 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.0 t-105 -119.5 -23.42 6.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.838 0.352 . . . . 0.0 110.672 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.73 173.51 14.52 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.232 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -82.01 116.37 21.59 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.87 0.366 . . . . 0.0 111.193 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.63 136.7 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -127.38 121.04 29.87 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.0 110.396 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 63.2 m -106.31 50.32 0.78 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.9 0.381 . . . . 0.0 112.024 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.409 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 52.5 m -87.38 -52.03 5.61 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.3 t -96.87 -12.22 23.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.077 0.465 . . . . 0.0 110.028 178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.11 163.84 15.06 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.948 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.86 146.22 25.13 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.909 0.385 . . . . 0.0 111.083 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -98.02 -177.32 3.7 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.817 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 8.8 pt20 -158.85 175.47 13.55 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.0 t -108.76 139.51 31.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 120.797 0.332 . . . . 0.0 111.073 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -122.68 128.35 7.08 Favored Glycine 0 N--CA 1.441 -0.967 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.46 113.08 8.93 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 -178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 66.6 m -156.86 164.09 38.46 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.717 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.39 -176.68 4.85 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.98 -31.88 65.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.872 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.0 -52.37 7.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.898 0.38 . . . . 0.0 110.63 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 137.49 33.35 0.21 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.824 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -117.57 153.14 33.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 110.2 179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 154.44 -155.26 26.08 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.049 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -72.47 168.75 23.47 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.897 2.398 . . . . 0.0 111.789 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -77.67 149.95 34.6 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -70.69 145.07 39.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.956 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 41.4 t -120.57 129.98 75.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -86.93 149.4 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.556 -179.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 10' ' ' SER . 30.3 pt -125.29 164.41 24.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.6 m -146.85 141.09 26.25 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.884 0.373 . . . . 0.0 110.905 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.2 m-85 -84.34 166.87 17.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.268 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.049 -179.8 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.586 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.933 0 CA-C-O 120.694 0.283 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.66 119.74 64.58 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.459 -179.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -84.39 161.84 12.95 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.549 2.166 . . . . 0.0 111.606 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.3 m -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.632 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.69 118.96 36.6 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.466 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -129.73 98.55 4.84 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 24.6 m -115.86 152.66 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.1 0.476 . . . . 0.0 111.278 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.8 m -108.5 92.71 10.43 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.561 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.8 Cg_exo -72.71 145.51 41.47 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.778 2.319 . . . . 0.0 112.622 -179.241 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.442 ' HA ' HD12 ' A' ' 13' ' ' LEU . 7.1 m -83.79 67.17 9.43 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.476 0.655 . . . . 0.0 110.102 178.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.28 97.39 7.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.988 -179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.08 25.33 27.03 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.553 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 88.9 mt -111.72 157.13 20.86 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.8 m -79.57 173.62 12.4 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.556 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -75.88 158.87 31.56 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.44 72.87 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.491 -0.862 . . . . 0.0 111.741 -178.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 5.8 m -81.52 155.51 25.73 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.983 -0.376 . . . . 0.0 109.983 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.18 115.4 42.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.829 0.347 . . . . 0.0 111.51 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 95' ' ' VAL . 21.7 t -80.58 117.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.281 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -87.46 118.08 26.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.596 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.57 112.62 40.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.13 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.42 111.9 16.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.026 0.441 . . . . 0.0 110.896 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -114.2 130.27 9.21 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.247 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.0 152.01 39.07 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.45 32.24 28.5 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.489 -0.862 . . . . 0.0 111.144 -178.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.446 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 96.3 mt -100.72 -164.84 1.15 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.282 -0.459 . . . . 0.0 110.623 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.7 tp60 -93.58 111.74 23.49 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.155 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.48 110.93 2.12 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.93 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.32 9.01 20.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.981 179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 p -113.81 144.24 43.33 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 117.681 0.741 . . . . 0.0 111.265 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.95 142.6 27.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.29 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 55.8 m-85 -121.84 147.45 45.96 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.178 0.513 . . . . 0.0 111.188 -178.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -102.81 110.86 22.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.311 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.2 t -124.46 128.61 73.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.745 -179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.71 -173.14 27.82 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -86.74 46.07 1.32 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.786 0.803 . . . . 0.0 109.635 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.5 m -59.97 104.14 0.27 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.799 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -109.45 177.79 4.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.109 179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -63.71 120.93 12.76 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.157 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 p -105.24 -26.79 3.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.994 0.426 . . . . 0.0 110.451 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -155.55 -167.4 2.5 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.962 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.8 m -70.48 94.62 0.98 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.137 0.494 . . . . 0.0 111.701 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.72 -6.19 81.4 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 112.205 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.9 t -108.6 137.47 40.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.874 0.369 . . . . 0.0 110.618 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 " H2'" ' A' ' 114' ' ' FLN . 4.5 mp -117.14 172.88 6.99 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.687 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.04 138.46 19.49 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.738 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.594 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 79.0 m -96.11 162.29 13.6 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.265 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 21.4 p-10 -99.8 110.91 60.68 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-O 121.113 0.482 . . . . 0.0 111.206 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 89.3 Cg_endo -81.16 2.18 8.76 Favored 'Trans proline' 0 CA--C 1.532 0.417 0 C-N-CA 122.661 2.24 . . . . 0.0 112.725 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.9 -26.38 22.76 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.83 39.33 1.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 120.575 -0.45 . . . . 0.0 111.832 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.6 p90 -104.59 169.18 8.61 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.9 m -140.3 122.26 15.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.79 0.329 . . . . 0.0 110.739 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.6 p -78.44 87.99 4.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.094 0.473 . . . . 0.0 110.099 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.5 p -85.27 146.37 6.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.349 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 t -124.59 146.56 48.98 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -70.77 135.96 48.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.672 0.273 . . . . 0.0 110.506 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -81.8 -175.13 5.42 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.07 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.45 -20.12 64.2 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.973 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 66.2 m-80 -86.82 -11.1 51.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.112 0.482 . . . . 0.0 110.217 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.61 34.42 22.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.847 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.49 153.81 46.77 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.627 0.251 . . . . 0.0 110.466 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.13 127.42 14.86 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.605 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.4 t -128.97 129.27 45.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -147.39 162.72 38.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.824 0.345 . . . . 0.0 110.807 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.9 m -125.06 125.92 44.55 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -110.22 135.77 50.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.835 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.22 107.17 18.66 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.487 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.489 HG12 ' O ' ' A' ' 17' ' ' THR . 4.5 p -72.59 118.14 17.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.291 0.567 . . . . 0.0 111.141 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -100.07 164.22 12.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.93 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.419 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 12.6 tpp180 -74.63 -45.07 47.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.011 0.434 . . . . 0.0 110.686 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.6 m -130.09 119.05 22.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -122.76 162.36 22.2 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.093 0.473 . . . . 0.0 111.629 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.23 133.2 33.69 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.66 127.93 8.75 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.732 -0.747 . . . . 0.0 113.2 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.489 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.5 m-85 -133.1 143.62 49.42 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.642 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 22.8 mt -91.1 165.88 13.27 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -73.71 -27.63 61.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.345 . . . . 0.0 111.046 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -67.96 -31.67 71.56 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.577 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 133.05 -28.41 3.34 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.484 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 77' ' ' LEU . 5.6 m -69.48 151.04 46.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.946 0.403 . . . . 0.0 111.048 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -104.15 164.55 11.64 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.269 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -115.71 -48.65 2.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.869 0.366 . . . . 0.0 110.06 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.98 -137.33 4.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.319 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.4 m -118.79 134.92 54.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.824 0.345 . . . . 0.0 110.742 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -114.24 112.23 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 120.992 0.425 . . . . 0.0 110.363 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -96.85 114.46 26.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.539 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.5 m -95.9 28.91 2.9 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.952 0.406 . . . . 0.0 111.163 -179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.419 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 27.1 m -78.95 -52.32 8.43 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -101.94 -9.41 20.7 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.1 179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.37 -177.69 3.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.213 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.31 140.26 39.52 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.37 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -108.24 163.46 13.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.828 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.54 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 8.9 pt20 -153.59 171.19 19.16 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.353 -0.239 . . . . 0.0 110.353 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.451 HG21 HG11 ' A' ' 19' ' ' VAL . 17.7 t -103.45 124.92 57.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.35 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -111.94 134.24 11.94 Favored Glycine 0 N--CA 1.441 -0.968 0 C-N-CA 120.806 -0.712 . . . . 0.0 111.743 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.89 128.38 19.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.031 0.443 . . . . 0.0 111.285 -179.139 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -156.93 166.31 33.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.814 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -82.92 -169.96 2.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.679 0.276 . . . . 0.0 110.757 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.5 -33.85 76.48 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.416 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 -43.24 65.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.152 0.501 . . . . 0.0 110.158 179.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.52 29.88 1.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.701 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -135.86 170.21 16.35 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.798 0.333 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 145.3 -154.76 26.13 Favored Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.34 159.59 39.08 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.756 2.304 . . . . 0.0 111.636 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -77.88 148.63 34.52 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.012 0.434 . . . . 0.0 111.327 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.34 153.11 50.47 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.65 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.6 t -113.87 125.94 71.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.584 0.231 . . . . 0.0 110.409 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.05 144.81 34.27 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.945 0.403 . . . . 0.0 110.598 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.3 pt -124.37 172.61 11.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.2 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 44.8 m -150.44 138.13 19.86 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.611 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.4 m-85 -85.88 154.05 21.8 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.33 -0.843 . . . . 0.0 110.622 179.798 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.642 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.56 121.86 76.59 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.897 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.06 175.58 10.24 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.833 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -116.27 110.33 18.61 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.715 0.293 . . . . 0.0 111.005 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.27 78.19 2.03 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.866 0.365 . . . . 0.0 110.7 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.49 88.49 7.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.265 0.555 . . . . 0.0 111.155 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.3 m -108.54 146.94 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.16 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 m -108.86 104.78 55.73 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.534 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -73.92 145.01 35.35 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.616 2.211 . . . . 0.0 112.714 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.428 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -94.03 29.15 2.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.245 179.854 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -63.08 124.28 20.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.106 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.71 -2.87 70.49 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.5 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 56.3 mt -104.03 172.64 6.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.643 0.221 . . . . 0.0 110.939 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -167.38 1.65 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.908 0.385 . . . . 0.0 111.203 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -80.95 153.76 27.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.25 6.06 71.84 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.501 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 75.8 m -72.47 139.83 47.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.861 0.363 . . . . 0.0 111.01 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.3 t -85.14 104.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.152 179.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.0 t -82.92 121.95 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.325 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -93.95 114.7 26.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.935 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.13 105.42 18.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.718 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.29 113.67 21.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.982 0.42 . . . . 0.0 111.125 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.74 134.06 11.99 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.024 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.556 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -123.45 149.01 45.6 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.37 33.01 40.77 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.12 -179.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 51.9 mt -94.08 -171.22 2.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.541 -0.33 . . . . 0.0 110.593 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 25.5 tp60 -97.37 105.02 17.09 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.74 136.67 45.83 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.67 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.72 -27.22 20.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.861 178.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 79.9 p -85.39 162.69 18.92 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.631 0.716 . . . . 0.0 111.262 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -111.21 139.31 46.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.33 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -117.27 132.29 56.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.998 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -101.65 127.14 48.52 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 t -129.32 133.9 64.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.705 0.288 . . . . 0.0 111.539 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.37 174.33 35.53 Favored Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 3.6 pt20 -86.17 121.01 28.17 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.511 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -119.58 126.35 51.0 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.971 0.415 . . . . 0.0 110.9 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.33 166.97 10.55 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.304 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.09 106.25 3.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.707 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.98 -21.03 6.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.474 . . . . 0.0 110.54 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -162.35 176.27 10.71 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.3 m -69.28 95.52 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.023 0.439 . . . . 0.0 110.771 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.34 4.48 59.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.209 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.41 135.22 64.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.989 0.424 . . . . 0.0 110.673 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.1 mp -119.74 173.75 6.84 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.584 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -161.07 134.47 6.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.6 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.798 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.6 m -104.54 168.22 9.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.67 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.658 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 30.8 p-10 -95.8 133.8 24.96 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 121.248 0.547 . . . . 0.0 111.922 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 43.9 Cg_endo -90.24 22.98 0.71 Allowed 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.178 2.586 . . . . 0.0 111.557 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.46 -60.46 1.62 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.166 -179.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 48' ' ' ASN . 27.9 m-20 -99.34 19.3 15.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.443 -178.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.485 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.2 p90 -76.46 159.54 30.33 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -146.43 126.07 13.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.963 0.411 . . . . 0.0 110.991 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.38 126.51 42.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.317 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -122.26 132.08 71.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 13.5 t -96.7 140.72 30.87 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.989 0.423 . . . . 0.0 110.065 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.98 132.75 48.57 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.005 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -178.3 3.33 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.582 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.82 -25.76 63.48 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.8 m-80 -82.8 -15.41 51.79 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.912 0.387 . . . . 0.0 110.836 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.22 28.64 19.63 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.885 -0.674 . . . . 0.0 111.681 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.81 152.41 38.39 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.819 0.342 . . . . 0.0 110.567 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -151.39 130.28 12.49 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.86 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -133.11 122.74 24.53 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.253 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.7 t -135.39 160.87 37.09 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.727 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.4 m -121.07 130.61 53.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.335 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.406 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.5 mm? -116.69 140.76 49.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.829 0.347 . . . . 0.0 111.521 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.0 m -92.98 103.11 15.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.0 p -77.57 109.23 11.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.366 0.603 . . . . 0.0 111.243 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -87.82 171.52 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.569 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -90.36 -25.12 20.6 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.015 0.436 . . . . 0.0 110.567 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -140.58 141.05 35.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.658 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 54.4 p90 -161.36 176.28 11.33 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.841 -0.343 . . . . 0.0 111.227 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 47.9 mt-10 -98.92 124.59 43.96 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.794 178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.71 135.28 13.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.906 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 4.8 m-85 -122.65 142.56 50.53 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.633 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 86.8 mt -75.73 166.49 23.46 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.124 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -65.97 -32.33 73.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.838 0.351 . . . . 0.0 110.705 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.58 -28.02 64.56 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.992 179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 127.19 -20.86 5.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.491 179.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -68.38 138.1 55.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 117.103 0.451 . . . . 0.0 111.162 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 3.1 ptp180 -86.93 149.24 24.94 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.173 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 -103.86 -55.78 2.32 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.951 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 160.39 -172.48 36.81 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.786 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.1 m -82.43 121.29 26.54 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.016 0.436 . . . . 0.0 110.83 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.6 m -105.39 177.56 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.903 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 12.2 t70 -136.18 148.85 48.33 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.799 0.333 . . . . 0.0 111.369 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.504 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 75.2 m -123.65 10.55 9.06 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.408 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 m -75.07 -44.36 48.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.918 0.389 . . . . 0.0 110.553 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.7 t -129.32 22.16 5.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.741 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -129.75 172.8 11.26 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.802 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.22 120.91 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.432 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.2 t -125.27 135.73 52.81 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.838 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.466 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 6.1 pt20 -141.71 171.41 14.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.128 0.489 . . . . 0.0 111.133 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.2 t -95.72 126.0 48.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -111.83 125.67 7.33 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.671 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -135.08 127.65 30.72 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -153.13 161.26 42.66 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -84.59 -169.93 2.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.067 179.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.34 -24.36 66.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.1 -37.0 17.8 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.07 0.462 . . . . 0.0 110.889 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.16 28.45 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.578 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -122.25 -174.65 2.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.17 -167.19 16.51 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.704 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -63.64 154.58 68.25 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.992 2.461 . . . . 0.0 112.113 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -72.2 149.43 44.63 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.857 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.65 153.62 22.16 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.548 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 2.6 t -117.49 148.31 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -87.92 152.26 22.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.45 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -126.86 155.96 37.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.525 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.6 m -131.01 134.03 46.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.506 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 73.0 m-85 -84.96 154.0 22.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.559 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.246 0.909 0 CA-C-O 118.383 -0.818 . . . . 0.0 110.348 179.754 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.798 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.05 107.03 56.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.68 0.276 . . . . 0.0 111.437 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.17 154.93 25.44 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.621 2.214 . . . . 0.0 111.655 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -123.09 91.38 3.47 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.922 0.392 . . . . 0.0 110.638 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.31 89.91 7.83 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.417 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -90.71 91.42 8.38 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.222 0.534 . . . . 0.0 110.618 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 16.6 m -108.21 146.55 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.315 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 m -112.28 97.02 37.84 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-O 120.801 0.334 . . . . 0.0 110.429 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.0 148.58 85.9 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.942 2.428 . . . . 0.0 112.403 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.39 34.37 3.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.248 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.5 m -62.42 116.19 4.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.77 -5.27 46.99 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.13 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.411 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.4 mt -100.96 157.61 16.62 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 122.705 -0.291 . . . . 0.0 110.41 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -78.39 -169.61 1.73 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.392 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.26 161.82 26.07 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.58 13.43 82.53 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.648 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.4 HG21 HD13 ' A' ' 13' ' ' LEU . 36.5 m -88.97 144.39 26.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.594 -0.303 . . . . 0.0 110.303 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 62.0 t -87.82 128.1 40.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.209 -179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.5 t -106.74 115.5 48.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.452 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -85.38 132.55 34.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.936 0.398 . . . . 0.0 111.37 -179.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.4 t -127.72 108.58 18.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.624 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.31 97.98 5.77 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.016 0.436 . . . . 0.0 110.262 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.13 113.12 4.63 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.152 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.44 152.85 26.93 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.88 24.24 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.729 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.6 mt -109.47 -174.16 2.44 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.756 0.312 . . . . 0.0 110.26 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -83.5 122.42 28.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.124 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 136.7 57.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.28 29.78 39.6 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.784 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.9 m -121.87 131.02 53.82 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.681 0.276 . . . . 0.0 111.163 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -88.86 142.29 27.78 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.436 179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -122.03 144.56 48.83 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.594 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.07 104.11 14.25 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 6.2 t -123.93 124.86 69.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.982 0.42 . . . . 0.0 111.302 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.03 178.82 33.23 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -84.32 118.46 24.22 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.217 -0.661 . . . . 0.0 109.217 178.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.8 m -123.62 172.84 8.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.818 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.516 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.12 174.01 12.75 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -77.31 92.9 3.94 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.989 0.423 . . . . 0.0 110.216 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.38 -21.77 12.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.558 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -153.48 179.53 8.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.056 179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.9 m -77.35 90.13 3.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.021 0.439 . . . . 0.0 110.855 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.53 -14.57 53.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.798 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.9 t -105.66 124.38 60.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.025 0.441 . . . . 0.0 110.664 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.8 mt -110.31 157.57 19.34 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.58 150.62 23.32 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.94 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.737 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -129.97 171.9 12.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.59 179.507 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -109.5 121.13 43.3 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.469 0.652 . . . . 0.0 111.186 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 50.3 Cg_endo -70.47 -9.33 25.63 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.823 2.349 . . . . 0.0 112.614 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.62 -28.44 64.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.465 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.39 23.79 8.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.274 0.559 . . . . 0.0 110.729 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.5 ' HB3' ' HA ' ' A' ' 49' ' ' PRO . 0.0 OUTLIER -100.15 157.67 16.41 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.494 179.598 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.9 m -125.28 125.47 43.6 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.219 0.533 . . . . 0.0 111.292 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.09 107.08 13.59 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.509 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.2 p -111.51 140.81 29.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.005 0.431 . . . . 0.0 111.101 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 t -120.15 134.57 55.22 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.649 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.79 130.84 46.65 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.723 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.3 p30 -69.96 -173.06 0.6 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.335 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.75 -7.8 42.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.704 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -98.1 -4.7 35.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.085 0.469 . . . . 0.0 109.841 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.43 32.61 41.89 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.516 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.74 145.64 50.53 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.708 0.289 . . . . 0.0 111.009 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -133.45 118.51 18.46 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.572 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.49 123.22 46.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.401 . . . . 0.0 110.327 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.1 t -143.54 169.97 16.7 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.191 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.471 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 34.7 m -144.8 122.93 12.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.164 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.52 157.81 17.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.997 0.427 . . . . 0.0 111.476 -178.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.3 m -116.35 105.95 13.09 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.4 p -79.16 128.01 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.155 0.502 . . . . 0.0 111.689 -178.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -98.55 175.45 6.01 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.024 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -77.35 -33.12 55.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.151 0.501 . . . . 0.0 109.825 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.4 m -134.61 151.37 51.01 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -160.78 167.81 26.04 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.192 0.52 . . . . 0.0 111.716 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -81.59 154.49 26.16 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.345 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.83 108.46 2.29 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.801 -0.714 . . . . 0.0 111.477 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.439 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 31.4 m-85 -122.87 145.67 48.24 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.588 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 72.3 mt -83.56 178.22 8.08 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.941 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -76.47 -14.19 60.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.958 0.409 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -17.16 30.13 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.43 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.0 -6.21 30.79 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.627 179.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 24.9 m -81.87 138.42 35.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 117.315 0.558 . . . . 0.0 110.551 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.499 ' NH2' ' HA2' ' A' ' 84' ' ' GLY . 4.7 ptm180 -85.39 139.49 31.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.958 0.409 . . . . 0.0 110.933 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 30.5 t-105 -104.66 -19.48 13.95 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.91 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.499 ' HA2' ' NH2' ' A' ' 82' ' ' ARG . . . 144.54 -153.45 25.14 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.239 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -112.4 138.05 49.7 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.637 0.256 . . . . 0.0 110.592 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.516 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.4 t -116.6 151.31 18.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -137.56 137.98 39.13 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.006 0.431 . . . . 0.0 111.156 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 94.8 m -118.04 25.93 10.0 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.775 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.26 -34.69 36.85 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.9 t -120.24 9.3 11.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.739 179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.94 168.19 20.06 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.258 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.39 143.36 26.7 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 120.893 0.378 . . . . 0.0 110.852 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -102.48 163.69 12.08 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -147.17 156.97 43.43 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.234 0.54 . . . . 0.0 111.466 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -88.89 121.96 39.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.253 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.47 109.15 3.55 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.842 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.38 116.35 23.86 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.655 0.264 . . . . 0.0 110.503 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.2 m -153.27 163.19 40.35 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.367 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -97.55 -162.33 0.95 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.046 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.66 81.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.702 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.64 -47.28 17.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.862 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.17 31.98 0.88 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.512 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -121.52 -172.84 2.5 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.534 0.207 . . . . 0.0 110.544 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.83 -149.84 17.11 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.005 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.9 156.06 56.97 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.5 2.134 . . . . 0.0 111.875 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -74.55 153.02 39.23 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.701 0.286 . . . . 0.0 110.68 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.94 150.0 45.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.88 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.6 t -119.31 123.48 71.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.44 135.91 33.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.552 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -129.0 151.48 35.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.517 -179.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 62.1 m -129.4 140.98 51.16 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.289 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -81.76 166.5 20.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.372 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.322 -0.847 . . . . 0.0 110.406 179.678 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.737 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 CA-C-O 120.654 0.264 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.98 122.43 87.45 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.438 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -90.17 -169.31 0.34 Allowed 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.983 2.455 . . . . 0.0 112.043 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.897 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.9 m -134.73 86.91 2.3 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.092 0.473 . . . . 0.0 110.277 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.71 68.88 9.56 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.175 0.512 . . . . 0.0 110.513 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.42 103.21 8.22 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.519 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 m -122.91 146.26 28.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.845 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -113.15 95.43 34.9 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.391 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -69.5 148.59 67.08 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 123.036 2.491 . . . . 0.0 112.458 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 m -95.42 39.67 1.12 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.29 0.567 . . . . 0.0 110.03 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.0 m -63.13 109.88 1.66 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.11 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.89 1.92 56.15 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.618 -0.801 . . . . 0.0 113.164 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.83 -172.86 2.38 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 122.683 -0.304 . . . . 0.0 110.358 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -107.47 179.33 4.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.693 0.282 . . . . 0.0 110.456 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -73.85 153.41 39.91 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.05 -6.94 66.9 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 69' ' ' VAL . 87.0 m -72.05 148.81 45.46 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.022 0.439 . . . . 0.0 110.954 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 t -95.53 118.04 40.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.047 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.9 t -88.01 121.34 38.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.664 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -89.67 124.79 34.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.944 0.402 . . . . 0.0 110.713 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.2 t -124.58 107.29 18.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.923 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.06 95.6 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.121 0.486 . . . . 0.0 110.101 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.63 119.86 6.1 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.446 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.897 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -113.73 150.95 32.61 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.55 24.41 50.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.424 -0.893 . . . . 0.0 110.912 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.447 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 90.8 mt -92.59 -163.31 1.03 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.155 -0.522 . . . . 0.0 110.404 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.1 tp60 -101.46 110.56 22.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.741 0.305 . . . . 0.0 110.542 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.5 135.26 57.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.439 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.35 -8.93 74.98 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.617 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 m -97.43 136.31 38.06 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.776 0.322 . . . . 0.0 110.968 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.33 128.71 35.91 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.415 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.447 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.1 m-85 -108.58 128.33 54.73 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.46 121.89 38.76 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -127.13 131.27 70.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 120.903 0.382 . . . . 0.0 111.409 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.31 179.75 26.78 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -86.97 53.89 2.99 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 117.646 0.723 . . . . 0.0 109.685 179.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.682 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.3 m -67.74 102.8 1.27 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.705 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -102.02 167.18 10.2 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.893 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -57.82 112.85 1.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.854 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.411 ' H ' ' HA ' ' A' ' 45' ' ' LEU . 1.6 p -99.15 -19.01 6.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.798 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -165.63 -178.0 4.65 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.8 m -69.19 100.35 1.28 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.144 0.497 . . . . 0.0 111.064 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.55 5.29 78.96 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.759 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 17.4 t -129.46 138.14 55.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.021 0.438 . . . . 0.0 110.807 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 40' ' ' VAL . 3.9 mp -120.26 171.87 8.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.682 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.07 130.77 20.17 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 121.003 -0.279 . . . . 0.0 111.237 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.633 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 87.3 m -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.076 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 22.8 p-10 -105.92 118.99 53.79 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.927 0.394 . . . . 0.0 110.994 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 68.3 Cg_endo -86.01 46.4 1.64 Allowed 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.975 2.45 . . . . 0.0 112.152 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.7 -66.04 0.34 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.274 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.438 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 7.8 m-20 -91.02 22.12 3.86 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.625 -179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 22.8 p90 -84.09 156.48 22.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.5 m -146.06 97.34 2.94 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.996 0.427 . . . . 0.0 110.759 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -66.7 134.9 53.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.586 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -128.62 133.64 66.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-O 121.081 0.467 . . . . 0.0 110.342 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 17.3 m -99.34 129.95 45.58 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.201 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.4 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -60.59 133.41 56.07 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -76.65 -178.73 4.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.666 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.17 -15.87 60.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.055 0.455 . . . . 0.0 111.398 -179.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -85.99 -8.94 57.62 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.015 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.33 31.09 35.05 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.955 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.88 147.72 50.46 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.829 0.347 . . . . 0.0 110.84 -179.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -144.04 115.08 7.87 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.65 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -113.35 130.33 56.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.723 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.9 t -137.37 164.73 27.92 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.602 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.06 114.53 17.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.073 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -105.65 142.14 35.89 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.737 0.303 . . . . 0.0 111.558 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.98 105.08 16.73 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 17' ' ' THR . 7.2 p -78.15 115.04 19.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.488 0.661 . . . . 0.0 111.481 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 39.3 mmt180 -93.84 166.59 12.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.651 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -80.79 -22.81 39.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.494 0.664 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -144.42 124.97 13.99 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.432 178.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -137.29 157.8 45.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.982 0.42 . . . . 0.0 110.921 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.42 114.74 20.38 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.639 178.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.88 122.42 7.6 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.463 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -128.24 138.52 52.48 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.528 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 33.1 mt -75.16 158.7 32.61 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 0.6 OUTLIER -62.79 -20.85 65.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.799 0.333 . . . . 0.0 111.645 -178.535 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.09 -26.48 33.6 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.496 179.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.33 -8.23 7.93 Favored Glycine 0 CA--C 1.522 0.484 0 C-N-CA 120.693 -0.765 . . . . 0.0 113.314 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.438 ' HB ' HD12 ' A' ' 77' ' ' LEU . 7.6 m -70.06 132.98 46.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.027 0.442 . . . . 0.0 111.394 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -85.12 130.09 34.68 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.099 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.7 t-105 -99.2 -69.17 0.77 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.854 0.359 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 178.78 176.51 46.7 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.735 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -79.69 119.8 23.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.76 0.314 . . . . 0.0 110.653 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -92.43 128.77 43.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.543 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -98.09 112.63 24.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.888 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.0 m -98.0 19.54 13.79 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.044 0.449 . . . . 0.0 110.196 179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.65 -43.5 10.7 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -101.26 0.43 37.35 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.783 179.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.89 -174.83 3.54 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.771 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.24 139.76 48.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.824 0.345 . . . . 0.0 110.425 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -88.47 161.24 17.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.028 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.476 ' HB2' ' HA ' ' A' ' 38' ' ' ALA . 26.1 mt-30 -138.88 159.49 42.0 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.4 t -98.81 124.45 52.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.968 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.58 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -109.85 116.67 4.55 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.15 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.39 124.36 28.55 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.709 0.29 . . . . 0.0 110.75 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 53.8 m -152.94 161.12 42.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.429 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -77.83 -166.43 0.79 Allowed 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 178.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.35 -32.0 73.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.637 0.256 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.76 -55.9 4.95 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.692 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.46 22.0 0.19 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.963 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.21 168.03 12.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.37 -148.71 20.09 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.531 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -67.98 172.16 11.26 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.923 2.415 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -80.51 148.72 30.3 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.306 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.72 140.38 19.46 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.8 t -111.84 143.18 22.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.537 0.169 . . . . 0.0 110.751 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.06 143.54 26.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.317 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -134.12 116.69 23.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.311 0.577 . . . . 0.0 111.005 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -102.29 142.64 33.2 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.272 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.3 m-85 -89.25 163.11 15.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.969 0.414 . . . . 0.0 111.115 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.3 p30 . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.681 -0.676 . . . . 0.0 110.261 -179.89 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.633 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.874 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.34 110.39 64.3 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.848 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -69.15 154.51 70.02 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.101 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.64 85.61 2.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.163 0.506 . . . . 0.0 110.418 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.75 102.91 14.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.377 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 119.02 34.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.185 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.424 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 2.8 m -127.29 135.06 64.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 120.882 0.373 . . . . 0.0 110.804 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.7 m -100.0 101.4 14.07 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.077 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 66.9 Cg_endo -77.29 136.76 16.27 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.412 2.075 . . . . 0.0 112.396 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.2 m -91.51 41.23 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.34 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.41 108.52 1.65 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.442 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.11 1.13 44.88 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.375 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 58.7 mt -103.11 157.54 16.92 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 121.144 -0.223 . . . . 0.0 110.416 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 m -81.66 -170.14 2.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.096 0.474 . . . . 0.0 111.702 -179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -75.34 164.35 26.51 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.843 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 79.87 11.51 84.49 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.795 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -87.54 144.6 26.62 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.806 0.336 . . . . 0.0 110.375 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.456 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.8 t -94.97 116.25 35.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.928 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.0 t -89.02 125.43 42.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.712 179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.3 ttmt -97.03 121.69 39.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.9 0.381 . . . . 0.0 111.129 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' SER . 94.5 t -115.96 125.41 73.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.761 179.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.09 95.0 3.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.925 0.393 . . . . 0.0 111.033 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.47 109.31 3.81 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.583 -0.818 . . . . 0.0 111.926 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.85 151.31 23.98 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.927 0.394 . . . . 0.0 111.123 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.11 33.61 62.09 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.988 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 81.8 mt -98.04 -174.08 2.77 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -83.68 106.48 15.43 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.03 0.443 . . . . 0.0 110.631 -179.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.66 138.75 58.04 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.718 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.33 21.89 55.6 Favored Glycine 0 N--CA 1.451 -0.366 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.768 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.4 m -121.22 140.33 52.18 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.842 0.321 . . . . 0.0 110.469 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.23 123.57 32.98 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.398 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -107.08 133.2 52.06 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.137 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -100.06 108.22 20.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.593 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 22.6 t -123.74 120.27 59.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.837 -179.081 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.98 168.9 30.07 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.35 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.425 ' NE2' ' HB2' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -80.2 130.81 35.49 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.44 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -140.03 179.97 6.3 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.776 -177.751 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.545 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.57 179.43 4.32 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.272 178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -76.93 101.41 5.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.727 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.1 p -76.39 -22.55 15.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.466 0.651 . . . . 0.0 109.984 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -155.3 167.98 28.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.449 -0.796 . . . . 0.0 108.881 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -70.27 81.49 0.53 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.302 0.572 . . . . 0.0 110.89 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 126.61 -24.25 5.55 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.44 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.77 135.57 42.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.106 0.479 . . . . 0.0 110.889 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.82 154.45 30.71 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 37' ' ' CYS . . . -150.98 142.42 23.44 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.426 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 81.4 m -101.83 -179.54 4.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.437 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.578 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 7.7 t-20 -102.59 127.31 30.6 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.726 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.519 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 85.2 Cg_endo -80.74 -4.98 13.07 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.774 2.316 . . . . 0.0 112.241 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.23 -66.72 0.89 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.087 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.86 72.87 10.07 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.291 0.567 . . . . 0.0 110.68 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -131.22 161.39 32.34 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.239 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.0 m -140.1 106.94 5.39 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.296 0.57 . . . . 0.0 111.285 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.03 112.69 15.22 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.199 178.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -117.82 129.93 73.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.224 0.535 . . . . 0.0 110.955 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.7 t -101.44 144.74 29.86 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.757 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.65 130.74 41.93 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -79.81 -174.7 4.5 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.454 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.13 -31.79 67.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.781 0.324 . . . . 0.0 111.732 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 -76.63 -9.96 59.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.933 0.397 . . . . 0.0 110.759 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.43 28.84 51.4 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.118 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.12 140.85 46.46 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.004 0.43 . . . . 0.0 110.73 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.14 101.62 5.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.341 179.369 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -116.46 140.46 49.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.302 179.828 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.7 t -156.15 -179.28 8.0 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.456 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 11.2 m -137.81 133.36 33.9 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.31 -179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.9 mm? -122.7 137.66 54.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.701 0.286 . . . . 0.0 111.643 -178.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.34 110.63 22.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 178.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -76.26 129.19 37.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.553 0.692 . . . . 0.0 111.421 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -105.88 -173.41 2.29 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.956 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -110.17 -42.82 4.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.965 0.412 . . . . 0.0 110.046 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -127.45 123.65 36.54 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 41.8 p90 -150.9 164.07 37.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.04 0.448 . . . . 0.0 111.85 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.96 138.59 44.29 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.514 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -96.84 118.1 5.95 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.485 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.471 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 8.0 m-85 -127.02 139.21 53.19 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.504 HD12 ' HB ' ' A' ' 81' ' ' THR . 50.4 mt -75.18 167.91 21.01 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -65.75 -23.66 66.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.662 0.268 . . . . 0.0 111.083 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.27 -20.96 36.49 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.838 0.352 . . . . 0.0 110.866 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.72 -12.31 10.95 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.707 -0.759 . . . . 0.0 113.582 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 77' ' ' LEU . 18.2 m -71.58 128.35 35.54 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 117.022 0.411 . . . . 0.0 111.116 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -84.47 142.97 29.69 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 178.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.4 ' HB3' HG21 ' A' ' 40' ' ' VAL . 16.3 t-105 -109.43 -31.16 7.63 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.911 0.386 . . . . 0.0 110.473 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.01 -140.66 7.16 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.039 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 57.0 m -115.74 127.39 55.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.934 0.397 . . . . 0.0 111.269 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.545 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.8 t -103.2 142.9 16.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -138.32 131.75 30.53 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.819 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 92.1 m -118.71 40.36 3.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.043 0.449 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -85.24 -39.11 18.14 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.374 178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -109.43 5.06 23.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.151 0.5 . . . . 0.0 110.314 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.06 179.68 6.3 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.019 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 150.24 24.0 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.609 0.242 . . . . 0.0 110.705 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -99.13 171.88 7.73 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.181 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -132.7 169.27 16.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.075 0.464 . . . . 0.0 110.892 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.6 t -111.65 116.07 51.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -92.39 114.49 4.61 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.209 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.428 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -129.44 108.59 10.39 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -140.61 155.16 46.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.74 0.305 . . . . 0.0 111.097 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.64 -168.57 2.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.636 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.08 -31.14 72.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.581 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.08 -53.36 5.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.968 0.413 . . . . 0.0 110.674 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.63 37.59 0.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.731 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -132.71 -168.96 2.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.17 -150.21 18.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.106 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.428 ' HG2' HD13 ' A' ' 97' ' ' LEU . 37.5 Cg_endo -68.21 168.8 18.25 Favored 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 122.666 2.244 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -74.75 154.13 38.51 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.54 130.59 13.44 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.988 -0.625 . . . . 0.0 111.68 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 9.4 t -104.62 136.05 39.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 O-C-N 122.821 -0.223 . . . . 0.0 110.566 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -103.34 140.12 37.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.239 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.5 pt -130.21 128.28 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.297 0.57 . . . . 0.0 111.002 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -108.31 145.84 33.82 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.074 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.8 m-85 -94.05 175.8 6.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.015 0.436 . . . . 0.0 110.651 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.8 p30 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.586 -0.721 . . . . 0.0 109.897 179.157 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.816 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.809 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.42 106.17 37.7 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.112 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.73 164.29 35.12 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.632 2.221 . . . . 0.0 112.343 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.81 98.8 6.54 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.341 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.99 110.92 22.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.751 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -113.75 84.33 2.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.885 0.374 . . . . 0.0 111.235 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -111.51 144.11 20.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.1 m -116.83 101.84 53.33 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.59 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -71.05 144.38 47.04 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.84 2.36 . . . . 0.0 112.577 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.8 m -89.17 52.29 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.014 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -70.78 110.02 5.32 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.178 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.03 -10.39 47.81 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.561 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.485 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 38.9 mt -94.28 149.14 21.52 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -77.84 -179.02 5.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.07 0.462 . . . . 0.0 111.648 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -71.31 158.6 36.08 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.137 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.17 -4.62 74.48 Favored Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 -178.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.48 HG21 HD13 ' A' ' 13' ' ' LEU . 33.3 m -81.95 144.13 31.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.469 -0.366 . . . . 0.0 110.834 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.72 116.98 37.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.012 0.434 . . . . 0.0 110.915 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG11 HG21 ' A' ' 95' ' ' VAL . 11.8 t -78.92 137.49 21.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.242 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.1 ttmt -93.55 116.17 28.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 64' ' ' SER . 88.1 t -118.45 116.42 51.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.005 179.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.47 108.57 8.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.308 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.74 123.02 6.24 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.059 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.87 138.78 54.56 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.782 0.325 . . . . 0.0 110.334 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.79 15.06 21.63 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 19.8 mt -91.14 171.44 9.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -75.34 115.48 15.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.071 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.87 140.63 55.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 111.821 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.26 -27.71 15.92 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.84 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.28 138.99 43.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.59 0.233 . . . . 0.0 111.071 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.95 126.79 39.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.338 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -110.42 129.12 55.83 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -95.22 129.25 42.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.683 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.711 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.9 t -126.87 137.0 59.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.088 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.63 178.58 39.77 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -85.41 75.46 10.21 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.394 0.616 . . . . 0.0 109.904 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.9 m -80.39 106.88 12.73 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.139 -179.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 45' ' ' LEU . . . -113.18 177.33 4.67 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.32 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -67.84 109.97 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.019 0.438 . . . . 0.0 111.161 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.0 p -102.73 -15.0 8.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.246 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.0 t70 -156.39 -164.7 1.73 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.418 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.06 94.04 2.34 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.481 . . . . 0.0 111.115 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.48 10.4 86.27 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.044 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.463 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 25.1 t -109.34 121.47 62.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 110.237 -0.282 . . . . 0.0 110.237 -179.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.472 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.6 mp -110.27 137.48 47.94 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.721 179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -141.66 150.76 42.33 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.526 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -122.09 155.06 36.48 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.665 0.269 . . . . 0.0 110.996 -178.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.489 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 18.8 p-10 -85.54 134.7 39.57 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.024 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 51.6 Cg_endo -85.76 -1.12 8.83 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.499 2.133 . . . . 0.0 111.928 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.58 60.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.09 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -122.45 12.3 10.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.968 0.413 . . . . 0.0 111.271 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.489 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -79.77 158.49 26.85 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.368 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.4 m -145.2 103.61 3.87 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -77.35 144.61 37.86 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.442 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.28 128.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.168 0.509 . . . . 0.0 110.334 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.2 t -86.19 137.96 32.25 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.401 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.12 124.3 22.24 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.229 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -69.8 -179.04 1.68 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.3 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.64 -9.32 53.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.186 -178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 -95.17 -6.8 40.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.58 28.42 32.62 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.119 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.51 156.07 34.9 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.957 0.408 . . . . 0.0 111.586 -179.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -150.68 122.91 8.33 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 9.5 t -135.82 144.07 45.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.048 0.452 . . . . 0.0 111.244 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -164.2 166.62 20.93 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.467 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.8 m -114.58 135.22 54.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.52 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -117.51 124.89 49.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.168 -179.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.95 100.15 11.92 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.984 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.95 125.29 32.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.273 0.558 . . . . 0.0 111.276 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -98.75 168.62 10.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.549 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.0 tpp180 -80.89 -37.45 29.71 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.785 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -131.8 131.0 42.52 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.562 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -148.62 170.79 17.33 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -104.5 125.81 51.02 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.52 123.96 8.53 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.384 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 12.4 m-85 -127.26 149.1 50.17 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.494 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 43.8 mt -89.46 179.76 5.99 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -77.06 -2.52 34.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.726 0.298 . . . . 0.0 111.762 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.494 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 24.7 p-10 -103.62 -12.28 17.16 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.773 0.321 . . . . 0.0 110.651 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.74 -0.46 36.43 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.304 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.2 m -74.38 135.9 42.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.867 0.365 . . . . 0.0 111.001 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -96.57 140.34 31.34 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.549 ' HB3' HG21 ' A' ' 40' ' ' VAL . 6.0 t-105 -108.97 -38.5 5.56 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.738 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.01 174.39 30.81 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.057 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.58 121.48 29.17 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.053 0.454 . . . . 0.0 111.551 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 62.6 t -101.92 128.53 54.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -117.94 125.4 50.37 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.876 0.369 . . . . 0.0 111.015 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 81.4 m -104.15 27.93 7.27 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -79.65 -32.96 41.64 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.236 -0.654 . . . . 0.0 109.236 178.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -115.39 15.56 16.8 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.185 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -152.15 -166.63 2.54 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.77 145.4 44.53 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.928 0.394 . . . . 0.0 111.231 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -91.67 169.09 11.01 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.534 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' A' ' 37' ' ' CYS . 43.5 mt-30 -134.41 160.13 38.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.783 0.325 . . . . 0.0 110.629 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.423 HG21 HG11 ' A' ' 19' ' ' VAL . 22.0 t -110.54 123.66 66.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -126.32 138.31 10.64 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.905 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.711 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -140.02 125.26 18.8 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.318 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.0 m -156.92 169.15 25.45 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.035 0.445 . . . . 0.0 110.785 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -94.7 -167.94 1.74 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.17 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.37 -28.62 69.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.509 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.22 -0.11 43.73 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.979 0.419 . . . . 0.0 110.759 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 69.22 33.05 72.91 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.896 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -124.2 158.74 31.72 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.733 0.301 . . . . 0.0 110.72 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 151.71 -165.3 30.54 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 121.086 -0.578 . . . . 0.0 111.879 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 97' ' ' LEU . 49.5 Cg_exo -57.52 156.43 26.68 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 123.016 2.477 . . . . 0.0 112.603 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -68.36 144.36 54.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.617 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.3 144.05 32.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.196 -0.526 . . . . 0.0 112.559 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.79 134.73 55.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.473 0.178 . . . . 0.0 110.529 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -91.45 144.94 25.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.568 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -132.34 127.91 57.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.351 0.596 . . . . 0.0 111.382 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -104.19 137.94 41.39 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.292 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.485 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 24.2 m-85 -82.99 164.49 20.35 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.0 p30 . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.703 -0.665 . . . . 0.0 110.489 179.572 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.495 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.991 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.27 117.65 63.68 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.4 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -83.14 -171.12 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.423 2.082 . . . . 0.0 112.088 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.6 m -123.49 99.92 6.56 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.53 86.46 5.22 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.35 0.595 . . . . 0.0 110.673 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.03 93.72 8.9 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.697 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.2 m -116.19 136.39 53.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.228 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -110.84 96.01 26.83 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.926 178.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -78.89 149.41 22.92 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.636 2.224 . . . . 0.0 113.006 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.82 48.57 1.66 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.096 0.474 . . . . 0.0 110.746 179.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -66.22 110.83 3.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.23 -11.17 65.57 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.562 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.474 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 38.0 mt -85.62 158.14 20.17 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.7 m -75.63 175.83 8.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.7 0.286 . . . . 0.0 111.168 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -72.4 157.65 37.25 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.0 -14.89 63.97 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.456 ' O ' HG12 ' A' ' 69' ' ' VAL . 23.9 m -66.93 147.14 53.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.006 0.431 . . . . 0.0 110.761 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 HG23 ' A' ' 68' ' ' THR . 1.7 t -99.6 118.07 45.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.75 -179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 66' ' ' SER . 39.2 t -80.62 133.31 29.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.214 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -99.35 123.17 43.41 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.068 0.461 . . . . 0.0 111.008 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.3 t -122.29 116.49 49.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.436 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.01 98.36 5.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.0 0.429 . . . . 0.0 110.901 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.0 115.11 5.15 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.128 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 135.41 51.49 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.32 31.81 8.17 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.163 -179.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.5 mt -98.96 -173.32 2.48 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -81.95 108.88 15.8 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.88 138.76 58.38 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.76 0.314 . . . . 0.0 111.615 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.97 7.4 74.2 Favored Glycine 0 CA--C 1.517 0.216 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.973 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -110.13 147.47 33.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.76 0.314 . . . . 0.0 110.901 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.64 134.46 40.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.113 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -115.27 120.36 39.41 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.908 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -89.68 109.49 20.45 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.2 t -119.82 123.59 71.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.78 176.25 26.71 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.438 -0.886 . . . . 0.0 111.679 178.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -83.48 126.6 32.94 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.37 169.68 16.17 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.029 -178.662 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.638 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.0 173.35 9.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.039 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 33.1 m95 -74.1 122.77 23.23 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 p -106.93 -28.11 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.667 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.486 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 25.5 t0 -147.66 175.11 11.15 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.78 99.89 0.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.947 0.403 . . . . 0.0 111.532 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.66 10.53 83.14 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.563 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 10.5 t -122.19 126.97 75.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.095 0.474 . . . . 0.0 111.077 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -112.38 169.65 8.73 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.481 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -161.04 139.48 9.81 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 121.035 -0.266 . . . . 0.0 111.212 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.855 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 59.7 m -102.39 161.46 13.69 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.149 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.577 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 25.6 t-20 -93.4 118.45 67.61 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.176 178.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -89.05 27.4 0.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.162 2.574 . . . . 0.0 112.886 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -113.05 -50.09 2.89 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.783 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.7 24.37 10.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -87.1 168.75 12.99 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.781 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -154.3 101.23 2.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.822 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.46 123.84 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.65 135.51 48.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 120.868 0.366 . . . . 0.0 110.538 -179.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.9 t -93.94 139.77 30.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.947 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.88 126.46 30.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.669 -0.241 . . . . 0.0 110.406 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -71.39 -177.56 1.83 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.498 -179.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.07 -13.6 62.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.741 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -87.61 -28.42 21.91 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.29 30.33 5.69 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.26 157.02 30.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.783 0.325 . . . . 0.0 110.981 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.06 117.46 6.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.488 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.44 129.84 54.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.749 0.309 . . . . 0.0 110.632 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.3 t -149.92 157.68 43.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.398 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 1.1 m -128.89 123.07 31.7 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.72 131.74 55.1 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -177.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.469 HG23 HG22 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -81.96 110.33 17.12 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -85.86 114.93 26.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.555 0.693 . . . . 0.0 112.209 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -92.75 163.2 13.83 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.7 ttt180 -82.95 -39.43 21.42 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.86 0.362 . . . . 0.0 110.622 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.0 m -122.23 132.59 54.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.0 p90 -159.75 166.15 31.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.958 0.408 . . . . 0.0 112.02 -178.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -83.7 140.78 31.92 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.416 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -103.14 131.41 10.61 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.071 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.481 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.98 143.58 51.04 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.423 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 39.6 mt -78.88 171.74 14.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -67.35 -29.26 68.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.881 0.372 . . . . 0.0 110.497 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -70.94 -25.33 62.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.646 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.68 -17.78 9.38 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.457 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -73.71 134.5 43.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.919 0.39 . . . . 0.0 111.395 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.6 141.3 35.17 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.026 178.595 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 31.8 t-105 -101.6 -30.84 11.14 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.349 -0.54 . . . . 0.0 109.914 179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.57 -148.21 18.1 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.728 -0.748 . . . . 0.0 111.598 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -108.22 135.97 48.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.65 0.262 . . . . 0.0 110.755 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.638 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.7 t -114.84 139.02 43.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -128.91 132.55 47.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.826 0.346 . . . . 0.0 111.347 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 53.0 m -117.08 37.44 3.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.469 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.567 ' HA ' ' NE ' ' A' ' 71' ' ' ARG . 9.3 m -80.8 -50.8 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -102.72 9.25 39.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.219 0.533 . . . . 0.0 110.21 179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -136.64 -177.69 4.85 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.654 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.7 152.29 26.73 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.006 0.431 . . . . 0.0 111.458 -179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -107.48 166.66 10.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.425 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -135.28 152.77 51.82 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.257 0.551 . . . . 0.0 111.213 179.433 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 5.1 t -85.78 115.53 27.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.042 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.578 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.34 96.69 1.95 Allowed Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.16 -179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.416 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -113.46 102.05 9.94 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.804 0.335 . . . . 0.0 110.347 -179.823 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.6 m -136.99 159.49 41.74 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.853 0.358 . . . . 0.0 110.873 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -86.03 -171.46 3.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.336 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.91 72.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.28 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.25 -49.37 17.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.857 0.36 . . . . 0.0 110.36 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.13 27.62 0.76 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.988 179.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -130.45 179.97 5.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.56 -141.63 12.21 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.89 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.416 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.4 Cg_exo -69.45 161.71 44.82 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.755 2.303 . . . . 0.0 111.833 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -82.27 133.97 35.26 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.844 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -61.92 147.8 48.35 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.218 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 19.8 t -119.74 135.05 61.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.448 0.166 . . . . 0.0 110.718 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.52 135.86 33.36 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.811 0.339 . . . . 0.0 110.651 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.7 pt -127.83 137.4 57.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.74 147.56 43.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.092 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.7 m-85 -95.26 161.89 13.91 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.249 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.669 -0.681 . . . . 0.0 110.374 -179.886 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.855 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.984 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.6 118.45 72.5 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.682 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.06 177.17 9.11 Favored 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.757 2.305 . . . . 0.0 112.01 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 m -117.9 112.7 20.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.016 0.436 . . . . 0.0 110.594 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.87 113.74 27.44 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.244 -179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.87 96.26 5.18 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.462 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.3 m -116.65 148.75 19.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.911 0.386 . . . . 0.0 110.689 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 19.7 m -110.89 106.09 57.45 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.41 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -73.9 148.03 40.03 Favored 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.455 2.103 . . . . 0.0 112.542 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.536 ' HA ' HD12 ' A' ' 13' ' ' LEU . 3.0 m -105.87 26.82 9.17 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.699 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -65.67 118.14 9.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.105 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.09 14.69 47.79 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.143 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 10' ' ' SER . 68.0 mt -118.93 168.32 10.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.688 0.28 . . . . 0.0 110.677 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.39 -176.67 5.36 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.298 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -81.09 158.52 25.01 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.54 6.29 88.73 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.145 -179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.9 m -71.12 141.07 50.79 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.877 0.37 . . . . 0.0 110.665 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.6 t -77.76 108.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.338 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.6 104.21 13.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -83.85 121.52 27.44 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.226 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.3 t -123.91 117.63 51.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.9 179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.8 118.22 18.74 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.787 0.327 . . . . 0.0 110.774 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -115.93 133.69 11.0 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.188 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.44 147.38 45.83 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.44 34.97 15.16 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.421 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.416 HD13 ' CE2' ' A' ' 32' ' ' TYR . 23.1 mt -107.23 176.03 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -72.73 110.94 7.44 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.639 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.65 120.15 11.87 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.12 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 11.75 25.83 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.472 -0.87 . . . . 0.0 113.424 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.7 p -106.89 174.23 5.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.031 0.415 . . . . 0.0 110.774 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -120.0 125.25 47.91 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.583 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.416 ' CE2' HD13 ' A' ' 26' ' ' LEU . 1.3 m-85 -104.11 120.21 40.61 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.875 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -85.75 110.96 19.7 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.435 HG22 ' HB2' ' A' ' 97' ' ' LEU . 16.3 t -112.95 125.45 70.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.969 -179.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.86 151.11 23.38 Favored Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.912 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.425 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -82.13 62.69 5.99 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.723 0.773 . . . . 0.0 109.777 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -69.93 112.41 6.32 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.928 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.83 166.99 11.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.175 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -62.41 119.16 8.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.78 0.324 . . . . 0.0 110.609 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.89 -16.08 9.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.103 0.478 . . . . 0.0 110.172 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.8 t70 -163.18 -176.0 4.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -75.34 91.96 2.75 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.116 0.484 . . . . 0.0 110.594 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.13 -16.5 58.16 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.591 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.431 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -98.5 132.85 42.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -112.74 167.99 10.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -154.79 132.06 11.09 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.714 0.293 . . . . 0.0 110.989 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.464 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -123.05 163.9 19.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.866 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 19.4 p-10 -98.36 126.13 40.72 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 121.166 0.508 . . . . 0.0 110.973 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.88 -7.99 22.47 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.829 2.353 . . . . 0.0 112.664 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -10.24 58.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.691 0.282 . . . . 0.0 111.223 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.449 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.5 OUTLIER -128.03 -4.59 5.65 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.693 0.282 . . . . 0.0 111.401 179.719 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.4 159.37 27.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.355 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.3 m -143.51 110.51 5.66 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.887 0.375 . . . . 0.0 110.202 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.67 87.47 7.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.006 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -79.14 131.75 33.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.296 0.569 . . . . 0.0 111.111 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.4 t -91.12 146.47 23.81 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.553 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.18 126.74 31.49 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.842 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -71.32 -178.53 2.11 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.533 0.521 . . . . 0.0 111.225 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.6 -14.39 62.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.79 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -90.24 -9.0 49.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.032 0.444 . . . . 0.0 110.32 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.36 32.57 25.02 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.719 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.17 152.66 44.18 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.959 0.409 . . . . 0.0 110.896 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.91 10.37 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.476 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.9 m -128.77 136.85 51.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.769 0.319 . . . . 0.0 110.565 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -148.47 166.76 27.21 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 m -125.82 112.43 16.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.089 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -96.66 140.59 31.03 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.103 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 m -102.18 108.81 20.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.921 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.29 121.15 35.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.439 0.638 . . . . 0.0 111.498 -179.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.9 mmt180 -91.59 164.96 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.291 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -82.31 -48.9 10.64 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.189 0.518 . . . . 0.0 109.628 179.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 m -131.12 119.52 22.04 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -143.84 -177.96 5.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.878 0.37 . . . . 0.0 111.238 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.493 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -94.47 137.62 33.39 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.182 179.638 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.4 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -101.43 129.12 9.79 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.064 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -118.4 153.55 33.88 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.571 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 55.2 mt -77.55 170.89 15.78 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.747 0.308 . . . . 0.0 110.492 179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.32 -31.95 71.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.012 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -21.95 39.93 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.262 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 120.51 -11.64 10.39 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.35 -0.928 . . . . 0.0 113.262 179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.8 m -68.48 124.96 25.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.236 0.518 . . . . 0.0 110.796 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -69.75 128.73 37.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.352 . . . . 0.0 110.678 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 67.1 t-105 -91.5 -46.55 7.92 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.1 0.476 . . . . 0.0 109.964 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 159.84 175.08 30.41 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.433 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.2 OUTLIER -76.69 138.0 39.74 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 120.84 0.352 . . . . 0.0 110.695 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.0 m -118.69 168.55 10.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.167 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 31.9 t70 -138.6 130.4 27.91 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.086 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.414 ' HB3' ' HB2' ' A' ' 93' ' ' CYS . 94.1 m -104.87 14.47 29.47 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.155 179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -86.22 -56.44 3.45 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.7 t -92.42 -9.93 39.83 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.25 0.548 . . . . 0.0 110.451 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -118.69 -173.14 2.42 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.666 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.27 171.11 10.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.961 0.41 . . . . 0.0 110.964 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.414 ' HB2' ' HB3' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -147.57 150.09 33.8 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.559 179.849 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.2 OUTLIER -155.07 177.4 11.37 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.703 0.287 . . . . 0.0 110.645 -179.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.3 p -139.54 139.54 38.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.031 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.64 162.0 28.01 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.559 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB2' HG22 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.27 145.18 31.16 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.759 0.314 . . . . 0.0 110.285 179.444 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 m -150.92 152.25 33.36 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.906 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.37 -174.68 1.7 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.692 0.282 . . . . 0.0 110.725 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.79 -34.2 62.37 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.987 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.42 -40.96 28.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.653 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.46 29.62 1.41 Allowed Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.862 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -120.23 -176.06 3.13 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.97 -150.97 19.22 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.176 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -69.53 164.43 34.33 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.494 2.129 . . . . 0.0 111.874 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -78.34 149.03 33.51 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.669 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -62.39 149.77 47.84 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.696 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.07 125.76 74.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-O 120.643 0.258 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.78 141.21 28.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.502 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.9 pt -131.95 179.99 3.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.064 0.459 . . . . 0.0 110.809 -179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.3 m -154.58 154.07 32.44 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 55.2 m-85 -92.45 170.6 9.63 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.3 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.022 -179.918 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.571 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.941 0.401 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.2 111.39 56.35 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.053 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.82 175.44 11.16 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.643 2.229 . . . . 0.0 112.325 -179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -119.04 91.66 3.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.953 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.68 82.55 8.37 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.026 0.441 . . . . 0.0 110.032 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.52 81.12 3.51 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.772 -179.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.3 m -105.3 158.62 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.37 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -126.46 87.49 56.25 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.701 -0.227 . . . . 0.0 110.737 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.85 152.89 64.04 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.525 2.15 . . . . 0.0 112.335 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.0 m -104.67 109.64 21.64 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.85 0.357 . . . . 0.0 110.479 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -121.97 114.02 20.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.399 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.94 -8.25 49.84 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.012 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.475 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 76.2 mt -94.17 153.65 17.98 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.8 m -71.31 175.33 5.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.101 0.476 . . . . 0.0 111.66 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -75.36 156.69 35.2 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.559 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.63 2.03 65.55 Favored Glycine 0 N--CA 1.446 -0.674 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.2 m -81.19 145.81 30.81 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.398 -0.401 . . . . 0.0 110.47 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 64.5 t -90.92 118.28 35.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.071 0.463 . . . . 0.0 110.993 -179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.4 t -94.25 126.42 46.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.846 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -91.16 133.26 35.5 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.195 0.521 . . . . 0.0 111.474 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.02 105.91 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.43 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -125.91 101.51 6.86 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.099 0.476 . . . . 0.0 110.798 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.24 127.83 9.35 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.241 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.82 155.86 24.92 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.37 24.95 49.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.747 -179.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.57 -173.31 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.121 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -90.71 110.13 21.31 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.589 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.07 134.81 57.4 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.682 -179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.43 -23.38 36.45 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.54 149.3 25.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.772 0.32 . . . . 0.0 111.135 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.46 140.3 31.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.205 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -120.88 114.27 21.33 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.273 0.558 . . . . 0.0 110.237 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.33 114.11 19.89 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.137 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 97' ' ' LEU . 18.9 t -122.56 128.59 75.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.899 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.34 172.84 34.19 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.838 179.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.458 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -83.16 132.65 35.07 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.457 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -136.11 172.73 12.59 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.787 0.327 . . . . 0.0 111.324 -178.254 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -161.51 176.77 10.72 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.556 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.463 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 2.5 t90 -74.57 98.53 3.4 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.945 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p -91.31 -40.39 12.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.496 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.461 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.7 t0 -135.83 178.05 7.35 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.463 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -71.12 93.03 1.01 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.009 0.433 . . . . 0.0 111.089 -179.559 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.02 -10.77 73.34 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.267 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 8.0 t -103.78 123.19 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.5 mt -109.34 153.52 23.81 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.0 144.59 24.99 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.366 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.844 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.8 m -106.39 169.95 8.21 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.854 0.359 . . . . 0.0 110.717 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.532 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.5 t-20 -95.9 127.52 40.78 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.416 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -88.22 -3.5 6.91 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.988 2.459 . . . . 0.0 113.084 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.32 -33.23 23.96 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.956 0.408 . . . . 0.0 110.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.02 66.25 1.28 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.946 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -139.19 171.2 14.65 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.204 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 51.1 m -152.93 119.88 5.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.843 0.354 . . . . 0.0 110.415 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.5 m -83.43 93.09 7.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -80.87 136.19 23.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.177 -178.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 t -99.45 146.68 26.08 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.979 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.77 37.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.679 0.276 . . . . 0.0 110.47 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -179.68 5.03 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.491 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.14 -31.76 70.39 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -73.7 -21.89 60.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.837 0.351 . . . . 0.0 110.631 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.16 29.3 8.55 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.135 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -118.8 141.19 48.86 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.928 0.394 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -129.33 98.7 4.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.377 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -102.22 126.54 49.24 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.73 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.4 t -146.81 173.54 12.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.603 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.525 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 37.0 m -145.74 126.62 14.47 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.425 HD22 ' N ' ' A' ' 67' ' ' LEU . 1.5 mm? -120.02 140.28 51.22 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.668 0.27 . . . . 0.0 111.491 -178.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 25.5 m -87.98 118.63 27.67 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.833 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -85.96 119.66 34.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.48 0.657 . . . . 0.0 111.834 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -95.68 158.74 15.32 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.581 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -79.96 -40.28 28.38 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.947 0.403 . . . . 0.0 110.882 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.4 m -126.95 128.8 46.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.532 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.5 p90 -155.4 169.25 24.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.142 0.496 . . . . 0.0 112.011 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -89.93 135.86 33.38 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.06 127.76 9.07 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.216 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 7.8 m-85 -126.23 147.07 49.75 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.654 0.264 . . . . 0.0 110.297 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.64 168.4 19.42 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.686 179.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -63.49 -29.33 70.62 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.86 0.362 . . . . 0.0 110.727 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.31 -24.86 63.99 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.792 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.73 -4.31 22.86 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.41 179.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.2 m -83.5 139.81 32.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.125 0.462 . . . . 0.0 111.118 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -78.11 138.17 38.6 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.178 179.432 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 39.7 t-105 -102.73 -44.98 5.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 109.774 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.34 174.36 35.64 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.85 139.87 39.32 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.628 0.214 . . . . 0.0 110.977 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.8 t -123.04 152.67 27.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -135.24 128.41 31.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.825 0.345 . . . . 0.0 110.611 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 76.8 m -111.06 22.02 15.75 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.03 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 m -81.43 -35.04 31.11 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -122.34 12.86 10.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.177 179.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.37 165.6 25.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.645 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -84.12 129.3 34.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.321 -179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.86 164.52 11.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.668 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.554 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -153.1 -179.35 7.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.86 0.362 . . . . 0.0 110.696 179.926 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 7.7 p -127.66 137.81 56.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.069 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -118.86 133.2 10.1 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.479 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -137.05 105.55 5.79 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 m -140.45 169.99 16.63 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.904 0.383 . . . . 0.0 111.462 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -85.55 -159.9 0.48 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.531 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.26 -34.38 74.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.262 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.99 -34.65 50.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.967 0.413 . . . . 0.0 110.742 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.88 28.08 3.53 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.99 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -116.55 174.31 6.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.92 -154.8 21.69 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.939 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.86 155.95 60.94 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.867 2.378 . . . . 0.0 112.074 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -69.38 143.62 53.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.908 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.89 156.54 51.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.133 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.7 t -123.8 135.37 63.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.555 0.217 . . . . 0.0 110.654 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.51 148.75 23.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.847 0.356 . . . . 0.0 110.554 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 15.7 pt -131.63 168.32 24.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.077 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 73.7 m -152.94 154.5 35.15 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 120.849 0.357 . . . . 0.0 110.874 -179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 25.5 m-85 -106.38 178.27 4.61 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--O 1.245 0.822 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.906 179.212 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.844 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.3 114.76 51.78 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.678 0.275 . . . . 0.0 111.106 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -80.8 160.87 21.5 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.619 2.213 . . . . 0.0 111.842 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.6 m -108.67 101.4 10.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.0 0.428 . . . . 0.0 111.065 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.43 98.96 9.81 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.584 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -110.13 90.83 3.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.698 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 21' ' ' VAL . 35.2 m -119.55 148.43 22.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.829 0.347 . . . . 0.0 111.084 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -108.88 104.08 53.75 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -79.23 151.76 23.52 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.587 2.191 . . . . 0.0 112.728 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.8 m -95.41 88.88 5.24 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.25 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -109.14 105.99 15.69 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.318 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.2 -15.72 56.13 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.877 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 13.7 mt -84.67 155.78 21.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.2 m -82.5 -179.38 7.4 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.781 0.324 . . . . 0.0 110.498 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -74.89 159.41 31.9 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.81 -9.21 75.9 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -178.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.404 HG21 HD13 ' A' ' 13' ' ' LEU . 30.4 m -68.99 145.89 53.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.964 0.412 . . . . 0.0 111.073 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -84.09 114.84 25.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.888 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 95' ' ' VAL . 42.4 t -90.89 126.89 43.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.713 179.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -98.99 124.37 43.91 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.869 0.366 . . . . 0.0 111.086 -179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' HA ' HG12 ' A' ' 7' ' ' VAL . 97.7 t -123.21 111.07 28.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.008 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.15 111.02 14.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.045 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.06 121.2 5.59 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.703 179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.83 159.05 25.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.744 0.307 . . . . 0.0 110.464 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.59 26.46 56.65 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.484 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 60.7 mt -103.59 -173.7 2.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.675 -0.263 . . . . 0.0 110.439 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.1 tp60 -81.25 118.43 22.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.481 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.13 134.15 50.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.993 0.425 . . . . 0.0 111.203 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.57 31.18 8.02 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.526 -0.845 . . . . 0.0 113.239 179.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -132.34 142.15 49.21 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.788 0.294 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -101.87 134.16 45.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.153 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -110.94 139.12 46.55 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.147 0.499 . . . . 0.0 111.381 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.22 89.63 6.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.31 -0.859 . . . . 0.0 108.776 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.1 t -98.2 125.04 51.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.223 0.535 . . . . 0.0 112.232 -177.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.18 175.12 36.16 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -81.01 64.99 5.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 117.497 0.648 . . . . 0.0 110.122 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.6 m -67.64 99.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.989 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB3' ' HZ ' ' A' ' 73' ' ' PHE . . . -107.63 175.24 5.56 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.415 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -63.84 109.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.019 0.438 . . . . 0.0 111.578 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.44 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -97.49 -21.81 5.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.428 0.632 . . . . 0.0 109.842 179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -150.45 -172.59 4.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.393 -0.821 . . . . 0.0 108.842 179.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.3 m -72.24 86.94 1.1 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.986 0.422 . . . . 0.0 111.497 -179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.73 -11.25 64.61 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.037 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.4 t -99.5 129.76 49.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.511 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 5.6 mp -108.5 161.39 15.1 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.143 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.93 144.67 17.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.725 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -113.61 162.04 16.69 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.247 -179.614 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -95.76 122.91 57.56 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-O 121.019 0.438 . . . . 0.0 111.135 -179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.688 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 79.7 Cg_endo -77.42 7.98 3.52 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.917 2.411 . . . . 0.0 111.812 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 -14.23 19.84 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.321 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -139.19 9.08 2.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.9 OUTLIER -87.74 171.94 10.05 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.62 0.248 . . . . 0.0 110.336 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.5 m -146.12 129.61 16.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.02 0.438 . . . . 0.0 110.862 179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.3 m -92.01 103.0 15.56 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.223 179.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.6 p -99.69 143.28 13.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.217 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.402 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.5 t -109.76 143.35 39.7 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.916 0.388 . . . . 0.0 110.85 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.18 122.89 18.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.77 178.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.6 p30 -70.49 -173.82 0.78 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.615 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.63 -13.45 61.17 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.418 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -90.69 -10.97 41.13 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.894 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.01 29.86 30.26 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.52 148.64 52.35 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 120.807 0.337 . . . . 0.0 111.422 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.65 114.86 10.93 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.363 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 6.1 m -119.85 123.03 42.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.577 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.0 t -141.84 172.65 12.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.532 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 17.1 m -131.89 138.97 48.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.545 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.96 156.84 32.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.03 -178.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 37.2 m -108.39 110.24 21.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.625 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.6 p -76.92 122.96 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.266 0.555 . . . . 0.0 111.653 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.0 mmt180 -100.36 169.13 9.31 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.505 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -86.11 -47.23 9.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.632 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.95 103.63 6.9 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.415 ' HZ ' ' HB3' ' A' ' 38' ' ' ALA . 42.3 p90 -121.78 164.9 16.67 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.876 0.369 . . . . 0.0 111.802 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -93.22 115.54 28.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.174 179.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.41 130.94 10.21 Favored Glycine 0 N--CA 1.445 -0.721 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.315 -179.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.511 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 6.3 m-85 -118.65 149.26 41.7 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.655 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.3 mt -86.36 174.0 9.32 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.738 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -73.12 -14.0 61.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.651 0.262 . . . . 0.0 111.441 -179.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.05 -21.16 33.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.409 179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.53 1.31 26.13 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.671 -0.776 . . . . 0.0 113.563 179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -100.74 145.98 27.81 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 117.321 0.56 . . . . 0.0 111.494 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 13.2 ptp180 -81.99 142.78 32.09 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.438 179.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.44 ' HB3' HG21 ' A' ' 40' ' ' VAL . 32.7 t-105 -107.5 -21.07 13.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.444 179.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.85 175.14 22.5 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.254 -0.974 . . . . 0.0 112.6 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.4 m -87.02 131.8 33.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.023 0.44 . . . . 0.0 110.775 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.5 t -108.85 126.52 65.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -117.33 140.21 49.85 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.191 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.8 m -128.35 43.26 3.17 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.068 0.461 . . . . 0.0 111.325 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.0 m -84.53 -42.51 15.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.126 0.488 . . . . 0.0 109.686 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.0 t -118.78 9.19 11.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.207 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.7 167.94 17.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.543 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -83.1 151.55 25.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.017 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -125.01 171.97 9.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.215 -179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -158.84 166.33 32.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.776 0.322 . . . . 0.0 110.752 179.251 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.44 HG21 HG11 ' A' ' 19' ' ' VAL . 21.6 t -117.28 134.03 62.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.714 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.83 148.31 17.57 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.327 -0.94 . . . . 0.0 113.289 -179.205 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -145.28 125.28 13.58 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.599 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.5 m -155.64 165.56 36.17 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.384 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -82.06 -164.85 0.87 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.701 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.33 -32.85 74.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.466 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.2 -56.51 4.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.001 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.81 41.22 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.575 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -125.88 155.17 41.65 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.11 176.92 25.29 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.739 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.96 143.82 91.11 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.07 2.513 . . . . 0.0 112.145 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -56.92 136.45 55.94 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.946 0.403 . . . . 0.0 111.92 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.47 157.62 44.21 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.947 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.67 133.38 65.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 120.702 0.287 . . . . 0.0 110.727 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.38 148.16 32.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.3 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -127.66 161.98 34.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 21.0 m -149.6 138.41 21.03 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.592 0.234 . . . . 0.0 110.402 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.9 m-85 -97.76 172.93 7.37 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.118 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.724 -0.655 . . . . 0.0 109.64 179.855 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.655 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.746 0.307 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.81 127.38 70.13 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.134 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -75.2 179.16 6.4 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.585 2.19 . . . . 0.0 112.466 -179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.43 81.14 1.79 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.453 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.11 123.25 37.37 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.411 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.16 93.47 3.82 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.314 179.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 m -117.22 150.04 19.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.925 0.393 . . . . 0.0 111.136 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.2 m -110.38 101.36 48.13 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.245 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.77 129.09 8.94 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.767 2.311 . . . . 0.0 113.01 -178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -73.28 93.29 1.87 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.85 179.494 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -110.36 105.4 14.39 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.86 8.56 56.92 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.962 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 94.2 mt -104.04 143.06 33.4 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.77 178.48 3.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.042 0.449 . . . . 0.0 112.071 -179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -68.56 150.13 48.38 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.483 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.16 -3.12 66.39 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.722 -0.752 . . . . 0.0 111.369 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 61.6 m -72.3 137.0 46.39 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 121.007 0.432 . . . . 0.0 110.675 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.495 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 11.1 t -87.92 120.96 37.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.775 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.6 t -89.65 137.97 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -95.9 121.53 37.73 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.678 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' SER . 97.6 t -120.16 103.02 13.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.054 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.3 98.64 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.038 0.447 . . . . 0.0 110.54 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.51 127.12 8.97 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.275 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.29 145.51 46.05 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.7 24.78 31.92 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.538 -179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.51 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 43.3 mt -89.81 -169.58 2.51 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -90.59 108.1 19.59 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.469 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.87 127.71 33.3 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.747 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.1 -2.98 55.14 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.608 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.7 p -106.58 158.76 16.69 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 117.352 0.576 . . . . 0.0 111.359 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.39 142.15 37.66 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.179 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.51 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 96.0 m-85 -118.23 135.29 54.35 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.121 0.486 . . . . 0.0 111.076 -179.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -98.58 103.04 14.95 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 21.5 t -118.68 124.1 72.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.328 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.6 179.34 33.41 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -84.33 128.13 34.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 2.1 m -125.81 159.16 33.16 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.975 0.416 . . . . 0.0 111.608 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -144.94 172.82 12.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.035 179.292 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.9 m95 -68.71 108.58 3.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.532 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -98.02 -21.95 5.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.078 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t70 -157.93 178.11 10.59 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -71.92 101.33 2.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.789 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.36 7.82 78.9 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.081 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 57.6 t -132.07 133.09 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 0.0 110.331 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -113.13 172.02 7.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -158.98 149.74 19.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.454 0.168 . . . . 0.0 111.246 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.751 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.72 172.31 7.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.703 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -102.79 115.7 63.81 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.349 0.595 . . . . 0.0 110.928 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -80.36 15.93 1.64 Allowed 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 123.143 2.562 . . . . 0.0 112.04 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.14 -18.0 14.69 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.642 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.22 18.85 5.93 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 111.022 -179.423 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -94.0 175.79 6.58 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.73 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 52.4 m -145.21 105.52 4.07 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.29 116.85 12.09 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.441 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.8 p -110.28 144.27 18.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.32 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.0 t -110.75 149.75 30.07 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.66 138.77 38.46 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.853 0.359 . . . . 0.0 110.665 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.4 p30 -86.49 -174.24 4.91 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.639 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.4 -17.41 63.73 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.747 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -90.26 -5.5 56.25 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.031 0.443 . . . . 0.0 109.925 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.67 30.78 51.99 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.464 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.13 150.58 43.08 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.97 0.414 . . . . 0.0 111.038 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.24 111.88 6.41 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.531 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.1 m -114.25 135.97 53.47 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.288 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.5 t -156.6 161.48 39.93 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.495 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 8.0 m -120.64 139.9 52.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.454 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.4 143.57 50.04 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-O 120.717 0.294 . . . . 0.0 110.937 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.3 m -101.53 110.23 22.19 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.32 121.87 32.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.571 0.7 . . . . 0.0 111.815 -178.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -95.97 161.76 13.85 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.403 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.414 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 8.9 tpp180 -74.7 -33.32 62.39 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -137.69 148.51 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.864 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.551 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 19.4 p90 -164.28 171.31 15.06 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 111.422 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -87.3 157.79 19.21 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.398 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.66 121.88 5.88 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.946 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.525 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 15.2 m-85 -124.59 144.61 50.06 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.503 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 34.9 mt -77.54 169.88 17.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 178.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -74.93 5.88 4.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.775 0.321 . . . . 0.0 111.574 -179.291 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.98 -20.19 16.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.082 178.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.46 -7.85 24.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.162 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.9 m -92.05 142.64 27.3 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.001 0.401 . . . . 0.0 110.549 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 33.6 ptt180 -81.82 151.87 27.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.929 0.395 . . . . 0.0 110.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.449 ' HB3' HG21 ' A' ' 40' ' ' VAL . 19.6 t-105 -125.47 10.69 7.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.364 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 130.0 -161.85 23.02 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.411 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.61 147.36 45.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.1 m -128.38 164.68 29.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.988 0.423 . . . . 0.0 110.971 -179.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 22.5 t70 -142.36 145.06 33.48 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.68 -179.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.551 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 93.3 m -116.59 15.99 15.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.831 0.348 . . . . 0.0 111.481 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.414 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.0 m -79.36 -46.72 17.08 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -111.06 5.48 20.23 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.366 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -128.55 171.84 11.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.71 -179.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -82.57 144.13 30.56 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.069 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -117.35 147.51 42.56 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.543 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -148.41 160.19 43.28 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.648 0.261 . . . . 0.0 110.419 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 39.0 t -101.3 128.43 53.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.445 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.85 116.6 5.45 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.947 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -117.68 103.08 9.68 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.5 m -153.34 160.8 42.76 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.966 0.412 . . . . 0.0 111.022 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -177.18 5.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.483 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.45 -30.88 63.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.723 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.05 -48.49 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.742 0.306 . . . . 0.0 110.6 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.42 23.08 0.6 Allowed Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.826 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -115.58 163.51 15.68 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 122.588 -0.36 . . . . 0.0 110.62 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.87 -158.56 26.73 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.498 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -66.96 158.0 58.86 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.585 2.19 . . . . 0.0 111.769 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -77.54 143.54 38.3 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.67 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.513 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.44 140.6 30.96 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.272 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 96.1 t -106.33 135.28 45.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 110.259 -0.274 . . . . 0.0 110.259 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.57 143.36 28.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.704 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.406 ' HB ' ' O ' ' A' ' 10' ' ' SER . 38.8 pt -124.57 172.42 12.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.827 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.8 m -154.23 141.76 19.8 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.853 0.359 . . . . 0.0 110.657 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 36.1 m-85 -87.28 162.79 17.22 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.649 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.037 -179.988 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.751 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 120.566 0.222 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.65 115.01 59.81 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.498 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -73.64 166.5 29.63 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.846 2.364 . . . . 0.0 112.498 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.833 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 11.9 m -99.4 101.66 12.99 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.344 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.59 89.47 6.73 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.81 98.18 7.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.369 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 108' ' ' VAL . 8.5 m -128.44 140.53 48.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.894 -179.67 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.0 m -111.8 101.78 52.11 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.433 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_endo -80.83 145.02 15.68 Favored 'Trans proline' 0 CA--C 1.531 0.343 0 C-N-CA 122.579 2.186 . . . . 0.0 113.32 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 m -87.26 48.43 1.65 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.5 m -68.83 107.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.845 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.68 0.08 49.28 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.973 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 80.2 mt -97.83 178.43 5.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.595 0.236 . . . . 0.0 110.553 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -99.98 178.02 4.93 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.43 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -71.57 163.1 28.37 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.77 -5.92 84.22 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.514 -0.85 . . . . 0.0 111.435 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.5 m -78.09 143.18 37.59 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 43.4 t -92.93 118.72 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.756 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 26.2 t -86.98 130.92 36.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.962 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -98.72 130.48 45.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.998 0.428 . . . . 0.0 111.263 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.7 t -127.06 111.39 25.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.568 179.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.01 95.44 4.5 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.119 0.485 . . . . 0.0 110.682 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.05 131.16 10.58 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.33 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.833 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.13 146.81 46.37 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 34.42 19.02 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.182 -179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.68 -170.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.319 -0.44 . . . . 0.0 110.157 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.9 tp60 -93.28 106.68 18.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.865 0.364 . . . . 0.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 120.14 10.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.809 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.43 -36.42 3.04 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.406 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 p -85.9 166.53 15.9 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.863 0.363 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -116.8 145.93 43.19 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.081 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -119.54 123.14 43.24 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.145 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 5.1 t0 -90.61 129.97 36.68 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.5 133.1 70.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 120.914 0.387 . . . . 0.0 111.551 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.69 172.74 34.4 Favored Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -84.61 56.74 3.98 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.432 0.634 . . . . 0.0 110.046 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -67.35 98.5 0.64 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.206 -0.907 . . . . 0.0 111.566 -179.085 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -101.11 173.62 6.38 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.058 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -60.27 111.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.442 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p -101.97 -26.51 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.599 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -159.1 -175.24 5.15 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.03 97.75 0.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.982 0.42 . . . . 0.0 111.485 -179.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.46 18.13 79.96 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.945 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -127.52 133.99 66.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 mp -119.63 166.89 12.59 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.37 132.07 14.95 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.917 -179.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.649 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 18.4 m -88.72 168.55 12.4 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.652 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.424 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -96.08 123.51 54.98 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.925 0.393 . . . . 0.0 110.439 179.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.47 -8.29 10.55 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.394 2.063 . . . . 0.0 112.576 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.77 -46.29 22.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -125.98 85.11 2.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.786 0.327 . . . . 0.0 110.323 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -133.67 158.18 43.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.0 m -149.13 113.68 5.31 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.973 0.416 . . . . 0.0 110.64 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.49 111.73 18.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.797 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -102.42 126.11 56.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.293 0.568 . . . . 0.0 110.427 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 2.9 t -93.85 147.03 23.45 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.053 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.62 131.26 42.21 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.962 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.0 p30 -73.07 179.71 3.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.196 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.21 -23.24 65.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.972 0.415 . . . . 0.0 111.706 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -80.9 -15.67 55.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.125 0.488 . . . . 0.0 110.602 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.32 33.98 9.02 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.646 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.07 156.93 39.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.553 0.216 . . . . 0.0 110.59 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.3 114.82 7.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.915 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.8 m -111.92 123.14 49.62 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.18 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.4 t -145.66 174.82 10.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.853 0.359 . . . . 0.0 110.537 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.541 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 58.8 m -155.38 137.74 14.9 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 67' ' ' LEU . 1.1 mm? -130.4 142.2 50.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.908 0.385 . . . . 0.0 111.46 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 m -86.44 110.01 19.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.97 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.9 p -77.79 128.82 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.231 0.539 . . . . 0.0 111.282 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 -102.03 164.08 11.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.659 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 71' ' ' ARG . 2.8 tpp180 -75.2 -51.7 12.72 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.987 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -118.52 135.75 54.22 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.424 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 25.3 p90 -148.85 175.03 11.6 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.905 0.383 . . . . 0.0 111.501 -178.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -98.77 139.17 34.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.635 179.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.54 128.25 8.79 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.42 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -128.47 137.65 51.91 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.354 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.6 mt -94.46 164.68 12.9 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.548 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -82.18 61.05 5.24 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.085 0.469 . . . . 0.0 110.879 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -163.26 -22.43 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.338 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.52 -9.02 11.85 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.847 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 8.1 m -89.05 136.1 33.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.767 0.284 . . . . 0.0 110.773 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.99 150.29 20.64 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 26.2 t-105 -98.19 -54.9 2.93 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.29 0.566 . . . . 0.0 110.628 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.45 -174.61 38.87 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 31.5 m -89.46 130.76 35.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.089 0.444 . . . . 0.0 110.952 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.2 m -123.27 154.84 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.524 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -128.17 138.93 52.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.438 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -113.69 26.64 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.035 179.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 91.6 m -78.34 -35.49 47.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.205 0.526 . . . . 0.0 109.886 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -115.67 20.58 14.55 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.384 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.77 -177.45 5.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.697 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -114.06 131.75 56.27 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.681 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -94.09 179.26 5.38 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.224 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.441 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -155.64 160.33 40.33 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.467 HG21 HG11 ' A' ' 19' ' ' VAL . 17.2 t -99.31 123.79 52.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.35 -179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -119.31 136.85 12.17 Favored Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.322 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 2.1 pt? -141.94 135.43 29.4 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.408 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 68.6 m -152.42 160.4 43.28 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.929 0.395 . . . . 0.0 111.255 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -86.09 -166.11 1.44 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.863 178.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.27 -32.6 73.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.927 0.394 . . . . 0.0 111.431 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.53 -46.35 15.94 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.945 0.402 . . . . 0.0 110.767 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 127.38 26.23 1.09 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.424 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -118.39 -176.42 3.07 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.49 -158.74 23.36 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.181 -0.533 . . . . 0.0 111.793 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.401 ' HG2' HD11 ' A' ' 97' ' ' LEU . 39.4 Cg_exo -62.96 163.82 21.16 Favored 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 123.2 2.6 . . . . 0.0 112.735 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -72.45 152.5 41.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.302 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.37 140.25 21.07 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 20.8 t -109.95 125.9 67.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.711 0.256 . . . . 0.0 110.983 -179.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -77.7 143.83 37.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.718 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 17.0 pt -131.74 124.13 53.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.298 0.57 . . . . 0.0 110.886 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 m -108.01 142.66 37.84 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.473 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.84 165.79 12.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.089 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.793 -0.622 . . . . 0.0 110.197 179.767 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.649 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.906 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.03 123.59 65.61 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.28 -173.52 1.87 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.847 2.365 . . . . 0.0 112.128 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -132.35 87.4 2.42 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.958 0.408 . . . . 0.0 111.263 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.89 130.19 34.69 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.68 78.62 1.62 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.124 0.488 . . . . 0.0 111.411 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.4 m -99.32 159.17 3.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.224 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.9 m -114.66 100.25 52.94 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.562 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.77 133.64 26.04 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.694 2.263 . . . . 0.0 112.265 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.88 34.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.515 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.8 m -67.43 120.02 13.22 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.686 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 -1.2 46.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 121.013 -0.613 . . . . 0.0 111.891 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.6 mt -104.5 -168.32 1.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.534 0.207 . . . . 0.0 110.511 -179.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -114.29 -171.71 1.96 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.743 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -78.44 160.05 27.94 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.98 -2.39 87.64 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.927 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.3 m -72.61 140.01 47.76 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 46.3 t -81.0 111.53 17.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.423 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.92 125.58 42.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.298 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -93.48 126.18 38.48 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.188 0.518 . . . . 0.0 110.991 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.429 HG21 HG11 ' A' ' 34' ' ' VAL . 94.9 t -123.26 108.83 21.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.769 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.57 115.17 19.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.178 0.513 . . . . 0.0 110.731 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -118.13 126.46 6.89 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.81 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.48 159.96 21.98 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.08 67.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.468 -0.873 . . . . 0.0 111.266 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.9 mt -93.74 179.77 5.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.429 -0.385 . . . . 0.0 110.058 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -79.94 111.1 15.95 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 134.56 57.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.431 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.29 2.74 63.71 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 114.084 178.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.9 p -102.66 159.98 14.98 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.428 0.614 . . . . 0.0 111.274 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -110.1 124.0 50.72 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.663 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 12.7 m-85 -103.57 122.65 45.4 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 33.6 m-20 -90.89 109.24 20.46 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.429 HG11 HG21 ' A' ' 21' ' ' VAL . 20.0 t -116.86 128.53 74.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 120.928 0.394 . . . . 0.0 111.524 -178.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.35 -179.33 30.4 Favored Glycine 0 N--CA 1.446 -0.657 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 20.5 pt20 -86.71 117.37 25.42 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.574 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -117.44 140.78 49.15 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.041 0.448 . . . . 0.0 111.751 -178.216 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.88 176.7 8.72 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.128 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.7 m95 -66.13 103.73 1.03 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.779 0.323 . . . . 0.0 110.679 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 p -88.05 -24.96 6.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.595 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -150.25 -163.98 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.291 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.84 82.66 2.15 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.98 -0.555 . . . . 0.0 112.194 -178.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.51 -10.49 64.93 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.8 t -103.1 130.0 53.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.681 0.277 . . . . 0.0 110.549 -179.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -105.06 159.91 15.47 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.56 145.1 25.72 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 121.295 -0.162 . . . . 0.0 110.705 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.788 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -101.78 170.37 8.2 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.434 0.459 . . . . 0.0 110.621 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.431 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 26.1 p-10 -85.49 135.33 38.68 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.68 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.626 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -95.29 -5.25 1.97 Allowed 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 123.083 2.522 . . . . 0.0 113.545 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.57 -71.91 0.6 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.795 0.331 . . . . 0.0 111.397 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.96 49.61 1.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.048 0.451 . . . . 0.0 111.838 -178.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -122.55 162.63 21.44 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.563 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.9 m -145.31 135.78 24.21 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.947 0.403 . . . . 0.0 110.735 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 m -94.17 114.35 26.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.6 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.4 p -105.65 136.99 37.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 121.179 0.514 . . . . 0.0 110.122 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.4 t -96.02 143.66 26.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.043 0.449 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.46 121.89 23.74 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -66.04 176.05 1.83 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.273 -178.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.61 -13.89 46.42 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.534 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -84.38 -19.65 33.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.19 26.51 15.85 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.279 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.9 149.61 45.65 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 111.276 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.49 117.06 9.72 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.256 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.5 t -123.43 134.51 53.94 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.228 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.8 t -153.13 171.26 18.73 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.206 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.463 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 13.7 m -133.56 129.42 37.02 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.826 0.346 . . . . 0.0 110.348 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -116.5 142.44 46.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.541 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -95.84 104.0 15.91 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.33 126.53 31.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.457 0.646 . . . . 0.0 111.677 -178.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -107.36 162.93 13.47 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.769 179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -81.12 -28.46 35.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.231 0.538 . . . . 0.0 110.091 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.18 128.5 47.35 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -145.7 157.55 43.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.248 0.547 . . . . 0.0 111.576 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -88.71 124.88 34.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.764 179.35 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -77.85 120.91 5.61 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.843 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -128.41 148.33 50.7 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.77 0.319 . . . . 0.0 110.418 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.477 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 16.1 mt -87.22 156.41 19.68 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.601 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -9.29 18.65 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -98.15 -0.71 43.76 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.695 0.283 . . . . 0.0 111.007 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.09 -3.6 57.03 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.706 178.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD12 ' A' ' 77' ' ' LEU . 32.8 m -81.45 139.53 35.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.984 0.421 . . . . 0.0 111.448 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 12.5 ptt180 -88.29 169.28 11.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.737 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -147.0 -64.91 0.28 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.639 0.257 . . . . 0.0 110.878 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -176.75 163.58 32.64 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.451 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -80.01 126.55 31.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.1 t -103.52 137.46 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.805 0.336 . . . . 0.0 111.225 -178.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 17.7 t70 -90.25 127.72 36.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.271 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.1 t -110.78 23.89 13.62 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -92.13 -59.08 2.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.839 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 t -90.09 -13.9 34.86 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.511 0.672 . . . . 0.0 110.041 179.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 87' ' ' ASP . . . -105.18 -172.77 2.16 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.254 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.57 140.39 48.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.28 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 64.5 m -110.97 155.86 22.08 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.575 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -128.95 159.07 37.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.028 0.442 . . . . 0.0 110.269 179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 t -78.67 122.23 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.839 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.574 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 118.59 6.11 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.317 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.7 mp -108.67 91.23 3.56 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.1 m -120.97 123.28 42.06 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.793 0.33 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -79.36 -169.96 2.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.349 -0.387 . . . . 0.0 109.971 179.151 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.86 -35.17 70.59 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.48 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.21 -30.1 38.64 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.044 0.449 . . . . 0.0 110.676 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 112.44 11.23 15.64 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.432 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -110.01 -170.27 1.62 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.567 0.223 . . . . 0.0 110.701 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.82 -169.06 23.01 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.348 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.8 156.91 50.75 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.892 2.395 . . . . 0.0 111.693 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -71.73 139.07 48.96 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.692 -179.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.45 157.15 52.59 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.912 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 42.4 t -122.08 130.98 74.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.6 139.8 33.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.025 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.0 pt -112.12 164.65 7.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.805 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.9 m -137.35 136.04 37.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.681 0.277 . . . . 0.0 110.507 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -92.44 143.39 26.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.657 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.573 -0.727 . . . . 0.0 110.147 179.888 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.788 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.9 116.93 63.68 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.213 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -85.87 170.53 8.6 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.76 2.307 . . . . 0.0 111.176 179.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.25 100.31 4.5 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.973 0.416 . . . . 0.0 111.242 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -103.18 120.19 40.26 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.488 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.07 70.01 1.29 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.583 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -104.55 138.19 30.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.831 0.348 . . . . 0.0 110.861 -179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -103.9 111.57 65.2 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.846 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HB3' HG11 ' A' ' 108' ' ' VAL . 58.1 Cg_endo -74.51 147.51 36.34 Favored 'Trans proline' 0 C--O 1.233 0.235 0 C-N-CA 122.375 2.05 . . . . 0.0 112.056 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.499 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -87.44 35.16 0.71 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.038 0.447 . . . . 0.0 111.038 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.1 m -65.54 116.63 7.0 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.952 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.29 -8.05 60.4 Favored Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.335 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.499 HD12 ' HA ' ' A' ' 10' ' ' SER . 6.7 mt -98.91 156.8 16.71 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.744 0.307 . . . . 0.0 110.813 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.7 m -81.3 -176.5 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.065 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -76.83 151.8 35.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.079 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.01 -6.29 76.28 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.624 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 13' ' ' LEU . 8.2 m -75.74 136.9 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 120.784 0.326 . . . . 0.0 110.148 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 35.9 t -73.76 126.45 34.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.416 -179.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 66' ' ' SER . 13.0 t -90.46 124.48 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.54 178.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -92.46 113.44 25.71 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.844 0.354 . . . . 0.0 110.806 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.6 t -114.65 123.53 70.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.208 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.67 115.46 10.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.719 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -119.79 132.39 9.42 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.634 -0.587 . . . . 0.0 111.634 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -125.12 148.57 48.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.789 0.328 . . . . 0.0 110.576 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.18 26.97 34.95 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.303 -179.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 52.1 mt -92.19 -170.66 2.58 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -89.49 106.34 18.39 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.62 138.56 56.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.744 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.83 5.39 81.26 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.953 -0.642 . . . . 0.0 113.168 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -110.39 149.73 29.83 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.716 0.258 . . . . 0.0 110.588 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.54 128.31 44.18 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.857 0.361 . . . . 0.0 111.268 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 67.0 m-85 -110.37 121.38 45.15 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.229 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -90.01 126.6 35.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.991 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' HB3' ' A' ' 97' ' ' LEU . 16.7 t -125.96 130.81 72.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.282 -178.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.85 172.31 32.56 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.423 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 19.5 pt20 -82.02 66.57 7.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.731 0.776 . . . . 0.0 110.087 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.4 m -65.94 101.23 0.64 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.523 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.543 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -103.59 170.28 8.03 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.453 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.557 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 1.4 t90 -68.12 104.46 1.79 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.566 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p -100.47 -32.54 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.053 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.462 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -143.45 173.05 11.97 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.557 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 4.5 m -66.1 97.24 0.36 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.982 0.42 . . . . 0.0 110.778 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.42 10.59 67.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.889 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.0 t -128.51 129.43 68.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.21 0.528 . . . . 0.0 110.769 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.2 mp -108.55 166.33 10.86 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.33 130.78 13.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.489 0.185 . . . . 0.0 110.899 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.704 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.5 m -98.34 165.23 11.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.96 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.5 p-10 -84.73 132.09 47.48 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.731 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 44.4 Cg_endo -93.24 4.2 3.23 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.005 2.47 . . . . 0.0 112.794 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.76 -68.9 0.8 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.721 0.296 . . . . 0.0 111.333 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -90.89 45.27 1.24 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.074 0.464 . . . . 0.0 111.306 -179.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.55 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.2 p90 -101.98 166.61 10.54 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -152.42 116.05 4.79 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.23 118.92 28.16 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -106.14 133.0 51.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.166 0.508 . . . . 0.0 111.156 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -90.85 146.19 24.14 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.124 0.487 . . . . 0.0 110.632 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 127.36 32.86 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.059 -0.518 . . . . 0.0 109.938 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -75.05 -178.39 3.8 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.257 0.551 . . . . 0.0 111.583 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.44 -8.04 43.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.359 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.23 -2.68 52.04 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.72 30.48 56.1 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.346 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.73 166.94 20.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.739 0.304 . . . . 0.0 111.313 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -157.8 128.73 6.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.104 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.9 OUTLIER -129.28 143.47 50.86 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.334 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.1 t -154.51 167.0 31.53 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.941 0.4 . . . . 0.0 110.564 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.528 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.9 OUTLIER -129.1 123.95 33.52 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.122 -179.848 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -108.8 147.75 31.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.983 0.421 . . . . 0.0 111.576 -178.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 12.2 m -100.14 106.11 17.8 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.511 -0.768 . . . . 0.0 108.95 178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -77.1 124.17 35.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.476 0.655 . . . . 0.0 111.996 -178.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -102.29 156.27 17.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.294 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.3 tpp180 -80.4 -30.14 37.75 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 m -134.92 120.47 19.28 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.449 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 23.9 p90 -140.75 168.09 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.184 0.516 . . . . 0.0 112.1 -178.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' HD3' ' A' ' 49' ' ' PRO . 2.1 mp0 -86.6 130.54 34.45 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.541 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.33 131.18 10.44 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.571 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -132.3 140.55 48.64 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-O 120.852 0.358 . . . . 0.0 110.314 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.423 HD11 ' CE3' ' A' ' 83' ' ' TRP . 19.4 mt -84.98 167.25 16.04 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.406 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.47 -13.46 60.1 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.558 0.207 . . . . 0.0 111.558 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -80.01 -25.37 40.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.756 0.312 . . . . 0.0 110.663 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.01 -7.83 9.25 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.79 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.0 m -94.47 153.1 18.09 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.713 0.292 . . . . 0.0 110.608 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.0 ptt85 -94.6 161.28 14.26 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.423 ' CE3' HD11 ' A' ' 77' ' ' LEU . 11.3 t-105 -126.17 4.52 7.12 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.898 0.38 . . . . 0.0 111.379 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.36 175.52 18.34 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.262 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.6 m -79.51 133.75 36.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.078 0.466 . . . . 0.0 111.378 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.12 113.76 45.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.22 117.01 33.56 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.02 0.438 . . . . 0.0 110.776 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.8 m -98.59 22.93 9.23 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.806 -0.633 . . . . 0.0 111.312 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.8 m -70.17 -40.16 74.87 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -122.71 1.72 9.44 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.164 178.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.78 150.34 28.49 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.683 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -75.02 107.12 6.87 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.944 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.91 155.54 29.0 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.37 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.543 ' CG ' ' HA ' ' A' ' 38' ' ' ALA . 1.2 pt20 -146.62 169.6 18.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.2 p -122.15 144.29 31.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.965 0.412 . . . . 0.0 111.118 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -131.68 142.84 14.29 Favored Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.21 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.492 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.84 120.43 13.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.8 m -158.51 163.71 36.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.683 0.278 . . . . 0.0 110.603 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.2 p-10 -80.57 -170.49 2.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.13 -29.51 69.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.779 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.51 -7.54 59.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.014 0.435 . . . . 0.0 111.015 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 79.99 33.64 32.55 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.349 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -118.44 168.54 10.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.701 0.286 . . . . 0.0 110.537 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.77 -152.1 19.52 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.11 166.19 25.83 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.496 2.131 . . . . 0.0 111.189 178.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -82.0 168.2 18.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.823 0.344 . . . . 0.0 111.074 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.32 151.97 37.27 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.408 HG11 ' HB3' ' A' ' 9' ' ' PRO . 44.5 t -112.57 131.86 62.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.729 0.299 . . . . 0.0 110.473 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.65 121.26 28.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.066 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.1 pt -109.84 164.99 5.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.898 0.38 . . . . 0.0 110.323 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.9 m -151.74 135.49 16.33 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.462 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 57.3 m-85 -85.64 170.54 12.44 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.782 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.161 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.704 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 120.746 0.308 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.0 109.31 41.22 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.393 -179.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.09 148.21 44.27 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.431 2.087 . . . . 0.0 111.664 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.06 98.83 8.23 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.104 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.11 112.85 24.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.732 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.4 p -115.15 97.78 6.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.716 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -116.67 146.34 21.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.189 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 m -109.6 92.79 12.68 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.667 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -76.68 138.34 19.01 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.484 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -75.35 87.81 2.56 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.124 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.2 m -104.49 98.16 7.97 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.104 0.478 . . . . 0.0 109.948 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.39 24.28 11.45 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.572 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 54.9 mt -123.35 135.38 54.14 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -179.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -69.37 176.04 3.62 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.334 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -71.51 158.72 35.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.39 -14.77 61.94 Favored Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.474 HG21 HD13 ' A' ' 13' ' ' LEU . 5.8 m -74.59 149.86 39.91 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.357 -0.422 . . . . 0.0 110.778 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 99.6 t -93.42 123.35 45.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.202 -179.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.1 t -90.82 127.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 21.2 tttt -94.2 119.63 33.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.051 0.453 . . . . 0.0 111.092 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.7 t -117.8 116.33 51.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.916 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -132.41 108.67 9.31 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.161 0.505 . . . . 0.0 111.626 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.39 124.54 7.81 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.678 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.99 135.18 54.75 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.11 32.44 8.92 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.451 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 65.8 mt -97.79 -164.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.34 -0.43 . . . . 0.0 110.458 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 48.6 tp60 -87.67 104.89 16.96 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.947 0.403 . . . . 0.0 110.725 -179.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.48 101.99 2.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.32 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.32 -26.24 2.45 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.897 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 20.4 p -102.51 163.24 12.34 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -109.03 156.68 19.47 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.746 0.308 . . . . 0.0 110.636 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.451 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.3 m-85 -124.52 127.3 47.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.003 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -89.68 127.78 35.98 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.743 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -123.99 141.43 44.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.106 0.479 . . . . 0.0 111.888 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.78 175.29 42.1 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 177.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -82.4 58.09 3.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 117.933 0.866 . . . . 0.0 109.031 178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.2 m -63.63 108.17 1.33 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.824 -1.08 . . . . 0.0 111.248 -179.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.45 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -112.76 163.99 13.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.137 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.7 106.56 1.0 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.477 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -100.43 -29.06 3.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.821 0.343 . . . . 0.0 111.32 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -143.54 -175.08 4.42 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.34 89.74 0.68 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.127 0.489 . . . . 0.0 111.31 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.43 -8.43 77.19 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.921 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -104.72 129.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.931 0.396 . . . . 0.0 110.424 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.552 HD22 " H2'" ' A' ' 114' ' ' FLN . 2.4 mp -109.73 169.66 8.57 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.661 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.32 132.87 17.73 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.963 -0.295 . . . . 0.0 111.543 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.638 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 13.2 m -96.79 167.14 11.29 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.141 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 19.7 p-10 -98.08 115.24 65.79 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.05 0.452 . . . . 0.0 111.461 -179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.51 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 71.8 Cg_endo -77.35 -20.68 12.34 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.533 2.155 . . . . 0.0 112.436 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.89 -25.31 61.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.241 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -146.58 64.53 1.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.827 0.346 . . . . 0.0 111.19 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.573 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.9 p90 -116.35 168.11 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.715 0.293 . . . . 0.0 110.39 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.1 m -149.88 117.31 6.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.979 0.419 . . . . 0.0 110.887 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.68 106.92 19.08 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.505 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -96.53 137.57 24.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.147 0.499 . . . . 0.0 111.331 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.4 t -97.59 141.42 30.66 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.046 179.353 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.19 131.74 40.64 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.6 p30 -76.05 179.49 5.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.943 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -69.86 -0.12 6.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.787 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -101.69 -7.2 22.85 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.48 30.57 36.26 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.872 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.43 143.86 51.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.072 0.463 . . . . 0.0 111.623 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.87 110.54 8.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.366 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.64 132.77 55.01 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 9.2 t -150.49 168.23 24.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.044 0.45 . . . . 0.0 111.419 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.466 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.4 m -129.71 125.24 35.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.924 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.588 HD21 ' HB ' ' A' ' 34' ' ' VAL . 4.6 mm? -114.36 132.69 56.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.502 -178.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.11 113.27 24.98 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 17' ' ' THR . 12.2 p -80.93 132.73 30.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.079 0.466 . . . . 0.0 111.528 -179.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.8 mmt180 -114.29 166.17 11.93 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -81.75 -35.76 29.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.927 0.394 . . . . 0.0 110.432 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.8 m -133.21 140.14 47.37 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 32.0 p90 -157.14 163.33 39.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.723 0.297 . . . . 0.0 111.22 -178.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.21 144.06 33.26 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.47 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.74 122.39 7.02 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.835 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.51 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -129.89 140.5 50.96 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 120.85 0.357 . . . . 0.0 110.804 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.493 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 15.5 mt -84.49 170.61 13.31 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.184 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -71.36 -15.83 62.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.574 0.226 . . . . 0.0 111.317 -179.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -88.87 -14.42 36.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.845 0.355 . . . . 0.0 110.685 179.561 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.02 -14.81 28.63 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.841 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 59.5 m -71.65 144.42 49.41 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.203 0.525 . . . . 0.0 110.572 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.44 ' NH1' ' HA ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -97.29 149.06 22.48 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.572 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -118.76 13.41 13.24 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.519 0.676 . . . . 0.0 109.741 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.44 -145.99 17.31 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.875 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.12 142.09 47.79 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.0 t -112.69 127.64 69.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -115.6 132.34 56.66 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.84 0.352 . . . . 0.0 110.818 -179.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 90.4 m -120.13 34.22 5.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.173 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.0 m -72.88 -46.26 53.75 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -115.12 -15.34 11.7 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.19 149.21 22.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.751 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.13 120.22 23.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.686 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 170.14 12.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.52 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 4.2 pt20 -154.88 163.91 39.61 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.331 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 t -125.65 136.75 59.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.324 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.29 159.77 28.11 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.265 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.743 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -145.2 149.77 35.53 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.587 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 48.9 m -157.6 164.49 37.21 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.215 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -80.9 -172.18 3.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.401 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.01 -28.92 68.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.882 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.91 -36.57 41.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.034 0.445 . . . . 0.0 110.543 179.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.38 26.67 3.9 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.382 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -127.93 175.38 8.41 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.76 0.314 . . . . 0.0 110.52 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.99 -124.46 2.69 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -85.5 172.43 8.1 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.421 2.08 . . . . 0.0 111.43 178.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -90.23 149.38 22.41 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.892 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -77.01 142.67 27.81 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.896 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.67 136.3 55.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.806 0.336 . . . . 0.0 110.65 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -83.27 156.71 22.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' HB ' ' O ' ' A' ' 10' ' ' SER . 35.9 pt -131.79 173.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.38 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -145.9 139.06 25.98 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.572 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 62.3 m-85 -87.73 159.23 18.56 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.425 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.426 -0.797 . . . . 0.0 110.781 -179.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.638 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.892 0 CA-C-O 120.643 0.258 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.29 110.84 64.5 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.964 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -83.93 -177.65 3.18 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.847 2.365 . . . . 0.0 112.033 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 m -129.9 111.71 12.83 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.852 0.358 . . . . 0.0 110.734 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.0 83.36 2.5 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.909 0.385 . . . . 0.0 111.152 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.64 116.98 23.48 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.082 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.9 m -135.19 141.44 42.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.93 0.395 . . . . 0.0 111.357 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 m -107.68 100.11 33.08 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.757 178.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.74 139.11 17.53 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.625 2.217 . . . . 0.0 112.694 -179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -86.49 33.15 0.63 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -65.02 109.2 2.05 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.92 -3.68 38.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.923 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.588 HD13 HG21 ' A' ' 17' ' ' THR . 74.6 mt -98.44 165.58 11.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.1 m -84.22 177.99 7.98 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.773 0.321 . . . . 0.0 111.542 -179.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -75.7 150.69 37.82 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.7 -10.97 68.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.469 -179.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.588 HG21 HD13 ' A' ' 13' ' ' LEU . 5.5 m -72.46 154.93 40.61 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.816 0.341 . . . . 0.0 110.641 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.457 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 44.9 t -91.93 137.5 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.128 0.49 . . . . 0.0 111.938 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.4 t -105.61 125.25 60.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -97.47 130.99 44.52 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.806 0.336 . . . . 0.0 111.573 -178.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 92.5 t -126.68 112.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.765 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.3 91.11 3.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.903 0.382 . . . . 0.0 111.045 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.31 124.59 7.12 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.327 -0.939 . . . . 0.0 111.864 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.97 136.99 54.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.835 0.35 . . . . 0.0 110.424 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 30.4 21.5 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 81.3 mt -90.39 -167.09 1.74 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.262 -0.469 . . . . 0.0 110.78 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -94.61 106.03 18.0 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.691 0.281 . . . . 0.0 110.398 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.09 137.76 55.37 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.879 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.95 -3.98 83.03 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.954 -0.641 . . . . 0.0 113.079 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -105.55 142.16 35.78 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.689 0.28 . . . . 0.0 111.052 -179.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.66 144.81 25.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.832 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.55 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 59.4 m-85 -119.1 127.58 53.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.236 0.541 . . . . 0.0 110.529 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.52 107.34 18.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.583 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 9.1 t -122.34 118.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.849 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.98 172.72 31.97 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.924 -0.655 . . . . 0.0 111.487 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.97 127.72 34.69 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.845 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.2 m -129.67 159.42 36.48 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.441 0.638 . . . . 0.0 111.877 -178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.536 ' HA ' ' NE2' ' A' ' 94' ' ' GLN . . . -142.15 174.51 10.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.681 179.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -74.1 104.23 4.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.8 p -87.76 -18.76 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.413 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.74 -177.82 6.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.349 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -65.98 100.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.785 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.61 12.02 84.9 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.204 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.2 t -120.47 129.25 75.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.978 0.418 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.7 mt -110.52 159.73 17.26 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.192 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.445 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.72 144.77 15.32 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.904 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.72 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -118.91 171.26 8.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -179.334 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.7 p-10 -103.78 118.34 57.57 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-O 121.254 0.549 . . . . 0.0 110.857 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 47.9 Cg_endo -69.21 -11.54 31.81 Favored 'Trans proline' 0 CA--C 1.528 0.203 0 C-N-CA 122.936 2.424 . . . . 0.0 112.685 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.74 -34.55 71.99 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.428 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -115.23 20.99 14.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.463 -179.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -95.06 156.84 16.15 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.7 m -129.47 127.43 40.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.983 0.421 . . . . 0.0 110.672 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.28 94.71 9.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.664 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.27 141.58 15.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.807 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -115.48 148.23 39.7 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.34 127.16 31.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.201 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 5.4 p30 -75.86 -174.69 2.71 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.354 -179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.83 -18.82 64.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.909 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 51.8 m-20 -89.78 -0.17 57.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.945 0.402 . . . . 0.0 110.137 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.51 32.0 60.2 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.787 -0.721 . . . . 0.0 111.613 -179.458 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.23 148.78 43.81 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.928 0.394 . . . . 0.0 111.364 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.06 97.62 3.08 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.121 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 t -107.65 132.73 53.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.877 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.1 t -151.23 163.02 39.81 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.457 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.7 m -124.28 128.57 49.35 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.342 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.84 154.93 27.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -109.55 121.12 44.48 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.16 122.31 42.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.479 0.657 . . . . 0.0 112.25 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -99.36 161.36 13.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.482 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -76.72 -40.25 49.23 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.866 0.365 . . . . 0.0 110.457 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 m -126.98 140.6 52.19 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -160.74 179.27 8.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.959 0.409 . . . . 0.0 111.64 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -96.29 159.45 14.94 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.169 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.35 118.19 4.59 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.857 -179.44 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 23.9 m-85 -129.19 158.09 40.0 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.07 -178.21 4.72 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -88.52 7.24 34.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.863 0.363 . . . . 0.0 111.031 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.08 -21.25 13.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.078 0.466 . . . . 0.0 110.774 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 117.37 -3.9 18.06 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.521 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 77.3 m -85.03 141.76 30.06 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.643 0.259 . . . . 0.0 110.492 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.501 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -99.05 142.75 30.14 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.416 ' HB3' HG21 ' A' ' 40' ' ' VAL . 10.3 t-105 -104.44 -39.04 6.58 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.565 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.75 -149.3 15.36 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.96 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.16 151.52 32.55 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.791 0.329 . . . . 0.0 110.656 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.5 m -132.79 163.53 37.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.836 179.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -152.31 129.64 11.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.548 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.4 m -106.77 30.1 6.4 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.257 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.3 m -83.13 -31.65 27.1 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -127.95 11.88 6.64 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.821 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.14 175.5 9.19 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.949 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 139.94 34.04 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.117 0.484 . . . . 0.0 111.382 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.41 142.89 33.79 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.643 179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.536 ' NE2' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -131.54 161.21 33.13 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.633 0.254 . . . . 0.0 110.37 179.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.03 119.58 47.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.769 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -95.06 115.8 5.19 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.294 -0.723 . . . . 0.0 111.294 179.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.02 109.42 10.01 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.902 0.382 . . . . 0.0 110.614 -179.142 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.3 m -150.39 156.35 41.32 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.453 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.47 -171.69 3.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.631 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.66 -32.98 69.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.564 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.34 -10.89 59.75 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.082 0.468 . . . . 0.0 110.718 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 85.75 22.31 50.37 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.393 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -123.04 175.95 6.31 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.868 0.366 . . . . 0.0 110.76 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.64 -149.51 21.17 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -65.82 157.3 59.73 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.445 2.096 . . . . 0.0 111.535 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -73.17 144.71 46.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.312 -0.404 . . . . 0.0 109.967 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.542 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.51 134.85 35.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 121.272 -0.489 . . . . 0.0 112.903 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 62.0 t -106.42 130.28 58.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -95.31 142.18 28.01 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.635 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 11.6 pt -124.79 168.26 17.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.913 0.387 . . . . 0.0 110.94 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.6 m -144.4 152.18 40.32 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.183 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 8.9 m-85 -101.3 159.41 15.28 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.993 -178.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.39 -0.814 . . . . 0.0 110.511 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.72 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.972 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.34 116.1 65.98 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.014 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.13 168.81 16.68 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.553 2.168 . . . . 0.0 111.912 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.9 m -116.6 99.89 7.46 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.975 0.416 . . . . 0.0 110.496 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.74 114.43 26.34 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.501 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -121.23 91.07 3.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.11 0.481 . . . . 0.0 110.946 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 108' ' ' VAL . 23.0 m -111.91 149.07 14.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.664 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.9 m -106.6 100.42 30.52 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 147.38 58.07 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.413 2.075 . . . . 0.0 112.55 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 32.33 1.23 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.435 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.1 m -67.06 121.51 15.74 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.941 0.4 . . . . 0.0 110.616 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.78 27.21 14.81 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.093 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.461 HD13 HG21 ' A' ' 17' ' ' THR . 20.1 mt -134.9 176.38 8.71 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.49 -166.2 1.36 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.78 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -80.09 163.04 24.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 80.67 9.35 86.5 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.502 -0.856 . . . . 0.0 111.624 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.461 HG21 HD13 ' A' ' 13' ' ' LEU . 55.0 m -82.09 143.07 31.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.3 t -92.66 126.38 45.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.488 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 95' ' ' VAL . 62.3 t -104.33 119.4 53.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.342 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.3 ttmt -85.71 121.03 27.79 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.8 t -116.07 116.11 51.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.888 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.77 132.34 42.13 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.503 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.11 116.86 1.29 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.509 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.31 142.5 33.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.48 27.52 17.39 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.425 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.7 mt -98.16 -176.55 3.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.559 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -75.75 99.47 4.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.455 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.35 128.01 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.012 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.23 -3.81 58.36 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.41 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 90.4 m -109.34 146.23 34.73 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.54 134.61 34.51 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -108.78 127.07 53.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.8 120.33 27.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.254 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.1 t -128.56 125.83 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.756 0.312 . . . . 0.0 111.338 -178.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.66 179.11 33.64 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -87.68 126.0 34.72 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.449 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -132.67 157.71 44.15 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 120.903 0.382 . . . . 0.0 111.058 -178.137 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.19 179.86 8.87 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.58 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -61.49 109.4 1.16 Allowed 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.276 0.36 . . . . 0.0 110.666 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.535 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -98.3 -16.56 7.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.473 0.654 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.4 t70 -159.18 -178.47 7.22 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.397 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -71.73 97.79 1.83 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.978 0.418 . . . . 0.0 110.64 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.37 0.74 79.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.341 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.478 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 9.1 t -114.96 135.28 55.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.979 0.418 . . . . 0.0 110.017 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mp -125.08 144.3 50.48 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.06 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.81 150.69 45.01 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.536 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.799 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.8 m -102.14 177.3 4.92 Favored 'General case' 0 C--N 1.327 -0.373 0 O-C-N 123.21 0.318 . . . . 0.0 110.692 -179.392 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.9 p-10 -98.15 132.11 25.15 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.029 0.442 . . . . 0.0 111.395 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -87.9 -5.96 6.76 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.602 2.201 . . . . 0.0 112.329 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.68 -30.24 26.95 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -132.09 26.43 4.56 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.582 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 4.9 p90 -80.67 166.59 20.92 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 44.4 m -148.41 127.09 12.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.999 0.428 . . . . 0.0 110.844 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.54 120.31 40.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.243 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.6 p -110.39 134.46 52.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.247 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 3.0 m -93.73 131.33 39.18 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.694 0.283 . . . . 0.0 111.068 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 122.74 17.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -77.4 -177.92 4.92 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.124 -178.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.77 -17.93 64.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.329 -178.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -87.33 -2.78 58.86 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.46 22.53 69.99 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.926 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.47 167.59 10.19 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.668 0.27 . . . . 0.0 111.108 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -163.23 106.67 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.022 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 6.7 t -122.8 133.36 54.45 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.931 0.396 . . . . 0.0 110.817 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -147.76 168.54 21.87 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.573 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -122.52 127.31 49.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.322 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -116.85 138.95 51.16 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.488 -0.323 . . . . 0.0 111.656 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m -98.08 118.18 34.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.437 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.4 p -88.76 125.2 41.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.384 0.612 . . . . 0.0 112.163 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.8 mmt180 -97.54 162.16 13.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.119 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.437 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 5.5 tpp180 -72.66 -40.46 66.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.074 0.464 . . . . 0.0 110.42 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 m -131.13 143.03 50.33 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.542 ' HE1' ' SG ' ' A' ' 88' ' ' CYS . 51.9 p90 -149.12 173.1 13.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.628 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -95.95 121.23 37.47 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.021 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.2 115.45 4.06 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.768 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -126.4 147.91 49.7 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 81' ' ' THR . 66.0 mt -83.34 168.53 16.54 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.047 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -64.06 -24.61 67.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.675 0.274 . . . . 0.0 111.235 -179.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -19.09 40.46 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.952 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.38 -8.65 22.51 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.967 179.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 77' ' ' LEU . 23.3 m -69.65 127.85 34.39 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.51 0.655 . . . . 0.0 111.181 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.92 143.13 34.5 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.535 ' HB3' HG21 ' A' ' 40' ' ' VAL . 3.9 t-105 -114.78 -41.64 3.36 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.788 0.328 . . . . 0.0 110.651 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.13 174.58 35.69 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -85.77 117.63 24.77 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.788 0.328 . . . . 0.0 110.611 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.8 t -93.83 135.17 29.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.914 0.388 . . . . 0.0 110.295 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -114.84 120.91 41.59 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.069 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.542 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 91.5 m -101.64 18.39 20.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.101 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.437 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.7 m -82.52 -52.49 6.8 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 t -101.65 -10.45 20.02 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.999 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.71 166.15 12.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.023 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.59 152.78 39.23 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.984 0.421 . . . . 0.0 110.88 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -129.09 158.15 39.76 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.498 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 20.8 pt20 -153.06 167.94 27.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 111.113 179.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 19' ' ' VAL . 32.8 t -98.75 129.52 48.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.056 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.24 128.52 8.12 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.213 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.91 128.86 25.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.871 0.367 . . . . 0.0 110.156 179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.8 m -152.38 159.51 43.41 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.597 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -78.84 -170.59 2.22 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.446 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.75 -35.16 72.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.189 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.26 -54.58 6.3 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.781 0.324 . . . . 0.0 110.613 179.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.2 23.92 0.28 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.333 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 -113.37 177.67 4.55 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.06 -169.12 22.7 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.949 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.91 141.58 98.29 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.912 2.408 . . . . 0.0 112.114 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -59.26 141.2 54.95 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.089 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -63.15 142.64 47.7 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.134 -0.555 . . . . 0.0 111.89 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 48.1 t -107.04 130.0 59.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.597 0.237 . . . . 0.0 110.921 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.498 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -82.12 148.78 28.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.061 0.458 . . . . 0.0 111.066 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.52 171.51 13.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.939 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.5 m -143.79 135.09 25.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.56 0.219 . . . . 0.0 110.412 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -86.68 155.07 20.53 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.499 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.625 -0.702 . . . . 0.0 110.631 -179.539 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.799 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.934 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.04 106.9 50.26 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.73 179.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -78.82 172.88 14.37 Favored 'Trans proline' 0 N--CA 1.459 -0.512 0 C-N-CA 122.459 2.106 . . . . 0.0 111.779 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 4.7 p -125.64 118.45 25.7 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.039 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -117.38 95.87 5.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.057 0.456 . . . . 0.0 110.216 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.44 96.67 6.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.825 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 m -107.46 160.89 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.312 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -105.62 99.89 23.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -72.13 145.36 44.08 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.281 1.988 . . . . 0.0 112.152 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.7 p -93.62 27.87 2.51 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.109 -179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.36 110.48 1.66 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.795 0.331 . . . . 0.0 111.012 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.34 -6.12 45.68 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.08 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.856 HD13 HG21 ' A' ' 17' ' ' THR . 88.7 mt -94.28 178.96 5.46 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 122.781 -0.247 . . . . 0.0 110.395 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 m -105.31 -170.21 1.71 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.631 0.253 . . . . 0.0 110.642 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -83.33 146.86 28.27 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.172 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.64 -3.96 59.47 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.856 HG21 HD13 ' A' ' 13' ' ' LEU . 1.5 m -78.98 147.25 32.99 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.918 0.389 . . . . 0.0 110.809 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.579 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 61.4 t -94.08 119.83 42.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.438 -179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.7 t -92.55 123.05 44.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.321 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -93.95 129.41 40.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.056 0.455 . . . . 0.0 111.109 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.613 HG21 HG11 ' A' ' 34' ' ' VAL . 81.0 t -117.43 120.53 65.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.683 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -128.55 116.68 20.04 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.811 0.339 . . . . 0.0 110.752 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.27 124.35 5.43 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.677 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.68 140.7 51.96 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.742 0.306 . . . . 0.0 110.321 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.98 30.71 8.64 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.666 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 28.6 mt -98.62 -154.09 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 -179.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.6 tp60 -100.41 113.05 25.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.35 . . . . 0.0 110.42 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.37 121.65 14.29 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.58 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.61 -25.13 13.87 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.188 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.3 p -86.13 147.96 25.91 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 117.327 0.564 . . . . 0.0 111.315 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.02 135.4 42.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -112.32 124.6 52.83 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.444 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.12 120.45 32.08 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.368 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.727 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.5 t -124.78 132.84 70.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.248 -178.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -160.17 173.81 36.84 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 178.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 2.1 pt20 -81.84 124.88 30.06 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.535 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -129.31 157.8 40.86 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.026 -178.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -153.44 -178.99 7.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.016 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 35.4 m95 -74.72 112.25 10.74 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 123.327 0.392 . . . . 0.0 110.21 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 p -99.32 -21.71 5.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.104 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -154.79 -172.58 4.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.894 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -70.14 91.58 0.71 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.093 0.473 . . . . 0.0 111.658 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -2.28 84.3 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.7 t -103.95 130.78 54.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.672 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.3 mt -113.49 154.5 26.95 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.694 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.24 141.86 25.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.831 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 14.4 m -104.73 163.87 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.27 -179.409 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.463 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 20.2 t-20 -82.4 122.28 78.91 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.793 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.74 27.39 0.44 Allowed 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.157 2.571 . . . . 0.0 112.941 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.32 -61.79 1.69 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.78 0.324 . . . . 0.0 111.077 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.46 26.27 3.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.879 0.371 . . . . 0.0 111.14 -179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.0 p90 -85.95 163.15 18.19 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.686 179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.9 m -151.91 107.72 3.37 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -74.15 129.72 38.38 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 178.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.425 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.6 p -116.74 133.57 62.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.148 0.499 . . . . 0.0 111.2 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.6 t -91.43 140.45 29.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.35 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.69 129.11 35.13 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -66.74 174.53 2.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.756 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.42 -13.74 33.07 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -91.59 -14.62 29.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.76 0.314 . . . . 0.0 110.362 -179.562 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.33 28.53 11.45 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.34 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -115.81 149.91 37.81 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.664 0.268 . . . . 0.0 110.438 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.46 120.3 7.6 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.933 0.397 . . . . 0.0 111.03 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.1 t -134.78 141.77 46.53 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 5.9 t -156.72 172.52 18.46 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.4 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.579 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.7 m -128.01 133.62 49.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.164 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -123.0 137.59 54.92 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.429 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.69 118.47 30.15 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -82.98 128.98 38.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.235 0.541 . . . . 0.0 111.553 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -110.03 162.91 14.09 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.211 179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.2 tpp180 -77.73 -36.24 51.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.414 0.625 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -133.69 146.65 51.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.862 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 40.0 p90 -163.29 168.85 19.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.199 0.523 . . . . 0.0 111.784 -178.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -85.07 145.57 27.6 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.534 178.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -97.14 122.8 7.57 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.219 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.9 144.19 51.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.767 0.317 . . . . 0.0 110.206 -178.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.456 HD12 ' HB ' ' A' ' 81' ' ' THR . 17.6 mt -94.52 158.59 15.48 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -68.5 -18.59 64.41 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -178.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.51 -19.23 56.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.877 0.37 . . . . 0.0 110.723 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.72 -1.87 27.51 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.036 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.456 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.4 m -93.45 146.78 23.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.925 0.393 . . . . 0.0 110.803 179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 39.5 ptt180 -96.96 150.51 20.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.46 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -112.66 -29.43 7.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.142 0.496 . . . . 0.0 110.322 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.92 -150.91 23.04 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 111.427 -0.669 . . . . 0.0 111.427 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.72 149.2 29.34 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 117.063 0.431 . . . . 0.0 110.346 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.3 t -126.71 152.6 34.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -138.19 134.63 34.75 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.614 0.245 . . . . 0.0 110.656 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.6 m -120.26 31.21 6.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.671 0.272 . . . . 0.0 111.121 -179.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.1 m -66.22 -37.82 86.47 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.3 t -122.38 -18.87 6.62 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.068 0.461 . . . . 0.0 109.858 178.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -86.18 173.58 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.552 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.36 133.53 48.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.458 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.1 m -105.95 157.82 17.23 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.521 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 3.6 pm0 -139.77 155.84 47.09 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.241 0.543 . . . . 0.0 111.042 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.0 t -85.2 114.62 25.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.386 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.535 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.16 119.6 6.46 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.708 -179.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.727 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.3 pt? -131.38 129.1 40.9 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 m -147.48 156.39 42.8 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.995 0.426 . . . . 0.0 110.968 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -80.45 -167.7 1.44 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.314 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.29 -32.04 71.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.294 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.78 -53.69 5.7 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.53 25.08 0.21 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.753 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -121.56 -172.18 2.37 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.85 -164.82 23.59 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.908 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.63 154.32 37.47 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.842 2.361 . . . . 0.0 112.139 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -64.03 148.9 48.63 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.325 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.88 153.63 45.73 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.643 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.5 t -119.73 126.3 75.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.889 0.345 . . . . 0.0 110.648 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.53 146.3 29.29 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 93' ' ' CYS . 2.2 pp -135.08 162.93 37.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.2 -0.454 . . . . 0.0 109.907 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.3 m -150.34 149.88 30.69 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.502 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 44.4 m-85 -92.54 162.47 14.19 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.5 p30 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.463 -0.78 . . . . 0.0 109.772 179.318 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.831 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.35 114.85 50.59 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -85.01 160.41 11.68 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.626 2.217 . . . . 0.0 111.778 179.484 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.621 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.7 m -100.73 111.09 23.25 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.815 0.34 . . . . 0.0 111.301 -179.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -100.37 71.88 1.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.291 0.567 . . . . 0.0 110.033 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -84.21 83.18 8.06 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.455 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.8 m -118.85 145.73 24.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.539 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -113.19 108.77 52.49 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.78 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.14 142.0 16.76 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 122.444 2.096 . . . . 0.0 112.785 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -87.23 57.7 4.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.491 . . . . 0.0 110.894 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -77.11 117.17 18.41 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.021 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.63 -9.13 68.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.995 -0.622 . . . . 0.0 112.791 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.4 mt -93.05 161.57 14.38 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.551 -0.382 . . . . 0.0 110.079 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -86.69 -176.15 5.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.798 0.332 . . . . 0.0 110.928 -179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -72.87 165.06 25.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.706 0.288 . . . . 0.0 110.24 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.98 -8.83 76.83 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.336 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 20.2 m -76.18 145.26 39.99 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 13.6 t -97.47 120.82 47.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.941 0.401 . . . . 0.0 110.843 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.6 t -80.15 129.1 38.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.061 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -87.27 115.76 24.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.308 -179.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.4 t -120.79 115.01 45.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.757 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.55 111.71 9.04 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.967 0.413 . . . . 0.0 110.717 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.61 126.47 8.04 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.666 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.621 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -118.2 147.32 43.5 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.3 -0.259 . . . . 0.0 110.3 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.08 33.13 30.15 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.327 -179.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.438 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.5 mt -97.74 -156.08 0.52 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.425 -0.387 . . . . 0.0 110.27 -179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.5 tp60 -103.65 113.54 27.12 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 134.67 57.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.75 0.31 . . . . 0.0 111.622 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 35.55 21.69 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.854 -0.688 . . . . 0.0 113.823 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -129.79 152.24 49.5 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 117.125 0.463 . . . . 0.0 110.508 179.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.71 132.37 51.04 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.703 -0.226 . . . . 0.0 110.668 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.492 ' HE2' ' HB2' ' A' ' 57' ' ' ALA . 94.1 m-85 -111.43 150.1 30.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.134 0.492 . . . . 0.0 110.801 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -117.37 109.59 17.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.184 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 40.9 t -124.94 132.18 71.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.853 0.359 . . . . 0.0 111.624 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.35 -179.45 34.18 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.525 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 pt20 -90.05 122.1 32.72 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -124.58 154.63 40.35 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.025 -178.7 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.54 164.91 28.65 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -65.99 109.94 2.73 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.052 0.453 . . . . 0.0 109.882 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.2 p -105.84 -12.28 9.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.047 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.475 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 6.3 t0 -167.67 176.44 6.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.507 . . . . 0.0 109.843 179.145 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.41 96.84 0.17 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.967 0.413 . . . . 0.0 111.45 -179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.58 9.41 83.29 Favored Glycine 0 N--CA 1.451 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.071 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 7.6 t -122.09 135.62 61.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.982 0.42 . . . . 0.0 110.822 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -123.58 171.39 9.57 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.21 127.63 13.13 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.804 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.6 m -101.69 171.49 7.52 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 123.158 0.287 . . . . 0.0 110.577 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -95.65 123.3 56.55 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 121.028 0.442 . . . . 0.0 110.995 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HD2' ' OE1' ' A' ' 74' ' ' GLU . 94.4 Cg_endo -86.37 -14.47 4.75 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.794 2.329 . . . . 0.0 113.125 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.82 -50.43 17.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.591 0.234 . . . . 0.0 111.417 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -105.41 43.29 1.13 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.91 0.386 . . . . 0.0 110.802 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -95.65 167.69 11.13 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.228 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -133.64 109.39 9.16 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.944 0.402 . . . . 0.0 111.507 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -84.8 78.98 9.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.2 179.094 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.9 p -87.73 145.54 7.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.112 0.482 . . . . 0.0 111.018 -179.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 2.3 t -115.56 148.14 39.89 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.812 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB2' ' HE2' ' A' ' 32' ' ' TYR . . . -76.16 133.85 40.1 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.3 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.8 p30 -71.47 -177.41 1.82 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.66 -7.79 47.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.781 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -94.13 -18.47 21.73 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.71 29.78 7.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.754 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.11 146.9 48.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.788 0.328 . . . . 0.0 111.184 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.02 112.2 9.09 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.21 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -117.12 130.73 56.82 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.524 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.3 t -151.46 176.22 11.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.021 0.438 . . . . 0.0 111.237 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.44 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 0.7 OUTLIER -130.47 135.86 48.4 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.069 -179.23 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.43 ' HA ' HD13 ' A' ' 67' ' ' LEU . 3.0 mm? -122.69 123.36 40.94 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.666 0.269 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.17 111.48 19.85 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 14.9 p -81.05 131.1 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.16 0.505 . . . . 0.0 111.043 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.5 mmt180 -110.77 162.29 14.93 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -83.53 -31.09 26.6 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.275 0.56 . . . . 0.0 109.908 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.8 m -132.99 120.56 21.55 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -135.73 170.64 15.65 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.082 0.468 . . . . 0.0 111.897 -178.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.462 ' OE1' ' HD2' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -93.31 113.95 26.26 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.382 179.177 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.26 122.28 6.8 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.515 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.451 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.5 m-85 -127.18 142.39 51.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.1 mt -84.53 167.85 15.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.832 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -63.49 -32.08 73.42 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.211 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.86 -22.31 59.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.884 0.373 . . . . 0.0 110.797 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.2 -4.18 20.27 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.289 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.6 m -65.68 130.8 44.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.048 0.451 . . . . 0.0 111.146 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -93.13 130.73 38.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.946 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -100.02 -46.97 5.16 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.802 0.334 . . . . 0.0 110.505 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.35 -172.41 30.88 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.736 -0.745 . . . . 0.0 111.989 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.6 m -79.72 119.71 23.01 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.854 0.359 . . . . 0.0 111.041 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.1 t -98.89 131.19 46.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -93.1 131.2 38.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -114.68 18.12 16.81 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.66 179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.44 -33.5 15.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.886 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -107.68 9.47 29.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.432 179.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.15 -162.46 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -132.45 148.67 52.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.983 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 79.0 m -119.61 157.0 29.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.634 0.254 . . . . 0.0 110.827 -179.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.475 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.4 OUTLIER -119.33 162.84 18.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.015 0.436 . . . . 0.0 111.171 -179.596 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.2 t -87.54 120.12 36.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.294 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -85.12 105.18 2.86 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.228 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 83.7 mt -102.24 101.75 12.07 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.3 151.82 47.94 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.85 0.357 . . . . 0.0 111.432 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -100.89 -160.51 0.8 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.145 179.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.47 -36.4 80.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 120.859 0.362 . . . . 0.0 110.498 178.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.14 -52.14 6.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.747 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.0 28.93 0.53 Allowed Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.644 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 83.2 m-20 -120.12 -178.64 3.71 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.41 -168.66 23.38 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.156 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -60.79 156.54 42.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.131 2.554 . . . . 0.0 112.212 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -68.84 144.76 54.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.313 -179.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.11 143.07 22.77 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.145 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.7 t -105.64 134.6 46.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -88.79 125.29 34.83 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.939 0.4 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 24.8 pt -104.1 159.99 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.019 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.8 m -138.4 140.96 39.59 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.412 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -87.27 171.95 10.24 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.248 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.9 p30 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.595 -0.717 . . . . 0.0 109.941 179.656 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.804 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.93 117.54 68.96 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.96 -179.768 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.41 160.39 35.51 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.256 1.971 . . . . 0.0 111.527 179.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.05 62.3 0.95 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.186 0.517 . . . . 0.0 111.167 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.45 121.35 25.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.919 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.58 104.79 9.58 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.043 0.449 . . . . 0.0 110.305 179.754 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 108' ' ' VAL . 13.9 m -119.46 142.19 35.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.379 -178.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 m -109.49 106.79 58.97 Favored Pre-proline 0 C--N 1.321 -0.672 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.07 179.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -72.41 150.65 52.53 Favored 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.669 2.246 . . . . 0.0 112.336 -179.657 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.5 m -101.29 31.42 3.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.022 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.0 m -66.01 113.34 4.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.715 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.38 -8.08 32.6 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 71.1 mt -96.15 167.95 10.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -90.54 -179.42 5.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.646 -178.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -74.35 153.77 39.14 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.23 -0.11 77.86 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.457 -0.878 . . . . 0.0 110.954 -178.904 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 87.2 m -79.61 142.0 36.02 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 120.968 0.414 . . . . 0.0 110.437 179.531 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.614 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 80.9 t -92.97 120.91 43.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.882 179.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.2 t -84.72 137.22 21.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.577 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.1 ttmt -96.44 118.9 33.92 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.854 0.359 . . . . 0.0 110.946 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.2 t -119.39 105.29 17.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.493 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.49 98.23 6.03 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.975 0.417 . . . . 0.0 110.725 179.804 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.6 134.23 11.66 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.627 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -132.74 154.09 50.55 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.409 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 36.29 46.26 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -178.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.4 mt -104.72 178.63 4.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.417 -0.392 . . . . 0.0 109.966 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.2 tp60 -79.05 109.27 13.2 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.23 135.94 56.01 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.289 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.53 -22.77 36.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.769 179.798 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.44 149.19 21.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.842 0.353 . . . . 0.0 111.288 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.93 151.16 19.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.521 179.388 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -124.05 139.68 53.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.602 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -104.94 113.9 27.78 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.421 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.5 t -127.18 127.21 69.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.248 -179.079 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.64 178.7 35.64 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.7 pt20 -83.02 126.53 32.65 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.304 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.521 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -135.9 165.05 26.54 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.772 0.32 . . . . 0.0 111.065 -178.387 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.676 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.78 -179.91 6.14 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.704 179.315 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -71.01 113.53 8.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.7 0.286 . . . . 0.0 110.346 179.666 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p -95.74 -27.88 4.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.111 0.482 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -146.46 -172.82 4.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.347 179.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.93 95.43 0.53 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.44 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.76 5.52 89.77 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.284 179.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.1 t -108.44 126.33 65.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.783 0.325 . . . . 0.0 110.59 -179.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 mt -105.01 152.97 22.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.889 179.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.42 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.71 140.87 21.29 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.031 -179.895 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.848 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 72.9 m -102.84 176.9 5.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.556 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.2 t-20 -110.81 116.66 51.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.357 179.194 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -83.93 0.1 9.42 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 123.015 2.477 . . . . 0.0 113.334 -179.25 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.83 -36.36 23.54 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.851 0.358 . . . . 0.0 110.637 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.06 37.24 4.42 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.936 -179.687 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -96.39 160.11 14.59 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.2 m -119.66 126.11 50.34 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.978 0.418 . . . . 0.0 111.234 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 m -87.62 94.78 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.799 179.238 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.65 143.18 20.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.43 -179.524 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.4 t -124.32 152.22 43.37 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.045 179.822 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.44 122.77 22.65 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -75.5 -175.24 2.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.608 -178.909 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.76 -11.16 33.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.236 -179.519 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 60.4 m-80 -98.27 -2.31 39.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.903 0.383 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.07 38.28 48.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.064 -0.588 . . . . 0.0 111.945 179.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.77 154.51 50.18 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.924 0.392 . . . . 0.0 111.03 -179.249 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.51 101.47 3.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.118 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.3 t -111.6 129.95 55.91 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.629 179.496 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.3 t -152.08 174.26 13.9 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.62 -179.466 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.614 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.1 m -124.71 138.21 54.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.532 -179.451 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.429 ' HA ' HD13 ' A' ' 67' ' ' LEU . 3.2 mm? -122.25 138.23 54.56 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-O 120.709 0.29 . . . . 0.0 111.477 -179.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -98.66 115.2 28.16 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.777 0.322 . . . . 0.0 110.27 179.06 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -91.04 123.0 43.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.519 0.676 . . . . 0.0 111.309 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -99.97 167.83 10.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.747 179.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -72.07 -44.74 62.81 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.0 0.429 . . . . 0.0 110.847 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.2 m -132.97 143.93 49.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 49.1 p90 -154.58 169.61 23.43 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.163 0.506 . . . . 0.0 112.001 -178.467 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -88.82 135.99 33.24 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.149 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -93.53 126.52 8.66 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.632 -178.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 11.9 m-85 -124.08 144.95 49.57 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.444 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 70.9 mt -83.97 165.94 18.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.73 -22.48 66.99 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.285 0.476 . . . . 0.0 112.285 -178.672 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -79.58 -28.02 41.11 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.284 -179.574 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.7 -18.73 5.65 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.217 179.698 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -81.62 140.43 34.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.756 0.278 . . . . 0.0 110.868 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.25 157.16 18.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.924 0.392 . . . . 0.0 110.616 179.578 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.441 ' CE3' HD11 ' A' ' 77' ' ' LEU . 19.6 t-105 -114.64 -27.08 7.61 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.637 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.75 -152.42 23.88 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.569 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 p -112.44 139.58 47.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.87 0.335 . . . . 0.0 111.093 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.676 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.5 t -114.96 137.35 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.755 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -117.68 122.31 43.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.973 0.416 . . . . 0.0 111.26 -179.31 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 80.6 m -106.65 25.44 11.2 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.466 0.65 . . . . 0.0 109.966 179.137 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.9 m -87.78 -47.33 8.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.575 -0.738 . . . . 0.0 109.255 178.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -98.28 -20.87 16.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.024 178.761 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.41 -178.35 3.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.522 179.942 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.07 162.68 13.78 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 -179.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -126.6 158.48 36.15 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -145.67 168.62 20.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.372 0.606 . . . . 0.0 111.492 179.537 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.1 t -100.43 127.21 53.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.711 -179.662 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.521 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.78 123.7 7.26 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 111.57 -0.612 . . . . 0.0 111.57 179.598 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.73 114.51 8.93 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.509 0.195 . . . . 0.0 110.815 -178.811 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.3 m -155.12 169.21 24.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 179.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.2 -172.93 4.31 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.3 179.262 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.07 70.57 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.712 0.291 . . . . 0.0 111.746 -179.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.01 -43.01 46.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.278 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 118.63 35.49 0.98 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.89 179.155 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -135.18 164.86 26.72 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 179.222 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 142.21 -145.47 15.72 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.907 -0.664 . . . . 0.0 112.092 179.75 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.29 150.76 87.7 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.642 2.228 . . . . 0.0 112.463 -179.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -73.87 138.39 44.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.51 -179.859 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.9 152.73 42.52 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.82 -179.61 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.417 HG21 HG21 ' A' ' 7' ' ' VAL . 15.9 t -117.82 129.84 73.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.398 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.79 139.11 30.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.517 179.523 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 16.4 pt -128.43 167.54 23.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.822 0.344 . . . . 0.0 110.38 -179.91 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.1 m -145.83 149.15 33.78 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.57 -179.959 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 68.7 m-85 -93.05 167.28 11.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.77 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.479 -0.772 . . . . 0.0 110.026 -179.841 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.848 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.028 0 CA-C-O 120.776 0.322 . . . . 0.0 110.581 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.72 121.57 84.42 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.088 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -82.58 177.28 7.09 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.785 2.324 . . . . 0.0 111.968 179.488 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.75 73.7 1.52 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.124 0.488 . . . . 0.0 111.118 -179.717 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.86 112.88 9.3 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.321 179.6 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.56 105.38 12.01 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.856 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.6 m -124.22 145.72 30.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.977 0.417 . . . . 0.0 111.538 -179.448 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -111.36 98.65 40.9 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.709 178.868 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.26 145.73 39.23 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.462 2.108 . . . . 0.0 112.538 -179.164 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.7 m -86.26 38.29 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.03 0.443 . . . . 0.0 111.216 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 m -67.72 128.33 36.07 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.626 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.31 9.08 65.57 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.16 179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 79.1 mt -116.34 -169.38 1.6 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.636 0.255 . . . . 0.0 110.891 -179.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -114.96 -172.2 2.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.783 -179.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -77.0 156.61 31.74 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.582 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.28 -1.29 72.93 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.461 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.1 m -78.27 149.11 33.62 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.842 0.353 . . . . 0.0 110.572 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 60.0 t -95.83 120.68 45.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.262 179.597 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.2 t -87.51 128.53 39.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.208 179.492 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -93.78 120.75 34.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.121 179.935 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.502 HG21 HG11 ' A' ' 34' ' ' VAL . 86.5 t -121.25 116.52 49.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.745 -179.871 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 95.3 4.5 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.221 0.534 . . . . 0.0 110.382 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.42 96.06 2.16 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.083 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -98.13 134.89 40.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.799 0.333 . . . . 0.0 110.418 179.689 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.4 32.26 8.35 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.778 -179.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.2 mt -101.19 -179.45 4.04 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 14.4 tp60 -84.41 108.11 17.04 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.919 0.39 . . . . 0.0 110.491 -179.669 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.06 133.62 52.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.677 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.31 -15.65 61.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.765 -0.731 . . . . 0.0 113.051 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.08 146.14 23.87 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.772 0.32 . . . . 0.0 111.041 -179.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.69 132.53 43.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.154 179.29 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -111.89 134.21 53.6 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.906 0.384 . . . . 0.0 110.776 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.4 121.14 33.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.016 -179.401 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 21' ' ' VAL . 9.5 t -129.99 126.8 62.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.939 0.399 . . . . 0.0 110.963 -179.456 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.86 -179.9 32.16 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.0 pt20 -85.99 50.4 1.97 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.484 0.659 . . . . 0.0 110.076 179.506 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.7 m -64.16 101.21 0.39 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.592 -179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.4 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -107.54 -179.0 3.79 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.761 -179.756 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -66.98 117.76 9.49 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.454 -179.719 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.521 HG23 HG22 ' A' ' 86' ' ' VAL . 8.8 p -103.63 -18.22 6.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.39 0.615 . . . . 0.0 110.195 179.67 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -161.51 -177.52 6.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.402 179.915 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.7 m -69.27 101.83 1.58 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.095 0.474 . . . . 0.0 110.538 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.57 2.75 90.66 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.036 -179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -115.91 132.5 65.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.04 0.448 . . . . 0.0 110.347 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.54 164.58 15.61 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.1 142.97 19.98 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.545 -179.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.649 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 58.6 m -93.87 169.84 10.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.519 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.554 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 20.9 p-10 -106.84 114.93 61.16 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.998 0.428 . . . . 0.0 110.444 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.8 Cg_endo -79.92 2.12 8.68 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.651 2.234 . . . . 0.0 112.484 -179.403 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.96 -24.29 16.46 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.712 -179.267 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 21.0 m-20 -140.02 41.52 1.96 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.281 -179.044 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.554 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 7.8 p90 -104.63 175.22 5.56 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.5 m -150.19 130.87 14.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.945 0.402 . . . . 0.0 110.893 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.83 106.87 19.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.487 179.076 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 p -96.81 124.92 49.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.436 0.636 . . . . 0.0 111.388 -178.788 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.0 t -92.21 132.16 36.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.412 179.138 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.87 124.99 24.52 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.428 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -72.73 179.0 3.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.971 -0.558 . . . . 0.0 111.45 -179.011 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.46 -8.3 25.27 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.78 -0.646 . . . . 0.0 112.238 -179.284 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.9 -14.8 22.85 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.024 0.44 . . . . 0.0 109.978 179.649 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.95 25.33 29.68 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.268 -0.733 . . . . 0.0 111.268 -179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.57 156.95 21.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.903 0.382 . . . . 0.0 110.733 -179.705 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.99 89.31 1.88 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.962 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 50.3 m -100.84 125.77 47.39 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.211 179.295 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -149.39 170.23 19.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.564 179.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.513 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -130.82 136.38 48.62 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.258 -179.276 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 67' ' ' LEU . 2.7 mm? -123.33 146.74 47.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 111.66 -179.213 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.0 113.47 26.49 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.258 179.015 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 p -85.21 123.96 39.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.134 0.493 . . . . 0.0 111.249 -179.444 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.9 mmt180 -97.2 161.21 13.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.088 179.482 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.0 tpp180 -76.86 -27.02 54.9 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.816 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -145.61 141.53 28.26 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.916 178.793 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.545 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.4 p90 -156.17 173.81 16.29 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.851 0.357 . . . . 0.0 111.163 -179.136 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -103.13 124.27 48.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.26 133.67 12.36 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.236 -178.68 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.482 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.1 m-85 -129.64 143.55 50.87 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.887 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.552 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 13.8 mt -86.06 169.1 13.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.442 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -64.96 -27.53 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -179.252 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -73.62 -24.53 60.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.615 179.686 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.86 -7.69 17.09 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.064 179.256 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.515 ' HB ' HD12 ' A' ' 77' ' ' LEU . 97.2 m -77.68 139.08 39.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.862 0.363 . . . . 0.0 111.018 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -90.22 115.34 27.38 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.293 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -73.19 -47.11 46.38 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.884 0.373 . . . . 0.0 110.308 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 169.66 -177.36 43.2 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.888 -0.672 . . . . 0.0 111.691 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -82.12 139.26 34.49 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.708 0.289 . . . . 0.0 110.645 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 40' ' ' VAL . 12.5 t -116.84 128.92 74.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -118.18 135.72 54.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.116 0.484 . . . . 0.0 111.248 -179.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.3 m -121.39 32.82 5.75 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.072 179.342 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -87.97 -44.49 10.97 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.758 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.5 t -102.86 0.23 32.24 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.365 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.81 177.24 7.56 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.079 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.87 144.21 37.08 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.438 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -94.11 -176.34 3.96 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.134 0.492 . . . . 0.0 110.933 -179.41 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.4 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 20.9 pt20 -158.33 172.56 18.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.506 179.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.1 t -113.75 127.62 71.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.728 0.299 . . . . 0.0 110.937 -179.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.63 122.27 6.37 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 111.674 -0.571 . . . . 0.0 111.674 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -133.86 113.51 12.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.639 0.257 . . . . 0.0 110.523 -179.44 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.8 m -156.93 168.16 28.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.73 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -83.08 -173.98 5.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.73 -31.84 71.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.682 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.06 -22.39 42.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.796 0.331 . . . . 0.0 110.775 179.782 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.16 28.51 6.81 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.823 179.542 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -119.2 170.95 8.64 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.693 0.282 . . . . 0.0 110.466 -179.787 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.83 -134.98 7.74 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.922 -0.656 . . . . 0.0 111.831 179.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -80.17 174.53 11.32 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.847 2.365 . . . . 0.0 111.858 179.585 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -92.06 148.77 21.93 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.634 -0.257 . . . . 0.0 110.776 179.805 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.9 151.75 47.9 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.331 -179.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 49.8 t -119.59 130.78 73.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.14 34.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.51 125.33 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.325 0.583 . . . . 0.0 111.092 -179.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -97.14 137.65 35.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.584 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -88.88 151.76 22.15 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.253 179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.9 p30 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.463 -0.779 . . . . 0.0 110.257 179.87 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.649 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.38 109.92 45.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-O 120.641 0.258 . . . . 0.0 110.483 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.07 166.93 14.4 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.652 2.234 . . . . 0.0 112.165 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 m -126.74 97.35 4.96 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.212 0.53 . . . . 0.0 110.861 -179.915 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.28 92.97 9.38 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.696 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.2 97.75 11.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.62 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 m -118.68 142.44 33.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.891 0.377 . . . . 0.0 111.127 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.25 94.07 44.19 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.024 179.002 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.65 155.95 61.99 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.936 2.424 . . . . 0.0 113.094 -179.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.6 30.3 3.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.413 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -62.57 107.63 0.98 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.12 0.486 . . . . 0.0 110.682 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.36 -11.83 19.27 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.972 -0.633 . . . . 0.0 111.538 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.5 HD13 HG21 ' A' ' 17' ' ' THR . 33.0 mt -102.9 155.37 18.39 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -76.29 174.05 10.65 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -179.686 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.63 157.62 36.88 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 120.976 0.417 . . . . 0.0 110.359 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.81 -7.83 67.93 Favored Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -178.347 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.5 HG21 HD13 ' A' ' 13' ' ' LEU . 29.9 m -77.69 146.6 35.93 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.863 0.363 . . . . 0.0 110.319 179.868 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.3 t -92.01 124.43 44.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.124 0.488 . . . . 0.0 111.29 -179.047 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.494 HG11 HG21 ' A' ' 95' ' ' VAL . 33.7 t -93.99 129.59 44.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.713 179.059 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -95.47 127.16 41.29 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.78 0.324 . . . . 0.0 110.964 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.8 t -125.68 106.43 16.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.974 179.267 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 64' ' ' SER . . . -119.59 98.56 6.18 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.96 0.409 . . . . 0.0 110.716 -179.865 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.01 117.33 5.47 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.4 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.72 140.77 40.27 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 178.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.23 29.64 10.08 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.346 -179.241 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.2 mt -97.69 174.89 6.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.341 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.0 tp60 -85.22 112.64 20.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.715 0.293 . . . . 0.0 110.269 -179.79 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.35 141.43 54.55 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.75 -179.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.89 -4.51 81.72 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.868 179.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.04 149.95 23.73 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.662 0.268 . . . . 0.0 110.938 -179.795 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -99.34 136.58 39.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.309 -0.405 . . . . 0.0 109.978 179.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -117.29 129.89 56.19 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.154 0.502 . . . . 0.0 111.134 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -90.29 127.09 36.06 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.949 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 48.7 t -131.43 128.97 61.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.694 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.78 176.73 35.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.049 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 18.7 pt20 -83.56 55.42 3.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 122.007 0.908 . . . . 0.0 109.081 179.192 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -65.12 106.19 1.24 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.11 -178.643 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.82 -177.22 3.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.023 179.565 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -67.04 124.75 23.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -109.34 -20.78 6.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.322 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -159.87 -169.47 2.55 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.622 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.8 m -72.51 99.19 2.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.096 0.474 . . . . 0.0 110.756 -179.731 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.54 -0.37 89.63 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.576 -179.872 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.5 t -110.35 137.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.75 0.309 . . . . 0.0 110.342 -179.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.5 mp -121.16 162.22 20.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.934 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -151.31 144.45 24.66 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.494 0.188 . . . . 0.0 111.209 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.631 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.6 m -95.3 168.55 10.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.845 -179.783 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 22.8 p-10 -90.29 123.63 65.14 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.001 0.429 . . . . 0.0 110.571 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' CG ' ' A' ' 76' ' ' PHE . 61.7 Cg_endo -86.19 10.34 3.69 Favored 'Trans proline' 0 C--O 1.233 0.271 0 C-N-CA 123.269 2.646 . . . . 0.0 113.585 -179.268 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.04 -75.85 0.62 Allowed 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.032 -179.555 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -97.13 68.21 2.24 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.048 0.451 . . . . 0.0 112.005 -178.705 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -120.1 166.78 12.95 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.4 m -150.43 102.23 3.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.632 -179.673 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -73.69 135.29 43.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.617 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 8.7 p -120.06 142.48 35.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.138 0.494 . . . . 0.0 111.299 -178.935 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 t -97.07 143.91 27.45 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.858 179.429 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.22 127.52 32.82 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.35 178.09 8.35 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.63 -179.136 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -26.78 68.44 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.928 -179.05 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -79.99 -2.5 44.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.845 -179.724 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.79 36.87 35.6 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.05 179.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.22 153.17 51.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.944 0.402 . . . . 0.0 111.002 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.64 110.77 6.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.53 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 5.4 m -109.76 129.43 55.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.308 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 11.1 t -143.02 167.31 22.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.465 -179.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.561 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 38.6 m -125.45 142.19 51.64 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.402 ' HA ' HD22 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -129.26 120.04 25.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.649 0.261 . . . . 0.0 110.984 -179.798 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -83.28 97.79 9.07 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.92 118.66 13.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.578 0.704 . . . . 0.0 111.667 -178.774 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -95.57 160.69 14.39 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.735 179.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -74.67 -35.24 62.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.114 0.483 . . . . 0.0 110.194 -179.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.9 m -131.15 133.16 45.3 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.325 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -142.8 178.73 7.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.047 0.451 . . . . 0.0 111.344 -178.718 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -107.31 145.19 33.1 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.37 122.84 6.21 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.926 -179.394 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.411 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -129.45 138.65 51.55 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.705 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.7 mt -92.09 168.39 11.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.179 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 7.3 m-85 -69.95 -25.05 63.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.808 0.337 . . . . 0.0 111.287 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -77.27 -14.6 59.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.364 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.07 1.19 38.82 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.679 -0.772 . . . . 0.0 113.609 178.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 26.9 m -87.73 140.83 29.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 117.356 0.578 . . . . 0.0 110.9 179.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -91.21 150.05 21.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.83 -61.48 1.6 Allowed 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.935 0.397 . . . . 0.0 110.812 -179.592 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.12 176.78 43.69 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.778 -179.767 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.6 m -77.08 124.96 28.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.99 0.395 . . . . 0.0 111.125 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.6 t -110.51 131.57 61.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.316 -0.402 . . . . 0.0 109.974 179.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -112.88 128.54 56.49 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.845 0.355 . . . . 0.0 111.163 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -110.71 27.74 9.37 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.037 0.446 . . . . 0.0 110.378 179.662 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.3 m -83.1 -37.3 23.99 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 178.711 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.8 t -113.81 18.6 17.27 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.961 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.32 166.4 24.84 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.107 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.5 118.49 31.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.724 0.297 . . . . 0.0 110.69 179.754 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -83.17 171.32 13.79 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.239 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 10.2 pt20 -152.7 172.37 16.77 Favored 'General case' 0 C--N 1.323 -0.571 0 O-C-N 122.329 -0.232 . . . . 0.0 110.385 179.809 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.494 HG21 HG11 ' A' ' 19' ' ' VAL . 8.3 t -114.46 138.68 43.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.607 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -130.02 145.78 16.87 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.516 179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.77 130.94 15.46 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 28.6 m -155.17 165.62 36.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.564 0.221 . . . . 0.0 110.586 179.646 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.14 -175.0 5.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.434 179.188 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.66 71.07 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.73 -39.45 57.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.078 0.466 . . . . 0.0 110.5 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.81 26.53 1.91 Allowed Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.709 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.6 m-20 -124.33 172.4 9.15 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.739 0.304 . . . . 0.0 110.296 179.884 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.33 -167.78 25.37 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.942 179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.62 151.05 40.65 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.877 2.384 . . . . 0.0 112.379 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -66.41 149.63 50.12 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.058 -179.622 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.53 170.97 54.42 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.1 t -136.05 131.44 49.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.524 0.202 . . . . 0.0 110.707 -179.454 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -91.4 142.48 27.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.24 179.417 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.1 pt -129.48 178.8 4.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.154 0.502 . . . . 0.0 111.016 -179.014 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.3 m -153.29 146.4 24.64 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.945 179.286 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -95.9 154.69 17.1 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.152 -179.984 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.631 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.107 0 CA-C-O 120.684 0.278 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.92 115.45 63.6 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.522 179.646 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -81.13 171.56 13.85 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.866 2.377 . . . . 0.0 112.979 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -104.67 96.22 6.43 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.142 179.61 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.9 70.41 4.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 110.504 179.744 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -92.69 109.07 20.48 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.673 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.95 148.68 32.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.423 179.57 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.7 m -98.89 110.85 59.06 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 120.723 0.297 . . . . 0.0 110.871 179.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -77.25 146.08 24.78 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.327 2.018 . . . . 0.0 112.232 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.5 m -103.24 34.28 2.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.192 0.52 . . . . 0.0 110.148 179.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.0 m -67.94 116.52 8.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.163 -179.473 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.33 5.66 56.96 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.49 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 25.9 mt -104.97 -173.12 2.23 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.366 -0.235 . . . . 0.0 110.366 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -107.91 172.39 6.86 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.57 0.224 . . . . 0.0 110.712 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -70.74 151.97 44.3 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.226 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.83 63.98 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.3 -0.952 . . . . 0.0 111.228 -179.251 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.3 m -73.88 142.38 46.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.455 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.3 t -88.12 121.92 39.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.991 0.424 . . . . 0.0 111.034 -179.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.6 t -88.28 127.1 41.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.814 179.314 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -94.61 127.74 40.77 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.971 0.415 . . . . 0.0 111.21 -179.56 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.1 t -121.76 125.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.267 179.705 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -136.91 93.69 2.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.004 0.43 . . . . 0.0 110.598 179.509 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.82 119.75 6.63 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.014 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.6 150.26 39.31 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.12 25.85 39.01 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.593 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 66.2 mt -96.93 -173.43 2.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 45.6 tp60 -83.42 107.58 16.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.783 0.325 . . . . 0.0 110.684 -179.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.6 141.41 58.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.036 -179.867 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.34 22.58 50.98 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.385 -179.946 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.63 142.58 49.9 Favored 'General case' 0 C--N 1.324 -0.54 0 O-C-N 122.813 -0.227 . . . . 0.0 110.577 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.5 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.38 125.02 36.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.791 0.329 . . . . 0.0 110.744 -179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 40.6 m-85 -105.48 118.15 35.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.981 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.32 120.8 23.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.5 179.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.7 t -128.2 123.78 60.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 0.0 111.173 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.47 178.21 32.21 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.08 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -82.84 65.31 7.9 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 117.942 0.871 . . . . 0.0 109.884 179.205 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.531 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 4.0 m -74.47 109.54 8.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.742 -179.85 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HA ' ' CG ' ' A' ' 94' ' ' GLN . . . -120.34 -176.43 3.21 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.981 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.33 111.39 5.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.22 -179.449 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p -99.25 -21.12 5.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.176 179.577 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -162.34 172.51 15.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.31 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -62.74 103.08 0.4 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.019 0.437 . . . . 0.0 111.236 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.78 11.71 78.88 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.368 179.803 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.08 130.41 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.875 0.369 . . . . 0.0 110.707 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.496 ' HB3' " H6'" ' A' ' 114' ' ' FLN . 4.8 mt -113.89 149.98 34.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.619 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.479 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -159.92 152.11 20.69 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.439 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -123.49 175.09 6.98 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 23.8 p-10 -103.46 123.88 40.0 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.27 0.557 . . . . 0.0 111.275 -179.638 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 69.7 Cg_endo -74.81 2.57 6.38 Favored 'Trans proline' 0 CA--C 1.53 0.299 0 C-N-CA 123.001 2.467 . . . . 0.0 112.873 -179.687 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.29 -12.05 26.84 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.724 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.6 OUTLIER -134.07 -7.31 2.69 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.562 0.578 . . . . 0.0 112.562 -179.413 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.595 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.0 p90 -67.87 157.63 34.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.737 0.303 . . . . 0.0 110.855 -179.717 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.3 m -147.57 95.26 2.49 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.825 0.345 . . . . 0.0 110.376 179.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.06 122.75 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.747 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -109.32 135.13 49.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.329 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.9 t -91.84 142.48 27.52 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.376 179.873 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.33 120.48 19.96 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.095 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.9 p-10 -69.23 -179.68 1.67 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.26 -179.068 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.22 -6.13 16.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.998 0.428 . . . . 0.0 111.99 -179.198 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -93.27 -6.19 48.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.436 0.636 . . . . 0.0 109.507 179.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.0 34.49 41.97 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.567 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.96 151.42 51.74 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.936 0.398 . . . . 0.0 111.62 -179.211 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -144.93 115.61 7.72 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.446 179.64 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.3 t -117.61 138.75 51.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.319 179.71 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 t -153.46 168.43 26.13 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.237 -179.818 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.551 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 15.2 m -137.47 130.48 30.48 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.359 -179.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -121.09 141.37 50.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.891 0.377 . . . . 0.0 111.24 -178.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.6 m -95.04 99.96 11.87 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -68.31 117.41 10.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.478 0.656 . . . . 0.0 111.869 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.3 mmt180 -88.4 165.26 15.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.711 178.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -76.53 -42.63 42.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.231 0.539 . . . . 0.0 110.03 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 m -132.59 134.27 44.71 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.041 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.77 163.62 37.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -179.302 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -88.32 132.06 34.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.461 179.179 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.83 127.78 8.9 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.609 -179.043 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.479 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 19.1 m-85 -126.17 144.16 50.86 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.856 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.555 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 52.8 mt -79.63 174.36 11.66 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.27 -25.53 68.36 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.954 0.407 . . . . 0.0 111.094 -179.192 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -82.82 -14.07 55.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.431 -179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.45 8.67 43.07 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.673 -0.775 . . . . 0.0 113.717 179.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.7 m -89.8 131.34 35.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 117.072 0.436 . . . . 0.0 111.262 179.442 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 82' ' ' ARG . 12.5 ttm180 -76.04 124.69 27.8 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.098 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 51.9 t-105 -94.6 -37.91 11.11 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.854 0.359 . . . . 0.0 110.264 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.14 -165.55 37.23 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 139.45 40.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.835 0.318 . . . . 0.0 110.896 179.741 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.4 HG11 ' HB3' ' A' ' 38' ' ' ALA . 5.4 t -112.85 116.56 52.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -107.47 110.3 22.22 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.593 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 73.9 m -97.07 18.04 15.71 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.343 -179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -79.46 -46.01 18.3 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.244 0.545 . . . . 0.0 109.684 178.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -105.21 -7.49 18.96 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.551 179.583 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.32 -179.32 4.03 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.676 -179.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.37 169.58 12.14 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.287 179.566 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.83 169.46 17.54 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 12.9 pt20 -159.48 171.49 19.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.751 0.31 . . . . 0.0 110.865 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 19' ' ' VAL . 10.7 t -110.44 139.75 32.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.587 -179.612 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -115.76 127.93 7.79 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.85 179.647 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.538 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -142.7 118.21 10.33 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.602 0.239 . . . . 0.0 110.447 -179.31 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 m -157.51 163.96 37.88 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.158 179.579 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 2.7 p-10 -81.04 -171.77 3.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.224 179.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.52 -30.41 68.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.663 0.268 . . . . 0.0 111.409 179.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.23 -49.81 11.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.005 0.431 . . . . 0.0 109.904 179.132 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.49 39.75 0.42 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.806 179.324 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -141.03 163.74 32.16 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.719 0.26 . . . . 0.0 110.569 179.536 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 146.25 -126.82 2.59 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' HD13 ' A' ' 97' ' ' LEU . 72.2 Cg_endo -78.56 160.22 28.5 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.489 2.126 . . . . 0.0 111.878 179.263 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -82.39 140.3 33.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.602 0.239 . . . . 0.0 110.862 -179.748 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.92 152.31 51.17 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.908 -179.507 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 t -122.59 138.83 51.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.627 0.251 . . . . 0.0 110.442 -179.587 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -94.84 147.56 23.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.556 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.6 pt -132.35 147.65 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.036 0.446 . . . . 0.0 110.71 -179.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -123.81 144.02 49.97 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.478 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -88.41 154.03 20.7 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.421 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 4.5 p30 . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.903 -179.345 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.555 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 CA-C-O 120.781 0.324 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -114.06 111.55 47.71 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.024 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.03 153.9 76.23 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.519 2.146 . . . . 0.0 112.481 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -108.78 73.79 0.88 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.177 0.513 . . . . 0.0 110.58 179.884 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.98 135.11 37.75 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.011 179.29 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -145.11 75.76 1.46 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.07 0.462 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.9 m -98.5 147.86 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.728 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.9 m -110.23 109.4 58.69 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.396 179.453 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.46 156.27 58.53 Favored 'Trans proline' 0 CA--C 1.53 0.321 0 C-N-CA 122.556 2.171 . . . . 0.0 112.604 -179.884 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -109.2 31.0 6.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 179.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.3 m -61.15 109.84 1.22 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.295 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 108.3 -6.44 34.2 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.625 179.706 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.8 mt -100.77 156.01 17.59 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -80.45 176.11 10.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.663 0.268 . . . . 0.0 110.565 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.81 154.71 40.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 110.152 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.23 -10.1 56.5 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.496 -178.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -69.88 140.9 53.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.381 179.563 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.48 97.48 6.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.94 0.4 . . . . 0.0 110.498 -179.761 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.9 t -63.47 125.37 19.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.4 ttmt -89.55 111.54 22.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.19 179.633 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.9 t -111.23 104.91 17.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.323 179.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -119.35 136.21 54.37 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.453 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -144.12 124.25 2.19 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.214 179.727 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -112.74 163.66 14.31 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 178.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.09 27.17 58.65 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.232 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.7 mt -96.63 -177.76 4.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.443 -179.426 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -88.65 111.68 22.21 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.856 0.36 . . . . 0.0 110.811 -179.142 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.12 120.77 10.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.435 -179.571 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.52 -17.15 26.12 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.3 m -86.24 142.77 28.33 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.663 0.268 . . . . 0.0 110.839 -179.814 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.86 123.1 35.89 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.96 179.252 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -105.96 120.55 42.05 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.928 0.394 . . . . 0.0 110.098 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.74 123.04 40.32 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.489 -179.261 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.609 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 14.2 t -130.88 125.67 58.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.025 -179.44 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.19 177.66 27.25 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 178.075 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.413 HE21 ' HB2' ' A' ' 36' ' ' GLN . 2.5 pt20 -86.28 127.01 34.71 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.58 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.7 m -131.31 168.14 18.04 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.694 -178.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.546 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.11 179.39 8.44 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 178.677 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -74.3 106.07 5.77 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.087 0.47 . . . . 0.0 110.453 -179.531 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.04 -20.36 7.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.261 0.553 . . . . 0.0 109.735 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -156.85 178.44 10.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.033 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.4 m -68.57 103.65 1.75 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.859 0.361 . . . . 0.0 110.615 179.905 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.67 -0.59 89.19 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.389 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.404 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.7 t -113.67 122.43 67.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.821 0.343 . . . . 0.0 110.639 -179.209 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -106.67 156.69 18.36 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.159 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.67 148.56 26.58 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.386 -179.557 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.805 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -116.83 178.84 4.2 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 123.468 0.48 . . . . 0.0 110.779 -179.644 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 51' ' ' ASP . 27.3 p-10 -109.02 119.31 49.19 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.376 0.607 . . . . 0.0 111.603 179.982 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -77.96 52.1 3.89 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.26 2.64 . . . . 0.0 112.925 -179.697 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -147.26 -53.14 0.21 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.258 179.039 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 0.3 OUTLIER -83.61 -6.29 59.4 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.094 179.692 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.55 150.07 48.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.309 179.512 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.4 m -139.22 89.08 2.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.835 0.35 . . . . 0.0 110.287 -179.687 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.19 143.98 51.17 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.653 179.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 p -133.76 126.63 51.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.258 179.475 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -86.96 139.89 30.14 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.22 129.02 37.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.973 0.416 . . . . 0.0 110.488 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -76.49 177.69 7.21 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.126 -179.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.88 -19.77 65.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.504 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -79.58 -15.27 57.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.151 0.501 . . . . 0.0 109.745 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.64 32.0 22.93 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.435 -179.596 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.91 160.64 28.4 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.056 0.455 . . . . 0.0 111.365 -179.361 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -152.44 128.07 10.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.879 179.182 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.95 128.34 34.28 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.2 t -144.63 165.73 27.2 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.914 0.388 . . . . 0.0 110.661 -179.78 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.6 m -127.36 132.4 50.19 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.256 -0.429 . . . . 0.0 109.893 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.454 ' HA ' HD13 ' A' ' 67' ' ' LEU . 2.6 mm? -121.65 124.63 44.76 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.944 0.402 . . . . 0.0 112.058 -178.517 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.8 m -82.66 101.93 11.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.697 178.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -75.02 110.93 10.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.553 0.692 . . . . 0.0 111.341 -178.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -86.28 169.46 12.97 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.805 179.057 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -77.14 -38.37 52.08 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.866 0.365 . . . . 0.0 110.346 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.4 m -135.51 153.04 51.85 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.267 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -163.03 173.54 13.45 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.915 0.388 . . . . 0.0 111.385 -178.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -84.9 155.62 21.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.532 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.99 112.47 3.48 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.165 -179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.514 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.8 m-85 -126.79 145.57 50.57 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -179.788 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.542 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.1 mt -80.62 164.53 22.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.98 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -69.23 -17.57 63.79 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.44 -179.014 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -86.33 -21.43 27.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.761 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.63 -18.82 7.6 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.544 -0.836 . . . . 0.0 113.363 179.471 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.3 m -69.14 137.71 53.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 117.0 0.4 . . . . 0.0 111.09 -179.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.89 139.28 30.82 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.159 179.397 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -104.77 -41.01 5.77 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.829 -179.646 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 166.19 -129.96 2.05 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.39 -0.91 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.03 51.05 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.679 0.276 . . . . 0.0 110.937 -179.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.59 156.32 37.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.01 0.433 . . . . 0.0 110.594 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -141.83 130.88 23.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.985 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 82.4 m -107.52 20.22 19.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.154 -179.717 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.9 m -71.44 -35.75 71.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.373 0.606 . . . . 0.0 109.629 179.388 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -126.78 23.8 6.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.636 179.738 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -143.1 171.51 13.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.594 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.17 125.05 44.66 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.918 0.389 . . . . 0.0 111.041 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.52 149.31 33.14 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.206 179.914 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -119.0 151.15 38.72 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.844 0.354 . . . . 0.0 110.628 -179.031 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 40.6 t -96.22 109.22 22.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.822 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -83.54 85.11 1.54 Allowed Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.158 -178.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.98 94.64 5.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 179.37 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 m -129.76 163.02 27.11 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.136 0.494 . . . . 0.0 111.709 -179.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.13 -171.7 3.37 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.843 178.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.16 -33.09 71.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.844 0.354 . . . . 0.0 111.804 -179.599 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.93 -50.29 10.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.637 179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.22 31.51 0.43 Allowed Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.482 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -133.13 -170.08 2.39 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.336 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.36 -136.04 8.66 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.439 179.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.99 159.83 49.19 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.903 2.402 . . . . 0.0 111.792 179.521 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -72.43 138.86 47.41 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.185 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -61.5 143.48 48.65 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.176 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.0 t -117.94 137.17 52.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.566 0.222 . . . . 0.0 110.619 -179.495 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -102.58 138.74 39.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.59 179.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.46 139.86 48.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.867 0.365 . . . . 0.0 110.678 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 39.9 m -117.11 155.13 29.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.811 179.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -87.11 -171.67 3.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.267 179.929 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.857 -0.592 . . . . 0.0 110.384 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.805 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -92.02 125.04 58.29 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.722 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 3.1 Cg_exo -78.6 161.34 27.99 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.735 2.29 . . . . 0.0 112.621 -179.85 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.8 m -113.38 104.77 12.63 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.448 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -99.1 106.96 19.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.59 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.9 m -105.27 95.73 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.09 0.472 . . . . 0.0 110.878 -179.673 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.08 141.07 41.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.606 179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 m -112.66 97.49 41.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.622 179.6 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.32 137.67 23.72 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.495 2.13 . . . . 0.0 112.194 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -82.37 58.45 4.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.347 -179.639 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.8 m -70.46 107.45 3.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.281 -179.669 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.99 10.19 52.61 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.2 178.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.3 mt -110.42 150.5 28.74 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.992 0.396 . . . . 0.0 110.31 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 m -73.03 178.23 4.47 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.303 -179.624 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -71.44 156.96 38.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.987 0.422 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.31 -2.18 65.2 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.571 -178.827 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.451 ' O ' HG12 ' A' ' 69' ' ' VAL . 30.9 m -75.92 140.51 42.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.045 0.45 . . . . 0.0 110.79 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 65.2 t -86.18 111.65 21.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.985 179.605 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.9 t -83.24 128.57 38.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.939 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -91.66 121.74 33.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.183 -179.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 86.4 t -124.63 107.39 18.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.238 179.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 108.0 10.38 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.136 0.494 . . . . 0.0 111.23 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.7 125.35 8.06 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.966 179.638 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -119.53 148.77 42.91 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.856 0.36 . . . . 0.0 110.698 179.774 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.74 31.33 27.11 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.799 -179.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 46.4 mt -101.62 -179.6 4.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.691 0.282 . . . . 0.0 110.601 -179.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 -83.47 113.08 20.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.955 179.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.39 146.15 54.14 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.711 -179.238 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.66 -13.12 63.35 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.748 179.692 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -84.28 147.03 27.44 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.877 0.37 . . . . 0.0 111.323 -179.594 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.44 131.56 38.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.57 -0.529 . . . . 0.0 109.57 178.463 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -116.44 131.63 56.89 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.047 0.451 . . . . 0.0 111.008 -179.432 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -105.24 121.55 44.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.767 -179.693 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.28 122.6 51.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.418 -179.59 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.03 171.78 29.24 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.901 179.383 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.2 pt20 -83.62 126.56 32.97 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.559 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 0.0 OUTLIER -130.66 172.17 12.26 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.974 0.416 . . . . 0.0 111.137 -179.002 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.595 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -163.45 174.97 11.22 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.614 179.225 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -75.78 98.58 4.17 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.399 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p -80.4 -28.64 11.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.396 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -144.38 -168.49 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.755 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.4 m -78.09 92.04 4.35 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.797 0.332 . . . . 0.0 110.171 179.685 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.4 -25.84 22.53 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.606 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.1 t -82.92 124.24 39.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.8 0.333 . . . . 0.0 110.134 179.729 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -112.86 156.54 22.74 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.408 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -155.36 140.86 17.82 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 121.077 -0.249 . . . . 0.0 110.866 -179.651 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.808 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.5 m -101.5 164.89 11.53 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.739 0.304 . . . . 0.0 111.197 -179.565 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.586 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.3 t-20 -95.75 119.99 64.05 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 61.3 Cg_endo -88.62 4.48 5.49 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 123.019 2.479 . . . . 0.0 112.633 179.456 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -86.47 -24.08 25.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.81 0.338 . . . . 0.0 111.34 -179.433 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.61 32.16 1.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.038 0.447 . . . . 0.0 110.929 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 6.8 p90 -84.34 160.69 20.63 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.147 179.563 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.8 m -133.4 98.64 4.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.405 -179.73 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -81.05 132.57 35.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.248 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -130.28 129.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.207 0.527 . . . . 0.0 110.713 -179.553 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.0 t -94.75 143.63 26.29 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.182 179.77 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.86 132.63 51.39 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.844 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.1 p30 -72.42 -163.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.04 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.82 0.7 29.84 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.908 0.385 . . . . 0.0 111.551 -179.728 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -110.35 -8.53 14.69 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.257 0.551 . . . . 0.0 110.057 179.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.7 30.97 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.081 -179.834 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.36 147.32 37.92 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.826 0.345 . . . . 0.0 110.808 -179.674 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.93 110.39 6.66 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.656 179.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.85 135.66 54.6 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.39 179.872 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -156.12 173.79 16.31 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.972 0.415 . . . . 0.0 110.907 -179.837 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.497 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 1.5 m -127.67 133.56 49.61 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.984 -179.634 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.48 141.8 47.23 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -178.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.18 106.96 19.38 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.594 178.576 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 17' ' ' THR . 7.7 p -84.02 111.72 20.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.571 0.7 . . . . 0.0 111.664 -179.296 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -89.83 166.25 13.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.602 178.575 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -81.05 -35.46 31.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.993 0.425 . . . . 0.0 110.274 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -134.29 141.47 46.96 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 51.4 p90 -161.62 161.24 29.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.872 0.368 . . . . 0.0 111.894 -178.573 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.0 OUTLIER -84.0 137.43 33.61 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.54 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.73 124.77 8.14 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.588 -179.814 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.462 ' CE1' ' HB3' ' A' ' 82' ' ' ARG . 5.5 m-85 -118.18 140.18 50.17 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.496 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 69.0 mt -77.78 175.11 10.28 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.426 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.72 -34.77 79.1 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 0.0 110.985 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -74.14 -22.0 59.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.1 -25.2 7.16 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.279 -0.963 . . . . 0.0 113.153 179.785 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 90.1 m -61.67 128.33 35.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 117.103 0.451 . . . . 0.0 111.535 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 18.6 ptt180 -85.13 125.76 33.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.216 179.373 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -83.89 -24.36 30.85 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.801 -179.168 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.02 -168.91 30.73 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.804 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 5.9 m -96.29 133.13 41.03 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.741 0.305 . . . . 0.0 110.731 179.7 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -109.96 145.0 17.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.61 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -132.52 139.18 47.79 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.697 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 36.4 m -122.97 31.76 5.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.854 179.264 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.4 m -76.68 -28.64 56.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.156 0.503 . . . . 0.0 110.218 179.725 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.2 t -129.67 18.02 5.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.52 0.676 . . . . 0.0 109.931 178.567 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.7 178.52 7.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.081 -179.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.65 140.19 39.09 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.719 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.474 ' SG ' ' HE2' ' A' ' 73' ' ' PHE . 1.2 m -98.61 -173.83 2.64 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.591 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.0 OUTLIER -156.39 168.62 26.77 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.346 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 p -110.9 125.47 68.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.129 0.49 . . . . 0.0 110.515 179.744 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.1 125.67 8.65 Favored Glycine 0 N--CA 1.445 -0.729 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.578 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -136.9 113.96 10.61 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 -179.132 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.4 m -148.24 165.52 30.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.942 0.401 . . . . 0.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.02 -173.08 4.27 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.541 179.62 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.04 -29.81 71.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.665 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 -42.91 59.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.979 0.419 . . . . 0.0 110.215 179.312 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.84 25.14 2.17 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.829 179.195 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -135.73 176.88 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.811 0.305 . . . . 0.0 110.191 179.764 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.96 -140.97 9.53 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.677 179.863 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.578 ' HG2' HD13 ' A' ' 97' ' ' LEU . 36.9 Cg_endo -67.27 164.79 29.08 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.514 2.142 . . . . 0.0 112.094 179.701 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -81.52 145.28 30.77 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -73.19 143.54 33.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.908 -179.536 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.0 t -117.64 134.39 61.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.575 0.226 . . . . 0.0 110.403 -179.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 149.76 27.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.401 . . . . 0.0 111.147 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.1 pt -132.52 116.57 28.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.262 0.553 . . . . 0.0 110.15 179.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 m -103.53 143.35 32.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 31.9 m-85 -90.34 173.82 7.91 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.725 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.0 p30 . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.472 -0.775 . . . . 0.0 109.322 179.424 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.808 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.536 0.208 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -132.43 100.3 15.29 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.77 0.319 . . . . 0.0 110.7 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 176.33 8.41 Favored 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 122.455 2.104 . . . . 0.0 112.142 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.3 m -125.59 117.88 24.51 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.876 0.369 . . . . 0.0 110.93 -179.784 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.44 81.92 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.041 0.448 . . . . 0.0 110.888 179.817 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.6 90.66 8.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.18 0.514 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.56 127.68 74.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.275 -179.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 m -102.55 105.31 43.34 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.739 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -80.23 165.09 21.53 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.498 2.132 . . . . 0.0 113.324 -179.082 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.84 34.47 3.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.831 -179.707 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.0 m -65.2 112.43 3.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.071 -179.633 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.0 -11.36 44.81 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.042 -0.599 . . . . 0.0 111.693 -179.698 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 98.0 mt -94.78 162.82 13.61 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.6 m -77.43 -179.52 5.82 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.801 0.334 . . . . 0.0 111.049 -179.212 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -77.05 162.93 27.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.482 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.95 -7.28 75.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.206 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 m -70.64 141.05 51.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.998 0.428 . . . . 0.0 110.507 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 93.2 t -85.84 122.69 38.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.654 -179.838 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 t -88.96 141.12 14.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.749 179.464 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -106.84 118.07 35.72 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.956 0.408 . . . . 0.0 110.863 -179.742 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.0 t -118.96 114.16 43.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.039 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.16 96.89 4.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.753 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.19 125.73 8.22 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.648 -0.787 . . . . 0.0 111.957 179.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.416 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -119.09 146.03 45.44 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.96 26.94 35.67 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.259 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 84.0 mt -94.42 177.96 5.77 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.411 -0.394 . . . . 0.0 110.408 -179.6 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 26.4 tp60 -85.9 108.64 18.26 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.22 136.23 53.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.736 -179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.55 -27.58 19.47 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.551 179.7 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -79.55 136.53 36.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.685 0.279 . . . . 0.0 111.218 -179.582 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -89.41 126.05 35.4 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.054 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -103.55 128.52 50.76 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.2 0.524 . . . . 0.0 110.835 -179.396 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -87.8 124.2 33.38 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.16 179.984 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.406 HG21 HG21 ' A' ' 65' ' ' THR . 18.7 t -124.14 134.55 66.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.986 0.422 . . . . 0.0 110.954 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.5 173.84 45.46 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.798 179.478 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -81.1 61.79 4.8 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.391 0.615 . . . . 0.0 109.654 179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.7 m -73.57 98.8 2.9 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.005 -179.341 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.403 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -105.85 -174.7 2.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.762 -179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -63.97 98.97 0.23 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.672 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.431 HG21 ' HB3' ' A' ' 83' ' ' TRP . 3.8 p -85.89 -21.06 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.459 0.647 . . . . 0.0 109.639 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -159.92 -175.04 4.88 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.102 -0.954 . . . . 0.0 108.83 178.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -76.39 93.25 3.46 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.029 0.442 . . . . 0.0 110.282 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.36 -21.8 39.94 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.053 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.33 133.76 40.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.705 0.288 . . . . 0.0 110.553 -179.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.0 mp -118.07 150.53 39.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.049 179.586 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -157.19 156.82 33.26 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.093 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -126.71 168.62 14.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.521 -179.972 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.7 p-10 -94.14 125.76 51.32 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.192 0.52 . . . . 0.0 111.132 -179.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.43 -13.56 25.19 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.942 2.428 . . . . 0.0 112.24 179.656 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.31 -21.84 62.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.879 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -141.09 48.83 1.67 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.232 0.539 . . . . 0.0 110.638 179.745 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -110.51 166.61 10.86 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.8 m -136.83 120.49 17.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.136 0.493 . . . . 0.0 111.032 179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.95 121.68 36.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.692 179.164 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.04 128.86 69.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.151 0.5 . . . . 0.0 110.397 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 15.0 t -96.57 148.48 22.79 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.485 -179.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.21 125.97 28.63 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.99 179.423 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.0 -177.68 2.51 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.143 -179.322 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.88 -26.27 65.74 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.836 -179.063 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.6 m-80 -85.96 -1.21 57.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.833 0.349 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.97 37.89 42.47 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.553 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.69 149.43 50.68 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.07 0.462 . . . . 0.0 111.281 -179.951 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.8 106.86 6.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.612 179.786 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.38 120.3 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.406 HG21 HG21 ' A' ' 34' ' ' VAL . 5.7 t -140.39 171.16 14.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.129 0.49 . . . . 0.0 111.313 -179.107 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 21.1 m -128.3 136.52 51.11 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.391 179.775 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -123.59 140.25 53.18 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.679 0.276 . . . . 0.0 111.49 -178.684 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.43 ' N ' HD13 ' A' ' 67' ' ' LEU . 1.7 m -100.64 107.3 18.9 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 178.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 110' ' ' ILE . 5.7 p -83.56 124.12 39.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.159 0.504 . . . . 0.0 111.634 -179.138 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -100.14 164.99 11.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.101 179.14 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -70.47 -41.67 72.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.981 0.42 . . . . 0.0 111.134 -179.36 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.0 m -134.4 135.85 42.9 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.38 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -143.16 170.3 15.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.0 0.429 . . . . 0.0 111.8 -178.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -103.09 128.61 49.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.635 178.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.86 126.47 7.58 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.487 -179.46 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 11.0 m-85 -122.85 151.02 42.1 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.688 0.28 . . . . 0.0 110.841 -179.384 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.584 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 97.3 mt -85.9 178.3 7.33 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.528 179.528 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -74.45 -14.0 60.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.571 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -89.67 -25.81 21.05 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.819 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.32 -2.85 14.09 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.363 -0.922 . . . . 0.0 113.131 179.621 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.4 m -83.78 144.47 29.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 117.46 0.63 . . . . 0.0 111.065 179.794 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -88.72 129.81 35.46 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.087 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.431 ' HB3' HG21 ' A' ' 40' ' ' VAL . 24.1 t-105 -90.42 -44.88 9.34 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.052 -179.073 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.58 175.71 42.34 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.059 -179.833 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.7 m -92.0 121.58 33.71 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.926 0.393 . . . . 0.0 110.846 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 48.6 t -105.19 120.62 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.098 0.475 . . . . 0.0 110.472 -179.499 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -105.08 124.38 49.44 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.538 -179.744 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 72.1 m -101.54 13.44 34.96 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.174 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.4 m -74.7 -44.92 47.65 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.101 0.477 . . . . 0.0 109.716 178.953 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.3 t -114.54 22.55 13.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.792 178.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.36 174.9 10.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.763 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.62 124.21 37.46 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.368 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -94.31 158.89 15.37 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.015 -0.538 . . . . 0.0 109.846 179.26 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.495 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 13.6 pt20 -153.23 159.65 42.65 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.516 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.2 t -113.93 130.3 68.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -127.45 155.49 20.02 Favored Glycine 0 N--CA 1.443 -0.884 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.883 -179.317 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -147.3 135.62 21.65 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.468 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.6 m -156.12 163.74 39.25 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.762 0.315 . . . . 0.0 110.466 -179.948 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -176.95 3.53 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.544 179.675 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.02 -38.65 73.44 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.638 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.55 -45.19 62.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.008 0.433 . . . . 0.0 110.761 179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.25 28.76 0.9 Allowed Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.366 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -119.88 176.08 5.59 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.56 -161.22 22.27 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.893 -179.689 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.23 157.29 45.8 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.76 2.307 . . . . 0.0 112.335 -179.904 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -75.52 158.57 32.37 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.237 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.6 151.87 27.0 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.521 179.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 60.3 t -113.74 125.46 71.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.898 0.38 . . . . 0.0 110.51 -179.517 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -79.8 138.6 37.28 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.654 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.557 HD11 HG21 ' A' ' 69' ' ' VAL . 19.5 pt -124.4 174.31 8.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.858 0.361 . . . . 0.0 110.388 -179.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 59.4 m -155.65 139.91 16.62 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.35 -0.386 . . . . 0.0 109.988 179.421 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.604 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 24.0 m-85 -86.52 168.22 13.91 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.597 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.8 p30 . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.508 -0.758 . . . . 0.0 110.011 179.852 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.584 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.953 0 CA-C-O 120.775 0.321 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.05 121.4 65.75 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.541 -0.299 . . . . 0.0 111.142 -179.775 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.73 -179.17 4.3 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.702 2.268 . . . . 0.0 111.937 179.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -120.24 98.19 5.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.968 0.413 . . . . 0.0 111.029 -179.873 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.0 119.78 37.24 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.73 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -129.02 104.94 7.87 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.03 0.443 . . . . 0.0 110.884 179.859 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.1 m -122.56 145.15 29.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.928 0.394 . . . . 0.0 110.814 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.9 m -97.66 105.64 27.89 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.758 179.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.94 143.72 33.32 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.537 2.158 . . . . 0.0 112.562 -178.955 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.434 ' H ' HG21 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -98.04 31.24 2.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.897 179.847 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.1 m -63.15 108.76 1.33 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.621 -179.902 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.96 -2.58 44.62 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.273 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.61 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 83.0 mt -101.9 158.53 16.07 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.579 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -89.14 -173.43 4.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.817 0.341 . . . . 0.0 111.577 -178.907 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -70.48 155.83 40.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.47 4.82 79.89 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.936 -0.65 . . . . 0.0 111.506 -179.242 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.6 m -77.91 136.69 38.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.051 0.453 . . . . 0.0 111.154 -179.765 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.6 t -84.62 108.92 17.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.424 179.345 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 66' ' ' SER . 18.7 t -84.69 130.08 36.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.277 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -102.04 123.27 45.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.932 0.396 . . . . 0.0 110.937 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.8 t -120.19 110.2 28.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.084 179.332 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -121.12 107.74 12.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.081 0.467 . . . . 0.0 110.944 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.81 125.61 7.66 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.68 144.78 44.91 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.199 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.03 27.9 24.74 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.479 -0.867 . . . . 0.0 110.955 -178.786 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.436 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 95.9 mt -89.37 -170.02 2.7 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.852 -179.438 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.524 ' HB3' ' OG1' ' A' ' 30' ' ' THR . 40.5 tp60 -96.18 108.59 21.07 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.286 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.68 113.65 2.35 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.361 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.79 -33.87 4.43 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.992 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.524 ' OG1' ' HB3' ' A' ' 27' ' ' GLN . 37.7 p -83.72 145.65 28.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.937 0.369 . . . . 0.0 111.189 -179.461 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.6 153.88 19.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.367 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 61.7 m-85 -124.63 152.72 43.26 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.378 -179.362 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.2 111.35 22.18 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 179.075 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.631 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.7 t -121.85 124.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.524 -178.814 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.77 -178.18 30.62 Favored Glycine 0 N--CA 1.45 -0.408 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 178.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.28 121.03 27.43 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.77 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.635 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.4 m -126.59 157.78 37.98 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.077 0.465 . . . . 0.0 111.346 -178.617 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -156.4 177.33 11.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.341 179.149 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -63.11 117.83 7.05 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.085 0.469 . . . . 0.0 110.779 179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p -105.23 -20.3 5.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -162.36 178.22 8.86 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.455 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 1.9 m -70.06 94.73 0.9 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.01 0.433 . . . . 0.0 110.975 179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.0 -5.4 63.5 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.343 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -119.08 137.67 52.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.812 0.339 . . . . 0.0 110.571 -179.455 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.77 170.72 8.57 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.617 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.446 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -157.11 149.2 22.79 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.553 -179.794 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.773 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.8 m -113.83 171.53 7.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.759 179.761 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.467 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 30.2 p-10 -97.03 135.52 21.96 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 121.12 0.486 . . . . 0.0 111.291 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -88.21 -11.83 4.25 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.722 2.281 . . . . 0.0 112.187 179.32 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.6 -35.82 57.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.11 -178.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.29 70.9 1.46 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.866 0.365 . . . . 0.0 111.095 -179.401 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -136.54 155.06 50.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.103 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.406 ' H ' HD11 ' A' ' 67' ' ' LEU . 49.7 m -120.0 123.57 43.81 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.999 0.428 . . . . 0.0 112.009 -178.818 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.21 84.13 6.06 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 178.384 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.9 p -89.24 145.81 6.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.01 -178.909 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.8 t -121.67 147.41 45.91 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.662 -0.495 . . . . 0.0 109.662 179.174 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.98 134.0 43.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.983 0.42 . . . . 0.0 110.9 -179.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 60' ' ' ASN . 1.4 p-10 -83.16 -173.23 4.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.81 -24.8 67.1 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.942 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' H ' ' CG ' ' A' ' 58' ' ' ASP . 44.7 m-80 -85.03 -5.1 59.36 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.898 0.38 . . . . 0.0 110.355 179.676 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.62 28.67 62.83 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 121.117 -0.564 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -122.7 147.77 46.09 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.841 0.353 . . . . 0.0 110.85 -179.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.4 119.76 7.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.729 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 22.6 t -127.04 129.83 48.78 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.863 0.363 . . . . 0.0 110.247 179.528 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.0 t -146.58 173.98 11.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.278 -179.788 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 5.4 m -125.5 154.47 42.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.679 0.276 . . . . 0.0 111.127 -179.697 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.406 HD11 ' H ' ' A' ' 53' ' ' SER . 1.7 mm? -133.47 136.63 45.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.939 -179.522 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.32 103.82 15.69 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.275 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -76.46 120.56 26.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 CA-C-O 121.313 0.578 . . . . 0.0 111.836 -178.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -96.83 163.01 13.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.506 179.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -73.56 -36.09 65.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.274 0.559 . . . . 0.0 110.397 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.8 m -137.32 149.13 46.83 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.2 p90 -156.69 176.94 12.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.476 0.655 . . . . 0.0 112.329 -178.779 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -94.66 130.42 41.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.536 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.94 122.14 5.93 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.471 -179.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.446 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 9.5 m-85 -128.89 144.72 51.26 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.981 0.42 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.3 mp -84.48 171.25 12.71 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.995 179.2 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -66.32 -26.0 67.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.618 -0.265 . . . . 0.0 111.646 -179.22 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.72 -22.66 46.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.488 179.637 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 114.7 0.09 23.14 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.165 179.513 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.6 m -81.96 130.69 35.15 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.603 -0.351 . . . . 0.0 110.831 179.439 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -80.73 145.16 31.69 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 178.97 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -113.33 -24.07 9.55 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.391 -179.243 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.81 -173.83 30.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.003 179.78 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.13 130.06 35.63 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.823 0.344 . . . . 0.0 110.78 179.836 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.41 HG11 ' HB3' ' A' ' 38' ' ' ALA . 11.3 t -112.5 134.88 53.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.001 -179.769 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -123.9 143.31 50.44 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.688 0.28 . . . . 0.0 111.294 -179.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.6 m -127.34 28.23 5.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.035 179.429 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 m -80.52 -22.83 40.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.527 0.68 . . . . 0.0 109.377 178.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.4 t -134.11 19.22 3.74 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.697 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.24 168.99 18.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.864 -179.367 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.51 141.25 31.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.944 0.402 . . . . 0.0 111.163 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.82 154.76 23.52 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.447 179.62 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.515 ' HG3' " H5'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -130.02 155.28 46.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.81 0.338 . . . . 0.0 110.765 179.272 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.9 t -83.53 114.53 24.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.305 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.635 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -89.92 108.36 3.51 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.42 179.733 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -126.6 107.14 9.93 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.966 0.412 . . . . 0.0 110.892 -179.435 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.1 m -149.94 162.13 40.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.253 179.332 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -77.02 -179.12 5.33 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.439 179.61 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.71 -29.2 64.52 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.31 -54.48 6.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.762 0.315 . . . . 0.0 110.226 179.046 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.05 32.64 0.16 Allowed Glycine 0 CA--C 1.52 0.388 0 C-N-CA 120.688 -0.768 . . . . 0.0 113.562 179.124 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -132.77 165.75 23.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.922 0.361 . . . . 0.0 110.167 179.161 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.69 -146.87 16.82 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.168 179.91 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.407 ' HB2' HD13 ' A' ' 97' ' ' LEU . 13.6 Cg_exo -69.61 167.14 25.11 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.743 2.296 . . . . 0.0 111.994 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -82.44 140.09 33.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.241 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -69.4 132.3 25.09 Favored Glycine 0 N--CA 1.445 -0.713 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.238 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.5 t -101.38 126.27 55.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.68 140.46 32.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.926 -179.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.434 HG21 ' H ' ' A' ' 10' ' ' SER . 31.1 pt -132.51 156.57 42.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.997 179.654 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.6 m -141.36 144.0 34.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.483 179.998 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.61 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 21.9 m-85 -82.2 152.41 26.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.518 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.5 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.628 -0.701 . . . . 0.0 110.48 -179.819 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.773 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.048 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.05 126.92 93.25 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -81.67 172.27 12.47 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.776 2.317 . . . . 0.0 112.29 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.86 102.97 9.19 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.947 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.39 132.89 35.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.259 179.734 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.7 76.89 1.57 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.809 179.778 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 m -111.55 141.01 28.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.858 0.361 . . . . 0.0 111.128 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.0 m -101.54 109.2 58.51 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.661 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.8 144.89 14.04 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.488 2.126 . . . . 0.0 112.95 -179.841 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -92.2 61.08 3.85 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.292 179.078 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -74.92 117.28 16.59 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.462 -178.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.52 27.36 69.66 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.341 178.791 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.8 mt -105.42 -169.73 1.64 Allowed 'General case' 0 C--N 1.322 -0.608 0 O-C-N 122.674 -0.309 . . . . 0.0 110.331 179.854 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.6 m -104.28 -177.94 3.51 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.483 0.182 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -82.41 154.7 25.06 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.745 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.62 7.48 86.04 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.704 -179.504 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.5 m -73.59 143.61 46.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.734 0.302 . . . . 0.0 110.87 -179.689 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.71 113.2 22.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.982 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.2 t -89.21 117.79 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.655 178.855 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -87.74 115.1 24.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.295 -179.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -113.68 110.3 31.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.453 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -127.7 114.5 17.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.93 179.654 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.79 137.84 13.85 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.024 179.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.496 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -127.34 147.02 50.26 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.28 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.39 23.31 31.92 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -178.685 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.4 mt -89.93 -175.07 4.48 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.454 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 50.9 tp60 -95.35 117.73 30.84 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.989 -0.374 . . . . 0.0 109.989 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.63 57.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 -179.446 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.22 9.27 73.5 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.418 179.901 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.4 m -108.47 137.89 45.68 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 122.295 0.238 . . . . 0.0 110.499 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.79 126.32 40.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.974 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.99 121.25 44.88 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.662 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -88.11 115.93 25.93 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.841 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 20.6 t -121.23 119.34 58.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.706 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -147.87 173.55 27.89 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.922 178.744 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -84.83 122.53 29.28 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.05 161.29 25.87 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.314 -178.932 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -158.2 176.57 12.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.496 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -70.39 98.82 1.47 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.069 0.461 . . . . 0.0 110.27 179.45 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.446 HG23 HG22 ' A' ' 86' ' ' VAL . 8.9 p -82.99 -16.81 11.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.259 0.552 . . . . 0.0 110.19 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.43 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 3.7 t70 -159.16 176.23 12.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 108.873 179.204 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 90.68 1.06 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.825 0.345 . . . . 0.0 110.687 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.97 2.47 56.05 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.797 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.9 t -117.51 133.51 64.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.761 0.315 . . . . 0.0 110.647 -179.59 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -117.54 153.16 33.67 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.76 144.85 22.84 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.626 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.81 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 2.9 m -111.61 164.57 12.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.859 0.361 . . . . 0.0 111.168 -179.508 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 28.4 t-20 -90.04 121.01 69.23 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.704 178.673 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -85.26 0.5 8.72 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.695 2.263 . . . . 0.0 113.839 -178.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.12 -51.16 5.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.945 0.402 . . . . 0.0 111.07 -179.53 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.69 33.9 1.77 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.58 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -112.11 159.13 18.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.308 -0.405 . . . . 0.0 109.967 179.739 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.6 m -132.4 130.53 40.76 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.126 0.489 . . . . 0.0 111.106 -179.918 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.77 97.72 11.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.536 179.024 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -84.42 139.67 17.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.38 -179.312 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.6 t -111.16 143.32 42.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.18 133.1 41.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.879 0.371 . . . . 0.0 110.734 -179.639 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -81.49 -176.67 6.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.173 179.862 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.66 -17.03 64.3 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -178.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -88.91 -15.06 35.29 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.262 0.554 . . . . 0.0 109.655 179.777 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.91 28.22 14.43 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.378 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.67 157.39 25.49 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.922 0.391 . . . . 0.0 110.884 -179.618 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.74 113.45 6.04 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.623 179.265 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.9 m -121.62 131.0 53.87 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.906 -179.343 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.8 t -153.07 168.74 24.87 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.293 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -124.88 132.6 53.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.763 0.316 . . . . 0.0 110.614 -179.725 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -114.22 145.04 42.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.053 -179.627 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.12 99.86 9.43 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.85 116.25 14.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.426 0.631 . . . . 0.0 111.702 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.9 mmt180 -94.01 164.2 13.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.166 179.016 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.8 tpp180 -69.99 -44.74 68.77 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.203 -179.671 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.22 147.41 50.7 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.436 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 52.2 p90 -158.08 160.56 37.49 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.589 -0.445 . . . . 0.0 112.058 -178.238 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.3 mp0 -82.33 124.34 29.9 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.238 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.53 130.6 10.14 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.766 -0.73 . . . . 0.0 113.127 -178.834 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.452 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 8.6 m-85 -125.4 144.67 50.41 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.419 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 47.9 mt -73.32 173.33 9.68 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -74.34 -12.73 60.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.949 0.404 . . . . 0.0 111.005 -179.271 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.27 -17.98 27.92 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.357 179.094 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.9 -3.42 27.28 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.034 179.941 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 37.0 m -85.86 127.76 34.66 Favored 'General case' 0 C--N 1.322 -0.587 0 O-C-N 122.512 -0.405 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 25.5 ptt-85 -76.42 140.24 41.24 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.34 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.42 ' HB3' HG21 ' A' ' 40' ' ' VAL . 23.9 t-105 -107.43 -37.72 6.13 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.843 0.354 . . . . 0.0 110.224 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 165.15 176.84 37.15 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.854 -0.688 . . . . 0.0 111.853 179.727 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 3.3 m -92.57 128.13 38.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.889 0.376 . . . . 0.0 110.685 -179.842 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.446 HG22 HG23 ' A' ' 40' ' ' VAL . 1.5 t -107.37 148.64 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.971 -178.872 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -124.44 130.13 51.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.991 179.361 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 66.5 m -107.09 22.39 16.07 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.744 0.307 . . . . 0.0 111.676 -179.37 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.1 m -80.33 -43.26 21.5 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.347 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -111.85 20.85 16.61 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.496 179.221 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.42 -171.39 3.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.242 -179.674 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 139.69 49.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.915 0.388 . . . . 0.0 111.097 -179.67 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -104.7 144.58 31.53 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.401 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -132.76 150.29 52.18 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.344 0.593 . . . . 0.0 111.269 179.736 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 47.5 t -84.79 118.44 31.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.644 -179.864 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.58 107.14 3.16 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.738 179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.55 109.95 16.3 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.885 0.374 . . . . 0.0 110.358 -179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.3 m -151.96 162.73 40.61 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.492 179.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -79.55 -176.55 5.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.26 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -54.14 -38.87 65.94 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.822 0.344 . . . . 0.0 111.744 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.16 -54.89 12.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.119 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.25 33.81 0.39 Allowed Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.471 179.725 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -123.72 171.8 9.32 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.735 -0.274 . . . . 0.0 110.331 179.597 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.38 -156.95 23.31 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.891 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -65.96 162.85 33.43 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.762 2.308 . . . . 0.0 111.578 179.645 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -77.34 148.88 35.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.063 -179.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.14 149.69 39.58 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.447 179.817 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 31.0 t -115.7 124.37 72.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.568 0.223 . . . . 0.0 110.425 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.01 138.99 31.03 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.1 pt -131.25 162.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.142 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 47.0 m -143.45 148.89 36.81 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -82.36 159.6 23.01 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--O 1.242 0.667 0 CA-C-O 118.605 -0.712 . . . . 0.0 110.385 -179.75 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.81 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 120.564 0.221 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.96 111.16 58.5 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.735 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -84.15 134.92 6.17 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.621 2.214 . . . . 0.0 112.5 179.633 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.46 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.2 m -98.72 77.12 2.24 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.199 0.523 . . . . 0.0 110.224 179.847 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.75 96.73 10.82 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.804 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -110.68 114.05 27.13 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.324 179.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -121.19 155.95 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.773 -179.595 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -110.51 95.2 21.67 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.138 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -73.18 143.21 35.3 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.751 2.301 . . . . 0.0 112.688 -178.75 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.422 ' HB3' HG21 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.78 41.02 1.02 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.202 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.14 113.64 3.67 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.988 -179.655 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.99 57.55 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.707 179.313 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.5 mt -93.95 171.57 8.78 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.1 m -95.46 -165.42 1.29 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.758 0.313 . . . . 0.0 111.562 -178.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.3 161.04 27.52 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.414 -179.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 81.15 10.25 85.07 Favored Glycine 0 C--O 1.229 -0.208 0 C-N-CA 120.876 -0.678 . . . . 0.0 111.993 -179.434 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.422 HG21 ' HB3' ' A' ' 10' ' ' SER . 33.5 m -84.36 143.67 29.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.983 0.42 . . . . 0.0 110.662 -179.726 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -92.49 116.29 33.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.701 -0.682 . . . . 0.0 111.179 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG11 HG21 ' A' ' 95' ' ' VAL . 14.7 t -89.16 129.15 40.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -99.83 128.63 45.92 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.761 0.315 . . . . 0.0 110.761 -179.642 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.615 ' O ' ' HA ' ' A' ' 64' ' ' SER . 90.6 t -120.62 116.71 50.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.947 179.542 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 89.51 3.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.235 0.541 . . . . 0.0 110.842 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -93.82 108.12 3.63 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.929 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -107.14 149.04 28.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.741 0.305 . . . . 0.0 110.54 179.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.09 32.72 34.87 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.259 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -108.61 -175.62 2.82 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.941 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -75.59 119.19 19.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.674 0.273 . . . . 0.0 110.446 -179.586 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.17 150.31 40.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.071 -179.855 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.11 22.82 73.02 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.518 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m -127.15 142.12 51.58 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.708 -0.29 . . . . 0.0 110.37 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.13 139.03 31.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.128 0.489 . . . . 0.0 110.548 179.724 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -118.81 131.08 56.08 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.348 -179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.42 116.61 25.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.901 -179.897 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 36.1 t -120.67 118.84 57.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.006 -179.72 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -150.89 174.68 30.13 Favored Glycine 0 N--CA 1.447 -0.631 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 178.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.49 54.02 2.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.819 0.81 . . . . 0.0 109.41 178.939 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.8 m -61.79 98.6 0.1 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.381 -178.901 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -102.67 177.23 4.91 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.419 179.718 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 4.6 m95 -66.23 117.91 9.18 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.15 0.5 . . . . 0.0 111.369 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.6 p -107.2 -21.68 5.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.893 179.536 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.414 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 5.2 t0 -154.39 176.13 12.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.196 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.9 m -64.78 96.38 0.18 Allowed 'General case' 0 C--N 1.323 -0.577 0 O-C-N 123.292 0.37 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.66 9.83 77.62 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 121.161 -0.543 . . . . 0.0 112.399 179.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 11.6 t -123.3 129.98 74.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.908 0.385 . . . . 0.0 110.27 -179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.469 HD22 " H2'" ' A' ' 114' ' ' FLN . 7.2 mp -110.54 159.67 17.32 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -145.74 135.3 23.22 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.406 -179.493 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.611 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 21.3 m -92.42 160.19 15.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.67 -178.886 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.552 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 21.0 p-10 -92.83 118.76 68.03 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.918 179.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 54.9 Cg_endo -85.79 -5.13 8.96 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 122.877 2.385 . . . . 0.0 112.854 -179.339 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.17 -5.21 44.54 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.234 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.508 ' OD2' ' HB ' ' A' ' 68' ' ' THR . 23.4 t0 -164.11 58.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.123 0.487 . . . . 0.0 111.464 -179.749 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.528 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 9.4 p90 -121.64 173.86 7.17 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.994 179.543 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.1 m -132.45 121.93 24.15 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.814 0.34 . . . . 0.0 111.241 -179.948 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.76 84.63 5.45 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 178.554 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -83.19 153.22 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.535 -178.471 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.9 t -125.38 143.34 51.03 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.61 128.07 34.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.235 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.1 p-10 -73.65 -176.21 2.29 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.546 -179.031 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.62 -0.75 4.22 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.19 -179.585 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -105.99 -3.64 21.45 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.121 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.58 28.07 55.92 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.418 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -120.27 142.6 48.93 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 111.256 -179.11 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.94 104.93 5.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.81 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -108.53 127.79 54.24 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.816 178.859 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 t -146.4 170.99 15.7 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.765 0.317 . . . . 0.0 111.289 -179.458 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.3 m -123.99 147.56 47.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.748 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 52' ' ' PHE . 0.6 OUTLIER -135.59 133.75 38.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.798 -179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' OD2' ' A' ' 51' ' ' ASP . 6.3 m -97.64 114.5 26.46 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.012 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.3 115.79 23.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.177 0.513 . . . . 0.0 111.01 -179.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.487 ' HD3' ' OD2' ' A' ' 51' ' ' ASP . 4.2 mmm180 -97.96 164.02 12.53 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 179.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -74.61 -46.65 37.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.911 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.0 m -128.34 136.16 50.57 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 179.876 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.552 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 45.3 p90 -150.77 164.38 36.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.977 0.418 . . . . 0.0 111.399 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -85.05 133.79 34.23 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.535 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.1 122.43 6.71 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 -179.578 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.6 m-85 -122.54 145.11 48.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 -179.442 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.453 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 14.0 mt -89.01 175.09 7.55 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.759 179.59 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -77.95 -9.42 59.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.608 0.242 . . . . 0.0 111.626 -179.271 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -92.98 -10.03 37.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.918 0.389 . . . . 0.0 110.559 179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.87 3.87 48.81 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.628 178.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.413 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 1.6 m -95.19 145.1 25.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 117.362 0.581 . . . . 0.0 110.992 179.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.5 ptm180 -95.1 136.95 34.79 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.323 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -101.1 -25.52 14.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.227 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.35 -175.85 32.39 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.086 179.788 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -92.82 125.55 37.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.673 0.273 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 t -102.74 139.52 23.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.111 179.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -124.43 144.76 49.88 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.635 -179.607 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.13 37.34 4.35 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.023 0.439 . . . . 0.0 110.92 -179.724 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.4 m -90.11 -38.26 13.66 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 122.3 -0.25 . . . . 0.0 111.587 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.6 t -119.86 0.32 10.82 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.775 0.321 . . . . 0.0 111.697 -179.312 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.42 168.95 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.879 -179.563 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.4 167.91 11.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.426 179.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 87.5 m -140.95 162.94 34.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.569 -179.495 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -131.88 168.08 18.48 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.731 -179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.408 HG21 HG11 ' A' ' 19' ' ' VAL . 12.4 t -98.77 119.98 47.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.866 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.616 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -92.5 121.12 6.35 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.873 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.72 107.65 5.99 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.824 0.345 . . . . 0.0 110.717 -179.622 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.7 m -153.28 163.46 39.86 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.699 0.285 . . . . 0.0 110.792 179.565 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.37 -179.22 6.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.454 -179.7 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.13 -32.71 68.4 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.84 -179.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.87 -38.28 58.05 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.684 0.278 . . . . 0.0 110.768 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 117.9 27.73 2.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.372 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -121.35 175.47 6.14 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 133.07 -142.57 14.11 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.889 179.487 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.44 166.57 25.77 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 123.161 2.574 . . . . 0.0 111.313 179.106 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -83.82 142.77 30.39 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.14 -0.319 . . . . 0.0 110.14 179.548 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.4 123.63 17.28 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.498 -179.713 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.7 t -90.74 129.02 42.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.805 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.95 143.3 26.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.265 -179.404 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.6 pt -132.93 169.15 22.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.769 -179.522 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.7 m -149.56 147.71 28.49 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.747 0.308 . . . . 0.0 110.212 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.9 m-85 -79.76 170.36 16.62 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 179.385 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--O 1.246 0.91 0 CA-C-O 118.597 -0.716 . . . . 0.0 110.257 179.447 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.611 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.87 94.36 40.86 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-O 120.684 0.278 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.43 146.64 75.33 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 122.257 1.971 . . . . 0.0 111.75 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -115.25 92.5 3.95 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.782 -179.673 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.43 121.01 37.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.28 -179.938 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 p -122.23 111.01 16.42 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.85 -179.721 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 108' ' ' VAL . 26.9 m -119.83 152.85 22.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 120.993 0.425 . . . . 0.0 111.051 -179.7 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.21 104.03 54.02 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.023 179.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.412 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 61.7 Cg_endo -74.82 133.27 16.67 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.576 2.184 . . . . 0.0 112.659 -178.846 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.4 m -88.86 28.05 1.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.753 179.669 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.412 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -61.89 120.57 11.0 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.232 -179.342 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.64 -3.55 63.2 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.594 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.62 -170.74 2.05 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.496 -0.414 . . . . 0.0 110.877 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 -165.16 1.07 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -87.9 159.78 18.22 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.579 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 84.48 3.82 88.2 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.602 -0.809 . . . . 0.0 111.631 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.5 m -69.82 144.46 52.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.167 0.508 . . . . 0.0 111.217 -179.791 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.572 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 52.1 t -85.65 103.46 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.421 179.782 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' SER . 4.8 t -78.53 114.51 19.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.817 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -92.37 121.66 34.07 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.197 -179.408 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 64' ' ' SER . 78.6 t -121.9 125.07 72.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.406 179.946 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.53 119.62 19.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.567 179.638 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.66 118.54 3.51 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.352 -179.467 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.98 144.8 37.99 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.951 0.405 . . . . 0.0 110.507 179.187 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.17 17.45 53.28 Favored Glycine 0 N--CA 1.447 -0.63 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -179.527 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.9 mt -86.19 -178.59 6.54 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.455 -0.372 . . . . 0.0 110.903 -179.679 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -75.65 96.86 3.66 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.013 0.435 . . . . 0.0 110.447 179.961 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.53 124.39 18.85 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.419 -179.689 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.89 -22.57 25.45 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.102 179.536 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.9 p -87.65 172.43 9.72 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 117.041 0.421 . . . . 0.0 111.173 -179.705 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.09 130.95 56.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.3 -179.942 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -109.31 118.8 37.62 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.627 179.677 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.91 115.69 26.65 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.772 -179.428 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.5 t -124.02 129.84 74.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.0 -179.202 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.23 -178.8 28.16 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 178.587 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 9.6 pt20 -88.32 128.34 35.49 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.899 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.628 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -133.23 166.68 21.9 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.16 -178.574 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.407 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -159.81 177.81 10.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.412 179.439 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.408 ' CZ3' ' HA ' ' A' ' 42' ' ' THR . 0.3 OUTLIER -72.21 100.31 2.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.375 -179.943 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.457 HG21 ' HB3' ' A' ' 83' ' ' TRP . 4.4 p -83.56 -22.26 8.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.212 0.53 . . . . 0.0 109.717 179.836 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -160.85 -176.86 5.76 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.528 179.039 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 39' ' ' TRP . 10.7 m -69.61 102.89 1.95 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.188 0.518 . . . . 0.0 111.869 -178.937 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.68 -3.98 80.77 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.666 179.615 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -112.7 126.12 70.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.018 0.437 . . . . 0.0 110.401 -179.607 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mp -112.69 160.01 18.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.596 179.714 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.4 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -149.11 141.23 23.92 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.673 -0.24 . . . . 0.0 110.633 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.811 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 17.2 m -104.13 167.04 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 O-C-N 123.273 0.358 . . . . 0.0 111.024 -179.608 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 74' ' ' GLU . 27.5 p-10 -77.86 134.22 64.88 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-O 120.87 0.367 . . . . 0.0 111.119 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 74' ' ' GLU . 60.3 Cg_endo -94.87 19.98 0.63 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.468 2.779 . . . . 0.0 113.822 -179.199 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.22 -67.91 0.89 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.674 -179.825 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.15 39.93 0.68 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.836 0.351 . . . . 0.0 111.453 -179.218 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -106.82 161.12 14.96 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.271 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.3 m -139.68 128.82 23.79 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.953 0.406 . . . . 0.0 110.808 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 m -94.5 104.61 16.57 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.273 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 p -93.37 136.22 25.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.14 0.495 . . . . 0.0 110.732 -179.468 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.2 t -102.72 141.1 36.09 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.242 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.43 127.62 33.35 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.977 179.831 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.32 178.47 8.06 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.547 -178.793 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.35 -29.53 68.96 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.251 -178.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -76.9 -9.34 58.62 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.047 0.451 . . . . 0.0 110.365 179.574 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 84.19 25.82 42.74 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.163 -0.541 . . . . 0.0 111.874 -179.758 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.85 163.89 16.83 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.717 0.294 . . . . 0.0 110.84 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -157.98 124.29 4.77 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.357 179.974 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 17.6 m -126.26 128.89 47.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.843 0.354 . . . . 0.0 110.52 179.827 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -141.67 165.75 26.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.829 -179.49 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.572 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.1 m -133.8 120.6 20.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.128 -179.437 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -104.53 147.45 27.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.765 0.317 . . . . 0.0 111.468 -178.346 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.4 m -96.91 105.86 18.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.674 178.825 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 11.4 p -82.26 118.84 30.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.71 . . . . 0.0 111.789 -179.113 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.3 mmt180 -100.36 167.37 10.44 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.433 178.866 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -76.99 -44.38 31.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.254 0.549 . . . . 0.0 109.66 179.267 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -124.77 134.91 52.62 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 178.777 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -143.88 175.48 9.98 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.015 0.436 . . . . 0.0 111.742 -178.306 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 1.5 mp0 -92.78 133.01 36.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.881 179.5 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.09 116.24 4.35 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.993 -0.622 . . . . 0.0 111.985 179.425 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.4 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.4 t80 -123.78 137.95 54.59 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.107 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 81.3 mt -86.28 170.68 11.86 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 178.895 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -82.9 -8.42 59.57 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.996 0.427 . . . . 0.0 110.906 -179.565 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -87.16 -23.97 24.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.266 178.917 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.24 -5.97 13.18 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.457 -0.878 . . . . 0.0 113.678 179.085 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 m -89.09 140.32 29.57 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 117.223 0.511 . . . . 0.0 110.878 -179.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -93.43 144.4 25.37 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.265 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.457 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 t-105 -103.53 -53.53 2.77 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.901 0.381 . . . . 0.0 110.713 -179.789 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 168.52 -174.04 43.22 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.665 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.3 m -81.84 128.12 33.7 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.013 0.435 . . . . 0.0 110.947 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.1 t -108.26 143.04 19.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.0 -0.546 . . . . 0.0 109.56 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -127.68 132.37 49.68 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.081 0.467 . . . . 0.0 111.102 -179.114 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 22.5 m -107.53 19.07 20.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.09 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.5 m -80.2 -28.51 38.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.073 0.463 . . . . 0.0 109.753 179.016 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -117.69 18.85 14.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.45 0.643 . . . . 0.0 110.275 179.42 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.72 -165.5 2.25 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.108 -179.731 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -117.84 144.48 45.35 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -101.25 143.07 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.867 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.458 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.2 OUTLIER -123.79 150.81 44.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 111.012 -179.573 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.22 114.84 25.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.316 -179.848 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.628 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.77 105.39 3.24 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.005 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.4 HD13 ' HG2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.78 116.22 26.56 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.671 0.272 . . . . 0.0 110.292 -179.935 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.9 m -150.22 162.02 41.28 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.837 179.945 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.23 -173.35 4.65 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.207 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -32.61 69.21 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.566 0.222 . . . . 0.0 111.499 179.523 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 -37.35 58.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.047 0.451 . . . . 0.0 110.177 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 116.46 21.85 4.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.213 179.082 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -124.02 -173.69 2.82 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.96 0.38 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.17 -138.45 10.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.808 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.4 ' HG2' HD13 ' A' ' 97' ' ' LEU . 59.1 Cg_endo -73.72 169.38 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.516 2.144 . . . . 0.0 111.734 179.237 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -84.87 139.71 31.68 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.48 -179.676 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.568 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -70.07 140.14 32.21 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.472 -179.827 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 7' ' ' VAL . 42.0 t -103.76 130.52 54.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.744 0.307 . . . . 0.0 110.548 -179.372 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.89 132.86 42.23 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.626 179.876 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 48.4 pt -124.16 172.24 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.969 0.414 . . . . 0.0 110.533 -179.458 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -144.37 148.41 34.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.236 179.673 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -85.25 160.21 19.91 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.147 179.553 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.5 p30 . . . . . 0 C--O 1.251 1.174 0 CA-C-O 118.7 -0.667 . . . . 0.0 110.271 -179.765 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.811 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.063 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 108.7 60.98 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.035 -179.746 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -83.24 168.92 13.04 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.707 2.271 . . . . 0.0 111.896 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 3.0 m -121.64 115.4 22.68 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.16 76.89 1.76 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.016 -179.694 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -79.1 69.01 5.21 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.645 -179.746 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 m -97.11 149.18 5.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.572 -179.898 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 22.5 m -118.21 108.57 41.84 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.351 179.815 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -73.42 161.42 42.56 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.639 2.226 . . . . 0.0 111.812 179.211 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 m -117.74 40.72 3.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.989 0.423 . . . . 0.0 110.714 -179.883 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -69.81 113.4 7.02 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.901 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.48 -6.78 31.89 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.977 -179.882 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.476 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 78.0 mt -100.08 163.02 12.61 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.891 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.0 m -87.73 -176.45 5.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.059 -179.149 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.71 154.63 39.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.933 0.397 . . . . 0.0 110.208 -179.992 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.28 -6.11 71.67 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.634 -0.793 . . . . 0.0 111.935 -179.28 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 69' ' ' VAL . 39.5 m -69.71 137.49 52.11 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.941 0.4 . . . . 0.0 110.336 179.565 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 10.7 t -85.96 103.43 12.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.362 -179.539 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 16.2 t -74.33 128.16 36.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.33 179.955 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -94.18 119.73 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.169 -179.431 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 91.1 t -121.56 105.71 17.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.634 179.456 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.58 115.51 19.62 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.928 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.64 143.28 15.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.551 -0.833 . . . . 0.0 111.878 179.622 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -128.47 143.29 50.96 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.508 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.04 33.44 17.94 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.083 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.477 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 15.8 mt -97.19 -175.56 3.27 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.808 -179.349 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -91.84 108.12 19.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.887 179.632 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.2 127.79 33.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.991 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.81 -1.78 36.04 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.354 -0.927 . . . . 0.0 113.171 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.0 p -110.08 153.0 25.28 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 117.209 0.505 . . . . 0.0 110.803 179.463 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.38 135.22 44.39 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.601 -179.66 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.477 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 80.9 m-85 -108.65 125.93 52.42 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.989 0.423 . . . . 0.0 111.062 -179.737 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -87.06 117.86 26.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.161 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.5 t -125.66 124.45 66.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.153 -178.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.63 170.75 31.79 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.052 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -82.85 59.01 4.6 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.652 0.739 . . . . 0.0 109.375 179.353 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 2.0 m -65.25 97.22 0.25 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.869 -178.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -99.84 173.8 6.51 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.98 179.159 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -65.55 121.75 15.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.817 0.341 . . . . 0.0 111.497 -179.691 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 83' ' ' TRP . 9.9 p -110.12 -27.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.09 0.472 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.406 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.1 t70 -142.54 -175.0 4.3 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.78 87.52 0.35 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.254 0.549 . . . . 0.0 111.251 -179.739 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 93.01 -0.76 69.66 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.177 179.896 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.406 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.4 t -110.71 132.69 58.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 O-C-N 122.801 -0.235 . . . . 0.0 110.45 -179.775 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 mp -106.83 168.8 8.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.01 179.889 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -150.67 134.61 16.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.043 179.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.704 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 11.0 m -92.66 166.45 12.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.785 -179.499 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 20.3 p-10 -93.13 128.95 41.08 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.517 179.772 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 55.8 Cg_endo -89.11 -4.14 6.01 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.947 2.432 . . . . 0.0 113.55 -179.194 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.18 -62.01 1.5 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.547 -179.174 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -104.5 65.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.718 0.294 . . . . 0.0 111.613 -179.323 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.427 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 15.0 p90 -114.95 161.28 18.51 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.3 m -147.03 103.29 3.59 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.797 0.332 . . . . 0.0 111.526 -179.724 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 m -83.97 127.99 34.24 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.375 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.83 135.52 53.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 121.078 0.466 . . . . 0.0 110.58 -179.549 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.4 t -93.55 137.16 33.1 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.076 179.524 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.95 122.53 17.22 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.379 179.894 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -71.54 179.45 3.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.581 -179.202 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.77 -7.81 23.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.947 -179.445 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -95.84 -4.71 43.26 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.342 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.02 30.37 47.29 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.462 -179.897 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -126.59 161.13 28.74 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.795 0.331 . . . . 0.0 110.786 -179.24 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -154.55 118.51 4.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.616 179.786 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m -117.37 129.22 55.73 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.13 179.845 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.1 t -138.63 162.28 35.01 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.071 0.462 . . . . 0.0 111.257 -179.432 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.531 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.4 m -124.41 127.51 47.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.733 179.953 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -117.18 133.21 56.26 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.458 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.13 99.73 12.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.802 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 17' ' ' THR . 9.8 p -72.9 122.22 25.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.422 0.629 . . . . 0.0 111.729 -179.215 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -104.17 158.2 16.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.809 179.239 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.433 ' HG3' ' OG1' ' A' ' 89' ' ' THR . 0.1 OUTLIER -78.04 -22.36 49.27 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.016 0.436 . . . . 0.0 110.404 -179.908 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 22.5 m -148.12 137.34 22.08 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.05 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 40.3 p90 -155.86 166.29 33.94 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.947 0.403 . . . . 0.0 111.409 -178.422 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -80.76 129.97 34.82 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 178.549 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -88.81 123.6 6.89 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.2 -179.153 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.466 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.5 m-85 -124.77 138.32 54.28 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.659 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.541 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.2 mt -77.95 171.96 14.21 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.913 179.77 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -70.94 -31.86 68.58 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.617 -179.255 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -32.37 72.09 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.608 179.484 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.16 -19.76 5.12 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.346 -0.93 . . . . 0.0 113.306 179.584 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.7 m -71.27 143.27 50.42 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.715 0.258 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -84.38 158.28 21.16 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.258 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.441 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.6 t-105 -133.04 12.26 4.27 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.276 -0.57 . . . . 0.0 111.386 179.923 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.31 -164.47 12.04 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.248 -0.977 . . . . 0.0 113.056 179.141 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.7 m -103.71 129.6 51.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.637 0.256 . . . . 0.0 110.528 -179.709 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.457 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.0 t -100.37 133.74 42.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.732 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -115.22 133.72 55.79 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.895 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 71' ' ' ARG . 71.3 m -115.55 22.09 13.46 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.395 0.617 . . . . 0.0 109.953 178.821 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.433 ' OG1' ' HG3' ' A' ' 71' ' ' ARG . 2.9 m -89.2 -46.99 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.907 179.349 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -108.84 -12.95 14.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.372 179.228 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.84 171.57 7.51 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.743 -179.554 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.79 171.02 12.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.282 -179.584 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.61 155.11 40.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -179.55 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.51 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 0.5 OUTLIER -158.11 171.98 19.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.551 0.215 . . . . 0.0 110.578 -179.852 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 50.0 t -121.25 130.99 74.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.099 179.985 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -115.77 148.58 18.9 Favored Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.858 -179.545 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.3 115.04 6.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.2 m -142.24 165.76 26.54 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.91 -179.26 2.19 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.397 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.16 -30.58 62.39 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.72 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.72 -52.28 6.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.789 0.328 . . . . 0.0 110.943 179.871 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.64 28.99 0.16 Allowed Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.258 179.777 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -118.75 165.14 14.37 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.939 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.37 -160.68 26.9 Favored Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.146 179.823 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -68.57 154.86 70.74 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.684 2.256 . . . . 0.0 111.649 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -66.66 145.67 55.32 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.695 0.283 . . . . 0.0 110.839 179.602 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -65.31 164.51 37.05 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.75 121.63 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.743 0.306 . . . . 0.0 111.317 -178.968 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.51 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -80.56 143.01 33.56 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.135 179.211 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.3 pt -129.77 169.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 110.866 -179.653 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.3 m -144.47 139.44 28.3 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.843 179.748 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 49.5 m-85 -94.31 152.73 18.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 179.822 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.564 -0.731 . . . . 0.0 110.683 -179.771 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.704 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.665 0.269 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.42 116.52 66.5 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.543 -179.818 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.13 163.43 30.6 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.637 2.224 . . . . 0.0 112.087 179.911 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.76 87.33 2.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.084 0.469 . . . . 0.0 110.857 -179.906 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.86 78.48 7.57 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.113 0.482 . . . . 0.0 110.79 -179.706 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -83.11 102.89 12.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.342 -179.827 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.22 157.03 26.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.869 0.366 . . . . 0.0 110.808 179.828 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.2 m -118.16 108.07 42.68 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.607 179.844 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -75.29 147.48 32.92 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.536 2.157 . . . . 0.0 112.163 179.89 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.1 m -94.32 37.04 1.12 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.556 179.644 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.62 107.15 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.848 179.914 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.22 5.42 26.66 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.51 HD13 HG21 ' A' ' 17' ' ' THR . 25.7 mt -119.4 150.25 40.49 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.724 0.297 . . . . 0.0 110.249 -179.882 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 68.6 m -77.66 178.53 7.23 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.786 0.326 . . . . 0.0 111.313 179.741 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -67.65 161.2 26.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.303 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.36 -16.12 60.61 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.66 -179.398 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.51 HG21 HD13 ' A' ' 13' ' ' LEU . 23.0 m -68.3 139.91 55.94 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-O 120.822 0.344 . . . . 0.0 110.088 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.569 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 41.2 t -86.4 116.4 29.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.219 -179.266 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.3 t -82.66 141.72 14.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.131 179.714 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -107.01 123.7 48.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.898 0.38 . . . . 0.0 111.097 -179.544 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.4 t -122.72 112.39 33.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.86 179.331 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.0 93.7 3.55 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.129 0.49 . . . . 0.0 110.912 179.648 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.33 127.48 9.15 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.307 -179.752 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.16 149.36 39.19 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.579 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.62 30.67 39.15 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.896 -179.558 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.7 mt -92.6 -171.15 2.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.915 0.388 . . . . 0.0 110.708 -179.503 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 13.9 tp60 -87.35 93.35 9.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.928 179.654 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 129.04 27.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.925 -179.493 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.16 -4.99 57.43 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.638 179.724 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -108.58 143.77 37.16 Favored 'General case' 0 C--N 1.323 -0.567 0 O-C-N 122.788 -0.242 . . . . 0.0 110.711 179.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -87.03 137.51 32.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.993 0.425 . . . . 0.0 111.471 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -115.41 121.1 41.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.299 179.544 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.51 121.09 29.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.936 -179.793 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 5.1 t -132.12 123.02 49.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.649 -0.25 . . . . 0.0 111.279 -179.818 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.88 -179.78 25.99 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.602 178.545 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.4 HE21 ' HB2' ' A' ' 36' ' ' GLN . 1.3 pt20 -83.73 126.76 33.22 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.647 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.707 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -137.7 171.99 13.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.752 -178.792 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.59 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -169.07 -173.77 1.86 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.798 178.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -74.22 113.96 12.02 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.851 0.358 . . . . 0.0 110.648 -179.676 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.6 p -100.09 -23.26 4.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 121.022 0.439 . . . . 0.0 110.63 -179.539 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -153.17 -168.19 2.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.724 -179.859 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.2 m -73.73 100.08 3.31 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 110.688 179.85 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.24 -5.63 62.72 Favored Glycine 0 C--N 1.329 0.172 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.236 -179.827 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.5 t -104.4 133.24 49.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 -179.379 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mp -113.83 164.92 13.11 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.398 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.27 19.63 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.205 -179.804 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.844 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 80.6 m -101.81 175.5 5.53 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.108 179.638 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -101.86 124.96 38.5 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.843 178.918 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 62.4 Cg_endo -85.61 5.71 5.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.136 2.557 . . . . 0.0 113.145 -179.318 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -108.98 -66.71 1.03 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -87.84 71.61 9.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.315 0.579 . . . . 0.0 110.713 -179.52 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.453 ' HA ' HD12 ' A' ' 67' ' ' LEU . 2.1 p90 -152.45 168.54 25.18 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.61 179.172 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.9 m -147.34 124.75 11.62 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.163 0.506 . . . . 0.0 111.251 -179.351 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 m -89.08 119.89 29.99 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.755 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.8 p -107.75 128.69 62.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.169 0.509 . . . . 0.0 110.597 -179.44 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.52 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -88.73 143.57 26.83 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.371 179.785 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.74 124.28 24.43 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.462 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -72.8 -177.94 2.53 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.326 -179.575 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.15 -22.52 66.97 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.376 -179.598 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 31.3 m-20 -77.87 -17.34 57.45 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 179.855 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.41 28.03 20.92 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.458 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.71 155.96 34.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.168 0.509 . . . . 0.0 111.406 -179.534 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.82 107.05 4.74 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.923 178.966 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 1.7 m -113.13 135.4 53.85 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.486 -179.749 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -153.04 167.06 30.47 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.941 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.569 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 19.0 m -130.02 132.29 46.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.146 -179.796 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.453 HD12 ' HA ' ' A' ' 52' ' ' PHE . 2.2 mm? -119.39 144.42 46.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.023 0.439 . . . . 0.0 111.926 -179.142 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.3 m -104.01 101.63 11.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.252 178.934 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD11 ' A' ' 110' ' ' ILE . 4.3 p -73.88 125.07 32.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.398 0.618 . . . . 0.0 112.199 -178.416 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -100.24 159.26 15.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.143 178.272 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -71.02 -42.71 69.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.379 . . . . 0.0 110.722 -179.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 m -126.44 136.66 52.93 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.099 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -152.18 158.79 43.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.134 0.492 . . . . 0.0 111.673 -179.092 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.16 128.34 33.17 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.554 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.66 123.98 7.18 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.733 -179.289 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.487 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 9.2 m-85 -125.77 142.73 51.37 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 179.767 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.535 HD11 ' CE3' ' A' ' 83' ' ' TRP . 58.2 mt -77.67 168.48 19.89 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.59 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -69.01 -22.84 64.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.749 0.309 . . . . 0.0 110.668 -179.394 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.83 -24.78 63.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.458 179.501 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 116.16 -9.11 18.1 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.891 179.281 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 25.2 m -90.59 142.86 27.31 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.653 0.263 . . . . 0.0 111.135 -179.664 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 ptt85 -80.7 154.93 27.02 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.207 179.327 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.535 ' CE3' HD11 ' A' ' 77' ' ' LEU . 35.2 t-105 -120.77 -44.96 2.41 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.118 0.485 . . . . 0.0 110.381 179.475 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 174.51 167.09 33.46 Favored Glycine 0 N--CA 1.448 -0.528 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.771 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -76.58 127.6 33.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.866 0.333 . . . . 0.0 110.374 179.793 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.59 HG11 ' HB3' ' A' ' 38' ' ' ALA . 3.6 t -101.13 125.28 55.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.587 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -115.02 124.71 52.33 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.122 0.487 . . . . 0.0 111.599 -178.886 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 20.1 m -109.17 25.8 11.38 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.627 179.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.7 m -79.33 -26.66 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.627 0.727 . . . . 0.0 109.256 178.844 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.0 t -124.04 10.89 8.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.622 178.659 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -140.46 179.1 6.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.608 -179.233 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.91 140.39 42.45 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.807 179.932 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.7 m -96.65 169.88 9.58 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.027 179.739 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.502 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -142.96 163.87 31.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.889 0.376 . . . . 0.0 110.919 179.288 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.6 t -90.25 121.06 40.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.707 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.29 107.24 3.2 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.17 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.11 121.04 37.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.724 0.297 . . . . 0.0 110.23 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -147.13 150.07 34.25 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.606 179.78 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -82.47 -173.66 4.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.546 179.751 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.11 -22.41 65.8 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.612 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -88.42 -43.71 11.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 179.385 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 131.63 13.2 1.87 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.501 179.736 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -114.31 -169.41 1.52 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.749 0.309 . . . . 0.0 110.699 -179.614 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.18 -150.6 20.04 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.845 179.695 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.53 165.61 31.98 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.638 2.225 . . . . 0.0 111.578 179.469 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -77.84 147.06 35.35 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.294 179.63 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.517 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -72.07 140.92 30.68 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.581 -179.555 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.0 t -114.22 127.86 71.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 -179.855 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.26 147.17 25.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.641 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 69' ' ' VAL . 39.6 pt -114.69 147.49 18.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.727 -179.805 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.1 m -111.6 125.13 53.6 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.189 179.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 91.9 m-85 -79.94 143.97 33.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.535 -0.745 . . . . 0.0 110.783 -179.92 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.844 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.887 0.375 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -92.56 122.68 63.83 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.589 -179.62 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -80.85 -171.8 1.34 Allowed 'Trans proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.881 2.387 . . . . 0.0 112.328 179.856 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 92.42 2.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.173 0.511 . . . . 0.0 110.233 179.883 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.77 84.2 6.26 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.376 -179.403 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -85.27 84.05 7.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.286 0.565 . . . . 0.0 111.033 179.813 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -102.3 145.46 11.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.073 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.4 m -120.12 97.66 49.22 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.33 179.505 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.24 167.25 27.82 Favored 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 122.453 2.102 . . . . 0.0 112.284 -179.647 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.8 m -120.16 45.49 2.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.979 0.418 . . . . 0.0 111.059 -179.854 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.424 ' HA ' ' H ' ' A' ' 111' ' ' SER . 4.4 m -70.64 116.25 10.75 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.476 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.1 -8.65 27.14 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.214 179.7 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 94.6 mt -104.32 162.34 13.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.729 0.299 . . . . 0.0 110.644 -179.789 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.75 176.96 9.18 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.743 -179.801 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -70.09 156.72 38.78 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.163 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -14.47 57.66 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -178.423 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.4 m -69.72 138.82 53.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.925 0.393 . . . . 0.0 110.69 179.179 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 66' ' ' SER . 0.4 OUTLIER -93.44 101.17 12.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.886 -179.292 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 95' ' ' VAL . 34.5 t -68.35 132.95 32.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -100.99 128.95 46.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.072 0.463 . . . . 0.0 111.099 -179.34 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 64' ' ' SER . 65.0 t -124.57 114.39 40.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.115 179.476 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.68 99.69 6.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.993 0.425 . . . . 0.0 110.272 179.417 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.34 119.76 6.5 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.714 -179.448 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.82 154.97 32.0 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.112 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.13 25.73 59.12 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.342 -0.932 . . . . 0.0 111.132 -179.082 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.468 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 76.9 mt -93.21 -155.54 0.44 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.368 -0.416 . . . . 0.0 110.704 -179.234 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.1 tp60 -107.46 118.63 37.22 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 110.497 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.04 131.38 48.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.316 -179.715 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.57 44.95 8.2 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.538 179.883 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -141.81 137.97 31.89 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.903 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.52 133.67 34.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.883 0.373 . . . . 0.0 111.066 -179.902 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 66.6 m-85 -117.2 126.3 52.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.439 179.913 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.56 112.04 20.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.513 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.7 t -118.72 122.2 68.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.041 0.448 . . . . 0.0 110.843 -179.312 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.63 173.45 35.64 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.443 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.411 ' HB2' HE21 ' A' ' 36' ' ' GLN . 1.5 pt20 -80.97 71.61 7.94 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.39 179.51 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 3.1 m -78.53 96.51 5.46 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.238 -179.982 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.04 167.21 11.2 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.254 0.55 . . . . 0.0 111.881 -178.996 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.596 ' CZ2' ' HA ' ' A' ' 42' ' ' THR . 0.5 OUTLIER -64.29 104.6 0.78 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.414 179.292 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -101.16 -26.64 3.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 121.01 0.433 . . . . 0.0 110.752 -179.588 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -151.85 176.65 11.23 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.509 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.596 ' HA ' ' CZ2' ' A' ' 39' ' ' TRP . 3.2 m -62.38 102.95 0.35 Allowed 'General case' 0 C--N 1.323 -0.545 0 O-C-N 123.448 0.468 . . . . 0.0 111.21 -179.492 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.82 15.37 81.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.306 -179.826 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.4 t -125.73 122.23 61.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.017 0.436 . . . . 0.0 110.663 -179.913 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.445 ' HB2' " H6'" ' A' ' 114' ' ' FLN . 6.6 mp -116.25 137.35 52.22 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.671 -0.862 . . . . 0.0 108.671 179.083 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -137.06 146.59 45.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.836 0.351 . . . . 0.0 111.527 -178.888 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.475 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -117.26 164.82 14.24 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.403 -179.986 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' HB2' ' A' ' 73' ' ' PHE . 21.3 p-10 -98.45 138.41 20.8 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 120.809 0.338 . . . . 0.0 111.649 -179.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.514 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 86.7 Cg_endo -86.56 12.37 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.804 2.336 . . . . 0.0 112.015 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.97 -1.24 27.87 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.547 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -157.32 35.94 0.28 Allowed 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.795 179.796 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.6 p90 -112.27 169.27 8.98 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.031 179.937 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.7 m -150.36 115.02 5.24 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.847 0.356 . . . . 0.0 110.299 179.447 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.87 98.78 10.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.713 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -89.71 138.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.155 179.797 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -105.12 136.62 44.28 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.909 0.385 . . . . 0.0 110.26 179.802 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.44 133.81 51.2 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.09 0.471 . . . . 0.0 110.928 -179.813 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -79.71 -172.48 3.34 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.829 -179.536 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.89 1.88 6.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.86 0.362 . . . . 0.0 111.578 -179.654 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -104.73 -2.19 25.23 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.391 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.27 31.44 63.68 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.742 -179.735 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -125.08 147.21 49.1 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.712 0.291 . . . . 0.0 111.288 -179.506 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.84 111.22 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -115.47 145.67 42.38 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.556 179.677 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.9 t -160.7 167.26 27.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.396 179.677 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.544 ' HB3' HG12 ' A' ' 18' ' ' VAL . 68.9 m -135.72 131.2 35.31 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.899 179.683 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -121.38 141.47 50.93 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.957 0.408 . . . . 0.0 111.645 -178.395 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.86 108.78 19.33 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.237 179.145 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.49 122.74 25.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.4 0.619 . . . . 0.0 111.677 -179.09 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 3.6 mmp_? -94.64 160.18 14.74 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.409 179.43 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.544 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 11.1 tpp180 -77.77 -40.26 41.38 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.27 0.557 . . . . 0.0 109.796 179.153 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -134.6 136.24 42.78 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.523 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.43 ' HB2' ' HB3' ' A' ' 48' ' ' ASN . 43.6 p90 -155.45 160.37 40.56 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.842 0.353 . . . . 0.0 111.142 -178.884 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -84.8 123.64 30.67 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.573 179.212 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -78.28 123.95 6.51 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 179.456 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -127.9 147.93 50.47 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.097 0.475 . . . . 0.0 111.683 -178.341 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.493 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 9.9 mp -92.11 172.21 8.58 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.957 178.27 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -70.31 -23.32 62.83 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.842 0.354 . . . . 0.0 111.451 -178.655 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -81.06 -25.52 37.02 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.882 -179.856 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 122.42 -6.0 10.0 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.244 -179.917 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.9 m -69.25 134.43 49.17 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.054 0.455 . . . . 0.0 110.656 179.609 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.28 126.6 45.15 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.907 179.608 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -88.42 -23.27 23.36 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.855 0.359 . . . . 0.0 111.16 -178.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.03 175.72 13.96 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.616 -179.96 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 14.0 m -79.57 117.74 20.77 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.136 0.493 . . . . 0.0 111.031 -179.841 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 2.0 t -94.16 123.71 46.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.364 179.485 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -116.46 133.88 55.51 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.636 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 68.0 m -118.0 31.89 6.44 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.211 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.544 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 24.5 m -67.82 -47.37 69.21 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.2 178.939 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.8 t -118.5 -11.37 9.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.139 0.495 . . . . 0.0 109.883 178.661 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.2 178.91 5.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.56 179.661 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -93.85 144.2 25.65 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.994 0.426 . . . . 0.0 111.159 179.984 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.17 150.62 46.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.009 179.504 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.45 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.7 OUTLIER -147.3 171.48 15.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.637 0.256 . . . . 0.0 110.627 179.799 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.521 HG21 HG11 ' A' ' 19' ' ' VAL . 57.6 t -114.66 139.4 40.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.241 -179.731 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.12 143.56 16.22 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.908 -179.061 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.544 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.94 117.59 6.6 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.829 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -156.34 170.43 22.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.93 -170.09 2.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.129 179.553 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.3 -28.25 69.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.904 0.383 . . . . 0.0 111.513 -179.88 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.71 -40.88 27.94 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.847 0.356 . . . . 0.0 110.553 179.683 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.09 21.53 3.12 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.136 179.66 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -112.6 153.82 26.98 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.683 0.278 . . . . 0.0 110.597 -179.594 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 152.83 -161.01 29.36 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.862 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.58 142.19 98.45 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.789 2.326 . . . . 0.0 111.792 179.197 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -62.65 130.7 46.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.203 -179.397 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.93 142.75 40.43 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.142 -0.551 . . . . 0.0 111.825 179.716 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 4.2 t -111.31 142.89 22.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.522 0.201 . . . . 0.0 110.517 -179.015 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.45 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -92.43 156.42 17.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.062 0.458 . . . . 0.0 111.194 -179.914 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.4 pt -127.97 -178.07 2.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.946 179.792 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.424 ' H ' ' HA ' ' A' ' 11' ' ' SER . 19.6 m -152.64 147.9 26.67 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.708 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -98.07 157.6 16.04 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.951 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.629 -0.7 . . . . 0.0 110.266 179.914 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.493 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.89 109.2 55.22 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.25 159.08 47.82 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.579 2.186 . . . . 0.0 112.445 179.844 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.508 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.2 m -110.77 104.34 12.97 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.923 -179.469 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.25 98.71 10.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.967 0.413 . . . . 0.0 110.16 179.512 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.39 65.39 0.85 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.288 -179.386 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -94.99 138.56 20.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.075 179.936 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.05 113.21 63.85 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.587 179.931 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -80.3 137.27 11.81 Favored 'Trans proline' 0 N--CA 1.46 -0.459 0 C-N-CA 122.663 2.242 . . . . 0.0 112.977 -179.614 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.1 m -85.37 59.55 5.7 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.794 179.717 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 m -78.61 118.08 20.39 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 -179.639 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.95 -7.37 64.79 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.806 179.315 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.65 HD13 HG21 ' A' ' 17' ' ' THR . 6.9 mt -96.04 150.72 20.16 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.121 -0.325 . . . . 0.0 110.121 -179.544 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -79.48 -172.94 3.48 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.998 0.428 . . . . 0.0 111.625 -179.598 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.67 157.46 37.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.325 179.552 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.02 -6.46 83.66 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.895 -179.341 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.65 HG21 HD13 ' A' ' 13' ' ' LEU . 57.0 m -71.78 141.72 49.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.053 0.454 . . . . 0.0 110.505 179.745 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -85.63 116.93 29.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.992 179.919 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.35 119.88 35.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.747 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.79 116.86 22.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.211 0.529 . . . . 0.0 111.018 -179.309 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 34' ' ' VAL . 57.9 t -113.79 107.99 24.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.056 179.916 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.13 123.08 29.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.017 0.436 . . . . 0.0 110.721 179.95 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.15 135.46 8.46 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.972 -0.632 . . . . 0.0 111.998 179.733 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.508 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -125.5 153.49 43.5 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.274 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.84 31.65 48.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.279 -0.963 . . . . 0.0 111.407 -179.301 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 69.0 mt -95.18 -156.84 0.53 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.621 -0.29 . . . . 0.0 110.239 -179.563 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.6 tp60 -105.38 104.96 14.79 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.738 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.5 123.38 17.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.949 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.66 -1.76 29.07 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.282 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 33.6 p -112.09 163.13 14.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.181 0.49 . . . . 0.0 111.355 179.922 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.62 145.31 42.14 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.123 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -123.54 127.96 49.07 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.895 0.379 . . . . 0.0 111.331 -179.26 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -93.54 112.2 24.04 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.039 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.402 HG11 HG21 ' A' ' 21' ' ' VAL . 28.2 t -118.02 134.8 60.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.275 -178.808 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.93 -176.21 28.74 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 178.663 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -86.74 47.82 1.55 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.759 0.78 . . . . 0.0 109.466 179.288 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.6 OUTLIER -62.35 96.6 0.08 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.163 -179.025 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -109.18 -173.13 2.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.194 179.748 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -67.15 104.57 1.47 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.076 179.69 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 p -84.78 -25.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.228 0.537 . . . . 0.0 110.037 -179.733 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -160.61 -179.17 7.41 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.308 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.81 101.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.879 0.371 . . . . 0.0 110.608 -179.729 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.63 9.08 86.84 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.191 -179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.36 133.99 67.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.804 0.335 . . . . 0.0 110.431 -179.725 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.82 153.11 41.5 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.577 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.78 146.99 28.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.198 -179.264 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.647 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 73.1 m -94.89 174.58 7.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.072 -179.545 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -107.56 105.05 55.05 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 121.125 0.488 . . . . 0.0 110.423 179.8 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.41 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 83.1 Cg_endo -78.19 3.58 6.97 Favored 'Trans proline' 0 CA--C 1.529 0.273 0 C-N-CA 122.928 2.418 . . . . 0.0 113.797 -178.549 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.52 -29.18 18.05 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.572 -179.892 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -130.06 19.45 5.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.653 0.263 . . . . 0.0 111.026 -179.843 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.454 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.1 p90 -71.23 159.23 35.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.19 0.519 . . . . 0.0 111.432 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 m -144.1 108.08 4.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.166 179.416 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.76 84.79 7.21 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.744 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -72.75 137.35 23.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.976 -179.22 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.53 145.35 28.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.87 179.557 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 130.49 39.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 7.0 p30 -77.43 179.27 6.57 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.709 179.789 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.03 -20.4 66.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.582 -179.251 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -82.72 -6.58 59.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 110.302 -179.657 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.89 34.32 34.49 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.568 -0.613 . . . . 0.0 111.568 -179.567 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.51 163.65 24.5 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.82 0.343 . . . . 0.0 110.933 -179.65 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.92 124.88 9.93 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.272 179.453 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -132.32 124.77 29.45 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.817 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.4 t -144.02 178.76 7.64 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.874 0.369 . . . . 0.0 110.953 -179.419 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.482 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.9 m -131.26 130.18 42.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.465 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 67' ' ' LEU . 0.2 OUTLIER -116.37 137.28 52.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.716 0.293 . . . . 0.0 111.136 -179.631 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -98.11 113.27 25.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.198 179.234 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -80.86 130.87 35.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.325 0.583 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 mmt180 -108.12 158.85 17.06 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.856 179.753 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.21 -22.78 54.84 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.805 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -142.31 132.67 24.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.078 -0.964 . . . . 0.0 108.478 178.891 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -143.18 149.05 37.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.791 -0.364 . . . . 0.0 111.34 -179.141 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.0 mp0 -83.92 115.15 22.15 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.045 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.23 128.9 10.18 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.874 -179.486 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.522 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 2.7 m-85 -126.39 139.55 53.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.776 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.478 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 7.3 mp -84.05 165.81 18.24 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.912 179.476 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -64.8 -21.58 66.81 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.535 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -87.96 -23.49 23.84 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.761 0.315 . . . . 0.0 110.99 179.937 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 124.13 -13.03 8.02 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.624 -179.729 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 50.9 m -61.64 130.31 45.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.947 0.403 . . . . 0.0 110.561 179.455 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -97.38 138.02 35.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.968 -179.674 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -97.54 -50.8 4.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.549 -179.995 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.03 -175.61 26.32 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.779 -179.641 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 18.0 m -80.37 118.28 21.86 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.957 0.408 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 3.3 t -93.2 130.49 42.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.7 179.527 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -90.15 123.3 33.87 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.918 0.389 . . . . 0.0 110.808 -179.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.2 t -106.41 22.87 15.08 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.419 0.628 . . . . 0.0 109.963 179.895 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -89.81 -30.22 18.1 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.298 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.7 t -114.82 10.94 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.388 179.145 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.04 165.65 26.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.209 -178.998 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.12 123.77 48.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.995 179.829 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 69.6 m -87.26 170.35 11.52 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.687 179.89 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.41 ' CB ' ' HA ' ' A' ' 109' ' ' ALA . 9.0 pt20 -147.3 164.21 33.95 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.625 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.3 t -98.35 117.96 44.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.945 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -101.63 128.41 9.55 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.497 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.9 115.05 27.08 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.702 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -133.04 127.63 34.49 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.768 0.318 . . . . 0.0 111.403 -179.158 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -76.76 -169.15 1.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.451 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.47 -31.84 64.39 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.756 0.312 . . . . 0.0 111.247 179.478 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.01 -52.96 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.521 178.842 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 138.56 29.53 0.24 Allowed Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -126.98 -174.49 3.16 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.27 -0.271 . . . . 0.0 110.27 -179.907 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.54 -155.09 20.97 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.713 179.849 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.68 148.85 86.06 Favored 'Trans proline' 0 C--O 1.235 0.355 0 C-N-CA 122.589 2.193 . . . . 0.0 111.917 179.235 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -69.18 145.27 53.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.716 -179.924 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.33 126.16 9.93 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.701 -179.771 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.85 132.26 41.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.825 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HA ' ' CB ' ' A' ' 94' ' ' GLN . . . -84.75 154.84 22.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.998 0.428 . . . . 0.0 111.551 -179.261 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 30.5 pt -136.79 169.95 19.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -152.1 140.84 20.91 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.736 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 15.1 m-85 -87.52 167.5 13.9 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.26 -179.486 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.6 -0.714 . . . . 0.0 109.892 179.262 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.647 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.712 0.292 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.01 124.79 74.09 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.166 -179.458 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -82.7 157.61 16.18 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.705 2.27 . . . . 0.0 111.733 178.885 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -107.59 108.22 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.984 0.421 . . . . 0.0 110.565 -179.912 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.73 80.68 3.41 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.2 0.524 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.1 86.41 7.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.561 179.523 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.6 m -112.39 153.04 14.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.831 0.348 . . . . 0.0 110.839 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -120.06 91.59 45.93 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.239 179.652 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -71.31 132.71 21.35 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.018 2.478 . . . . 0.0 112.132 -179.818 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.8 m -84.29 67.28 9.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.01 0.433 . . . . 0.0 110.927 179.886 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.5 m -90.52 123.49 34.23 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.504 179.846 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.19 -10.51 63.61 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.173 179.88 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.3 mt -92.52 170.78 9.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.732 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -89.57 -176.98 5.19 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.728 0.299 . . . . 0.0 111.037 -179.589 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.8 160.98 29.42 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.049 179.186 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.42 -12.39 66.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.504 -179.363 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 m -69.45 144.06 53.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.993 0.425 . . . . 0.0 110.434 179.675 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.3 t -88.63 127.13 41.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.955 -179.722 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.3 t -94.23 121.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.755 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -92.43 125.3 37.02 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.934 0.397 . . . . 0.0 111.053 -179.256 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 78.5 t -124.11 113.0 34.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.801 179.136 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.86 104.48 9.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.084 0.469 . . . . 0.0 110.99 179.956 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.86 122.6 7.12 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.998 -179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.49 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.02 138.62 50.14 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.701 0.286 . . . . 0.0 110.437 179.618 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.84 38.91 9.89 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.565 -0.826 . . . . 0.0 111.185 -179.492 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.8 mt -101.38 177.42 4.93 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.567 -0.316 . . . . 0.0 110.276 -179.23 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.9 tp60 -87.3 117.66 26.21 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.876 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.74 144.49 56.39 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.826 0.346 . . . . 0.0 111.737 -179.245 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.84 1.43 90.24 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.802 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.5 m -100.45 139.06 36.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.694 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -90.7 127.96 36.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.16 179.485 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -110.24 120.43 42.42 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.909 0.385 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -86.6 119.69 27.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.58 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 18.2 t -133.26 124.91 50.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.689 -179.786 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.76 173.19 31.08 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 179.016 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.32 120.18 29.44 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.24 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.486 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -124.66 174.48 7.84 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.919 0.39 . . . . 0.0 111.435 -178.413 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.95 -179.85 6.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.353 178.919 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -75.82 101.64 5.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 0.0 111.08 -179.849 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.26 -23.13 6.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.65 179.553 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -138.75 -175.44 4.14 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.482 -0.781 . . . . 0.0 108.931 179.532 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.59 66.57 4.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.147 0.499 . . . . 0.0 111.194 -179.699 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 127.86 -33.69 3.17 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.964 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.27 136.02 23.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.99 0.424 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.6 mp -110.93 169.53 8.71 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.235 -179.79 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -162.95 147.6 11.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.669 179.895 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.721 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.2 OUTLIER -120.8 168.08 11.82 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.133 0.27 . . . . 0.0 110.624 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -98.6 135.21 21.17 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 121.082 0.468 . . . . 0.0 110.932 179.356 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.84 9.01 4.14 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.74 2.294 . . . . 0.0 112.826 -179.365 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.18 -37.61 14.05 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.063 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -108.53 -1.85 19.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.932 -179.779 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -68.19 150.56 48.17 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 24.6 m -147.77 94.95 2.43 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.934 0.397 . . . . 0.0 110.543 -179.704 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.03 127.2 31.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.711 179.648 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -115.38 130.62 69.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.119 0.485 . . . . 0.0 110.64 -179.556 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 14.7 t -88.61 136.87 32.78 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.034 179.239 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.38 128.14 35.51 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.76 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.8 p30 -72.38 178.74 3.79 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.321 -179.449 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.01 -12.66 40.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.871 -179.909 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.4 m-20 -87.97 -12.36 44.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.994 0.426 . . . . 0.0 110.12 179.799 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.8 34.21 22.42 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.694 -179.519 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -132.07 150.18 52.22 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.625 0.25 . . . . 0.0 110.64 -179.561 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.8 113.2 6.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.274 -179.965 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.43 129.48 56.01 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.043 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.1 t -140.99 156.69 46.0 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.511 180.0 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.552 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.6 m -130.06 124.89 33.91 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.823 179.809 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.93 141.7 47.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.7 0.286 . . . . 0.0 111.75 -178.416 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.6 m -94.51 105.21 17.17 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.745 178.957 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.33 122.09 35.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.674 0.749 . . . . 0.0 111.45 -179.194 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 23.6 mmt180 -95.79 166.59 11.74 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.847 179.342 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.1 tpp180 -77.08 -34.83 56.93 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.172 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -132.33 131.55 42.06 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.747 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -144.9 169.21 18.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.496 0.665 . . . . 0.0 112.203 -178.302 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.94 141.71 31.06 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.766 179.82 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -100.76 116.95 5.72 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.459 -0.877 . . . . 0.0 112.662 -179.242 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.417 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 20.7 m-85 -124.67 142.11 51.62 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.703 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.543 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 73.6 mt -77.05 173.54 11.69 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.699 -179.977 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -64.13 -30.92 71.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.948 0.404 . . . . 0.0 111.481 -179.11 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.46 -18.13 55.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.41 -3.6 28.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.642 -0.789 . . . . 0.0 113.397 179.894 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.7 m -77.18 132.0 38.55 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.038 0.447 . . . . 0.0 110.933 179.472 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.8 ttt-85 -75.19 126.55 31.26 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.614 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 47.9 t-105 -98.65 -20.74 16.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.041 0.448 . . . . 0.0 110.301 179.452 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.8 -142.87 10.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.15 179.747 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.2 m -124.06 145.67 49.08 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.979 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.487 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.6 t -124.4 129.22 73.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.635 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -114.61 121.86 44.71 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.683 -179.755 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 26.5 m -100.06 14.71 29.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 179.852 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 m -80.15 -28.29 38.88 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 177.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.1 t -119.3 11.41 12.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.682 -1.145 . . . . 0.0 109.908 179.27 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.99 -164.16 1.9 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.151 -179.213 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.73 145.1 48.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 111.174 -179.557 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -105.29 159.08 16.17 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.486 -179.607 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.68 159.06 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 179.183 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.6 t -89.0 115.94 29.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.59 115.31 5.18 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.134 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.92 121.71 23.25 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.809 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.4 m -148.03 151.64 36.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.668 0.27 . . . . 0.0 111.163 179.934 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.72 -173.01 3.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.159 179.554 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -57.37 -35.18 69.65 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.66 0.266 . . . . 0.0 111.53 179.872 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -77.94 -43.85 28.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 109.937 178.932 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.38 23.96 1.66 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.614 179.396 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 57.7 m-80 -126.13 -169.44 2.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.65 0.262 . . . . 0.0 110.73 -179.74 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.5 -148.78 16.98 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.233 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.25 150.03 86.59 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.356 2.037 . . . . 0.0 111.662 179.203 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -75.09 150.34 38.85 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.892 -179.535 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.81 146.69 43.77 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.99 -0.55 . . . . 0.0 112.503 -179.773 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 15.3 t -117.71 129.73 73.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 -179.92 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -89.23 154.49 20.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.486 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.2 pt -136.09 164.52 31.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 66.2 m -137.34 142.83 41.81 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.142 179.473 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -94.2 163.4 13.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.35 179.976 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.7 p30 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.917 -0.563 . . . . 0.0 110.216 -179.936 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.721 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.548 0.214 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.96 107.64 60.78 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.782 179.865 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -75.94 163.63 32.95 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.47 2.113 . . . . 0.0 111.966 179.758 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.28 109.07 20.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.817 0.342 . . . . 0.0 110.944 -179.564 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.08 84.62 2.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.984 0.421 . . . . 0.0 110.386 179.816 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -89.58 102.09 14.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.256 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.9 m -118.61 149.15 21.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.739 179.798 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -117.07 94.65 45.32 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.457 179.458 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.65 138.01 25.91 Favored 'Trans proline' 0 N--CA 1.462 -0.333 0 C-N-CA 123.059 2.506 . . . . 0.0 112.173 -179.761 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.8 m -86.88 64.48 8.51 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.12 179.833 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.4 m -80.5 118.06 21.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.901 -179.634 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.99 -7.05 69.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.742 179.599 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.1 mt -93.85 157.3 16.2 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 122.729 -0.277 . . . . 0.0 110.374 -179.716 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.3 m -82.71 -175.0 5.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.799 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.78 161.35 29.11 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.492 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.88 0.72 80.96 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -178.883 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.9 m -80.26 150.61 29.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.416 -0.392 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.404 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 40.2 t -97.63 115.43 37.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.145 0.498 . . . . 0.0 111.182 -179.358 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.84 122.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.821 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 28.7 ttmt -101.19 132.07 46.86 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.399 0.618 . . . . 0.0 111.772 -179.214 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.8 t -123.46 110.61 26.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.521 178.893 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.56 103.57 9.26 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.023 0.44 . . . . 0.0 111.125 -179.41 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.05 140.12 14.72 Favored Glycine 0 N--CA 1.446 -0.694 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.194 -179.984 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -127.81 136.11 51.01 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.452 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.08 31.34 8.57 Favored Glycine 0 N--CA 1.448 -0.548 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -178.992 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 32' ' ' TYR . 31.5 mt -93.75 -173.86 3.28 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.288 -0.456 . . . . 0.0 110.33 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -85.55 104.17 15.07 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.577 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.82 110.71 0.95 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.66 -179.342 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.12 -7.77 16.48 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.941 179.667 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.2 m -98.79 144.29 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.954 0.407 . . . . 0.0 110.98 179.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.65 126.36 36.71 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.73 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 26' ' ' LEU . 56.9 m-85 -104.31 124.13 48.63 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.17 0.51 . . . . 0.0 110.705 -179.441 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.07 125.14 36.64 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.15 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.463 HG13 ' HB3' ' A' ' 97' ' ' LEU . 13.2 t -133.18 124.41 49.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.438 -179.629 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.83 176.67 27.51 Favored Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.158 178.883 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 46.9 tt0 -85.61 115.33 23.24 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.966 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.59 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -121.58 163.57 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.116 0.484 . . . . 0.0 111.898 -178.31 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.431 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -162.96 172.94 14.31 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.195 179.1 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 116.86 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 179.561 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.4 p -101.78 -24.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.644 -179.66 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -159.16 -172.95 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.39 179.649 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 m -62.48 94.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.052 0.453 . . . . 0.0 112.021 -179.236 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.21 9.2 86.86 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.311 179.327 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -117.09 134.05 61.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.845 0.355 . . . . 0.0 110.522 -179.385 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.9 mp -117.37 161.69 19.14 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.281 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.47 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.08 147.13 26.71 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.684 -179.898 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.758 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.9 m -111.29 162.13 15.32 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 123.108 0.255 . . . . 0.0 111.299 -178.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.488 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 29.0 p-10 -87.69 123.72 68.78 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.296 0.569 . . . . 0.0 111.032 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 4.33 7.04 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.756 2.304 . . . . 0.0 112.254 179.914 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.09 -57.87 3.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.643 -179.407 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.402 ' HB2' HD21 ' A' ' 48' ' ' ASN . 23.2 m-20 -100.44 21.32 13.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.963 -178.601 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -78.9 149.25 32.45 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.337 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -145.58 96.82 2.88 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.962 0.41 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.9 p -74.7 117.68 16.81 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.432 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -100.11 136.27 32.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.361 -179.424 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 11.3 t -87.66 136.63 32.87 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.057 179.511 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.51 124.69 26.35 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.371 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -69.84 177.17 3.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.012 -179.281 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.75 -8.56 44.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.195 -179.167 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -90.14 -19.84 23.8 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.255 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.72 25.82 11.36 Favored Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.367 179.647 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -121.09 159.04 26.57 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.901 0.381 . . . . 0.0 111.146 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -155.12 132.75 11.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.35 179.135 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 m -133.35 131.7 40.39 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.298 179.68 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.3 t -140.93 158.25 44.2 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.875 0.369 . . . . 0.0 110.604 -179.81 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 2.1 m -124.33 122.47 37.81 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.375 -179.875 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.09 138.02 50.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.851 0.358 . . . . 0.0 111.199 -178.854 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.8 m -92.97 111.71 23.42 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.61 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.3 p -76.28 135.65 26.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.404 0.621 . . . . 0.0 111.376 -178.93 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -114.93 169.5 9.04 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.664 179.759 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 tpp180 -85.2 -38.65 18.73 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.246 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.1 m -130.0 143.58 50.87 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.429 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.488 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.1 p90 -153.32 160.46 42.7 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.555 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -87.51 121.65 30.22 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.087 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.36 130.13 9.5 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.58 -178.805 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.8 m-85 -133.49 153.41 51.65 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.787 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.417 HD22 ' H5 ' ' A' ' 114' ' ' FLN . 17.3 mt -89.11 169.53 11.41 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.445 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -72.88 6.0 2.88 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.505 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -117.85 -1.63 11.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.707 0.289 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.08 -5.81 56.22 Favored Glycine 0 C--O 1.236 0.227 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.25 179.204 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -71.9 136.96 47.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.799 0.333 . . . . 0.0 110.93 179.678 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -98.46 130.78 45.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.32 179.948 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.405 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.1 t-105 -104.17 -56.07 2.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.764 0.316 . . . . 0.0 110.283 -179.862 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 173.92 174.8 41.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 111.926 -179.918 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.69 136.17 33.47 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.697 0.284 . . . . 0.0 110.957 -179.918 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 ' HB3' ' A' ' 38' ' ' ALA . 19.6 t -116.91 138.26 48.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.447 -179.77 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -113.18 129.7 56.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.296 179.762 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.1 m -113.47 28.31 8.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.903 0.383 . . . . 0.0 110.927 -179.815 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.8 m -79.85 -39.6 30.26 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 177.988 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 t -105.84 -11.35 16.27 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.737 179.601 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.51 -174.76 2.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.65 -179.23 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.58 145.19 43.55 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.453 179.85 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -108.41 156.86 18.97 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.0 -179.976 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.96 145.19 51.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.006 0.431 . . . . 0.0 110.759 179.877 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.8 t -76.66 119.08 24.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.327 -179.781 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.59 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -102.59 110.54 3.78 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.018 -179.622 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -126.9 122.47 34.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.992 0.425 . . . . 0.0 110.278 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 34.1 m -152.1 161.8 42.08 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -90.33 -167.87 1.96 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.734 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.75 -24.99 67.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.745 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.56 -3.68 58.75 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.17 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 77.87 22.58 68.72 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.241 179.88 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -119.59 173.87 6.74 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.795 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.35 -154.85 26.0 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.906 179.215 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.81 160.73 47.11 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.952 2.434 . . . . 0.0 112.288 179.851 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -73.69 139.36 45.3 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.737 -179.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.415 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -68.36 155.39 53.26 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.139 -0.553 . . . . 0.0 112.303 -179.807 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.0 t -117.48 132.28 67.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 -179.753 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 137.86 31.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.022 0.439 . . . . 0.0 111.021 -179.963 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.17 157.55 31.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.124 179.853 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 22.8 m -141.49 139.84 33.38 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.95 179.196 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -81.86 173.74 11.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.131 -179.871 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.775 -0.631 . . . . 0.0 109.432 179.45 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.758 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.678 0.275 . . . . 0.0 110.647 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -86.16 120.75 72.62 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.869 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -80.37 176.91 8.73 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.793 2.329 . . . . 0.0 112.01 179.952 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 6.5 m -135.23 91.45 2.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.015 0.436 . . . . 0.0 110.559 179.362 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.41 93.63 7.78 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 p -99.18 99.49 10.48 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.2 179.516 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.7 m -119.18 143.16 31.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.652 179.991 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.15 90.2 11.12 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.101 179.249 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.2 146.19 68.99 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.73 2.287 . . . . 0.0 112.876 -178.923 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.438 ' HA ' HD12 ' A' ' 13' ' ' LEU . 2.5 p -83.39 52.52 2.24 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.555 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.6 m -73.31 114.67 11.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.376 -179.44 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.79 10.38 63.13 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.249 178.754 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.644 HD13 HG21 ' A' ' 17' ' ' THR . 16.0 mt -103.73 176.93 4.99 Favored 'General case' 0 C--N 1.319 -0.724 0 O-C-N 122.762 -0.258 . . . . 0.0 110.306 179.93 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -175.75 3.93 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.781 0.324 . . . . 0.0 111.013 -179.719 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.14 152.43 36.71 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 178.94 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.33 10.83 73.39 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.469 -179.384 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.644 HG21 HD13 ' A' ' 13' ' ' LEU . 97.6 m -78.86 140.93 38.05 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.027 0.442 . . . . 0.0 110.927 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.576 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.4 t -89.97 107.91 18.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.955 -179.727 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.6 t -84.41 122.08 37.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -91.03 124.02 34.94 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.087 0.47 . . . . 0.0 110.669 -179.595 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -120.34 110.63 29.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.058 -179.843 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.33 104.01 8.85 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.982 0.42 . . . . 0.0 110.836 179.909 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.43 124.11 8.01 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.323 -179.741 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.486 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.43 152.12 33.49 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.368 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.43 34.01 26.85 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.45 -0.881 . . . . 0.0 110.972 -179.038 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 71.7 mt -100.06 -160.38 0.8 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.758 -178.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.9 tp60 -105.77 116.73 32.44 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.87 -179.285 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.76 125.86 25.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.677 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.95 3.42 58.04 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.418 -179.821 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.2 m -103.26 133.42 48.36 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.797 0.332 . . . . 0.0 110.612 179.73 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.08 127.65 37.63 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.419 179.517 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.526 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 72.7 m-85 -107.37 129.26 54.94 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.765 -179.563 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -92.73 118.26 30.88 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.166 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.1 t -125.91 120.49 57.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.981 -179.242 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.38 169.87 29.65 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 111.474 -0.65 . . . . 0.0 111.474 179.214 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -88.44 127.42 35.51 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.103 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -129.61 -177.84 4.44 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.682 -179.098 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.483 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -165.22 154.82 12.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.362 178.592 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.515 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -63.98 107.54 1.27 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.227 179.428 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.52 -38.2 6.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.958 -179.006 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.493 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 22.8 t0 -137.1 169.09 18.36 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.515 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.6 m -59.88 94.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.601 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.82 1.52 70.53 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.12 -0.562 . . . . 0.0 113.071 178.983 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 4.2 t -122.08 134.63 64.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 0.0 110.855 -179.44 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -127.6 170.72 12.34 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.643 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.405 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -151.39 138.32 19.03 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.513 -0.18 . . . . 0.0 110.513 -179.996 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.806 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.0 m -110.82 171.37 7.5 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 29.4 p-10 -87.13 136.3 33.96 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.453 -179.589 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 42.3 Cg_endo -94.14 -1.14 3.01 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.009 2.473 . . . . 0.0 113.775 -179.869 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.94 -69.2 0.79 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 111.811 0.301 . . . . 0.0 111.811 -179.315 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.67 44.68 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.727 -179.638 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' HD11 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -111.52 170.83 7.86 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.519 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.6 m -148.8 110.6 4.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.928 0.394 . . . . 0.0 111.462 -179.676 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.12 134.47 35.33 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.901 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -125.76 137.55 57.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.923 0.392 . . . . 0.0 110.627 -179.76 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.3 t -103.72 133.78 48.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.578 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.13 124.15 23.02 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 110.254 -179.978 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.77 -177.24 1.22 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.667 -179.22 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.42 -26.74 63.61 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.096 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -80.93 -6.71 59.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.178 0.513 . . . . 0.0 110.375 179.652 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.89 41.03 34.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.973 -179.878 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.91 139.23 48.67 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 110.703 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.41 117.16 17.73 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.701 -179.898 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -120.88 134.53 55.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.311 179.916 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -151.33 168.74 23.84 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.943 0.402 . . . . 0.0 111.294 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.576 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 42.5 m -127.13 127.73 45.06 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.057 179.644 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.435 HD11 ' HA ' ' A' ' 52' ' ' PHE . 2.6 mm? -116.44 125.53 52.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.753 0.311 . . . . 0.0 111.768 -178.779 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.06 104.03 16.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 178.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.411 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.5 p -82.75 124.81 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 121.208 0.527 . . . . 0.0 111.887 -178.663 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.4 mmt180 -97.9 165.82 11.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.315 179.217 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 tpp180 -74.49 -32.36 62.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.321 0.582 . . . . 0.0 109.768 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 m -131.84 138.93 48.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 178.649 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -154.34 177.39 11.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.22 0.533 . . . . 0.0 112.171 -178.452 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -89.2 149.76 22.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.028 179.222 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.51 118.62 4.7 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.851 -179.86 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.405 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 7.9 m-85 -129.02 139.12 52.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.945 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 51.0 mt -80.3 166.48 21.3 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.194 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.36 -30.93 71.97 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.083 -178.583 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -81.6 -5.47 58.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.71 0.29 . . . . 0.0 111.62 -179.462 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.01 -13.96 48.99 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.66 -0.781 . . . . 0.0 113.066 179.354 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 80.5 m -64.68 130.7 44.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.766 0.317 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.498 ' HD3' ' H ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -87.12 145.53 26.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.763 0.316 . . . . 0.0 110.594 -179.922 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.0 t-105 -109.08 -46.44 3.59 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.884 179.11 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 153.5 -134.96 4.6 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.254 -179.837 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.7 m -111.19 127.39 55.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.926 0.393 . . . . 0.0 110.948 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.483 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -106.9 142.46 19.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.187 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -128.5 140.9 51.57 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -177.733 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 87.4 m -122.98 24.53 8.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.962 179.085 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.1 m -80.55 -38.6 29.3 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-O 121.273 0.559 . . . . 0.0 109.875 179.385 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.4 t -111.65 18.54 18.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.232 0.539 . . . . 0.0 110.379 179.302 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -153.14 -176.16 5.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.061 -179.404 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.42 145.86 29.66 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.469 179.629 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -91.38 164.92 13.66 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.326 179.958 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -130.2 146.31 51.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.875 0.369 . . . . 0.0 110.564 179.758 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 48.0 t -93.84 116.69 35.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.359 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.79 130.83 10.37 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.709 -179.207 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -148.31 125.06 11.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.724 0.297 . . . . 0.0 110.313 179.931 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 66.8 m -152.24 163.93 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.979 179.661 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -87.49 -159.56 0.53 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.571 179.546 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -69.46 -27.58 65.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.701 0.286 . . . . 0.0 111.384 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.92 -48.2 7.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.93 0.395 . . . . 0.0 110.822 179.823 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.15 33.47 0.28 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.51 -0.853 . . . . 0.0 112.77 179.689 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -126.62 -173.22 2.82 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.78 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.97 19.23 Favored Glycine 0 N--CA 1.446 -0.633 0 C-N-CA 121.053 -0.594 . . . . 0.0 111.695 179.35 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -69.14 172.26 12.35 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.918 2.412 . . . . 0.0 111.69 179.243 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -86.74 143.29 27.61 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.833 -179.14 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.56 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -69.79 134.52 25.82 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.189 -0.529 . . . . 0.0 111.886 179.497 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.4 t -106.27 136.44 40.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.775 0.321 . . . . 0.0 111.302 -179.084 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.78 136.22 33.05 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.196 178.72 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 6.5 pt -125.34 123.53 65.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.217 0.532 . . . . 0.0 110.81 -179.5 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.4 m -110.71 138.04 47.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.441 179.859 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -90.26 160.28 16.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.774 -179.494 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.974 179.913 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.806 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.001 0 CA-C-O 120.725 0.298 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.74 110.11 39.3 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.447 179.825 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.46 161.6 42.64 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.637 2.225 . . . . 0.0 112.274 -179.827 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.7 m -117.33 81.23 1.62 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.271 0.558 . . . . 0.0 109.933 179.658 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.35 106.17 17.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -179.522 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.37 101.4 11.1 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.165 179.527 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.8 m -117.9 143.25 29.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.782 0.325 . . . . 0.0 111.309 -179.367 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 26.5 m -105.33 107.07 58.22 Favored Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.707 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -78.04 133.77 12.6 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.455 2.103 . . . . 0.0 111.624 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -86.96 39.33 0.85 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.283 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -63.83 112.35 2.86 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.155 -179.422 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 -2.06 49.55 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.02 -0.609 . . . . 0.0 112.587 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.5 mt -104.66 149.89 25.18 Favored 'General case' 0 C--N 1.322 -0.589 0 O-C-N 122.499 -0.413 . . . . 0.0 110.039 -179.89 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -77.79 -177.5 4.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.959 0.409 . . . . 0.0 111.822 -178.912 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -71.51 152.96 42.56 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.755 -179.901 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.61 -7.09 68.13 Favored Glycine 0 N--CA 1.449 -0.448 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -179.325 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 57.2 m -73.99 141.65 45.84 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.157 -0.521 . . . . 0.0 110.713 179.869 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.467 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.1 t -88.69 119.29 35.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.424 -179.525 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -88.52 131.66 35.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.368 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -101.7 131.4 47.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.042 0.449 . . . . 0.0 111.035 -179.017 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 64' ' ' SER . 70.8 t -127.56 122.43 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.417 179.399 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -133.11 91.74 2.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.974 0.416 . . . . 0.0 110.139 179.408 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.22 113.74 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.152 -179.545 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.97 145.06 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.267 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.2 19.66 35.28 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.27 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.81 -178.44 5.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.586 -0.307 . . . . 0.0 110.366 -179.659 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 41.6 tp60 -85.55 106.66 17.03 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.289 -179.79 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.64 141.86 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.814 -179.533 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.36 8.49 83.34 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.978 179.76 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.85 143.67 46.82 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.794 0.297 . . . . 0.0 110.742 -179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -85.48 129.01 34.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.057 0.456 . . . . 0.0 111.582 -179.641 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -114.57 105.57 13.24 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.666 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -79.49 122.31 26.29 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.346 -178.819 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 15.8 t -129.6 131.75 66.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.742 -179.606 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.51 -177.49 22.82 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 178.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.34 42.2 1.09 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.642 0.721 . . . . 0.0 109.368 178.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.603 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -58.56 123.02 14.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.663 -179.185 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.479 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -119.01 179.37 4.18 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.303 -179.396 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -64.03 116.6 6.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.911 -179.549 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p -103.28 -28.34 3.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.876 0.37 . . . . 0.0 110.971 -179.627 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -157.89 178.75 9.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.343 -0.39 . . . . 0.0 109.972 179.649 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.474 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 2.7 m -64.82 103.48 0.71 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.836 0.351 . . . . 0.0 110.974 -179.587 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.94 11.18 84.11 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.751 -0.659 . . . . 0.0 112.444 -179.907 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 t -129.11 138.76 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.946 0.403 . . . . 0.0 110.481 -179.638 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.19 157.68 37.54 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.423 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -143.61 147.4 34.32 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.749 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.449 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 63.5 m -97.65 177.94 5.33 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.017 -179.22 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.629 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 24.1 p-10 -119.79 113.52 34.53 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.214 0.531 . . . . 0.0 110.546 179.424 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.555 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 71.6 Cg_endo -78.16 30.49 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 122.917 2.411 . . . . 0.0 112.5 -179.922 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -124.52 -15.65 6.54 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.23 -179.799 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -146.16 19.92 1.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.978 0.418 . . . . 0.0 110.968 -179.787 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.555 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 4.7 p90 -87.25 159.74 18.7 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.855 179.646 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m -152.49 92.84 1.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.736 0.303 . . . . 0.0 110.448 -179.993 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.43 123.0 19.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.413 179.771 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.428 HG13 ' HB1' ' A' ' 63' ' ' ALA . 5.1 p -113.14 131.84 63.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.97 0.414 . . . . 0.0 110.121 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.4 t -88.41 152.49 21.87 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.431 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.86 29.92 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.32 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -74.26 -175.7 2.38 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.299 -179.245 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.37 -8.45 40.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.643 -179.654 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -95.97 -7.12 37.34 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.482 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.73 33.11 35.0 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.411 -179.482 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.56 158.34 37.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.891 0.376 . . . . 0.0 111.201 -179.458 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.428 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -148.18 116.34 6.49 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.412 179.35 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -119.62 134.79 55.08 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.186 179.773 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.9 t -149.88 165.68 31.83 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.794 -179.045 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.467 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 14.7 m -122.03 131.78 54.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.564 -179.639 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -122.35 123.66 41.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.856 0.36 . . . . 0.0 111.614 -179.135 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.94 102.76 15.04 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.628 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.1 p -76.93 124.11 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.354 0.597 . . . . 0.0 111.524 -178.885 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -100.74 174.58 5.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.464 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.8 tpp180 -80.14 -32.91 38.9 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.989 0.423 . . . . 0.0 110.662 -179.502 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -146.7 149.4 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.89 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.629 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -160.48 165.98 29.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.913 0.387 . . . . 0.0 111.264 -179.187 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -85.58 120.53 27.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.099 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.44 126.19 8.46 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.845 -179.038 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.501 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 13.7 m-85 -129.54 143.88 51.02 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.728 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.526 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 75.6 mt -76.1 176.74 7.71 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.304 179.766 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -66.44 -35.88 81.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.951 0.405 . . . . 0.0 110.557 -179.012 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -73.47 -17.72 61.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.362 -179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 109.97 -2.77 30.13 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.207 179.517 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.6 m -76.16 130.9 38.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.809 0.337 . . . . 0.0 110.344 179.521 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -75.91 145.91 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.668 -179.592 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 11.5 t-105 -118.06 -65.79 1.14 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.838 0.352 . . . . 0.0 110.36 179.797 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -166.83 160.68 34.4 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.958 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.94 125.76 28.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.836 0.35 . . . . 0.0 110.771 -179.965 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 38' ' ' ALA . 20.3 t -100.6 129.04 52.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.731 179.814 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -123.61 123.24 40.14 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.634 -179.43 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.9 m -109.48 36.48 2.93 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.184 -179.905 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.1 m -80.84 -42.57 21.38 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.41 0.624 . . . . 0.0 109.477 178.224 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -105.71 8.32 32.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.111 179.788 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -142.3 -175.8 4.58 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.107 -179.461 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -118.75 139.91 50.8 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.871 0.367 . . . . 0.0 110.668 -179.948 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 18.6 m -87.57 -176.13 5.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.462 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.437 ' HG2' ' HA ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -149.07 172.06 15.39 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 178.815 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.03 125.95 44.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.725 0.298 . . . . 0.0 110.616 179.803 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.603 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -99.18 115.22 5.25 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.702 -179.531 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.1 mp -125.75 119.43 27.93 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.84 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 57.3 m -153.09 137.47 16.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.88 0.372 . . . . 0.0 110.341 179.28 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.83 -167.29 1.61 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.502 179.782 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.23 -35.35 67.25 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.232 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.17 -39.19 25.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.128 0.49 . . . . 0.0 110.549 179.383 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.58 21.23 5.16 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.844 179.582 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.3 m-80 -117.45 -163.41 0.93 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 -179.365 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 119.34 -166.39 13.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.491 -179.975 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -55.88 142.35 84.37 Favored 'Trans proline' 0 C--O 1.235 0.327 0 C-N-CA 122.863 2.375 . . . . 0.0 112.09 179.863 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -68.67 143.05 54.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.936 -179.558 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.83 142.52 38.35 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.466 -179.969 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.0 t -115.1 135.91 53.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.865 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -77.3 139.8 39.88 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.241 -179.579 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 13.3 pt -125.03 109.84 23.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.112 -179.889 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.8 m -93.59 143.25 26.48 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.059 -179.161 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -91.65 165.62 13.23 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.328 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.325 -0.845 . . . . 0.0 110.536 179.531 . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.526 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 120.769 0.319 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.73 119.55 68.41 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.944 -179.601 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -72.13 172.28 15.1 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.64 2.227 . . . . 0.0 112.213 179.86 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.7 m -114.01 93.1 4.21 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.133 0.492 . . . . 0.0 110.728 -179.94 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.39 87.95 7.55 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.574 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 p -94.99 102.96 14.8 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.005 0.431 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.6 m -120.57 146.89 24.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.334 179.998 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -108.48 100.57 38.75 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.185 179.621 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.68 135.94 20.43 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.218 1.946 . . . . 0.0 112.174 179.981 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -81.16 48.21 1.1 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.983 0.421 . . . . 0.0 111.299 179.925 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.78 111.07 4.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.681 -179.316 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.21 1.13 61.16 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.973 179.068 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.8 mt -100.5 164.31 11.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.699 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.5 m -91.09 -175.72 4.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.787 0.327 . . . . 0.0 111.307 -179.447 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -73.7 160.73 31.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.869 0.366 . . . . 0.0 110.451 179.837 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.92 -1.95 87.82 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.645 -179.201 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 66.1 m -76.72 142.05 40.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.003 0.43 . . . . 0.0 110.869 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.3 t -87.33 114.03 25.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.586 179.931 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -84.33 134.42 27.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.725 179.304 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -100.45 119.23 38.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.792 0.33 . . . . 0.0 110.79 -179.661 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 64' ' ' SER . 58.0 t -122.05 110.02 26.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.816 179.229 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.52 102.32 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.888 0.375 . . . . 0.0 111.09 -179.82 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.75 114.19 4.95 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.973 179.694 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.81 139.35 40.51 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.891 0.376 . . . . 0.0 110.599 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.43 35.65 10.42 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.98 179.871 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 98.7 mt -95.05 -161.96 0.91 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.968 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 tp60 -102.84 106.64 17.27 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.668 0.271 . . . . 0.0 110.402 -179.902 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.3 130.76 47.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.984 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.07 -24.98 14.96 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.08 -179.956 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.75 146.96 23.82 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.735 0.302 . . . . 0.0 111.378 -179.752 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.94 147.71 24.19 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 178.843 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 87.0 m-85 -121.4 143.35 49.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.091 0.472 . . . . 0.0 110.9 -178.978 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.03 123.35 47.64 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.271 179.652 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 t -129.19 122.51 56.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-O 120.88 0.372 . . . . 0.0 111.646 -178.915 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.86 171.92 32.57 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 178.3 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 pt20 -86.32 120.51 27.74 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.595 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.5 m -121.29 144.91 48.37 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.417 -178.76 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.648 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -127.86 165.12 20.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.81 179.678 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.421 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -70.47 101.78 2.06 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.205 -179.989 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.7 -20.4 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.417 -179.086 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.441 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t0 -158.75 176.9 11.78 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.879 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.421 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 4.4 m -71.01 99.8 1.87 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.948 0.404 . . . . 0.0 110.998 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.74 -9.78 74.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.058 -0.592 . . . . 0.0 112.547 179.821 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 12.5 t -112.53 126.99 69.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.061 0.458 . . . . 0.0 110.413 -179.733 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.8 mp -121.38 165.22 15.87 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.414 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -144.44 139.46 28.36 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.817 -0.353 . . . . 0.0 111.123 -179.056 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.792 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.7 m -110.36 176.94 4.85 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 123.303 0.377 . . . . 0.0 111.33 -179.584 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 28.9 p-10 -103.07 108.41 58.63 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-O 121.45 0.643 . . . . 0.0 111.759 -179.941 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 71.5 Cg_endo -75.78 -6.11 17.16 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.512 2.141 . . . . 0.0 112.043 179.367 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.22 -22.84 41.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.747 -179.65 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.487 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 9.4 m-20 -130.76 9.17 4.95 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.925 -179.184 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -71.69 154.27 41.48 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 -179.882 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.3 m -117.4 129.14 55.66 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.732 -179.556 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.0 m -86.74 105.8 17.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.722 179.456 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.9 p -110.08 153.2 11.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 120.779 0.323 . . . . 0.0 110.604 -179.222 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.4 t -132.05 151.95 51.46 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.686 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.87 125.24 28.96 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.887 0.375 . . . . 0.0 110.628 -179.952 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -76.36 -175.41 3.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.007 -179.349 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.12 -21.64 65.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.62 -179.812 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -90.36 1.12 56.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 110.9 -179.899 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.55 33.54 60.86 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.38 179.783 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.64 146.64 46.79 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.937 0.399 . . . . 0.0 110.655 179.974 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.82 104.33 5.25 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.094 179.427 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.7 OUTLIER -118.59 136.92 53.6 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.235 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 t -153.02 170.34 20.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.735 -179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 50.1 m -116.89 142.89 46.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.384 179.762 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -126.26 137.15 53.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.264 -179.684 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 23.2 m -100.42 108.07 19.98 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.212 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG23 ' NE2' ' A' ' 36' ' ' GLN . 6.4 p -79.45 129.27 37.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.05 0.452 . . . . 0.0 111.564 -178.783 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.4 mmt180 -105.15 162.46 13.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.662 179.285 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -83.71 -21.0 32.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.402 0.62 . . . . 0.0 110.22 179.576 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.3 m -151.22 137.66 18.61 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.808 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.542 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.8 p90 -155.57 172.65 17.91 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.187 0.518 . . . . 0.0 111.58 -178.615 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -94.43 121.61 36.14 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.135 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.56 132.83 11.4 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.846 -179.336 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.45 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 6.2 m-85 -128.04 154.39 45.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.411 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 70.4 mt -84.85 165.29 17.85 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.352 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 5.5 t80 -63.53 -19.69 64.99 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.515 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.23 -19.86 31.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.75 0.31 . . . . 0.0 110.655 179.951 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 118.97 -13.57 11.38 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.576 -0.821 . . . . 0.0 113.199 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.0 m -73.95 133.35 43.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 117.089 0.445 . . . . 0.0 111.226 -179.738 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.68 151.47 37.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.902 0.382 . . . . 0.0 110.548 179.68 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 35.7 t-105 -114.32 -42.58 3.31 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.024 179.024 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.1 -176.1 30.54 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.437 179.877 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 34.7 m -74.41 129.51 37.91 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.03 0.443 . . . . 0.0 111.382 -179.787 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.648 HG11 ' HB3' ' A' ' 38' ' ' ALA . 77.7 t -114.58 122.8 69.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.158 179.275 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -93.17 139.92 30.07 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.203 0.525 . . . . 0.0 111.872 -178.744 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.8 22.43 10.46 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.198 178.826 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 m -98.29 -43.9 6.77 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.987 179.637 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.5 t -96.07 -8.82 32.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.38 0.61 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 169.26 18.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.264 179.999 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.27 162.89 12.57 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.376 179.876 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 81.7 m -124.05 156.79 35.9 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.194 -179.982 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -119.32 154.99 32.68 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.111 0.481 . . . . 0.0 110.876 -179.838 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.74 113.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.949 179.859 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.595 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -98.87 119.1 6.37 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.328 -179.269 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.27 128.54 30.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.748 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 15.1 m -152.37 158.46 42.73 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.82 -168.58 1.47 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.633 179.689 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.26 72.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 111.401 179.449 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -79.69 -52.04 8.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.154 179.359 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.22 32.2 0.3 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.427 -0.892 . . . . 0.0 112.83 179.45 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -133.92 174.97 9.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.921 0.361 . . . . 0.0 110.328 179.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.1 -150.22 21.38 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -60.4 159.69 26.35 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 122.948 2.432 . . . . 0.0 112.271 179.083 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -78.2 149.19 33.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.072 -179.136 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.23 142.83 28.84 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.409 179.849 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.24 127.34 70.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HA ' ' A' ' 94' ' ' GLN . . . -83.95 137.26 33.72 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.869 0.366 . . . . 0.0 111.675 -179.284 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.0 pt -120.69 160.19 21.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.649 179.547 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 49.3 m -145.43 147.53 32.32 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.774 0.321 . . . . 0.0 110.954 179.742 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 39.2 m-85 -88.61 168.67 12.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.634 -179.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.922 -0.561 . . . . 0.0 109.749 179.213 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.792 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.975 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 041 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.94 114.89 41.43 Favored Pre-proline 0 C--N 1.327 -0.382 0 O-C-N 123.437 0.461 . . . . 0.0 110.656 -179.959 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -74.54 168.05 25.71 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.677 2.252 . . . . 0.0 112.648 -179.329 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -119.77 99.43 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.039 179.708 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.7 80.07 3.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.604 -179.442 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.04 105.36 12.2 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.795 179.95 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 108' ' ' VAL . 15.3 m -126.25 148.46 30.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.496 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -115.98 99.95 53.07 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.239 179.615 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -79.35 136.58 12.7 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.573 2.182 . . . . 0.0 113.351 -179.508 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -82.74 60.64 5.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.481 179.368 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 m -79.5 110.78 15.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.266 -179.321 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.81 5.03 61.47 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.13 179.64 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 39.3 mt -101.92 157.75 16.63 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.462 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.21 -178.18 6.8 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.999 0.428 . . . . 0.0 111.061 -179.224 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -73.5 157.6 36.48 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.395 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.68 -4.41 81.99 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.045 -179.242 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 60.2 m -70.34 146.12 50.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.151 0.5 . . . . 0.0 111.068 -179.651 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.491 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 48.4 t -87.4 112.73 23.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.95 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 66' ' ' SER . 23.2 t -87.36 128.2 40.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.737 179.403 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -101.41 124.51 47.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.898 0.38 . . . . 0.0 111.306 -179.035 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 64' ' ' SER . 74.8 t -125.62 112.04 29.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.958 179.317 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -122.83 106.86 11.26 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.911 0.386 . . . . 0.0 110.997 -179.739 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.52 116.24 5.52 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.811 179.795 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -110.93 137.34 48.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.383 . . . . 0.0 110.056 179.003 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.61 26.41 17.61 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.479 -179.174 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.443 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 46.3 mt -88.64 -168.44 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -99.18 106.78 18.99 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.587 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.67 133.39 36.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.057 -179.504 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.89 1.24 67.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.454 178.987 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 m -109.22 141.8 40.96 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.896 0.348 . . . . 0.0 110.674 179.954 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -91.21 137.68 32.18 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.685 179.714 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.443 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 78.1 m-85 -117.57 118.7 32.86 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.184 179.588 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.07 117.15 21.41 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.057 -179.806 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 t -120.59 127.15 75.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 N-CA-C 111.844 0.313 . . . . 0.0 111.844 -178.899 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.57 170.49 34.63 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 178.126 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 2.3 pt20 -82.9 64.63 7.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.92 0.86 . . . . 0.0 109.527 179.295 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 1.6 m -67.49 96.57 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.26 -179.708 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -97.64 176.38 5.86 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.262 -179.703 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.406 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -76.37 90.01 3.21 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.624 -179.657 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.55 -29.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.224 -179.378 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -154.0 178.9 9.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.285 179.793 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.406 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.72 103.61 0.72 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.962 0.411 . . . . 0.0 111.276 -179.507 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.49 9.32 87.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.014 -0.613 . . . . 0.0 111.867 179.847 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 t -121.65 124.52 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 120.832 0.348 . . . . 0.0 110.369 -179.721 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.4 mp -118.36 152.27 36.15 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.301 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.613 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -148.56 140.58 23.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.557 0.218 . . . . 0.0 111.287 -178.988 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.66 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 7.8 m -92.18 177.78 6.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.156 -179.233 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.6 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 26.4 p-10 -114.78 99.64 52.18 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-O 121.316 0.579 . . . . 0.0 112.003 -179.416 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.507 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 34.2 Cg_exo -64.06 -11.83 29.33 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.578 2.186 . . . . 0.0 112.6 179.129 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.22 -28.55 63.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.694 179.703 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.95 27.81 2.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.037 0.446 . . . . 0.0 110.968 -179.567 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.507 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.1 p90 -87.83 164.55 15.85 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.597 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 67.2 m -151.54 111.0 3.96 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.37 179.261 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.76 102.98 11.12 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.717 179.182 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -93.5 129.8 43.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.558 -179.524 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 9.1 t -92.29 136.81 32.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.179 179.469 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.71 126.29 28.92 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.158 -179.954 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -69.01 175.97 3.43 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.899 -179.444 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.1 -14.65 56.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.981 -179.09 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -85.94 -19.09 30.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.075 0.464 . . . . 0.0 109.84 179.57 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.25 32.63 7.31 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.785 -179.554 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.37 156.23 43.44 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.728 0.299 . . . . 0.0 111.048 -179.679 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.97 110.03 3.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.716 179.544 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.6 t -119.19 132.65 55.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.143 179.756 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.7 t -145.93 170.79 15.9 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.49 179.866 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.491 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 66.7 m -130.97 130.38 43.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.614 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.419 ' N ' HD22 ' A' ' 67' ' ' LEU . 2.6 mm? -114.09 163.16 15.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.591 -179.299 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.76 111.64 21.57 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.307 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.26 122.38 28.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.167 0.508 . . . . 0.0 110.173 179.979 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.52 161.13 13.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.914 -179.856 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.0 tpp180 -76.4 -36.77 57.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.365 0.602 . . . . 0.0 109.836 179.738 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -140.88 133.22 28.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.831 179.033 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.6 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 47.1 p90 -146.65 160.33 42.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.137 0.494 . . . . 0.0 111.589 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -83.08 118.78 23.78 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 177.801 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -79.6 129.33 9.07 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.865 -179.843 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.567 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 23.3 m-85 -126.05 141.96 51.73 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.735 0.302 . . . . 0.0 111.24 -179.643 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.477 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 5.7 mt -81.83 174.44 11.31 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.287 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -73.79 -10.29 59.52 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.754 0.311 . . . . 0.0 111.621 -178.958 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 1.9 p-10 -85.25 -21.02 29.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.733 0.302 . . . . 0.0 110.607 179.466 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.86 -2.78 27.32 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.697 179.235 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.6 m -94.08 139.0 31.52 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 117.001 0.4 . . . . 0.0 110.788 179.854 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.501 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -83.49 139.18 33.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.617 179.302 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 37.3 t-105 -93.79 -39.68 10.61 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.579 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 167.57 178.55 39.77 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.062 179.836 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -80.29 120.4 24.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.913 0.387 . . . . 0.0 110.9 -179.784 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.6 t -99.66 118.44 46.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.51 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -113.8 134.03 55.03 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.449 -179.605 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 74.0 m -117.17 30.55 7.25 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.416 -179.733 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.3 m -66.55 -44.29 82.76 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.132 0.492 . . . . 0.0 109.822 179.326 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 87.2 m -119.09 -29.15 5.32 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.81 178.474 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.43 167.26 22.04 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.376 179.557 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.26 139.12 31.31 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.486 -179.912 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -111.33 150.79 29.21 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.872 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -145.76 157.12 43.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.732 0.301 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 36' ' ' GLN . 42.1 t -119.27 127.73 75.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.768 179.82 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -135.92 173.93 21.62 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.977 -179.427 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.52 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.4 pt? -156.52 152.42 27.32 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.962 0.411 . . . . 0.0 110.443 -179.619 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 51.1 m -148.75 150.04 32.44 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.512 179.153 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -79.1 -166.43 0.92 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.603 179.852 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -62.42 -29.18 70.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.907 0.384 . . . . 0.0 111.045 179.727 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.96 -44.58 17.98 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.551 179.598 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.22 22.8 1.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.991 179.436 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -129.09 173.86 10.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 110.576 179.844 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 150.6 -155.42 26.17 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.206 -179.98 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.42 153.07 62.97 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.84 2.36 . . . . 0.0 112.286 179.721 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -68.37 142.27 55.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.583 -179.806 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.41 137.91 31.62 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 121.024 -0.608 . . . . 0.0 111.868 -179.755 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 7' ' ' VAL . 28.4 t -106.8 130.11 59.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.914 0.388 . . . . 0.0 111.296 -179.046 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.07 143.1 27.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.89 172.06 15.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.179 179.596 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.9 m -151.91 149.25 28.73 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 179.953 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.487 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 23.4 m-85 -97.7 166.28 11.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.603 -179.549 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--O 1.25 1.12 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.655 179.194 . . . . . . . . 0 0 . 1 . 041 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.66 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.926 0.393 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 042 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.86 122.75 68.82 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.051 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -80.07 176.11 9.69 Favored 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.57 2.18 . . . . 0.0 111.554 179.292 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.12 96.25 4.97 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.152 0.501 . . . . 0.0 110.827 179.887 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.74 75.91 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.049 -179.674 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -77.51 91.4 3.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.263 0.554 . . . . 0.0 110.501 179.347 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 108' ' ' VAL . 3.9 m -112.53 154.09 14.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 120.985 0.421 . . . . 0.0 111.581 -178.974 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -127.91 93.58 39.2 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.804 179.312 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.84 151.66 28.09 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.728 2.285 . . . . 0.0 113.15 -178.971 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 19' ' ' VAL . 1.3 m -88.05 90.92 8.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.983 179.156 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -94.32 93.48 7.74 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.396 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.19 55.16 2.55 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.766 179.23 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.89 -177.3 4.07 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.814 0.34 . . . . 0.0 110.36 179.452 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.03 169.89 10.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.815 -179.581 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -77.93 144.5 36.79 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 178.273 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.7 19.07 35.72 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -177.847 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.2 m -83.63 141.01 31.84 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.186 -0.507 . . . . 0.0 111.187 -179.613 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.4 t -86.55 103.25 12.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.842 179.649 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 10' ' ' SER . 34.8 t -82.53 131.7 33.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.341 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -98.75 130.26 45.21 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.228 0.537 . . . . 0.0 111.322 -179.698 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 70.8 t -125.41 122.53 62.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.695 179.453 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.06 108.15 7.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.917 0.389 . . . . 0.0 110.613 179.774 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.67 115.82 4.14 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.307 179.849 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.03 148.08 32.35 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.273 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.29 34.41 26.22 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.25 -179.312 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -97.37 -167.65 1.57 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.978 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 39.7 tp60 -90.1 109.38 20.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.869 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.03 136.89 57.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.979 179.752 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.72 17.84 62.89 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.665 179.735 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 m -120.62 137.9 54.19 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 122.606 -0.35 . . . . 0.0 110.943 179.73 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.76 119.92 32.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.979 179.483 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -101.66 118.93 37.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.488 -179.897 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.65 116.77 23.38 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.43 179.662 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 3.4 t -123.79 128.15 74.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.575 -179.505 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -158.01 177.39 34.76 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 178.845 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.439 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.7 pt20 -84.82 122.79 29.65 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.832 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.672 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 1.6 m -125.03 158.48 33.63 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-O 120.798 0.332 . . . . 0.0 111.039 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.707 ' HA ' ' OE1' ' A' ' 94' ' ' GLN . . . -148.19 171.98 15.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.164 179.285 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 55.0 m95 -66.89 112.13 4.13 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.828 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p -103.75 -30.99 2.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.064 0.459 . . . . 0.0 110.097 179.773 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.518 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 4.0 t70 -144.34 -176.31 4.98 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.498 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.7 m -68.53 101.21 1.22 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.139 0.495 . . . . 0.0 111.028 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.04 -1.26 80.58 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.443 179.351 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.0 t -111.72 121.88 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.168 0.509 . . . . 0.0 110.428 -179.714 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -104.97 159.1 16.08 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.4 179.565 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.403 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.85 145.37 28.68 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 121.106 -0.238 . . . . 0.0 111.019 -179.656 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.767 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.4 m -110.16 171.92 7.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.524 -179.558 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 22.8 p-10 -104.46 141.94 23.58 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-O 121.179 0.514 . . . . 0.0 111.358 -179.852 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.436 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.3 Cg_endo -90.29 12.29 2.52 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.792 2.328 . . . . 0.0 112.114 179.321 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.96 -15.95 20.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.98 -179.152 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.2 33.13 0.81 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.086 0.469 . . . . 0.0 111.579 -179.824 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 2.9 p90 -99.68 168.69 9.77 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.603 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 68.3 m -150.43 127.66 11.3 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.913 0.387 . . . . 0.0 110.973 179.482 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.7 m -90.75 103.18 15.91 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.456 179.135 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.475 HG22 ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -98.25 126.0 51.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.288 0.566 . . . . 0.0 110.558 -179.407 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.5 t -94.31 143.02 26.75 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.714 -179.655 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.75 127.93 34.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.81 179.164 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -71.49 -176.0 1.44 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.431 -178.989 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.77 -26.02 67.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.025 -179.431 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 61.5 m-80 -82.72 -17.65 43.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.846 0.355 . . . . 0.0 110.306 179.742 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.98 29.19 9.26 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.277 179.818 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 149.65 44.18 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.538 0.208 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.475 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -142.75 123.74 14.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.046 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 t -127.29 140.63 52.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.697 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -155.41 172.35 18.37 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.608 -179.621 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 20.9 m -129.05 132.26 47.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.386 -179.816 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -121.6 130.08 53.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.646 0.26 . . . . 0.0 111.547 -179.05 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.78 106.17 18.19 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 178.846 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.1 p -75.73 116.69 19.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.298 0.57 . . . . 0.0 111.817 -178.884 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.2 mmt180 -92.01 168.63 11.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.544 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 6.4 tpp180 -80.67 -40.56 25.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 110.848 -179.171 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -134.02 145.12 49.15 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.286 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.423 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 48.7 p90 -158.71 -177.0 6.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.02 0.438 . . . . 0.0 111.265 -178.825 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -104.66 130.56 52.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 179.592 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.01 126.83 8.0 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.667 -179.721 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.403 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 12.2 m-85 -121.52 143.69 49.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.811 0.339 . . . . 0.0 110.697 -179.642 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.446 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 62.0 mt -79.88 172.72 13.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.248 179.597 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.74 -23.71 66.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.963 0.411 . . . . 0.0 111.791 -178.843 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.34 -19.64 49.8 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.36 179.68 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.45 -0.79 29.38 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.686 -0.769 . . . . 0.0 113.688 179.22 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.0 m -91.65 137.5 32.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 117.25 0.525 . . . . 0.0 110.674 179.738 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.412 ' NH1' ' HA2' ' A' ' 84' ' ' GLY . 0.0 OUTLIER -75.32 135.02 40.91 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.96 0.409 . . . . 0.0 110.155 179.548 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.435 ' CE3' HD11 ' A' ' 77' ' ' LEU . 32.3 t-105 -99.61 -27.11 13.84 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.063 0.459 . . . . 0.0 110.331 179.882 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.412 ' HA2' ' NH1' ' A' ' 82' ' ' ARG . . . 164.5 166.56 23.62 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.107 179.636 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.2 m -80.16 141.9 35.26 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.253 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.613 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.3 t -125.79 145.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.94 0.4 . . . . 0.0 110.898 -179.238 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -132.61 134.75 45.29 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.873 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 5.4 m -119.26 33.9 5.45 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.27 179.945 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.439 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 5.3 m -81.98 -32.24 30.75 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.531 0.681 . . . . 0.0 109.325 178.931 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -119.6 21.47 12.05 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.53 179.178 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -145.88 176.48 9.65 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.098 -179.671 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -114.64 120.2 39.33 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.882 0.372 . . . . 0.0 110.562 -179.949 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.423 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.5 m -80.9 177.03 9.31 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.795 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.707 ' OE1' ' HA ' ' A' ' 38' ' ' ALA . 0.0 OUTLIER -141.95 166.48 24.59 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.026 0.441 . . . . 0.0 110.759 179.363 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 42.5 t -96.64 122.12 47.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.16 179.763 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.672 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -100.76 110.69 3.97 Favored Glycine 0 N--CA 1.444 -0.825 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.517 -179.602 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -125.35 113.71 17.92 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.599 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.464 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 46.5 m -152.32 157.43 41.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.879 0.371 . . . . 0.0 111.241 -179.773 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -82.19 -164.5 0.83 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.494 179.506 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.51 -36.22 79.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.611 0.243 . . . . 0.0 111.321 179.646 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -82.8 -49.02 10.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.861 0.362 . . . . 0.0 111.151 -179.793 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 132.31 40.34 0.21 Allowed Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.471 179.902 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 51.8 m-80 -125.92 -177.93 4.11 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.791 0.329 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 124.21 -150.56 17.04 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.499 -0.641 . . . . 0.0 111.499 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -68.99 158.3 58.48 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.432 2.088 . . . . 0.0 111.306 179.334 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -74.75 152.17 39.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.746 0.308 . . . . 0.0 110.695 179.994 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.81 135.29 20.16 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.544 -179.623 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 7' ' ' VAL . 12.4 t -102.16 135.96 36.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.927 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -90.97 143.29 26.88 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.531 -179.951 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 27.3 pt -123.45 166.19 18.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.295 179.872 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.4 m -146.34 143.38 29.06 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.958 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -83.84 162.15 20.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.69 -179.972 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.2 p30 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.012 -179.387 . . . . . . . . 0 0 . 1 . 042 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.767 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.947 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 043 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.0 106.04 53.87 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-O 120.678 0.275 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -82.54 169.21 13.96 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 122.61 2.207 . . . . 0.0 111.747 179.648 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.447 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -119.97 112.36 19.07 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.895 0.379 . . . . 0.0 110.507 179.791 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -101.05 114.25 28.01 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.236 179.972 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -125.62 97.75 5.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.059 0.457 . . . . 0.0 111.042 179.908 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 27.7 m -119.16 145.81 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.626 179.845 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.6 m -107.57 95.7 14.68 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.144 179.452 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 8.4 Cg_exo -72.84 135.09 22.89 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.211 2.607 . . . . 0.0 112.916 -178.671 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.415 ' OG ' HG22 ' A' ' 19' ' ' VAL . 4.7 m -86.3 39.06 0.8 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.907 179.591 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.75 110.28 1.47 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.085 -179.757 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.44 -0.28 55.69 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.739 179.504 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.55 HD13 HG21 ' A' ' 17' ' ' THR . 97.9 mt -101.34 165.82 11.07 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.452 -0.44 . . . . 0.0 110.284 -179.791 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.63 -179.61 6.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.64 0.257 . . . . 0.0 111.258 -179.162 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -73.9 155.78 38.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.198 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.31 -6.34 75.23 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.651 -0.785 . . . . 0.0 111.189 -178.798 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.55 HG21 HD13 ' A' ' 13' ' ' LEU . 31.2 m -77.28 130.25 36.95 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.246 -0.477 . . . . 0.0 110.542 179.754 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 54.7 t -75.54 122.59 29.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.984 -179.934 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.415 HG22 ' OG ' ' A' ' 10' ' ' SER . 22.3 t -98.23 121.38 48.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.503 179.225 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -94.27 131.2 40.12 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.25 0.548 . . . . 0.0 111.295 -179.719 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.1 t -123.17 124.91 71.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.412 179.444 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.09 110.27 8.92 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.012 0.434 . . . . 0.0 111.013 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.92 128.03 8.39 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.087 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.447 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -117.9 148.39 42.19 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.574 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.24 26.89 35.04 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.105 -179.17 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.2 mt -93.49 -171.42 2.62 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.341 -0.429 . . . . 0.0 110.236 -179.535 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -92.41 110.02 21.42 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.848 0.356 . . . . 0.0 110.151 179.671 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.74 124.57 22.28 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.341 -179.991 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.76 -5.4 37.1 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.251 -179.629 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -101.8 142.75 32.64 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.802 0.334 . . . . 0.0 110.855 179.508 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.73 131.82 34.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.554 179.732 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -114.87 124.38 51.58 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.787 179.813 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -98.85 121.16 40.44 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.82 -179.503 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.5 t -124.78 130.83 73.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.643 -179.869 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -156.99 176.22 34.29 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.792 179.038 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.41 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.5 125.63 33.2 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 178.863 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -131.65 174.92 9.63 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.386 -178.784 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -168.98 174.76 6.17 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.03 178.862 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -69.79 103.4 2.16 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 123.312 0.383 . . . . 0.0 110.706 179.604 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.462 HG21 ' HB3' ' A' ' 83' ' ' TRP . 11.6 p -91.12 -24.29 5.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.135 0.493 . . . . 0.0 109.88 179.949 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.465 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 10.4 t0 -155.71 174.58 15.09 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.356 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.8 m -65.06 103.68 0.78 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.08 0.467 . . . . 0.0 110.852 179.707 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.95 9.74 85.88 Favored Glycine 0 N--CA 1.444 -0.781 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.276 -179.854 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.0 t -121.68 118.75 56.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.889 0.376 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -115.21 140.35 49.16 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.753 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.448 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -141.21 149.38 41.32 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.695 -0.229 . . . . 0.0 110.727 -179.069 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.788 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -109.38 164.03 12.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.811 0.339 . . . . 0.0 111.4 -178.872 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 3.5 t-20 -85.2 125.14 70.92 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.948 178.751 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.461 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 54.8 Cg_endo -89.95 29.45 0.41 Allowed 'Trans proline' 0 N--CA 1.463 -0.279 0 C-N-CA 123.114 2.543 . . . . 0.0 113.426 -179.106 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.02 -52.9 2.71 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.82 0.343 . . . . 0.0 110.608 179.779 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.32 5.44 50.93 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.246 -179.488 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.3 p90 -74.81 165.16 25.69 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.065 179.809 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.0 m -138.95 132.81 30.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.387 0.613 . . . . 0.0 111.509 -179.713 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 68.3 m -93.73 107.75 19.59 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.695 179.104 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.17 135.75 47.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 120.94 0.4 . . . . 0.0 110.327 -179.225 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.0 t -106.3 138.71 42.01 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.267 -179.921 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.83 135.41 56.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.981 -179.299 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.0 p30 -80.44 -179.47 7.17 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.307 -179.29 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.32 -20.73 65.76 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.578 -179.9 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -77.89 -28.58 49.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.297 0.57 . . . . 0.0 109.91 179.908 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.67 29.05 6.74 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.159 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.5 p -129.75 153.38 48.25 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 -179.738 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.11 129.41 17.75 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.231 179.621 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.509 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 8.5 t -134.69 139.15 45.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.773 0.32 . . . . 0.0 110.444 179.717 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.6 t -149.11 178.44 8.72 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.187 -179.923 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.562 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.5 m -137.86 129.5 28.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.577 0.227 . . . . 0.0 110.414 -179.473 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -116.68 146.73 42.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.75 0.309 . . . . 0.0 111.492 -178.8 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.01 101.13 10.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 178.173 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.36 126.59 35.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.069 0.461 . . . . 0.0 111.753 -178.546 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 22.0 mmt180 -103.29 169.29 8.64 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.388 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -83.32 -42.61 16.91 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.898 0.38 . . . . 0.0 110.616 -179.532 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -117.43 125.79 51.55 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.726 178.902 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.435 ' HB2' ' HB2' ' A' ' 48' ' ' ASN . 14.7 p90 -152.18 170.87 18.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.091 0.472 . . . . 0.0 111.793 -178.632 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -97.47 145.65 25.99 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.016 179.321 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.71 115.94 5.44 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.937 179.793 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.461 ' CG ' ' HG3' ' A' ' 49' ' ' PRO . 8.2 m-85 -124.01 141.24 52.22 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.871 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.439 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 57.2 mt -85.34 173.57 10.22 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.417 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.439 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 3.0 m-85 -68.95 -10.98 60.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.717 0.294 . . . . 0.0 111.682 -179.143 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.439 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 20.8 p30 -95.13 -1.78 51.26 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.972 0.415 . . . . 0.0 110.265 179.146 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.67 4.56 72.82 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.757 -0.656 . . . . 0.0 113.322 179.29 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.5 m -82.51 133.41 35.2 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 117.158 0.479 . . . . 0.0 111.122 179.64 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 -88.36 140.44 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.138 179.679 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB3' HG21 ' A' ' 40' ' ' VAL . 4.7 t-105 -112.94 -3.89 14.01 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.327 0.584 . . . . 0.0 110.632 179.598 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.35 -175.97 17.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.09 179.774 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -86.53 138.49 31.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.788 0.328 . . . . 0.0 110.698 179.784 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.471 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.3 t -113.55 131.47 65.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.656 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -107.8 121.1 44.04 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.075 0.464 . . . . 0.0 111.363 -179.369 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.7 m -110.67 27.87 9.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.593 178.638 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.0 m -84.42 -48.51 9.57 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.301 179.935 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 t -101.65 1.53 37.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.287 0.565 . . . . 0.0 110.042 179.21 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.63 -176.8 3.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.701 -179.62 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.96 140.8 45.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.674 179.832 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -91.6 166.33 12.88 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.223 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.94 146.35 45.33 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.926 0.393 . . . . 0.0 110.433 179.461 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.8 t -87.69 123.94 40.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.245 179.977 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -110.25 117.66 4.78 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.861 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.542 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -129.89 101.54 5.9 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.787 0.327 . . . . 0.0 110.318 -179.787 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 m -133.63 160.33 37.83 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.758 0.314 . . . . 0.0 110.936 -179.655 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.2 -171.92 3.8 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.372 179.588 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.45 -29.37 66.1 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.916 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.7 -2.46 58.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.993 0.425 . . . . 0.0 110.959 179.59 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.03 25.26 67.06 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.704 179.618 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -119.29 -176.51 3.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.768 0.318 . . . . 0.0 110.831 -179.786 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 127.27 -165.02 20.59 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.524 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.96 158.14 35.35 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.702 2.268 . . . . 0.0 112.151 179.518 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -70.44 152.98 43.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.653 -179.347 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.517 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -77.87 165.83 52.63 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.524 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 7' ' ' VAL . 23.4 t -125.6 128.13 72.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.824 0.312 . . . . 0.0 110.732 -179.264 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.3 136.51 33.46 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.469 179.187 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 18.3 pt -129.84 134.8 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.187 0.517 . . . . 0.0 110.782 -179.714 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -108.34 144.01 36.45 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.087 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 60.1 m-85 -89.43 154.27 20.18 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.091 179.956 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.298 179.901 . . . . . . . . 0 0 . 1 . 043 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.788 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.027 0 CA-C-O 120.722 0.296 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 044 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.04 123.14 37.79 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.461 179.404 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.38 159.03 40.4 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.594 2.196 . . . . 0.0 112.647 -179.774 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.82 94.43 5.27 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.841 179.239 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.19 114.84 27.03 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.284 -179.126 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.06 115.3 26.6 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.347 179.474 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.6 m -131.29 141.31 46.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.755 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -107.75 98.05 23.14 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.291 179.788 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.82 139.04 32.74 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.684 2.256 . . . . 0.0 112.731 -179.256 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 m -90.05 35.06 0.85 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.948 179.886 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.05 107.22 0.83 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.073 -179.603 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.63 -8.29 37.1 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.757 179.535 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.488 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 59.4 mt -94.13 162.9 13.68 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.513 -0.404 . . . . 0.0 110.756 -179.531 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -83.87 -171.9 3.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.368 -179.381 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.03 158.15 30.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.286 179.661 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.58 1.75 85.35 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.979 -179.537 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 67.8 m -73.0 148.39 44.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.001 0.429 . . . . 0.0 110.964 179.973 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -95.7 115.16 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.945 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.438 HG11 HG21 ' A' ' 95' ' ' VAL . 16.7 t -90.16 124.93 43.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.509 179.377 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.849 0.356 . . . . 0.0 110.935 -179.772 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.3 t -123.47 109.85 24.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.583 178.876 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -129.49 102.84 6.57 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.739 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.61 128.91 9.29 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.699 -179.061 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -113.03 150.64 31.68 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.335 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 91.5 20.33 38.25 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.426 -0.892 . . . . 0.0 111.123 -179.292 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.437 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 48.3 mt -88.29 -174.01 4.45 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -89.47 109.82 20.71 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.242 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.07 136.78 56.35 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.39 -179.506 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.31 31.66 45.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.73 179.628 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -131.24 147.18 52.56 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.457 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.62 132.51 37.88 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.195 0.521 . . . . 0.0 111.444 -179.356 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.437 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 30.4 m-85 -116.33 125.29 51.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.393 179.269 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.72 128.25 38.52 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 -179.189 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 41.4 t -128.16 125.41 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.58 -179.886 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 158.32 27.63 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.422 178.85 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -80.83 111.39 17.24 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.56 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.544 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.0 m -112.06 144.19 41.83 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.094 -178.249 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.445 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -129.6 170.29 13.96 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.525 178.796 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 95.3 m95 -71.82 98.12 1.93 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 123.38 0.425 . . . . 0.0 110.593 179.741 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p -83.56 -25.71 7.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.342 0.592 . . . . 0.0 109.639 179.594 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.9 t70 -152.12 179.44 8.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.352 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.1 m -75.52 103.6 5.71 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 120.905 0.383 . . . . 0.0 110.08 179.591 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.8 7.38 71.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.353 -179.642 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 61.9 t -127.41 125.89 66.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.789 0.328 . . . . 0.0 110.487 -179.733 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.501 HD12 " H6'" ' A' ' 114' ' ' FLN . 87.8 mt -100.12 168.0 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.236 179.562 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -155.67 126.84 7.11 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.261 -0.274 . . . . 0.0 110.261 179.405 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.736 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.69 161.2 15.63 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -179.637 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.483 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 13.9 p-10 -94.52 133.82 26.34 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.318 0.58 . . . . 0.0 111.049 -179.899 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -82.65 1.23 9.28 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.812 2.341 . . . . 0.0 112.186 179.897 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.18 -39.86 18.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.491 -179.296 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -107.97 -5.31 17.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.424 -179.076 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.1 OUTLIER -59.79 146.82 40.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.923 0.392 . . . . 0.0 110.239 -179.761 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.8 m -140.83 125.05 17.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 -179.764 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 m -89.11 125.45 35.04 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.99 179.312 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.9 p -112.07 140.82 29.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.665 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.7 t -104.7 135.6 45.78 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.67 126.58 30.17 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.564 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 13.0 p30 -72.65 -177.02 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.697 -179.055 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.28 -17.82 62.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.307 -179.278 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -91.27 -11.2 38.84 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.18 0.514 . . . . 0.0 110.615 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.95 35.17 11.58 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.162 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.93 151.04 44.02 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.686 0.279 . . . . 0.0 110.488 179.871 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.12 112.18 7.24 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.861 179.719 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.0 t -114.31 130.01 56.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.757 179.623 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.4 t -150.94 166.68 29.91 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 179.989 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.9 m -127.18 128.21 45.74 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.246 -179.782 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.69 135.69 54.34 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.859 -179.201 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.4 m -93.76 124.89 38.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.984 179.257 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.0 p -94.74 118.44 40.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.437 0.636 . . . . 0.0 112.002 -179.284 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -92.97 167.11 12.03 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.046 178.919 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.8 tpp180 -86.49 -39.14 16.57 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.178 0.514 . . . . 0.0 109.692 179.45 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.46 132.43 45.68 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.439 -0.801 . . . . 0.0 108.841 178.919 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.483 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 50.9 p90 -153.82 174.89 13.97 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -178.338 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.401 ' O ' ' HA ' ' A' ' 48' ' ' ASN . 0.4 OUTLIER -90.98 114.9 27.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.732 179.625 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.47 130.39 9.69 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.896 -179.102 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -124.47 148.8 47.44 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.956 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.595 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 32.8 mt -76.17 170.33 16.51 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.758 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -63.01 -31.2 72.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.994 0.426 . . . . 0.0 110.538 -179.534 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.75 -24.7 48.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.715 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.96 -3.74 12.96 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.525 -0.845 . . . . 0.0 113.453 179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.483 ' HB ' HD12 ' A' ' 77' ' ' LEU . 28.6 m -70.18 125.98 28.34 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 117.181 0.491 . . . . 0.0 110.685 179.446 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.18 131.38 38.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.652 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -103.24 -30.17 10.82 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.815 0.34 . . . . 0.0 111.281 -179.759 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.65 -173.77 23.35 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.534 179.742 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.4 m -78.6 136.19 37.45 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.91 0.386 . . . . 0.0 110.829 -179.842 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 38' ' ' ALA . 4.7 t -116.41 142.28 30.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.84 179.42 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -118.35 120.15 36.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.761 -179.155 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 99.2 m -100.01 16.72 23.04 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.124 0.488 . . . . 0.0 110.327 179.17 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.61 -43.48 13.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.425 178.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.5 t -101.84 -12.25 18.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.79 178.829 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -116.82 -179.19 3.62 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.88 -179.572 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.05 154.14 17.79 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.775 179.913 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -128.19 147.95 50.59 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.502 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -143.49 176.59 9.07 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.106 0.479 . . . . 0.0 110.996 179.557 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG11 ' A' ' 19' ' ' VAL . 11.4 t -110.75 123.5 66.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.61 -179.728 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -106.01 127.6 9.01 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.235 179.567 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -145.64 131.59 19.21 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 110.344 -0.243 . . . . 0.0 110.344 -179.916 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.4 p -162.17 168.52 22.35 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.434 -179.852 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -81.48 -168.58 1.92 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.8 0.333 . . . . 0.0 110.99 179.961 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.3 -40.6 86.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.401 179.575 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.44 -39.8 62.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.047 0.451 . . . . 0.0 110.847 -179.907 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 120.16 28.51 1.81 Allowed Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.432 -0.89 . . . . 0.0 112.535 179.543 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -118.98 171.0 8.55 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.113 -0.328 . . . . 0.0 110.113 179.762 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 138.92 -155.54 23.84 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.786 -0.721 . . . . 0.0 111.81 179.86 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -66.38 158.72 53.79 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.875 2.383 . . . . 0.0 111.962 179.712 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -72.27 153.18 41.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.046 0.45 . . . . 0.0 111.515 -179.263 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.27 127.41 7.9 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.512 179.653 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.7 t -96.54 133.2 38.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.71 0.29 . . . . 0.0 110.329 -179.715 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -87.57 152.06 22.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.582 179.931 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.0 164.96 33.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.545 179.991 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.3 m -140.39 147.27 39.5 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.031 179.845 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 65.1 m-85 -91.74 169.7 10.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.678 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.247 0.973 0 CA-C-O 118.456 -0.783 . . . . 0.0 110.144 179.288 . . . . . . . . 0 0 . 1 . 044 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.736 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 045 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.5 117.83 69.78 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.984 -179.644 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -77.64 173.53 14.02 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.006 2.47 . . . . 0.0 112.069 179.875 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -128.84 98.1 4.86 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.131 0.491 . . . . 0.0 111.135 -179.741 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.63 110.52 23.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.477 179.876 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.31 95.94 5.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.638 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.76 156.78 20.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.903 0.382 . . . . 0.0 111.032 -179.719 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -115.46 105.31 52.36 Favored Pre-proline 0 C--N 1.321 -0.635 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.277 179.731 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -78.25 147.58 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.308 0 C-N-CA 122.437 2.091 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.0 38.05 1.26 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 m -62.75 112.08 2.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.211 -179.722 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.17 11.23 56.47 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.048 179.23 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -106.94 172.16 6.97 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.776 0.322 . . . . 0.0 110.716 -179.808 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -82.43 175.34 10.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.004 -179.738 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -80.83 150.59 29.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.677 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.35 0.5 65.19 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.61 -179.126 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.475 ' O ' HG12 ' A' ' 69' ' ' VAL . 18.4 m -72.46 150.94 42.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.955 0.407 . . . . 0.0 110.879 179.588 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 14.2 t -92.18 121.1 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.747 179.764 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 66' ' ' SER . 47.9 t -94.32 126.23 46.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.473 179.627 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -95.34 127.54 41.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.714 0.293 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.6 t -125.8 115.61 43.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.123 179.571 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -123.79 109.2 13.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.123 0.487 . . . . 0.0 110.955 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.63 124.8 7.87 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 179.558 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -124.38 152.44 43.19 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.01 32.39 29.41 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.205 -179.006 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.8 mt -112.12 169.73 8.65 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.423 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -70.65 127.48 32.8 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.782 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.55 152.02 42.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.269 -179.437 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.67 -32.5 4.22 Favored Glycine 0 CA--C 1.518 0.232 0 C-N-CA 121.041 -0.599 . . . . 0.0 112.903 179.505 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.81 144.49 52.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.859 0.361 . . . . 0.0 111.58 179.781 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.1 140.83 29.48 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.602 178.67 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -119.81 120.99 38.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.25 0.547 . . . . 0.0 111.218 -179.257 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.51 107.21 19.02 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.972 -179.634 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.85 119.7 60.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.739 -179.547 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.95 175.43 25.45 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.134 -1.031 . . . . 0.0 112.199 179.184 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -82.22 128.24 33.98 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 178.674 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.507 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -132.78 172.4 12.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.928 -178.644 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.428 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -166.84 171.52 11.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.993 179.319 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -74.85 110.74 9.4 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.153 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.75 -27.18 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.907 0.384 . . . . 0.0 110.944 -179.078 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.5 t0 -150.37 176.89 10.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.178 179.93 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.6 m -63.51 102.23 0.41 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 179.967 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 19.11 79.31 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.92 -179.976 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 40.7 t -130.37 124.92 58.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.136 0.493 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.7 mp -114.7 159.18 20.82 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.97 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -150.7 142.91 24.18 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.313 -179.461 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.806 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 12.6 m -109.94 163.65 13.35 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.833 0.349 . . . . 0.0 111.214 -179.429 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.543 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.1 t-20 -90.43 124.42 62.82 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.859 179.307 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -91.39 17.1 1.42 Allowed 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.05 2.5 . . . . 0.0 113.808 -179.674 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -111.14 -52.16 2.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.728 0.299 . . . . 0.0 111.643 -179.522 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.66 32.01 3.0 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.963 0.411 . . . . 0.0 112.08 -178.855 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.5 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -117.78 169.62 9.46 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.89 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.0 m -140.48 135.12 31.63 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.252 -179.188 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 16.3 m -95.17 93.12 7.14 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.527 179.127 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.0 p -86.45 141.87 13.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.18 0.514 . . . . 0.0 111.115 -179.004 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 t -104.46 152.38 22.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.063 179.395 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.29 132.8 36.57 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.996 0.427 . . . . 0.0 110.99 -179.701 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -79.9 -177.8 6.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.222 -179.259 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.25 -11.0 36.71 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.79 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 57.4 m-80 -96.65 0.05 49.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 110.44 179.33 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.07 32.22 56.69 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.366 179.915 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.94 157.29 43.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.691 0.281 . . . . 0.0 111.074 -179.529 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.5 127.22 8.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.53 179.766 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 8.7 m -126.08 138.15 53.68 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.55 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 t -151.52 164.32 37.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.95 0.405 . . . . 0.0 111.008 -179.288 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.53 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 75.5 m -127.38 126.96 43.39 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.499 179.009 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -111.69 146.72 37.0 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.607 -179.241 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 m -96.27 110.22 22.57 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.74 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 17' ' ' THR . 7.3 p -84.4 111.28 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.46 0.647 . . . . 0.0 111.77 -178.624 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -90.04 160.97 16.06 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.816 179.298 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -77.68 -44.4 28.11 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.163 0.506 . . . . 0.0 110.487 179.677 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.7 m -125.97 120.43 30.31 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.441 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.543 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 51.8 p90 -139.15 162.4 35.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -177.442 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -80.08 130.33 35.17 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.79 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.99 129.2 9.77 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.015 -178.983 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.436 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 10.6 m-85 -130.15 149.74 51.72 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.886 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.419 HD12 ' HB ' ' A' ' 81' ' ' THR . 14.4 mt -87.04 161.42 18.18 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.106 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 98' ' ' SER . 6.3 m-85 -67.62 -11.5 58.31 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.046 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -91.3 -19.37 23.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.112 179.854 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 121.09 -19.74 8.69 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.9 -0.667 . . . . 0.0 113.085 179.997 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' HD12 ' A' ' 77' ' ' LEU . 39.5 m -68.3 139.55 55.93 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.578 0.227 . . . . 0.0 110.749 -179.991 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.45 147.2 26.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.769 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -108.04 -44.16 4.24 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.042 0.449 . . . . 0.0 111.086 -179.685 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.54 -172.13 33.01 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.738 179.958 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 2.7 m -81.45 126.6 31.85 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.999 0.428 . . . . 0.0 111.303 -179.236 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.428 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.6 t -102.88 147.44 9.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -136.24 129.83 32.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 111.858 -178.755 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 51.0 m -115.32 29.45 8.01 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.258 178.669 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.2 m -79.34 -23.37 43.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.746 0.784 . . . . 0.0 109.364 179.031 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -134.14 23.54 3.83 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.375 179.079 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.22 178.16 9.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.102 -179.311 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.61 141.08 39.64 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.669 0.271 . . . . 0.0 110.454 179.869 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.48 172.94 6.67 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.836 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 1.6 pt20 -147.35 166.89 25.77 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.053 179.471 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 t -102.21 123.73 55.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 179.983 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.507 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -103.23 107.43 3.05 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.026 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -114.69 112.04 22.24 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.776 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 17.4 m -144.71 157.54 44.15 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.711 0.291 . . . . 0.0 110.82 179.799 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.57 -171.05 3.35 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.02 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.17 -34.06 69.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.89 -47.68 12.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.716 0.293 . . . . 0.0 110.948 179.538 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.42 32.57 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.654 179.593 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.3 m-80 -119.99 -175.54 3.0 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 179.888 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.96 -149.86 19.25 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.576 179.822 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -76.51 163.98 31.24 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 122.729 2.286 . . . . 0.0 112.012 179.839 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -74.33 143.33 44.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.107 179.513 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -65.56 142.98 44.88 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.554 179.947 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.1 t -114.69 129.04 71.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 110.437 -0.208 . . . . 0.0 110.437 -179.422 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.94 145.4 29.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.702 0.287 . . . . 0.0 110.876 179.576 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 8.3 pt -138.63 116.86 12.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.173 0.511 . . . . 0.0 111.48 -179.798 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.5 m -100.01 144.73 28.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.871 179.196 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -85.92 160.37 19.41 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.778 0.323 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.446 -0.788 . . . . 0.0 110.363 179.972 . . . . . . . . 0 0 . 1 . 045 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.806 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 046 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.33 125.77 82.55 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.766 179.627 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -86.32 -168.43 0.45 Allowed 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.933 2.422 . . . . 0.0 112.088 179.507 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.5 m -140.34 88.36 2.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.937 0.399 . . . . 0.0 110.658 179.428 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.8 88.84 7.23 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.78 0.324 . . . . 0.0 110.781 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -90.25 88.07 7.08 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.042 0.449 . . . . 0.0 111.594 -179.57 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.96 140.91 20.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.997 179.119 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 m -109.48 108.12 59.75 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.89 -179.263 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.09 164.73 33.68 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.546 2.164 . . . . 0.0 112.371 179.579 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 m -116.83 34.07 5.28 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.786 179.905 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.8 m -64.75 110.76 2.5 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.48 179.894 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 117.41 -17.61 12.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.84 -179.887 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 5.9 mp -93.55 161.96 14.15 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.719 0.295 . . . . 0.0 110.501 -179.639 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -79.07 -172.4 3.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.054 -179.628 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -81.28 160.79 24.13 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.531 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 82.38 13.33 78.89 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -178.883 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.4 m -86.07 148.41 25.73 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 115.287 -0.457 . . . . 0.0 111.127 -179.644 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 45.9 t -89.97 113.04 25.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.17 -179.754 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.4 t -90.77 131.05 38.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.139 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt -101.23 128.87 47.15 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.122 0.486 . . . . 0.0 111.483 -179.035 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 42.2 t -124.87 108.04 19.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.54 179.135 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.07 101.53 7.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.968 0.413 . . . . 0.0 110.503 179.81 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.04 132.9 11.34 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.87 -179.328 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -120.86 146.06 46.98 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 178.949 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.2 30.29 10.3 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.262 -179.238 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 35.0 mt -101.9 169.57 8.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.753 0.311 . . . . 0.0 110.468 -179.343 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -75.17 108.59 8.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.746 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.0 126.89 29.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.515 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.89 -9.63 43.85 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.625 -0.797 . . . . 0.0 113.032 -179.961 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.7 m -92.91 144.72 24.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.698 0.285 . . . . 0.0 110.938 -179.842 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.49 133.65 42.56 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.33 179.169 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -116.29 122.48 45.06 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.012 0.434 . . . . 0.0 110.89 -179.344 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -89.61 112.78 24.11 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.497 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.5 t -112.93 135.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.817 0.341 . . . . 0.0 111.839 -178.569 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.02 179.24 40.87 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.908 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -79.9 75.82 6.61 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 117.93 0.865 . . . . 0.0 109.881 178.902 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 4.1 m -75.68 89.17 2.79 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.061 -179.593 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.405 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -103.23 173.98 6.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.322 -179.992 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.494 ' CZ3' ' HA2' ' A' ' 43' ' ' GLY . 22.6 m95 -67.39 114.5 6.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.153 0.501 . . . . 0.0 110.711 -179.816 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 83' ' ' TRP . 8.8 p -96.75 -21.88 5.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.671 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -152.86 -162.5 1.51 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.913 179.839 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.71 89.09 1.76 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.017 0.437 . . . . 0.0 110.909 -179.581 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.494 ' HA2' ' CZ3' ' A' ' 39' ' ' TRP . . . 90.92 -17.87 53.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.62 179.737 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.32 127.71 42.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.666 0.269 . . . . 0.0 110.309 -179.674 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.92 159.32 16.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.39 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -156.49 145.47 20.3 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.768 -0.196 . . . . 0.0 110.816 -179.879 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.688 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -99.9 175.55 5.74 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.381 -179.735 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.588 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 25.8 p-10 -98.48 126.86 37.84 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-O 121.052 0.453 . . . . 0.0 110.578 179.651 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 80.4 Cg_endo -86.18 4.37 6.49 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.655 2.237 . . . . 0.0 112.523 -179.505 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.04 -31.29 13.66 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.235 -178.692 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.473 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 13.1 m-20 -131.32 30.42 4.49 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.633 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 5.8 p90 -92.66 163.63 13.7 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 -179.9 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.3 m -139.17 117.84 12.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.9 0.381 . . . . 0.0 110.596 179.945 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.76 100.88 11.81 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 178.618 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.79 128.17 46.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.111 0.481 . . . . 0.0 110.406 -179.404 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 5.9 t -94.94 137.07 34.49 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.046 179.749 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.03 119.13 11.47 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 -179.741 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.66 178.66 1.6 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.648 -179.856 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.86 -18.39 62.84 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.18 -179.38 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -86.21 -10.18 55.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.912 0.387 . . . . 0.0 109.959 179.75 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.6 37.78 22.52 Favored Glycine 0 N--CA 1.446 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.664 -179.553 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.44 166.06 16.65 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.448 0.166 . . . . 0.0 110.671 -179.791 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -153.92 109.17 3.16 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.328 179.673 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.82 117.57 28.52 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.045 -179.725 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.2 t -146.38 176.61 9.65 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.229 -179.962 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.453 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -140.4 142.17 35.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.806 0.336 . . . . 0.0 110.694 179.857 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.426 ' N ' HD22 ' A' ' 67' ' ' LEU . 1.7 mm? -122.59 148.53 45.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.514 -178.759 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -100.05 103.41 14.93 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 178.649 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -74.64 122.64 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.173 0.511 . . . . 0.0 111.517 -178.743 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -99.07 158.25 15.79 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.432 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -70.15 -38.88 75.58 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.342 0.592 . . . . 0.0 109.405 179.612 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.1 m -130.9 139.39 50.09 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 177.914 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 37.7 p90 -149.03 170.55 18.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.938 0.399 . . . . 0.0 111.994 -178.362 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -97.23 122.32 40.12 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.615 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -75.46 130.38 11.18 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.933 -178.734 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -121.14 125.6 47.63 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.912 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.2 mt -80.17 172.41 13.81 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.673 179.743 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -65.14 -32.43 74.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.318 -178.852 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.28 -9.36 59.73 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.126 -179.884 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.07 -0.82 51.17 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.594 -179.84 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.5 m -74.58 130.74 40.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 111.156 179.638 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.64 99.91 12.26 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.704 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB3' HG21 ' A' ' 40' ' ' VAL . 20.3 t-105 -63.77 -42.79 97.72 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.093 -178.29 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.28 -173.72 39.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.934 -179.739 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.4 m -89.22 126.04 35.33 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.149 0.499 . . . . 0.0 111.408 -179.698 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 49.0 t -102.66 136.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.703 179.525 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -117.18 122.99 45.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.893 0.377 . . . . 0.0 111.116 -179.523 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 70.6 m -105.52 19.53 20.41 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.519 179.688 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 m -84.3 -43.33 14.9 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 178.917 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.4 t -104.38 6.43 35.09 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.081 179.598 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.36 -176.2 4.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.087 -179.271 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.54 162.77 15.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.525 179.885 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.6 162.48 32.17 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.942 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.516 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 0.0 OUTLIER -155.62 168.1 28.24 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.728 0.299 . . . . 0.0 111.031 -179.861 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.7 p -129.86 141.58 46.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.487 -179.956 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -153.17 174.41 31.89 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.284 179.793 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.622 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.67 142.11 33.36 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.93 0.395 . . . . 0.0 110.842 179.779 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 50.9 m -126.23 134.83 51.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.555 179.331 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -79.53 -167.44 1.22 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.172 179.455 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.23 72.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.744 0.307 . . . . 0.0 111.628 -179.97 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.34 -51.69 6.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.648 -179.866 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 130.86 36.48 0.35 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.228 -179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 -136.25 -175.37 3.97 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.741 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.71 -165.55 26.12 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.731 179.94 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.61 157.39 37.26 Favored 'Trans proline' 0 CA--C 1.528 0.199 0 C-N-CA 122.923 2.415 . . . . 0.0 112.162 179.339 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -67.2 141.44 57.32 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.162 -179.858 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -66.75 149.88 51.6 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.936 179.068 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -114.36 125.0 71.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.835 0.35 . . . . 0.0 111.085 -179.101 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.516 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -84.94 149.5 25.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.766 179.629 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 26.2 pt -136.67 176.73 7.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.077 -179.648 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.8 m -153.42 147.76 25.9 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.509 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 41.8 m-85 -94.96 157.51 15.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.976 179.962 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.5 p30 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.749 -179.836 . . . . . . . . 0 0 . 1 . 046 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.688 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 047 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.68 100.6 39.72 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.938 179.707 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.48 164.64 33.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.832 2.355 . . . . 0.0 111.199 179.076 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.617 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 2.5 m -120.32 113.73 20.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.874 0.369 . . . . 0.0 111.763 -179.118 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.84 130.47 38.43 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.57 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.56 61.47 1.55 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.169 0.509 . . . . 0.0 110.814 -179.435 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.2 m -103.55 151.1 6.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.563 -179.555 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.3 m -111.64 111.76 54.27 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.453 179.803 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.85 143.38 13.12 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.411 2.074 . . . . 0.0 112.708 -179.717 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.3 m -93.94 49.43 1.33 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.563 179.925 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.91 103.86 1.92 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.956 -179.497 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.28 6.22 45.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.699 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.493 ' O ' ' HD1' ' A' ' 112' ' ' PHE . 76.9 mt -106.23 148.88 27.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -78.86 178.64 7.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.994 0.426 . . . . 0.0 111.906 -179.182 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.66 158.11 34.8 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.352 179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.22 75.16 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.567 -179.34 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.427 HG21 HD13 ' A' ' 13' ' ' LEU . 60.3 m -73.44 142.33 46.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.919 0.39 . . . . 0.0 110.67 179.86 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.622 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 81.1 t -86.02 119.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.917 -179.997 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 66' ' ' SER . 12.4 t -93.91 123.41 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.073 179.435 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -88.93 126.31 35.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.925 0.393 . . . . 0.0 111.253 -179.71 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -123.91 104.21 13.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.886 179.389 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.87 141.66 51.88 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.111 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.41 150.77 22.15 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.355 -179.802 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.617 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -131.25 150.55 52.1 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.334 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 22.28 51.45 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.372 -179.374 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.8 mt -92.78 167.15 12.06 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.893 0.378 . . . . 0.0 110.756 -179.544 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.2 tp60 -70.69 109.69 5.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.671 179.87 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.44 127.41 31.21 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.763 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.97 -3.21 44.72 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.473 -0.87 . . . . 0.0 113.311 179.876 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.7 p -101.96 162.07 13.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.306 0.553 . . . . 0.0 111.073 -179.95 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.51 139.21 49.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.435 179.854 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -119.63 127.3 52.81 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.834 -179.913 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -85.84 118.54 25.39 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.03 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.496 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.2 t -119.61 130.19 74.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-O 120.939 0.4 . . . . 0.0 111.705 -178.569 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.19 178.74 37.89 Favored Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 178.452 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -84.33 59.56 5.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.451 0.643 . . . . 0.0 109.498 179.304 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 46' ' ' ALA . 0.8 OUTLIER -67.97 98.48 0.76 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.521 -179.304 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.08 177.88 4.72 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.655 179.982 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.03 114.57 8.33 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.427 179.89 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 83' ' ' TRP . 7.2 p -102.95 -22.82 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.461 . . . . 0.0 110.464 179.873 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.9 t70 -150.43 -175.8 5.23 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 178.937 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.3 m -71.67 91.23 1.09 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.307 0.575 . . . . 0.0 110.936 -179.599 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.47 -2.28 67.52 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.277 179.416 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 39.9 t -105.35 124.71 60.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.985 0.422 . . . . 0.0 110.731 -179.358 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.51 143.89 43.76 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.072 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.618 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -138.36 139.89 39.21 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.409 -179.051 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.645 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 32.7 m -94.06 166.21 12.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.958 -179.499 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.694 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 16.4 p-10 -96.41 125.83 46.03 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.594 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.497 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 87.5 Cg_endo -83.43 -7.24 10.83 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.786 2.324 . . . . 0.0 113.225 -179.355 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.82 -53.16 5.29 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.042 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -110.8 52.47 0.73 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.941 0.4 . . . . 0.0 111.16 -178.895 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.694 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 3.2 p90 -112.96 167.89 10.14 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.254 -0.43 . . . . 0.0 109.915 179.373 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 70.8 m -151.58 116.29 5.15 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.066 0.46 . . . . 0.0 110.367 178.681 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.5 p -89.95 88.71 7.42 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.289 -179.816 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.0 p -82.01 145.29 8.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.814 -179.562 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.5 t -107.45 150.67 26.52 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.758 179.839 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.33 121.87 25.02 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.619 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -72.03 -173.04 0.96 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.776 -178.907 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.41 -12.17 55.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.78 -179.669 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -94.34 -0.08 55.18 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.49 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 71.26 29.3 68.66 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -179.747 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.18 155.87 36.21 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 120.968 0.413 . . . . 0.0 111.08 -179.548 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -148.08 129.22 14.59 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.898 179.439 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.8 t -137.43 130.58 30.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.97 0.414 . . . . 0.0 110.904 -179.933 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.423 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.1 t -146.9 170.89 16.12 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.257 179.212 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.622 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 49.4 m -137.49 133.58 34.77 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.524 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -117.2 155.0 30.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 0.0 111.38 -178.536 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.8 m -101.23 104.35 15.39 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.423 178.847 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.0 p -73.92 123.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.31 0.576 . . . . 0.0 111.4 -178.837 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 -104.04 172.13 6.97 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.199 179.679 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -81.24 -36.18 30.29 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.592 179.187 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -136.44 137.75 40.76 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.019 179.08 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.477 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 44.7 p90 -148.7 168.6 22.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.607 0.241 . . . . 0.0 110.691 -179.265 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.21 126.13 37.17 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.371 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -86.6 123.85 6.68 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.512 -179.32 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.497 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.7 m-85 -124.9 142.93 51.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.975 0.417 . . . . 0.0 110.324 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -94.06 177.75 5.87 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.23 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -76.46 -14.35 60.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.786 0.327 . . . . 0.0 111.464 -178.886 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -89.03 0.68 56.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.88 0.372 . . . . 0.0 110.916 179.884 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.52 -0.11 76.94 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.119 -0.562 . . . . 0.0 113.376 179.106 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 52.0 m -88.52 144.58 26.24 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 117.202 0.501 . . . . 0.0 111.06 -179.685 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 30.3 ptt180 -103.74 140.87 37.02 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 178.862 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.493 ' HB3' HG21 ' A' ' 40' ' ' VAL . 2.8 t-105 -102.45 -5.48 24.02 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.987 0.422 . . . . 0.0 110.683 -179.469 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 122.66 -168.47 15.03 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.01 179.555 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 21.7 m -91.15 131.18 36.86 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.769 0.318 . . . . 0.0 110.7 -179.655 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 HG23 ' A' ' 40' ' ' VAL . 8.9 t -101.21 139.91 21.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.868 179.684 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -118.97 137.89 53.19 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.662 -179.652 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 98.4 m -125.77 36.97 4.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.911 0.386 . . . . 0.0 110.899 179.751 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.7 m -89.0 -35.23 16.5 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.491 -179.558 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.0 t -111.45 -5.87 14.53 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.026 0.441 . . . . 0.0 110.776 -179.921 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.54 -176.73 3.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.565 -179.811 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.4 114.73 29.08 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.604 179.34 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -73.21 168.93 18.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.156 179.553 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.435 ' HG3' ' O ' ' A' ' 37' ' ' CYS . 9.5 pt20 -151.6 158.75 43.93 Favored 'General case' 0 C--N 1.318 -0.773 0 O-C-N 122.186 -0.321 . . . . 0.0 110.62 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 95.0 t -125.94 128.54 72.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.689 179.703 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -140.5 167.98 25.35 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.693 -179.9 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.496 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.8 pt? -141.27 145.18 35.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.81 0.338 . . . . 0.0 110.155 -179.88 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 75.4 m -147.53 150.71 35.05 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.485 179.668 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -78.53 -173.48 3.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.312 179.806 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.18 -36.6 68.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.248 179.558 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -73.21 -50.18 23.88 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.897 0.379 . . . . 0.0 110.212 179.42 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.39 24.48 0.76 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.934 179.422 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.52 171.89 8.48 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 122.709 -0.289 . . . . 0.0 110.552 -179.881 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 148.58 -165.13 29.12 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.966 -179.906 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.26 151.57 72.75 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.938 2.425 . . . . 0.0 112.037 179.483 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -66.01 141.07 58.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.941 -179.789 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.35 145.32 34.37 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.841 179.574 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 t -109.69 133.21 55.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.657 0.265 . . . . 0.0 110.612 -179.341 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -88.3 141.41 28.57 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.663 179.812 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.8 pt -124.42 171.97 12.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.786 -179.691 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.3 m -152.0 142.27 22.4 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 110.347 -0.242 . . . . 0.0 110.347 179.75 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HD1' ' O ' ' A' ' 13' ' ' LEU . 18.5 m-85 -86.99 155.91 19.98 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.98 179.982 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.9 p30 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.595 179.966 . . . . . . . . 0 0 . 1 . 047 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.645 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.664 0.269 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 048 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.45 119.83 78.87 Favored Pre-proline 0 C--N 1.325 -0.498 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.006 -179.837 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -80.49 157.1 22.08 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.82 2.347 . . . . 0.0 112.819 -179.809 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.58 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -118.06 83.48 2.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.0 110.494 179.976 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.7 104.01 16.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.802 -179.736 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.04 96.06 6.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.417 179.667 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.87 155.21 12.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.79 0.328 . . . . 0.0 110.876 -179.721 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.0 m -115.56 97.18 48.13 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.106 179.01 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 58.6 Cg_endo -72.63 140.85 33.34 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.4 179.738 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.405 ' H ' HG21 ' A' ' 110' ' ' ILE . 1.5 m -91.51 28.99 1.57 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.859 179.39 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -59.49 112.52 1.8 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.341 -179.345 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 113' ' ' ASN . . . 110.77 -16.06 28.63 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.295 179.985 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.6 mt -97.93 163.49 12.76 Favored 'General case' 0 C--N 1.323 -0.582 0 O-C-N 122.841 -0.211 . . . . 0.0 110.532 -179.553 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.5 m -82.45 -173.72 4.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.949 0.404 . . . . 0.0 111.157 -179.724 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.63 163.77 27.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.025 179.459 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.87 -6.84 82.22 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.736 -179.292 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' VAL . 61.1 m -72.32 146.01 47.43 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.114 0.483 . . . . 0.0 111.202 -179.813 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 21.2 t -87.07 120.31 36.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.09 -179.998 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 95' ' ' VAL . 24.1 t -95.16 119.85 43.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.599 179.077 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -95.29 126.98 40.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.86 0.362 . . . . 0.0 110.846 -179.415 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.78 104.63 13.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.891 179.5 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -116.94 102.14 9.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.927 0.394 . . . . 0.0 110.492 179.688 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 117.22 5.64 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.603 -179.639 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -108.09 141.39 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.086 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.79 26.13 9.3 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.152 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.3 mt -96.37 174.86 6.66 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 -179.898 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -81.67 109.21 15.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.314 -179.008 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.63 106.44 0.47 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 134.22 -38.41 1.84 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.167 -179.58 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 p -75.65 147.54 39.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.866 0.365 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -100.77 139.9 35.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.355 179.947 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -120.89 131.95 54.69 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.622 -179.601 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 37.6 m-20 -96.74 128.17 43.43 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 178.944 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 97' ' ' LEU . 2.7 t -123.86 137.99 55.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 -179.376 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -167.22 174.53 42.44 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.836 179.613 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -80.87 63.61 5.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.518 0.675 . . . . 0.0 109.902 179.358 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.2 m -74.87 106.81 6.58 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.002 -179.185 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.697 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -111.46 170.99 7.75 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.454 -179.97 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -59.56 106.81 0.5 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.341 0.591 . . . . 0.0 112.134 -179.363 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -96.23 -17.0 7.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.887 0.851 . . . . 0.0 109.279 178.985 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -149.47 -172.96 4.27 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.003 179.769 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.37 84.1 3.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.063 0.459 . . . . 0.0 110.442 179.714 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 105.04 -17.76 44.07 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.732 -179.918 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.79 131.6 42.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.67 0.271 . . . . 0.0 110.384 179.973 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.541 ' HB2' " H2'" ' A' ' 114' ' ' FLN . 5.5 mp -112.22 154.07 26.13 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.041 179.603 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.64 148.58 25.67 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.757 0.313 . . . . 0.0 110.568 179.403 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -121.18 164.87 16.22 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.744 -179.353 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -89.95 137.62 28.1 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.285 0.564 . . . . 0.0 110.387 179.581 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.511 ' HA ' ' CD1' ' A' ' 52' ' ' PHE . 66.5 Cg_endo -73.09 -16.68 25.31 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.592 2.195 . . . . 0.0 112.536 -179.474 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.79 -17.04 60.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.072 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.424 ' CG ' ' HE ' ' A' ' 70' ' ' ARG . 17.2 m-20 -131.27 4.12 4.35 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -178.656 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.511 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -84.54 162.73 19.73 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.646 -0.421 . . . . 0.0 109.894 179.695 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 60.3 m -143.25 141.81 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.866 0.365 . . . . 0.0 111.179 179.935 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.2 m -102.92 129.2 49.55 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.954 179.578 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.58 129.33 64.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.12 0.486 . . . . 0.0 110.432 179.855 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -93.57 144.47 25.34 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.519 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.69 125.94 27.42 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.78 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.5 178.57 3.41 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.844 -179.521 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -58.5 -27.91 64.91 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.997 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -76.95 -18.35 58.3 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 121.11 0.481 . . . . 0.0 110.424 179.174 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.81 35.39 6.84 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.599 -179.751 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.1 152.44 50.39 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.763 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -137.1 112.68 9.39 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.249 179.492 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.5 t -116.83 127.71 54.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.063 179.7 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.3 t -146.09 163.05 36.53 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.136 -179.981 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.49 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 57.2 m -127.28 132.24 50.37 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.668 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.411 ' N ' HD22 ' A' ' 67' ' ' LEU . 2.5 mm? -114.48 153.56 29.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.753 0.311 . . . . 0.0 111.16 -178.702 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.86 103.6 13.13 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.661 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 17' ' ' THR . 7.6 p -75.29 124.37 33.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.207 0.527 . . . . 0.0 111.93 -178.747 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.424 ' HE ' ' CG ' ' A' ' 51' ' ' ASP . 34.9 mmt180 -99.97 161.34 13.67 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.36 179.438 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.7 tpp180 -77.24 -44.3 30.37 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.097 179.724 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.4 m -126.12 126.97 45.03 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.897 179.248 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -150.18 170.07 19.82 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.095 0.474 . . . . 0.0 111.366 -179.172 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 1.4 mp0 -102.51 147.17 27.09 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.903 179.372 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.31 125.35 8.33 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.26 -179.49 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 10.7 m-85 -118.88 146.58 44.79 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.585 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.686 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 74.0 mt -87.29 166.9 14.55 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.467 -179.846 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.06 -15.55 63.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.616 -178.509 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.48 -14.17 55.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.874 0.368 . . . . 0.0 110.46 179.526 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 104.66 -5.56 43.83 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.985 179.622 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -95.57 139.11 32.31 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 117.058 0.429 . . . . 0.0 110.797 -179.669 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -73.52 142.33 46.73 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.421 179.143 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -107.63 -30.5 8.56 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.96 0.41 . . . . 0.0 110.341 179.612 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.58 -157.12 23.3 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.995 -179.972 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -123.44 141.99 51.44 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.944 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.697 HG11 ' HB3' ' A' ' 38' ' ' ALA . 17.4 t -124.52 117.24 49.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.145 0.497 . . . . 0.0 110.555 -179.561 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -102.83 129.32 49.47 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.474 179.726 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 83.4 m -108.02 21.84 16.8 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.329 179.77 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 2.2 m -87.78 -31.91 19.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.332 0.587 . . . . 0.0 109.492 178.946 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.9 t -116.23 13.45 15.67 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.423 179.508 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -150.91 161.64 42.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.703 -179.712 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -78.73 133.92 37.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.069 179.243 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -85.48 175.89 8.56 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.948 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 109' ' ' ALA . 4.6 pt20 -160.87 160.24 30.76 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 179.97 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 19' ' ' VAL . 57.8 t -134.72 138.57 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.405 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.46 174.51 28.11 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.578 179.186 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.85 153.54 45.79 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.826 0.346 . . . . 0.0 110.44 -179.914 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.7 m -150.21 148.75 29.29 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.186 179.223 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -81.9 -169.23 2.26 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.075 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.63 -37.39 75.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.006 179.48 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.49 -53.39 8.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.416 179.674 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 132.35 40.41 0.21 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.535 179.658 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -136.25 173.73 11.39 Favored 'General case' 0 C--N 1.323 -0.565 0 O-C-N 122.799 -0.236 . . . . 0.0 110.822 179.863 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 144.64 -153.0 24.88 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 179.957 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.58 169.68 15.34 Favored 'Trans proline' 0 CA--C 1.53 0.288 0 C-N-CA 122.682 2.255 . . . . 0.0 111.912 178.996 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -79.15 158.86 27.64 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.839 0.352 . . . . 0.0 111.045 -179.384 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.45 141.17 20.3 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.966 -0.635 . . . . 0.0 111.827 179.522 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 44.7 t -111.89 134.85 53.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 120.758 0.313 . . . . 0.0 110.542 -179.108 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 94' ' ' GLN . . . -89.85 147.37 23.81 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.952 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.405 HG21 ' H ' ' A' ' 10' ' ' SER . 10.5 pt -135.77 107.19 6.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.209 0.528 . . . . 0.0 110.317 179.853 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -89.06 139.76 30.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.106 179.877 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 19.1 m-85 -84.55 166.49 17.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.21 179.903 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.406 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 11.8 p30 . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.672 -0.68 . . . . 0.0 109.879 179.373 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.686 ' H5 ' ' HA ' ' A' ' 77' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 049 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.97 111.44 35.75 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.465 -179.971 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.65 156.46 31.75 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.473 2.116 . . . . 0.0 112.143 -179.737 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.06 101.95 10.2 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.691 -179.95 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -102.9 116.48 32.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.085 0.469 . . . . 0.0 110.962 -179.849 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.5 m -116.35 101.09 8.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.395 179.584 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.4 m -118.67 149.06 21.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.425 -179.782 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.3 m -116.83 94.36 43.94 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.139 179.332 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.67 143.28 67.41 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.532 2.155 . . . . 0.0 112.568 -179.52 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.3 37.97 1.22 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.96 179.906 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.1 m -62.57 110.54 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.02 -179.78 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.35 -5.94 41.8 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.707 179.621 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.74 158.38 15.66 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.782 0.291 . . . . 0.0 110.29 -179.637 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -84.92 179.53 7.29 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.961 -179.356 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -68.34 157.95 34.58 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 120.872 0.368 . . . . 0.0 110.019 179.573 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.71 -11.12 70.25 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.402 -178.874 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.7 m -67.34 137.8 56.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.93 0.395 . . . . 0.0 110.735 179.882 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.601 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 19.7 t -92.57 102.34 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.309 -179.947 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.1 t -70.67 141.07 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.177 -179.872 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -107.84 120.59 42.71 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.855 0.36 . . . . 0.0 110.409 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.22 117.84 51.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.922 179.71 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.87 118.63 21.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.993 0.425 . . . . 0.0 110.699 -179.895 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.437 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -113.69 130.11 9.19 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.625 179.447 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -121.37 134.52 55.12 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.872 0.367 . . . . 0.0 110.568 179.762 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.68 22.29 18.96 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.252 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.403 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 68.9 mt -83.41 -171.46 3.59 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-N 115.216 -0.492 . . . . 0.0 110.682 -179.614 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.4 tp60 -91.51 117.78 30.01 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.023 179.668 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.02 141.38 54.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.973 -179.79 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 97.7 -35.26 4.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 121.171 -0.538 . . . . 0.0 112.696 179.929 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.62 146.24 28.39 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.954 0.407 . . . . 0.0 111.74 -179.447 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -97.57 146.8 24.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.876 179.205 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.403 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 26.0 m-85 -114.13 145.33 41.79 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.889 0.376 . . . . 0.0 110.51 -179.604 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -111.08 120.14 41.36 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.188 -179.273 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 44.3 t -129.87 125.67 61.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.349 -179.854 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -153.36 179.02 30.05 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.093 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -91.72 118.6 30.81 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.386 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -123.26 161.24 24.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.686 -179.288 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -154.38 177.26 11.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.557 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -71.31 95.87 1.36 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.914 179.835 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.03 -18.86 8.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.431 0.634 . . . . 0.0 109.951 179.915 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -157.42 -175.55 5.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.299 178.884 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -71.09 91.83 0.93 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.54 0.686 . . . . 0.0 111.484 -179.201 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.61 -11.96 70.9 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.306 179.75 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.8 t -93.36 118.53 39.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.356 0.598 . . . . 0.0 110.423 179.992 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mp -118.44 133.5 55.82 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.12 179.087 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -143.21 150.16 38.97 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.447 -179.628 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.734 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -109.23 176.06 5.23 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.433 -179.336 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -103.01 129.38 25.73 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 121.189 0.518 . . . . 0.0 111.199 -179.803 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD3' ' HB2' ' A' ' 76' ' ' PHE . 89.8 Cg_endo -84.62 11.9 3.22 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.745 2.297 . . . . 0.0 111.963 179.72 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.55 -32.33 13.51 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.612 -179.805 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.43 19.08 8.9 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.912 0.387 . . . . 0.0 111.286 -179.376 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -82.09 165.87 20.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.306 179.899 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 50.4 m -129.76 119.95 24.27 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.022 0.439 . . . . 0.0 110.909 179.419 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.2 122.74 33.41 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.44 133.59 65.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.007 0.432 . . . . 0.0 111.634 -179.078 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.2 t -101.06 153.2 19.76 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.941 178.855 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.36 145.53 41.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.474 -179.981 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 9.3 p30 -92.97 -176.12 4.09 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.6 179.722 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.97 -12.87 61.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.709 -179.573 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -95.07 -2.06 50.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.173 0.511 . . . . 0.0 109.699 179.422 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.68 25.73 66.8 Favored Glycine 0 N--CA 1.446 -0.668 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.193 179.971 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -117.66 156.57 27.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.91 0.385 . . . . 0.0 111.157 -179.637 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -149.03 121.51 8.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.821 179.446 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 m -121.35 132.9 55.04 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.842 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.2 t -143.59 159.69 41.99 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.123 0.487 . . . . 0.0 111.656 -179.202 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.601 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.1 m -118.76 128.96 54.98 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.45 -179.243 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 67' ' ' LEU . 3.4 mm? -118.77 131.74 56.12 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -178.73 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 6.9 m -96.25 99.66 11.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.301 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.7 123.54 29.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.247 0.546 . . . . 0.0 111.685 -178.934 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -98.44 163.81 12.54 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.506 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -76.34 -29.19 57.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.069 0.461 . . . . 0.0 110.18 179.628 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -138.66 145.25 40.19 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.684 179.517 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -157.0 -170.53 3.32 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-O 120.685 0.278 . . . . 0.0 111.071 -179.257 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -117.85 143.42 46.31 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.483 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -95.1 112.83 4.46 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.55 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 82' ' ' ARG . 27.1 m-85 -119.58 143.88 47.39 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.839 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.5 mt -82.04 175.53 10.28 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.258 179.776 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.407 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 0.1 OUTLIER -69.64 -17.08 63.48 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.082 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.74 -10.06 38.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.863 0.363 . . . . 0.0 111.253 -179.716 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.14 -7.15 40.46 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.798 179.095 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.5 m -76.8 132.57 39.29 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 117.511 0.655 . . . . 0.0 111.104 -179.832 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -87.8 138.92 31.04 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 178.809 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 12.5 t-105 -99.02 -36.59 9.67 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.281 0.562 . . . . 0.0 109.61 179.62 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.82 179.7 38.99 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.436 -179.869 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.86 138.31 31.53 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.612 0.244 . . . . 0.0 110.384 179.567 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.78 137.85 52.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.238 0.542 . . . . 0.0 110.842 -179.285 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -120.38 134.33 55.29 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.62 -179.668 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 64.2 m -112.97 25.87 11.01 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.33 -179.69 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.2 m -79.55 -46.99 16.29 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.388 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -103.9 4.45 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.708 178.704 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.31 -174.62 3.33 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.114 -179.876 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -116.36 141.36 48.27 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.006 0.431 . . . . 0.0 110.852 -179.725 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.1 m -100.03 144.35 29.18 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.471 -0.786 . . . . 0.0 108.928 178.94 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -129.53 146.58 51.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.297 0.57 . . . . 0.0 111.164 179.58 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.5 t -77.26 119.29 25.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.079 179.9 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.97 109.4 3.84 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.304 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.3 mp -98.98 109.84 22.54 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.512 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.2 m -127.57 140.94 51.79 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.982 0.42 . . . . 0.0 111.405 -179.735 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -95.39 -174.67 3.26 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.74 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -58.3 -31.46 67.52 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 179.773 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.413 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -82.96 -37.12 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.597 179.527 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.0 6.9 5.73 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.702 179.669 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.406 ' HB3' ' H ' ' A' ' 104' ' ' GLY . 44.3 m-80 -108.35 -151.24 0.46 Allowed 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.918 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.406 ' H ' ' HB3' ' A' ' 103' ' ' ASN . . . 120.95 -160.58 15.24 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.553 179.944 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.83 156.57 65.47 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.715 2.277 . . . . 0.0 111.84 179.683 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -67.65 161.22 26.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.205 -179.733 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.69 144.08 29.84 Favored Glycine 0 N--CA 1.451 -0.359 0 CA-C-N 115.909 -0.587 . . . . 0.0 113.04 -179.459 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 13.8 t -113.55 112.92 42.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.982 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.73 136.24 33.8 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.806 0.336 . . . . 0.0 111.266 -179.777 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.6 pt -127.55 143.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.929 0.395 . . . . 0.0 110.845 179.969 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.4 m -114.09 147.32 38.95 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.41 179.695 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -87.22 174.57 8.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.571 -179.739 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.429 -0.796 . . . . 0.0 109.944 179.072 . . . . . . . . 0 0 . 1 . 049 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.734 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 120.707 0.289 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 050 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.43 115.27 56.4 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.63 179.775 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.59 162.68 35.25 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.615 2.21 . . . . 0.0 112.699 -179.794 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.495 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 4.4 m -107.13 102.58 11.9 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.847 -179.877 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.96 81.79 3.45 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.193 0.52 . . . . 0.0 110.639 179.877 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.47 84.39 2.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.4 -179.375 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.89 152.34 12.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.846 -179.807 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 20.6 m -108.9 104.83 55.93 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.824 179.93 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -74.1 149.27 41.01 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.524 2.149 . . . . 0.0 112.369 179.734 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.479 ' H ' HG21 ' A' ' 110' ' ' ILE . 21.0 m -105.5 51.56 0.75 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.226 0.536 . . . . 0.0 110.329 179.688 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.5 m -76.28 126.0 30.2 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.907 -179.607 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.97 81.5 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.169 179.556 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 53.4 mt -103.94 159.42 15.67 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.655 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.29 -179.11 6.63 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.671 0.272 . . . . 0.0 111.297 -178.508 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -72.61 149.07 44.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.937 0.398 . . . . 0.0 110.414 179.982 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.44 -1.99 62.58 Favored Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.602 -179.634 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.8 m -71.03 142.12 50.92 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.077 0.465 . . . . 0.0 111.017 -179.776 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.454 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 28.5 t -94.31 110.23 23.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 179.689 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.14 130.35 35.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 179.623 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt -100.74 121.64 42.0 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.083 0.468 . . . . 0.0 110.888 -179.594 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 64' ' ' SER . 98.6 t -114.71 122.1 68.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.791 179.246 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.17 100.65 4.32 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.137 0.494 . . . . 0.0 110.893 179.59 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.15 124.02 6.94 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.292 -179.714 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.495 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -115.97 155.43 28.05 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.389 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 24.7 31.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.327 -179.215 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.7 mt -97.44 -168.42 1.68 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.397 -0.402 . . . . 0.0 109.999 -179.995 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.4 tp60 -98.87 113.86 26.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.637 -179.422 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.16 133.61 55.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.864 179.563 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 90.34 24.94 27.48 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.524 -0.846 . . . . 0.0 113.001 -179.954 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.4 m -126.43 136.45 52.67 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 117.062 0.431 . . . . 0.0 110.623 179.602 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.8 127.21 40.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 -179.884 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -109.98 130.64 55.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.991 -179.581 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.9 119.52 32.29 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.345 179.445 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -127.21 121.84 58.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.08 -179.408 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.408 ' HA2' HD11 ' A' ' 67' ' ' LEU . . . -149.28 173.8 29.03 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.543 178.487 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 13.1 pt20 -86.25 123.09 31.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.837 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.57 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 2.4 m -121.58 147.63 45.57 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.057 0.456 . . . . 0.0 111.434 -178.035 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.4 171.62 16.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.66 179.6 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 3.0 m95 -70.07 101.22 1.77 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.67 179.935 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.76 -28.78 8.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.622 -179.797 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -154.05 -174.21 4.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.356 179.978 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.9 m -61.57 98.03 0.08 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.773 -179.329 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.05 14.63 81.64 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 112.348 179.522 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.2 t -114.61 127.81 71.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 111.151 -179.194 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 18.7 mt -106.58 150.19 26.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.81 179.19 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -153.92 144.99 22.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.696 -0.229 . . . . 0.0 110.791 179.966 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.858 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 1.9 m -117.63 165.45 13.57 Favored 'General case' 0 C--O 1.236 0.357 0 O-C-N 123.103 0.252 . . . . 0.0 111.392 -179.947 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.592 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 19.3 p-10 -76.12 116.4 55.55 Favored Pre-proline 0 N--CA 1.464 0.225 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.198 -179.963 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 78.8 Cg_endo -85.22 -15.41 5.45 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.845 2.363 . . . . 0.0 113.864 -178.972 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.72 5.37 26.66 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.789 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.88 23.63 2.23 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.872 0.367 . . . . 0.0 110.87 -179.604 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.592 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 1.7 p90 -107.03 172.51 6.78 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.86 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 45.5 m -142.37 118.57 10.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.833 0.349 . . . . 0.0 111.058 -179.877 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.06 131.27 34.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.183 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.407 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 3.7 p -120.78 135.28 61.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 120.911 0.386 . . . . 0.0 111.327 -178.835 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.6 t -96.81 139.66 32.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.76 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.77 125.6 27.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.147 179.993 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.3 p30 -70.68 -179.28 2.1 Favored 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.339 0.399 . . . . 0.0 111.302 -179.284 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.14 -20.54 65.48 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.794 -178.9 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -82.95 -14.95 53.12 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.202 0.525 . . . . 0.0 109.841 179.932 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.17 32.56 12.04 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.395 -179.65 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.85 143.28 50.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.228 0.537 . . . . 0.0 111.128 -179.647 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -132.06 116.97 17.75 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.293 179.818 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.0 t -127.09 140.22 52.43 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.82 0.343 . . . . 0.0 110.744 179.816 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.407 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 2.5 t -157.63 169.17 25.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.57 -179.81 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.454 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.8 m -121.28 131.38 54.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.29 -179.817 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.501 HD11 ' HA ' ' A' ' 52' ' ' PHE . 1.6 mm? -115.27 141.5 47.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.525 -179.184 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -101.59 108.2 19.68 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.303 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.69 117.02 29.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.502 0.667 . . . . 0.0 110.926 -179.696 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -106.26 168.22 9.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.921 -179.894 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -78.96 -44.81 21.68 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.198 0.523 . . . . 0.0 109.66 179.343 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.9 m -119.5 136.77 54.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.278 179.274 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.0 p90 -156.4 161.73 40.09 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 0.0 111.593 -178.771 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -79.53 136.7 36.96 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.625 179.437 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -103.43 130.08 10.11 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.521 -179.408 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 4.0 m-85 -131.35 146.99 52.52 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.811 HD12 ' HB ' ' A' ' 81' ' ' THR . 69.7 mt -76.93 173.46 11.73 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 123.303 0.377 . . . . 0.0 110.771 -179.626 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -75.79 -28.25 58.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.383 -178.404 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -77.01 -23.91 52.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.064 -179.716 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.33 -11.8 8.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.367 179.709 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.811 ' HB ' HD12 ' A' ' 77' ' ' LEU . 24.5 m -75.19 143.49 43.16 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.62 -0.341 . . . . 0.0 110.521 -179.949 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.431 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 14.1 ptm180 -92.36 152.93 19.49 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.611 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.434 ' HE3' HD11 ' A' ' 77' ' ' LEU . 14.7 t-105 -122.7 -58.14 1.69 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.842 0.353 . . . . 0.0 111.244 -179.058 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.75 170.93 39.15 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -179.739 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 139.91 46.71 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.954 0.407 . . . . 0.0 111.025 179.787 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 1.4 t -112.02 154.04 13.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.973 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -143.2 137.69 29.17 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.544 -179.402 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 2.7 m -119.53 36.33 4.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.619 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.0 m -75.97 -28.46 57.88 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 121.081 0.467 . . . . 0.0 110.443 179.021 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 t -130.64 9.0 4.99 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.551 0.691 . . . . 0.0 109.677 179.133 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.71 166.83 17.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.493 -179.513 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.83 34.73 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.976 0.417 . . . . 0.0 110.95 179.962 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.6 m -104.68 143.73 32.69 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 179.347 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -122.11 153.6 38.48 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.168 0.508 . . . . 0.0 111.349 179.879 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 24.1 t -81.35 112.28 19.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.705 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.57 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -95.85 112.98 4.53 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.649 179.623 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.75 118.3 22.58 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 -179.372 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.2 m -153.11 154.77 35.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.726 0.298 . . . . 0.0 110.585 179.666 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -83.02 -172.01 3.89 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.393 179.636 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -60.31 -35.82 76.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.069 179.785 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.11 -35.57 71.84 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.933 0.397 . . . . 0.0 110.34 179.223 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 113.47 24.74 4.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.423 178.955 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -126.06 -178.34 4.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.017 0.409 . . . . 0.0 110.306 179.759 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.98 -143.34 14.29 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.84 179.872 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.22 163.6 37.58 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 122.83 2.353 . . . . 0.0 111.618 179.408 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -80.77 155.04 26.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.449 -179.772 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.17 129.77 10.86 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.497 -179.675 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.1 t -102.85 119.02 50.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.575 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.11 138.22 32.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.844 0.354 . . . . 0.0 111.282 -179.359 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.479 HG21 ' H ' ' A' ' 10' ' ' SER . 21.6 pt -131.18 153.15 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.978 179.861 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.3 m -132.85 147.6 52.3 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.483 -179.917 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 63.0 m-85 -79.08 167.2 21.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.88 -179.237 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.6 p30 . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.637 -0.697 . . . . 0.0 110.325 179.924 . . . . . . . . 0 0 . 1 . 050 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.858 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.531 ' O ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.054 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 . . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.78 101.93 11.95 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.804 -179.969 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 1' ' ' ALA . 6.2 Cg_exo -78.34 173.8 13.3 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 123.112 2.541 . . . . 0.0 111.811 -179.986 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.433 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 20.4 m -121.69 102.12 8.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.113 0.482 . . . . 0.0 110.678 -179.796 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -96.81 82.55 3.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.343 179.531 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -91.68 104.1 16.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.184 -179.845 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 108' ' ' VAL . 6.9 m -119.66 150.02 22.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.998 -179.896 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 m -118.82 84.24 24.95 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.762 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.64 147.0 44.62 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.757 2.305 . . . . 0.0 113.063 -178.748 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -95.64 72.22 3.12 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.064 0.459 . . . . 0.0 110.768 179.581 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -87.64 111.41 21.24 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.659 -179.573 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.34 -7.97 54.71 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.906 179.905 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.458 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 89.4 mt -91.66 150.43 21.15 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.957 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.29 169.22 12.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.444 -179.061 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.97 154.91 40.62 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.888 0.375 . . . . 0.0 110.011 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.01 4.29 61.52 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.388 -179.271 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.9 m -85.0 143.56 28.85 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.153 -0.314 . . . . 0.0 110.153 179.257 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 16.3 t -92.27 116.38 33.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.037 0.446 . . . . 0.0 110.859 -179.524 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.507 HG11 HG21 ' A' ' 95' ' ' VAL . 27.0 t -88.51 132.07 34.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.239 -179.91 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.5 ttmt -97.35 127.48 43.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.994 0.426 . . . . 0.0 111.075 179.924 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 64' ' ' SER . 80.3 t -122.66 113.33 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.675 178.879 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -124.83 101.26 7.0 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.008 0.433 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.65 126.11 8.78 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.321 -179.908 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -121.52 154.16 37.02 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.349 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.21 29.81 36.14 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.058 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 76.0 mt -104.06 -171.03 1.86 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.479 -0.36 . . . . 0.0 110.36 -179.527 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.5 tp60 -89.71 112.43 23.7 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.259 -179.676 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.85 132.76 54.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.908 0.385 . . . . 0.0 111.866 -179.752 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.83 -30.2 10.71 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.819 -0.705 . . . . 0.0 113.193 179.317 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.39 146.05 47.28 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.322 -179.636 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -98.44 124.53 43.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.794 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -104.99 117.75 34.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.101 0.477 . . . . 0.0 110.292 -179.593 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 31.9 t70 -85.77 123.35 31.05 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.961 -179.677 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.3 t -128.02 135.99 61.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.929 0.395 . . . . 0.0 111.817 -178.94 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -165.54 174.67 41.32 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 178.412 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -81.17 124.69 29.47 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.514 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -128.19 163.3 24.99 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.18 0.515 . . . . 0.0 111.8 -178.217 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.733 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -161.47 175.63 11.96 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.261 178.981 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 1.7 m0 -69.29 109.87 4.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.065 0.459 . . . . 0.0 110.883 -179.874 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.469 HG21 ' HB3' ' A' ' 83' ' ' TRP . 5.1 p -94.97 -16.75 7.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.341 0.591 . . . . 0.0 110.17 179.8 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -152.39 -164.32 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.464 179.953 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.25 87.6 4.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.82 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.26 -13.02 68.17 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 121.119 -0.562 . . . . 0.0 112.161 -179.919 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.4 t -91.1 128.96 42.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.964 0.411 . . . . 0.0 110.717 -179.672 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.3 mt -105.87 152.39 23.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.421 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -147.75 144.87 28.56 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.622 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.839 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 4.9 m -108.83 167.58 9.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.895 0.379 . . . . 0.0 111.415 -179.032 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.5 ' ND2' ' HB2' ' A' ' 73' ' ' PHE . 24.5 t-20 -81.49 124.63 80.02 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.019 179.653 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.52 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 52.6 Cg_endo -86.06 22.09 0.99 Allowed 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 123.244 2.63 . . . . 0.0 113.339 -179.404 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -117.11 -56.85 2.22 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.792 0.33 . . . . 0.0 111.519 -179.803 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.03 21.14 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.034 0.445 . . . . 0.0 111.478 -179.203 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 9.5 p90 -79.74 162.01 25.42 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.29 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.6 m -156.75 107.2 2.33 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.88 0.371 . . . . 0.0 110.278 179.424 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.38 119.46 28.82 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.922 -179.953 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.454 HG13 ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -111.53 134.07 55.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.855 0.36 . . . . 0.0 110.307 -179.514 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 4.1 t -90.99 145.41 24.72 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.039 0.447 . . . . 0.0 110.724 179.982 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.45 132.06 46.35 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.241 179.543 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -74.48 -174.46 2.06 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.748 179.946 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.92 -7.95 32.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.482 -179.78 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -95.2 -6.5 41.46 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.575 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.93 32.39 45.1 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.506 -179.491 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.46 153.83 49.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.764 0.316 . . . . 0.0 111.275 -179.544 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 55' ' ' VAL . . . -147.76 124.23 11.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.703 179.697 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 0.0 OUTLIER -122.81 130.1 52.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.301 179.442 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.8 t -138.77 166.86 23.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.687 -179.778 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 7.8 m -129.8 122.93 29.75 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.893 -179.791 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -118.76 134.48 55.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.892 0.377 . . . . 0.0 111.965 -178.236 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.01 109.65 20.9 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.88 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 p -79.72 117.14 24.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.46 0.648 . . . . 0.0 111.477 -179.176 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -94.34 167.64 11.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.933 179.588 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -76.2 -45.07 34.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.3 m -124.74 139.37 53.91 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.481 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.5 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . 45.5 p90 -157.67 153.25 26.41 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.847 0.356 . . . . 0.0 111.912 -178.806 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 2.4 mp0 -75.63 142.37 42.63 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 177.956 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.99 127.46 9.26 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.86 -179.481 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.52 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 2.6 m-85 -124.85 142.49 51.4 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.909 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.469 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 44.0 mt -80.99 175.35 10.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.43 -179.795 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -84.84 67.25 10.05 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.173 0.511 . . . . 0.0 110.807 -178.789 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -179.59 -32.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.984 179.762 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 130.9 -11.42 5.65 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.859 -179.608 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 95.3 m -67.31 125.93 27.64 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.083 0.468 . . . . 0.0 110.095 179.056 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.94 153.79 20.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.0 t-105 -126.44 -40.99 1.91 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.162 -179.06 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.71 -145.92 10.78 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.81 -0.71 . . . . 0.0 111.831 -179.97 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' GLU . 9.0 m -125.47 136.6 53.55 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.865 0.364 . . . . 0.0 110.664 179.901 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.733 HG11 ' HB3' ' A' ' 38' ' ' ALA . 9.6 t -111.61 141.36 27.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.7 179.436 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -126.59 131.82 51.42 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.737 -179.468 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 96.5 m -112.31 29.53 7.84 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.554 -0.293 . . . . 0.0 111.652 -179.753 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 m -71.86 -36.18 70.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.823 178.782 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.4 t -124.16 17.04 9.17 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.802 0.81 . . . . 0.0 109.524 178.975 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.71 -176.82 4.36 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.289 -179.519 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.7 139.66 44.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.029 0.442 . . . . 0.0 111.29 -179.572 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.438 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.2 m -106.72 145.96 31.4 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.947 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -127.74 154.82 44.9 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.318 -179.816 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.507 HG21 HG11 ' A' ' 19' ' ' VAL . 11.7 t -88.6 124.45 41.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.168 179.42 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -120.92 141.68 15.07 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.485 -0.864 . . . . 0.0 113.14 -178.819 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.512 ' HB3' HG13 ' A' ' 34' ' ' VAL . 1.7 pt? -143.33 144.46 32.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.663 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.509 ' HB3' ' HA2' ' A' ' 102' ' ' GLY . 19.5 m -143.8 148.71 35.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 111.525 -179.366 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.62 -146.89 0.11 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.696 179.965 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.86 -15.38 59.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.762 0.315 . . . . 0.0 111.655 179.973 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -108.8 -44.94 3.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.996 0.427 . . . . 0.0 111.196 -179.624 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.509 ' HA2' ' HB3' ' A' ' 98' ' ' SER . . . 138.33 20.62 0.49 Allowed Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.915 -0.66 . . . . 0.0 111.846 -179.575 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -115.85 -165.91 1.09 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.861 0.362 . . . . 0.0 110.766 -178.984 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 125.09 -169.03 17.04 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.792 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -52.5 141.32 52.24 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 122.57 2.18 . . . . 0.0 112.192 179.284 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -61.92 149.37 40.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.657 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.01 167.13 53.06 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.642 -179.722 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 7' ' ' VAL . 34.7 t -130.05 121.76 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 110.437 -179.782 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.03 132.1 35.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.857 179.413 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.6 pt -127.54 171.09 16.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.048 179.634 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 16.7 m -148.73 154.65 39.9 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.766 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 16.1 m-85 -96.94 162.36 13.43 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.581 -179.744 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.8 p30 . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.584 -0.722 . . . . 0.0 110.552 -179.984 . . . . . . . . 0 0 . 1 . 051 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.839 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 052 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.1 112.05 62.22 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-O 120.71 0.291 . . . . 0.0 110.716 179.868 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -77.69 -168.73 0.63 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.55 2.167 . . . . 0.0 111.8 179.631 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.76 87.61 1.86 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.176 0.512 . . . . 0.0 110.975 179.98 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.96 102.45 15.15 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.134 179.792 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.06 97.41 6.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.644 179.74 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.54 ' O ' ' HD3' ' A' ' 9' ' ' PRO . 15.4 m -108.7 160.27 7.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 120.808 0.337 . . . . 0.0 110.874 -179.704 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 m -110.72 89.95 9.95 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.225 179.248 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 7' ' ' VAL . 7.7 Cg_exo -72.48 133.95 21.61 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.985 2.456 . . . . 0.0 112.301 -179.607 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 1.3 m -89.05 78.66 7.39 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.373 179.457 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.5 m -100.93 95.08 6.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.973 0.416 . . . . 0.0 109.955 179.668 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.38 8.95 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.025 -0.607 . . . . 0.0 111.995 -179.268 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 19.5 mt -114.7 153.04 30.98 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 -179.923 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.4 m -75.53 175.09 8.85 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.393 179.288 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -68.14 163.44 22.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.913 0.387 . . . . 0.0 109.965 179.841 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.11 -5.45 84.36 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -178.456 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.7 m -69.94 132.94 46.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-O 121.107 0.479 . . . . 0.0 110.756 179.628 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 26.5 t -76.55 101.87 3.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.542 -179.98 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 66' ' ' SER . 21.8 t -76.75 129.5 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.82 179.585 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -103.96 132.02 50.62 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.697 0.284 . . . . 0.0 111.079 -179.073 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 64' ' ' SER . 76.3 t -126.25 118.15 50.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -126.13 97.24 5.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.113 0.482 . . . . 0.0 110.224 179.424 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.13 125.97 8.59 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.574 -179.106 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.39 153.22 34.42 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.211 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.81 24.87 43.78 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.258 -179.321 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.421 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 64.6 mt -94.63 -176.84 4.02 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.528 -0.336 . . . . 0.0 110.3 -179.974 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.5 tp60 -87.35 116.76 25.67 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 120.893 0.378 . . . . 0.0 110.244 179.779 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.52 133.26 52.03 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.932 179.592 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 86.31 31.45 19.45 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.202 -179.49 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 85.2 m -137.38 131.9 32.74 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.292 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -86.69 126.71 34.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.43 179.936 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.421 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 81.9 m-85 -103.46 118.8 37.58 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.979 0.418 . . . . 0.0 110.823 -179.773 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 98.23 7.44 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.814 179.877 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 124.66 71.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -152.74 179.47 29.18 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.091 179.751 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -85.35 122.01 28.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.051 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.631 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -125.56 174.88 7.94 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.779 -179.135 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.655 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -167.74 -178.74 3.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.03 179.601 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -73.45 100.2 3.18 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.61 179.889 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 p -90.02 -28.3 5.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 120.801 0.334 . . . . 0.0 111.134 -179.647 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.5 t70 -146.97 -169.99 3.43 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -72.33 76.92 1.01 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.097 0.475 . . . . 0.0 111.153 -179.801 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 104.02 -27.85 17.72 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.74 -179.932 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.418 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 21.9 t -72.3 128.97 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.563 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 22.9 mt -111.56 147.05 36.24 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.849 179.768 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.78 143.93 27.87 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.742 -179.829 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.81 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 15.4 m -109.6 159.97 16.65 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.811 0.339 . . . . 0.0 111.433 -179.064 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.595 ' HB2' ' CD2' ' A' ' 73' ' ' PHE . 19.3 t-20 -85.98 119.23 71.66 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.572 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HG3' ' CG ' ' A' ' 76' ' ' PHE . 97.1 Cg_endo -81.56 -9.69 12.25 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.93 2.42 . . . . 0.0 113.175 -178.52 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.78 -43.17 37.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.794 0.33 . . . . 0.0 111.126 -179.416 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.26 18.56 21.49 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -178.882 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 0.0 OUTLIER -91.24 154.85 18.99 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.291 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -138.67 116.38 11.44 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.685 0.279 . . . . 0.0 110.544 179.733 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.84 108.98 12.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.171 179.828 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.418 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 9.3 p -102.01 129.27 53.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.938 0.399 . . . . 0.0 110.041 179.835 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 14.7 t -94.59 144.5 25.54 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.425 179.537 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.04 130.35 39.66 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.613 179.91 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.1 p30 -74.81 -174.64 2.24 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.257 -179.514 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -15.66 63.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.091 179.783 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -88.18 -5.08 58.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.351 179.535 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.48 30.15 57.0 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.385 179.317 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.6 p -129.76 154.53 47.12 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.705 0.288 . . . . 0.0 111.295 -179.726 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.11 130.59 17.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.234 179.946 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 14.5 m -127.15 135.64 50.98 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.217 179.546 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.418 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 9.2 t -153.16 156.86 39.4 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.711 179.955 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 6.1 m -118.98 132.84 56.09 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.44 179.861 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.17 140.26 49.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.824 -179.318 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.2 m -99.17 100.29 11.39 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.481 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 5.7 p -74.11 118.5 19.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.225 0.536 . . . . 0.0 111.747 -178.707 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -90.49 170.21 10.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.181 179.038 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HD2' ' HA ' ' A' ' 89' ' ' THR . 10.4 tpp180 -77.23 -53.94 7.11 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.196 179.553 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.8 m -125.95 138.53 53.77 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 178.61 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD2' ' HB2' ' A' ' 48' ' ' ASN . 48.7 p90 -155.14 170.62 21.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.176 0.512 . . . . 0.0 111.953 -177.762 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -89.71 133.87 34.45 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 178.149 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -92.98 129.21 9.77 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.166 -179.834 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' CZ ' ' HB2' ' A' ' 82' ' ' ARG . 9.8 m-85 -126.72 151.35 48.28 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -179.681 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.435 ' HB2' ' OD1' ' A' ' 79' ' ' ASP . 38.3 mt -85.25 176.08 8.55 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.568 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -64.99 -29.55 70.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.251 0.548 . . . . 0.0 110.399 179.566 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD1' ' HB2' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -71.06 -24.75 62.4 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.195 -179.859 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 110.95 6.63 26.09 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.304 179.279 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 97.5 m -88.01 139.04 30.91 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.916 0.389 . . . . 0.0 111.303 179.67 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 ttp-105 -85.54 121.41 28.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.842 179.02 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -87.14 -40.69 14.39 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.1 0.476 . . . . 0.0 109.976 179.861 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.2 179.09 41.52 Favored Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.743 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.83 130.15 34.93 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.584 0.23 . . . . 0.0 110.536 179.62 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.2 t -110.23 134.23 53.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.791 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -119.26 125.61 49.53 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.042 0.449 . . . . 0.0 111.885 -179.013 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 18.4 m -108.0 28.11 8.57 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.077 178.84 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.548 ' HA ' ' HD2' ' A' ' 71' ' ' ARG . 26.4 m -82.98 -39.46 21.31 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-O 121.414 0.626 . . . . 0.0 109.346 178.711 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.5 t -115.71 10.42 15.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.641 178.858 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.04 171.1 14.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.8 179.677 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.72 138.57 40.17 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.862 0.363 . . . . 0.0 111.304 -179.774 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 73' ' ' PHE . 1.6 m -85.2 163.57 18.62 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.78 179.194 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -139.55 160.57 39.54 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.181 0.515 . . . . 0.0 111.03 179.788 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.9 t -94.42 120.46 43.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.878 179.439 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.631 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -107.22 127.49 8.83 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 -179.601 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.2 mp -121.9 107.87 12.77 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 -179.783 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.4 m -127.7 129.81 47.78 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.809 0.337 . . . . 0.0 110.815 179.757 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -88.92 -169.69 2.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.397 179.38 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.7 -26.76 65.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.769 -179.747 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.95 -33.77 19.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.934 0.397 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 115.83 21.97 4.81 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.391 179.913 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -130.2 -156.06 0.73 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.551 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 128.07 -153.31 19.36 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.932 179.484 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -62.28 153.88 67.22 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 122.847 2.365 . . . . 0.0 111.754 179.323 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -70.78 146.85 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.003 -179.386 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.84 146.02 33.28 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.917 -0.658 . . . . 0.0 112.512 -179.623 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 5.6 t -124.4 131.06 73.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.915 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.62 142.66 27.5 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.984 0.421 . . . . 0.0 111.011 -179.836 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.493 ' HB ' ' O ' ' A' ' 10' ' ' SER . 19.9 pt -105.27 178.86 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.467 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 50.0 m -148.93 140.49 23.43 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.691 0.281 . . . . 0.0 110.591 -179.822 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.5 m-85 -99.98 150.84 22.01 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.944 179.75 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.1 p30 . . . . . 0 C--O 1.243 0.741 0 CA-C-O 118.647 -0.692 . . . . 0.0 109.667 179.468 . . . . . . . . 0 0 . 1 . 052 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.81 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.046 0 CA-C-O 120.581 0.229 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 053 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . . . -82.91 115.77 60.54 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.375 179.996 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 2' ' ' ALA . 6.4 Cg_exo -73.16 165.29 33.08 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.7 2.267 . . . . 0.0 112.157 179.519 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.9 92.28 3.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.4 179.537 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.22 109.84 21.9 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.844 -179.812 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.91 102.51 9.43 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.537 179.799 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 m -119.75 153.95 22.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.212 -179.79 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -110.62 94.48 19.61 Favored Pre-proline 0 C--N 1.321 -0.646 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.003 178.884 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.57 140.57 52.36 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.6 2.2 . . . . 0.0 112.771 -179.473 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.87 43.89 0.95 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.939 -179.871 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.5 m -70.84 116.52 11.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.069 -179.619 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.99 60.71 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.461 179.686 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 1.6 mt -118.43 146.56 44.36 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.789 0.328 . . . . 0.0 110.575 -179.778 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.33 177.9 6.24 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.402 -179.337 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -68.81 151.84 46.09 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.166 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.86 -11.74 62.51 Favored Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -178.222 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.0 m -73.11 137.27 45.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.041 0.448 . . . . 0.0 110.338 179.446 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 39.9 t -89.14 124.0 41.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.383 -179.224 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 66' ' ' SER . 46.2 t -90.38 128.16 42.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.677 179.216 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -95.95 129.05 43.33 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.017 0.437 . . . . 0.0 110.895 -179.392 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' SER . 82.6 t -123.64 121.38 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 179.813 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -134.11 101.96 5.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.0 110.418 179.171 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.83 121.95 6.95 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.236 -179.686 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.1 137.59 51.53 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.369 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.66 45.85 4.46 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.176 -179.204 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.63 -172.59 2.06 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.626 -0.287 . . . . 0.0 110.307 -179.629 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -83.22 108.39 16.42 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.956 0.408 . . . . 0.0 110.233 179.971 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.43 130.47 46.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.317 -179.348 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.51 -6.71 74.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.263 179.566 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 m -99.27 146.6 26.05 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 117.072 0.436 . . . . 0.0 110.788 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.5 141.09 29.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.406 179.543 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 99' ' ' ASP . 47.1 m-85 -120.12 120.82 37.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.898 0.38 . . . . 0.0 110.816 -179.631 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -84.27 116.49 23.01 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.484 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 t -127.3 120.98 56.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 120.815 0.34 . . . . 0.0 111.205 -179.262 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.06 166.15 30.42 Favored Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 178.445 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.17 124.37 29.83 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.463 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -128.05 166.64 18.04 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.987 0.422 . . . . 0.0 111.876 -177.906 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' SG ' ' A' ' 93' ' ' CYS . . . -156.6 176.94 12.05 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.578 179.107 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -69.73 126.09 28.69 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.685 0.279 . . . . 0.0 110.42 179.867 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG23 HG22 ' A' ' 86' ' ' VAL . 7.2 p -112.33 -23.38 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.908 0.385 . . . . 0.0 111.233 -179.249 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -149.33 -167.33 2.8 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.844 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.97 87.24 3.5 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.334 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 99.74 -24.8 30.73 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.587 -179.42 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.4 t -88.51 137.26 21.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 110.995 -179.709 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.3 mp -122.83 160.78 25.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.343 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' HB1' ' N ' ' A' ' 76' ' ' PHE . . . -153.02 152.68 31.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.64 0.257 . . . . 0.0 111.676 -179.415 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.777 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.3 m -108.24 174.73 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.27 179.765 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.5 HD21 ' HB2' ' A' ' 51' ' ' ASP . 28.4 p-10 -91.15 137.92 26.13 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-O 120.991 0.424 . . . . 0.0 110.449 179.786 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 55.7 Cg_endo -86.86 15.13 2.26 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 123.17 2.58 . . . . 0.0 112.715 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.8 -65.59 1.08 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.744 0.307 . . . . 0.0 111.465 -179.375 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HB2' HD21 ' A' ' 48' ' ' ASN . 6.8 m-20 -95.58 67.21 2.83 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.913 0.387 . . . . 0.0 111.271 -178.95 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -130.32 148.65 52.16 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.842 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 37.2 m -145.1 120.59 10.36 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 111.412 -179.477 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.81 96.48 9.76 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.808 179.188 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -81.29 137.83 20.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.796 -179.57 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 4.5 t -98.58 136.99 37.88 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.314 179.737 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.62 127.07 31.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.951 179.376 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.83 -178.96 3.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.136 -179.114 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.46 -26.96 67.17 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.26 -179.042 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -80.32 -9.26 59.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.745 0.307 . . . . 0.0 111.106 -179.758 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.4 36.19 15.14 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.869 179.524 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.03 153.85 47.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.86 0.362 . . . . 0.0 111.127 -179.718 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.84 127.06 14.78 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.716 179.892 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 3.8 t -133.21 139.48 47.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.806 0.336 . . . . 0.0 110.455 179.668 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 13.3 t -158.67 168.38 27.03 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.878 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.568 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 35.6 m -132.24 129.22 39.36 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.624 0.25 . . . . 0.0 110.759 -179.518 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -117.26 144.55 44.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.487 -178.753 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.5 m -94.19 121.64 35.89 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.921 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.8 p -81.91 139.02 18.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.054 0.455 . . . . 0.0 111.027 -179.93 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.8 mmt180 -117.35 157.71 25.67 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.394 -179.883 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.1 tpp180 -76.72 -37.86 55.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.36 0.6 . . . . 0.0 109.952 179.562 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 m -138.96 139.51 37.96 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.596 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -153.88 176.55 12.03 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.258 0.551 . . . . 0.0 111.842 -178.467 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -91.03 139.57 30.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.367 179.16 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -91.35 121.36 6.3 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.673 -179.51 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.46 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 3.7 m-85 -124.85 142.41 51.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.595 0.236 . . . . 0.0 110.684 -179.176 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.559 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 21.4 mt -84.4 177.76 8.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.141 179.641 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -68.35 -20.75 64.74 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -178.514 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.09 -12.25 28.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.711 0.291 . . . . 0.0 111.188 -179.859 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 107.88 2.02 34.27 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.307 -179.836 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 96.5 m -74.67 133.86 42.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.908 0.385 . . . . 0.0 110.446 179.226 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.9 ttt85 -86.67 129.57 34.82 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.137 179.208 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 16.5 t-105 -99.31 -26.38 14.18 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.042 0.449 . . . . 0.0 110.489 179.722 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.47 -144.04 11.57 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.844 -0.693 . . . . 0.0 111.951 179.884 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -112.31 141.54 45.89 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.689 0.281 . . . . 0.0 110.751 -179.903 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 40' ' ' VAL . 4.1 t -121.8 128.55 75.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.645 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -110.44 134.17 52.59 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.194 0.521 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.37 16.12 16.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.675 -179.535 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 m -79.69 -26.14 41.03 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.285 0.564 . . . . 0.0 110.595 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 t -126.37 9.79 7.28 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.655 0.741 . . . . 0.0 110.023 179.348 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.8 175.01 9.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.691 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -113.57 133.58 55.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.807 0.336 . . . . 0.0 110.618 179.731 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.43 ' SG ' ' HB2' ' A' ' 38' ' ' ALA . 97.9 m -98.69 -178.04 3.86 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.73 -179.693 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.51 ' HG3' " H3'" ' A' ' 114' ' ' FLN . 0.3 OUTLIER -152.83 159.66 43.06 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.292 179.875 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 15.1 t -86.7 113.39 24.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.292 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.47 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -94.24 108.33 3.66 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.248 -179.557 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -123.61 118.35 27.1 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.035 0.445 . . . . 0.0 110.453 179.91 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.3 m -149.25 145.95 27.35 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.275 179.75 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -70.55 -179.66 2.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.167 179.414 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.35 -31.08 31.83 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.645 179.749 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.74 -55.62 4.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.812 0.339 . . . . 0.0 110.501 179.179 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 141.16 34.02 0.12 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.341 -0.933 . . . . 0.0 113.442 179.495 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -140.13 -179.77 6.17 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.383 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 141.18 -131.51 4.92 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.838 179.865 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.37 175.09 11.74 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.801 2.334 . . . . 0.0 111.941 179.671 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -89.7 144.48 25.95 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.726 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.69 143.17 30.96 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.968 179.801 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.3 t -115.34 128.11 72.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.84 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.6 147.26 33.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.775 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.1 pp -132.81 160.95 42.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.601 -179.953 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -148.37 145.59 28.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.389 179.777 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 18.7 m-85 -84.68 171.21 12.57 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.169 -179.705 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 12.1 p30 . . . . . 0 C--O 1.245 0.852 0 CA-C-O 118.635 -0.697 . . . . 0.0 110.13 179.779 . . . . . . . . 0 0 . 1 . 053 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.777 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.013 0 CA-C-O 120.631 0.253 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 054 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.53 104.14 53.34 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.376 179.463 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -62.69 151.42 83.78 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 122.675 2.25 . . . . 0.0 112.333 -179.859 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.32 97.99 7.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.771 -179.729 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.26 115.79 28.39 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.342 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.7 93.45 4.01 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.356 0.598 . . . . 0.0 110.658 179.616 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -115.18 145.92 20.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.99 -179.621 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.2 m -112.85 101.14 52.65 Favored Pre-proline 0 C--N 1.323 -0.546 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.128 179.013 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -81.87 136.11 9.2 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.614 2.209 . . . . 0.0 112.492 -179.451 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.95 50.75 1.61 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.571 -179.788 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.21 114.34 5.24 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.524 -179.504 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.59 -1.09 78.32 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.864 179.019 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 112' ' ' PHE . 85.8 mt -93.76 162.92 13.73 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 122.49 -0.418 . . . . 0.0 110.577 -179.282 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.87 176.5 8.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.074 -179.192 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -72.37 152.28 42.15 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.38 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.27 -7.25 60.0 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.483 -178.861 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.7 m -69.23 147.38 51.33 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.1 0.476 . . . . 0.0 111.15 179.98 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.625 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 88.5 t -93.18 111.45 24.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.723 -179.986 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.529 HG11 HG21 ' A' ' 95' ' ' VAL . 14.1 t -85.08 123.25 39.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.266 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -96.91 127.35 42.8 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.838 0.351 . . . . 0.0 111.092 -179.121 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 96.4 t -122.95 105.5 16.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.74 179.191 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -117.62 110.84 18.4 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.984 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.56 126.28 8.13 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.056 -179.813 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.5 148.84 39.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.81 0.338 . . . . 0.0 110.197 179.518 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.51 38.0 34.04 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.305 -179.097 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 86.4 mt -100.51 -170.07 1.81 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 -179.622 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 44.8 tp60 -93.31 103.96 16.16 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.816 0.341 . . . . 0.0 111.014 -179.307 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.05 119.12 6.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.423 179.699 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.28 -12.31 16.59 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.728 179.925 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 68.5 p -101.08 160.46 14.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.791 0.329 . . . . 0.0 110.99 -179.987 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -115.54 146.65 41.52 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.597 -179.932 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -125.99 119.06 26.7 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.649 -179.717 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.38 98.62 8.94 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 179.351 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -103.96 135.58 41.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.725 -178.356 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -163.87 179.47 38.82 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.638 -0.585 . . . . 0.0 111.638 178.398 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -88.44 129.38 35.45 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 178.366 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -132.64 168.66 17.88 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.083 0.468 . . . . 0.0 111.934 -177.689 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -157.69 173.29 17.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.051 179.337 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -72.55 98.33 2.29 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 123.444 0.465 . . . . 0.0 110.533 179.872 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p -87.27 -20.87 7.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.368 -179.983 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.2 t70 -152.82 -177.71 6.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.809 179.106 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.4 m -71.79 100.38 2.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.955 0.407 . . . . 0.0 110.899 -179.673 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.62 6.77 88.86 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.327 179.765 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 3.6 t -120.59 122.06 67.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.956 0.407 . . . . 0.0 110.232 179.985 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mp -112.68 148.58 34.37 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.661 179.877 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -142.06 144.55 33.63 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.784 -0.189 . . . . 0.0 110.899 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.792 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 3.7 m -103.49 175.35 5.51 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.1 -179.424 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' HB3' ' CD2' ' A' ' 73' ' ' PHE . 27.9 p-10 -93.47 135.4 25.38 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.996 0.427 . . . . 0.0 111.984 -179.397 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -92.59 20.86 0.75 Allowed 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 123.073 2.515 . . . . 0.0 112.056 179.161 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.65 -48.24 4.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.543 -179.09 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.421 ' HB2' HD21 ' A' ' 48' ' ' ASN . 28.1 m-20 -111.94 21.55 15.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.473 -179.614 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.41 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 12.1 p90 -70.55 156.69 39.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.292 179.78 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 49.2 m -145.55 107.1 4.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.999 0.428 . . . . 0.0 110.719 179.283 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -82.35 90.09 6.64 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.777 179.309 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.1 p -82.75 142.6 13.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.985 -178.742 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 t -107.9 142.84 37.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.253 179.629 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.98 125.5 26.94 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.69 -179.931 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.84 -179.13 3.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.417 -179.479 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.84 -28.91 67.9 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.25 -179.243 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -80.79 -3.59 51.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.933 0.397 . . . . 0.0 110.841 179.688 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.27 40.15 24.82 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.138 179.806 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -136.68 159.44 41.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.767 0.317 . . . . 0.0 110.655 -179.702 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.61 124.74 11.44 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.706 179.716 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -128.02 126.03 40.52 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.66 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 11.4 t -144.3 167.75 21.7 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.704 0.288 . . . . 0.0 110.63 179.941 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.625 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 17.1 m -124.37 130.61 52.79 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.845 -179.376 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -113.18 135.88 53.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.546 -178.928 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.2 m -95.08 107.85 19.93 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 178.681 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.4 p -83.56 126.59 40.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.448 0.642 . . . . 0.0 111.893 -178.675 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -101.83 168.51 9.39 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.873 179.027 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.5 tpp180 -77.33 -32.63 55.36 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.157 0.503 . . . . 0.0 109.837 179.666 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -137.67 145.07 42.19 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.811 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.43 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 43.5 p90 -156.24 165.61 35.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 111.799 -178.744 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.77 124.76 34.46 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.466 178.656 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -82.99 119.28 4.82 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.524 -179.765 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -122.75 141.79 51.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.71 0.29 . . . . 0.0 110.524 -179.302 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 86.2 mt -78.6 172.04 14.26 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' H ' ' H5 ' ' A' ' 114' ' ' FLN . 37.6 t80 -63.44 -33.14 74.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 -178.905 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.05 -26.41 56.55 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.999 -179.81 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 123.32 -6.61 9.25 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.554 -0.832 . . . . 0.0 113.03 179.395 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -73.82 123.8 24.88 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.831 0.316 . . . . 0.0 110.899 179.827 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ppt_? -78.78 136.37 37.35 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.72 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 14.2 t-105 -106.38 -14.45 15.09 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.704 -0.399 . . . . 0.0 110.906 -179.529 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.14 164.64 10.78 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.185 179.466 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -83.6 123.03 29.37 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 120.809 0.338 . . . . 0.0 110.287 179.419 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.36 150.95 5.66 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.146 -179.501 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -130.69 136.33 48.69 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.894 -179.261 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 88.9 m -114.85 17.22 17.1 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.669 179.906 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.8 m -75.96 -40.77 53.24 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.426 0.632 . . . . 0.0 109.54 178.994 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.3 t -117.43 29.42 7.88 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 122.055 0.931 . . . . 0.0 109.081 179.142 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -154.8 -167.94 2.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.14 -179.72 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -112.98 151.17 30.91 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.848 0.356 . . . . 0.0 111.001 -179.655 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -115.19 159.58 20.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.61 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -149.49 163.17 38.55 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.93 179.226 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.529 HG21 HG11 ' A' ' 19' ' ' VAL . 2.7 t -101.06 143.27 14.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.401 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.41 159.98 28.17 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.392 179.891 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -147.14 154.16 40.77 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.868 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.1 m -143.05 130.73 21.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.162 0.506 . . . . 0.0 111.369 179.773 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -86.77 -151.23 0.16 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.32 178.68 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.07 -30.78 70.92 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.18 0.514 . . . . 0.0 110.112 178.598 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.15 -59.12 1.91 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.178 178.905 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.23 54.33 0.11 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.56 179.687 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.5 m-80 -144.43 -164.37 1.89 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.573 0.225 . . . . 0.0 110.509 -179.79 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 122.91 -143.38 15.19 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.705 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -61.05 159.9 28.14 Favored 'Trans proline' 0 C--O 1.235 0.374 0 C-N-CA 122.577 2.185 . . . . 0.0 112.143 179.123 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 23.8 tt0 -80.21 152.82 28.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.584 -179.893 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.01 138.85 33.53 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.395 -179.905 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.5 t -110.02 116.99 53.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 -179.682 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.16 140.89 30.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.024 0.44 . . . . 0.0 111.13 -179.581 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 pt -139.8 147.48 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.795 -179.799 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.7 m -122.0 147.23 46.33 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.267 179.325 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 35.6 m-85 -89.58 163.79 15.03 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.368 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.9 p30 . . . . . 0 C--O 1.243 0.712 0 CA-C-O 118.674 -0.679 . . . . 0.0 110.0 -179.843 . . . . . . . . 0 0 . 1 . 054 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.792 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 055 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.54 115.04 52.13 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.591 -0.277 . . . . 0.0 111.065 -179.765 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -79.4 -175.93 2.99 Favored 'Trans proline' 0 CA--C 1.531 0.328 0 C-N-CA 122.869 2.38 . . . . 0.0 112.297 179.82 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.555 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.1 m -126.91 100.78 6.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.971 0.415 . . . . 0.0 110.58 179.839 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.06 71.08 8.47 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.904 0.383 . . . . 0.0 110.906 -179.617 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -79.16 85.68 5.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.997 0.427 . . . . 0.0 111.02 179.909 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.4 m -109.65 147.7 13.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 120.946 0.403 . . . . 0.0 111.199 -179.708 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.6 m -105.19 105.07 50.47 Favored Pre-proline 0 C--N 1.324 -0.524 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.223 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -72.63 -176.05 2.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.985 2.457 . . . . 0.0 113.416 -179.03 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.439 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 20.2 m -140.66 84.07 1.93 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.921 179.779 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 m -112.05 107.52 16.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.543 -179.29 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.73 3.85 52.32 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.569 -0.825 . . . . 0.0 112.264 179.805 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.67 HD13 HG21 ' A' ' 17' ' ' THR . 58.9 mt -94.54 177.31 5.97 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -105.78 -176.12 2.99 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.431 -0.211 . . . . 0.0 110.431 -179.801 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -73.74 156.68 37.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.456 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.42 -1.24 85.9 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.705 -179.292 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.67 HG21 HD13 ' A' ' 13' ' ' LEU . 51.5 m -70.1 144.81 51.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.054 0.454 . . . . 0.0 111.04 179.971 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 47.1 t -93.03 116.09 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.609 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.224 -179.493 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.85 122.39 41.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.014 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -94.53 126.83 40.06 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.944 0.402 . . . . 0.0 110.745 -179.81 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 64' ' ' SER . 86.9 t -122.71 117.17 51.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.331 -179.698 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -130.22 103.99 7.03 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.91 0.386 . . . . 0.0 110.555 179.676 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.32 126.33 8.87 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.356 179.998 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.555 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -114.49 146.21 40.96 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.426 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.62 17.39 60.22 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.111 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.7 mt -83.91 177.2 8.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.367 -0.416 . . . . 0.0 110.691 -179.731 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.0 tp60 -80.52 110.67 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.194 179.993 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.19 120.21 9.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.739 -179.82 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 104.24 -3.14 43.73 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.021 -179.417 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.9 m -99.77 132.61 45.01 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.88 0.371 . . . . 0.0 111.279 -179.903 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.511 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -93.75 125.66 38.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.366 179.438 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -105.12 125.51 51.06 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.69 -179.599 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -80.07 111.0 16.0 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.19 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.7 t -118.51 126.12 74.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.804 0.335 . . . . 0.0 111.181 -179.211 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.62 172.87 33.74 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.625 179.002 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.47 HE21 ' HB2' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -87.9 125.04 34.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.887 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.516 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -130.69 176.54 8.11 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.071 0.462 . . . . 0.0 111.739 -177.979 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.532 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -164.74 179.62 6.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.118 178.951 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -78.66 110.54 13.89 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.859 0.361 . . . . 0.0 110.552 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 p -98.05 -23.41 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.379 -179.784 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 2.4 t0 -155.23 177.84 10.89 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.904 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.5 m -65.31 101.7 0.59 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 110.899 -179.785 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.69 12.25 84.41 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.503 179.695 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.408 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 30.7 t -117.26 121.0 66.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 121.198 0.523 . . . . 0.0 111.368 -179.508 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 24.5 mt -108.92 141.48 40.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.453 179.212 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.43 141.03 25.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.284 -179.358 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.75 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.8 OUTLIER -114.75 169.79 8.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.043 -179.969 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -97.28 133.09 24.34 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-O 121.068 0.461 . . . . 0.0 110.297 179.408 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -79.23 -6.37 14.78 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.72 2.28 . . . . 0.0 112.569 -179.811 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.08 -60.11 2.49 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.786 -179.518 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -96.69 15.54 21.53 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.576 -178.694 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 152.6 25.05 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.704 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.3 m -140.71 118.45 11.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.369 -179.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.6 p -82.95 101.09 10.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.357 179.596 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 13.7 p -90.95 132.5 35.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.068 0.461 . . . . 0.0 110.473 -179.895 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 12.3 t -104.13 140.89 37.16 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.886 0.374 . . . . 0.0 110.536 -179.956 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.94 119.92 17.86 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.963 179.554 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.92 -174.76 1.56 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.657 -179.118 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.46 -20.2 62.88 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.916 -179.375 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.62 -4.9 59.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.073 0.463 . . . . 0.0 109.959 179.973 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.37 26.49 65.71 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.811 -179.836 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.73 151.78 39.12 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.303 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -142.83 101.22 3.81 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.641 179.562 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 26.4 t -109.74 130.84 55.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.249 179.556 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 6.4 t -149.08 176.37 10.52 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.325 179.916 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.459 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 4.7 m -139.2 132.94 30.69 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.394 -179.452 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -118.5 150.78 39.04 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.051 -179.056 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.1 m -106.11 118.84 37.65 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.429 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.504 HG21 HD11 ' A' ' 110' ' ' ILE . 8.3 p -90.2 124.96 43.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.527 0.679 . . . . 0.0 111.96 -178.806 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.9 mmt180 -96.48 170.6 9.11 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.913 178.933 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -84.15 -42.76 15.67 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.223 0.535 . . . . 0.0 110.009 179.392 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -130.51 130.12 43.77 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.852 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -145.69 174.01 11.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.717 0.294 . . . . 0.0 111.369 -178.371 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.5 tp10 -98.69 125.79 44.11 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -84.52 129.22 9.08 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.659 -179.184 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 82' ' ' ARG . 25.3 m-85 -125.59 157.63 36.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.696 0.284 . . . . 0.0 110.699 -179.567 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.45 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 91.8 mt -90.74 -172.53 3.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.324 179.354 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -77.37 -31.97 54.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.011 -179.303 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -76.34 -30.86 57.8 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.359 -179.313 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 128.72 -6.85 6.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.156 -1.021 . . . . 0.0 113.508 179.821 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -81.74 139.09 35.06 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.134 0.467 . . . . 0.0 110.61 179.327 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HA ' ' HA ' ' A' ' 76' ' ' PHE . 13.8 ptt85 -85.14 154.51 21.97 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.432 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 15.2 t-105 -110.92 -38.1 5.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.028 0.442 . . . . 0.0 109.999 179.615 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 161.95 165.61 19.18 Favored Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -179.958 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.5 m -73.59 121.14 20.19 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.969 0.414 . . . . 0.0 111.166 -179.849 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.532 HG11 ' HB3' ' A' ' 38' ' ' ALA . 1.7 t -101.11 131.06 49.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.888 -179.924 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -120.31 131.51 54.91 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.97 -179.336 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -109.07 18.97 20.05 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.212 -179.944 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 27.4 m -70.79 -31.16 67.83 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.722 0.772 . . . . 0.0 109.026 178.3 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -127.19 20.94 6.8 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.01 -0.995 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -141.76 177.2 8.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.748 -179.752 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.69 124.56 51.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.991 0.424 . . . . 0.0 110.914 -179.977 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.5 m -85.79 165.43 16.88 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.034 179.633 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -147.39 163.6 35.95 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.066 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 t -95.26 118.97 42.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.96 122.4 7.54 Favored Glycine 0 N--CA 1.444 -0.804 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.912 -179.771 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.417 ' HB3' HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -138.64 122.36 17.54 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.649 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 m -152.34 158.74 43.15 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.794 0.331 . . . . 0.0 111.285 -179.787 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.56 -168.94 2.23 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.579 179.569 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -61.33 -26.23 67.66 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.492 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -88.64 -20.08 25.4 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.955 0.407 . . . . 0.0 111.178 -179.757 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 25.83 10.27 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.21 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -120.09 -172.71 2.4 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 -179.949 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 129.49 -158.86 22.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.46 -0.876 . . . . 0.0 112.245 179.652 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -65.58 154.29 74.39 Favored 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 122.592 2.195 . . . . 0.0 111.816 179.709 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.47 136.74 47.75 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.25 179.564 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.45 157.4 53.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.976 -0.631 . . . . 0.0 112.232 179.837 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.8 t -124.5 134.33 67.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 -179.779 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.13 147.57 26.56 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.469 179.592 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.504 HD11 HG21 ' A' ' 69' ' ' VAL . 29.4 pt -120.04 169.86 10.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.805 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 51.1 m -152.09 133.86 14.8 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.873 0.368 . . . . 0.0 110.767 -179.951 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 45.2 m-85 -84.03 158.38 21.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 -179.944 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.3 p30 . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.596 -0.716 . . . . 0.0 110.744 179.898 . . . . . . . . 0 0 . 1 . 055 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.75 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 056 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.71 118.86 70.29 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.262 -179.821 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.05 177.82 8.33 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.655 2.237 . . . . 0.0 112.048 179.736 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.439 ' HB ' ' HB3' ' A' ' 24' ' ' ALA . 1.8 m -118.42 111.77 19.12 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 120.934 0.397 . . . . 0.0 110.931 -179.595 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.3 75.98 2.29 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.094 0.473 . . . . 0.0 110.18 179.827 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -84.89 92.09 8.2 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.165 -179.704 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.1 m -123.31 143.09 37.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.765 -179.917 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.5 m -113.16 100.63 51.92 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.935 0.398 . . . . 0.0 110.487 179.311 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -77.67 143.64 21.49 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.791 2.327 . . . . 0.0 112.367 -179.624 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.2 m -82.11 61.69 5.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.268 0.556 . . . . 0.0 111.102 -179.92 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.13 115.0 11.92 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.2 -179.603 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.22 23.82 50.13 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.518 179.12 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.573 HD13 HG21 ' A' ' 17' ' ' THR . 88.5 mt -119.65 157.92 27.49 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.99 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -85.48 176.47 8.23 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.093 -179.22 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.2 147.53 49.71 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.201 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.94 -7.87 45.24 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -178.114 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.573 HG21 HD13 ' A' ' 13' ' ' LEU . 44.9 m -75.46 146.58 40.55 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.213 -0.493 . . . . 0.0 110.12 179.222 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 5.9 t -95.68 123.96 48.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.017 0.437 . . . . 0.0 110.916 -179.547 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.1 t -91.14 123.14 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.92 179.286 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.5 ttmt -90.87 115.53 27.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.915 0.388 . . . . 0.0 111.09 -179.649 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 79.6 t -116.67 109.09 26.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.112 179.421 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.83 93.49 3.85 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.116 0.484 . . . . 0.0 110.575 -179.766 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.48 136.12 13.5 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.792 -179.922 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 4' ' ' THR . . . -130.25 149.15 52.08 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.946 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 79.15 31.03 44.0 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.702 -179.629 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.6 mt -95.23 -150.99 0.32 Allowed 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 110.21 -0.292 . . . . 0.0 110.21 -179.424 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -112.31 115.1 28.22 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.865 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.9 144.4 57.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.486 179.776 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 12.24 74.53 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.646 -179.742 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 m -117.4 143.95 45.46 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.862 -0.199 . . . . 0.0 110.629 -179.412 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 126.51 48.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.585 179.772 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.66 137.66 46.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.577 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -105.84 119.91 40.37 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.677 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.0 t -125.88 129.44 72.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.292 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.76 179.24 31.0 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 178.894 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 11.5 pt20 -86.86 124.11 32.73 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.617 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.69 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.6 OUTLIER -127.19 172.57 10.45 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.741 -178.498 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -164.79 162.77 21.25 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.883 179.542 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 5.3 m95 -65.66 105.5 1.25 Allowed 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.4 0.437 . . . . 0.0 110.092 179.225 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p -94.53 -19.27 6.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 110.684 -179.244 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -158.43 -174.03 4.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.318 179.365 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 m -67.88 94.01 0.44 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.979 0.418 . . . . 0.0 111.279 -179.796 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.38 -13.05 64.77 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.963 -0.636 . . . . 0.0 112.649 179.277 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 t -98.2 129.74 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.907 0.384 . . . . 0.0 110.835 -179.435 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.1 mp -116.86 159.27 22.64 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.147 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 37' ' ' CYS . . . -143.11 139.24 30.35 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.23 -0.188 . . . . 0.0 110.778 -179.745 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.831 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 8.8 m -108.3 169.41 8.65 Favored 'General case' 0 N--CA 1.464 0.25 0 O-C-N 123.301 0.375 . . . . 0.0 111.3 -179.329 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 52' ' ' PHE . 27.4 p-10 -87.04 128.64 55.0 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.053 179.829 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 48.3 Cg_endo -92.67 5.76 3.26 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.831 2.354 . . . . 0.0 112.981 179.659 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.24 -63.69 1.11 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.434 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -90.85 32.35 1.0 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.425 -179.321 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.536 ' HB3' ' O ' ' A' ' 48' ' ' ASN . 2.9 p90 -91.79 167.9 11.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.678 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -138.57 121.53 16.66 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.017 0.437 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.73 99.6 12.58 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.263 179.661 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 65' ' ' THR . 7.7 p -100.95 129.24 52.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.448 0.642 . . . . 0.0 111.354 -179.065 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.02 148.37 25.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.383 179.413 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.11 138.69 47.92 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.819 0.343 . . . . 0.0 110.697 -179.869 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -78.53 -175.54 4.36 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.763 179.973 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.69 -15.12 63.42 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.603 -179.802 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -84.3 -41.67 16.6 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 109.589 -179.895 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.7 21.4 2.97 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.672 -179.75 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.25 157.74 24.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.87 0.366 . . . . 0.0 111.206 -179.568 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -145.15 110.98 5.44 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.46 179.708 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 t -113.01 137.84 50.8 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.739 0.304 . . . . 0.0 110.338 179.931 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.405 ' HB ' ' HB ' ' A' ' 55' ' ' VAL . 7.4 t -154.5 169.21 24.33 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.03 0.443 . . . . 0.0 111.151 -179.671 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.518 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 16.2 m -126.54 127.54 45.46 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.974 179.754 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -114.65 130.74 56.84 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.581 -179.615 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.6 m -92.65 111.94 23.71 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 178.712 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -85.97 119.84 34.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.321 0.581 . . . . 0.0 111.596 -178.992 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -97.69 170.32 9.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.35 178.902 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 tpp180 -87.27 -26.6 23.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.286 0.565 . . . . 0.0 109.596 178.886 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.2 m -137.57 135.21 36.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.101 -0.704 . . . . 0.0 109.101 178.788 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.428 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 33.9 p90 -151.53 172.11 16.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.078 0.466 . . . . 0.0 111.825 -178.78 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -90.06 127.41 36.06 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.839 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -85.77 116.92 4.45 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.015 -179.632 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.6 m-85 -126.59 146.99 49.94 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-O 120.862 0.363 . . . . 0.0 110.721 -179.122 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.431 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 53.6 mt -85.7 174.88 9.06 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.326 178.973 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 98' ' ' SER . 1.0 OUTLIER -80.26 -1.68 41.79 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.968 0.413 . . . . 0.0 111.47 -179.141 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.9 -21.25 15.77 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.975 179.74 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 119.44 -10.16 11.63 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.784 179.873 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.7 m -75.16 140.23 43.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 111.159 -179.845 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 ptp180 -102.51 135.04 44.85 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.587 179.486 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -97.06 -35.28 10.87 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.155 0.502 . . . . 0.0 110.38 -179.769 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.21 -160.49 28.92 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.476 -0.649 . . . . 0.0 111.476 -179.755 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.7 m -96.1 126.28 41.22 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.947 0.403 . . . . 0.0 110.649 -179.965 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 13.5 t -105.42 137.06 36.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.78 -179.953 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -123.58 143.56 50.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.729 0.3 . . . . 0.0 110.854 -179.352 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 15.4 m -125.15 34.49 4.95 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.6 m -74.89 -39.21 61.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.123 0.487 . . . . 0.0 110.411 179.802 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 t -114.99 -12.11 12.04 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.497 0.665 . . . . 0.0 109.386 178.436 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.03 -171.89 2.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.766 179.653 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -125.62 130.36 51.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.276 179.529 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 2.9 m -90.06 168.17 12.2 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.642 179.915 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG2' ' O ' ' A' ' 37' ' ' CYS . 0.0 OUTLIER -141.48 150.1 41.79 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.001 0.429 . . . . 0.0 110.565 179.471 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 37.7 t -81.08 114.12 21.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.944 179.887 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.69 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -101.42 120.64 6.94 Favored Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.236 -179.632 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.33 118.69 19.74 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.798 0.333 . . . . 0.0 110.308 -179.553 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 68.8 m -149.71 154.52 38.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.9 0.381 . . . . 0.0 110.73 179.339 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' H ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -83.45 -174.34 5.23 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 179.608 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -59.73 -26.96 66.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.819 0.342 . . . . 0.0 111.679 179.765 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.425 ' H ' ' CG ' ' A' ' 99' ' ' ASP . . . -86.74 -1.47 57.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.813 0.339 . . . . 0.0 110.841 179.503 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 76.05 29.67 58.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.322 -0.466 . . . . 0.0 112.641 179.752 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -128.78 -178.38 4.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.685 0.279 . . . . 0.0 110.716 -179.683 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.25 -142.62 14.11 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 111.572 -0.611 . . . . 0.0 111.572 179.929 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.24 170.63 19.73 Favored 'Trans proline' 0 C--O 1.234 0.31 0 C-N-CA 123.029 2.486 . . . . 0.0 111.748 179.334 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -84.24 151.58 24.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.513 179.985 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.04 144.35 37.76 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.613 -179.934 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 48.2 t -112.63 118.31 57.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.871 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -76.54 143.52 40.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.059 -179.472 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.2 pt -128.27 127.6 67.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.149 0.5 . . . . 0.0 110.548 179.822 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.8 m -105.26 135.55 46.43 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.044 179.439 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -77.11 170.98 15.55 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.171 -179.97 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.6 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.451 -0.785 . . . . 0.0 111.003 -179.567 . . . . . . . . 0 0 . 1 . 056 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.831 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 057 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.51 107.57 60.24 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 179.767 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.37 173.87 13.49 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 122.397 2.065 . . . . 0.0 111.945 179.842 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.05 90.3 2.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.033 0.444 . . . . 0.0 110.604 -179.409 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.01 102.06 14.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.781 -179.757 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -104.63 96.1 6.36 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.782 179.947 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.93 150.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.864 0.364 . . . . 0.0 111.103 -179.607 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.4 m -109.02 101.78 46.07 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.669 179.506 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.42 142.5 72.45 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.041 2.494 . . . . 0.0 112.143 179.943 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.83 14.42 17.43 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.567 -179.726 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.4 m -61.26 117.18 5.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.989 0.424 . . . . 0.0 110.887 179.782 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.48 -11.89 23.58 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.048 -179.849 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.685 HD13 HG21 ' A' ' 17' ' ' THR . 7.0 mt -101.79 -169.53 1.7 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.555 0.217 . . . . 0.0 110.441 -179.839 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.05 -170.83 1.72 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.733 0.301 . . . . 0.0 110.608 -179.499 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -78.44 150.58 33.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.318 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.0 67.04 Favored Glycine 0 N--CA 1.449 -0.453 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -178.976 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.685 HG21 HD13 ' A' ' 13' ' ' LEU . 38.9 m -72.14 142.09 49.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.066 0.46 . . . . 0.0 110.771 179.898 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 38.5 t -93.02 111.85 25.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.178 -179.394 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 t -82.27 132.8 30.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.703 179.246 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -100.5 124.03 45.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.993 0.425 . . . . 0.0 111.01 -179.751 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 64' ' ' SER . 55.8 t -117.19 109.66 28.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.893 179.174 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -125.73 100.89 6.62 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 0.0 110.907 179.865 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.07 123.32 7.78 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.103 179.944 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.61 143.81 44.41 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.522 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.16 44.5 6.63 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.454 -0.879 . . . . 0.0 111.332 -179.215 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 62.4 mt -113.33 -166.66 1.11 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.609 -0.296 . . . . 0.0 110.336 -179.694 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -93.63 112.13 23.95 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.81 0.338 . . . . 0.0 110.19 -179.791 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.22 132.87 54.16 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.011 -179.216 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.97 4.19 61.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.82 -0.705 . . . . 0.0 113.963 178.821 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 46.0 p -109.62 139.63 44.42 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.812 0.806 . . . . 0.0 111.3 -179.727 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.35 134.49 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.801 179.642 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -112.03 137.48 50.0 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.953 0.406 . . . . 0.0 111.034 -179.689 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -97.17 108.11 20.77 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.249 179.258 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 11.0 t -122.85 121.15 62.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.591 -179.557 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.76 173.96 28.54 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.879 179.378 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.6 116.3 24.63 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.253 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -116.44 165.25 13.43 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.884 -178.958 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -159.57 -178.89 7.43 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.175 179.413 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.4 ' CH2' ' HA ' ' A' ' 42' ' ' THR . 0.0 OUTLIER -72.14 98.88 2.21 Favored 'General case' 0 C--N 1.328 -0.362 0 O-C-N 123.542 0.526 . . . . 0.0 110.176 -179.894 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 86' ' ' VAL . 7.3 p -92.97 -23.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.983 -179.334 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 44' ' ' VAL . 1.8 t70 -154.12 179.89 8.52 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.4 ' HA ' ' CH2' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.71 95.43 0.15 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.942 0.401 . . . . 0.0 111.39 -179.555 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.58 15.94 78.68 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.465 179.823 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 41' ' ' ASP . 22.8 t -121.03 134.29 64.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.782 0.325 . . . . 0.0 110.631 -179.688 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 14.6 mt -114.64 149.95 35.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.141 -179.853 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.02 146.51 26.26 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 179.715 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.698 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 0.0 OUTLIER -124.4 164.4 19.76 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.966 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 30.0 p-10 -98.68 135.98 20.88 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.995 0.426 . . . . 0.0 110.663 179.598 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 48' ' ' ASN . 31.5 Cg_endo -86.58 6.65 5.29 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.713 2.276 . . . . 0.0 112.222 179.752 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.11 -53.51 6.33 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.655 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -92.76 0.87 57.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.697 0.284 . . . . 0.0 111.609 -179.323 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.4 153.48 37.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.072 179.599 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.4 m -124.03 125.76 45.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.819 0.342 . . . . 0.0 110.765 -179.767 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -88.48 108.43 19.38 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.337 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -119.64 142.64 34.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.044 0.45 . . . . 0.0 110.913 -179.65 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.0 t -111.16 155.45 22.87 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.842 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.65 131.68 36.76 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.594 179.687 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -75.3 -178.07 3.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.59 -179.802 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.49 -28.16 66.78 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.188 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -79.54 -5.13 54.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.875 0.369 . . . . 0.0 110.751 179.88 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.7 28.88 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.303 179.57 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.95 150.96 51.85 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.695 0.283 . . . . 0.0 110.708 179.836 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -141.06 120.44 13.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.3 m -124.37 136.14 53.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.188 179.789 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -154.37 176.32 12.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.679 0.276 . . . . 0.0 110.973 -179.683 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.57 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 5.4 m -124.2 145.85 49.07 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.817 -179.428 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -131.25 126.83 36.46 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.773 179.722 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.26 103.67 15.9 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.924 0.392 . . . . 0.0 110.427 179.362 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.08 116.7 24.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.611 0.72 . . . . 0.0 111.727 -178.977 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -98.69 168.33 10.22 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.559 178.903 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -80.81 -37.3 30.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.199 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.5 m -124.09 132.76 53.69 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.941 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 27.3 p90 -149.26 171.14 16.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.932 0.396 . . . . 0.0 111.459 -178.686 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -83.99 146.9 27.74 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.207 179.597 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.54 111.55 4.05 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.571 179.761 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -124.37 143.18 50.74 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 -179.301 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.506 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 66.1 mt -82.48 173.36 12.06 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.058 179.386 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -72.94 -28.16 62.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.505 -179.721 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.13 -36.03 66.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.7 179.446 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.92 -27.42 2.92 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.687 -179.807 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.1 m -63.62 137.23 58.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.766 0.317 . . . . 0.0 111.011 -179.967 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.03 151.64 21.56 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.695 0.283 . . . . 0.0 110.308 179.36 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 9.3 t-105 -108.07 -25.98 10.86 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.976 0.417 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.21 -138.68 8.12 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.826 -179.923 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 3.0 m -116.79 135.73 53.52 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.742 0.306 . . . . 0.0 110.442 179.867 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.422 HG22 HG23 ' A' ' 40' ' ' VAL . 1.0 OUTLIER -116.28 127.87 73.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.85 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -118.44 135.3 54.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 -179.885 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 6.2 m -115.45 25.28 10.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.398 179.731 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 35.8 m -68.74 -30.77 69.46 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 121.105 0.479 . . . . 0.0 110.114 179.459 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -133.68 30.94 3.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.603 0.716 . . . . 0.0 109.863 178.887 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -146.91 175.38 10.7 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.204 179.819 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.82 141.94 31.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.767 0.318 . . . . 0.0 111.275 -179.765 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -112.26 167.43 10.43 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.871 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.434 HE21 " H5'" ' A' ' 114' ' ' FLN . 17.5 pt20 -149.08 162.83 39.16 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.994 0.426 . . . . 0.0 111.418 -179.962 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.4 t -96.97 122.85 48.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.011 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -102.09 122.86 7.69 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.09 -179.167 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.407 ' HG ' HG13 ' A' ' 34' ' ' VAL . 3.0 mp -119.23 122.67 42.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.671 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 103' ' ' ASN . 61.4 m -149.78 137.65 20.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.8 0.334 . . . . 0.0 111.287 179.602 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.89 -174.27 5.18 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.114 -0.494 . . . . 0.0 109.776 178.861 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -56.41 -32.58 64.99 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.752 0.311 . . . . 0.0 111.523 179.801 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.58 -23.89 36.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.937 0.399 . . . . 0.0 111.089 179.851 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 105.27 18.46 12.0 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.735 -179.814 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 98' ' ' SER . 62.5 m-80 -118.03 -162.33 0.88 Allowed 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.994 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 121.71 -154.47 16.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.258 179.493 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_exo -62.76 153.98 68.89 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.995 2.464 . . . . 0.0 112.073 179.444 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -75.02 145.92 42.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.511 -179.614 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.22 143.01 42.22 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.761 -179.864 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.52 125.55 68.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 120.626 0.251 . . . . 0.0 110.364 -179.773 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.47 134.01 34.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.162 179.629 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 19.7 pt -122.83 158.79 27.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.251 0.548 . . . . 0.0 110.791 -179.33 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.9 m -139.27 144.38 38.36 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.382 179.636 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -88.86 164.55 15.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.15 -179.573 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 C--O 1.246 0.874 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.694 179.778 . . . . . . . . 0 0 . 1 . 057 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.698 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.668 0.27 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 058 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.59 110.98 45.07 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.067 -179.514 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -75.84 -178.26 4.21 Favored 'Trans proline' 0 C--O 1.237 0.441 0 C-N-CA 122.293 1.995 . . . . 0.0 111.773 179.258 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -135.2 88.22 2.4 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 120.97 0.414 . . . . 0.0 111.482 -178.939 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.26 108.19 19.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.291 179.289 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.57 103.7 12.32 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.136 0.494 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 31.7 m -121.41 155.89 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.68 -179.856 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 23.2 m -112.11 103.91 55.64 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.939 179.874 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -74.87 127.03 10.44 Favored 'Trans proline' 0 N--CA 1.462 -0.361 0 C-N-CA 122.441 2.094 . . . . 0.0 112.237 179.218 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.8 49.17 1.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.184 -179.752 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 m -74.47 117.3 16.14 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.016 -179.736 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.82 10.94 58.4 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.56 179.415 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD13 HG21 ' A' ' 17' ' ' THR . 83.9 mt -107.48 179.56 4.21 Favored 'General case' 0 C--N 1.323 -0.583 0 O-C-N 122.513 -0.404 . . . . 0.0 110.711 -179.669 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -97.4 177.15 5.63 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.758 -179.116 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -75.12 152.52 38.51 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.216 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.37 -7.49 77.94 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.231 -179.427 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.459 HG21 HD13 ' A' ' 13' ' ' LEU . 35.4 m -66.16 139.94 58.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.0 -179.792 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' CG1' ' HB3' ' A' ' 66' ' ' SER . 57.0 t -81.02 114.95 22.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.734 179.772 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.1 t -87.03 129.57 38.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 179.309 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 32.4 ttmt -95.96 125.57 40.61 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.941 0.4 . . . . 0.0 111.102 -179.718 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' SER . 96.1 t -125.66 103.06 11.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.539 178.982 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -120.95 97.5 5.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 111.036 -179.798 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.29 130.76 10.35 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.247 -179.99 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -122.44 143.06 49.92 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.353 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.64 37.06 8.21 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -178.918 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.415 ' HB3' ' OH ' ' A' ' 32' ' ' TYR . 23.5 mt -101.64 -170.35 1.81 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.542 -0.329 . . . . 0.0 110.419 -179.081 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 54.2 tp60 -91.23 105.23 17.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.873 0.368 . . . . 0.0 110.318 179.692 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -60.26 121.72 12.7 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.255 -179.731 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 -2.85 30.84 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.541 179.439 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.0 p -108.68 155.84 20.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.311 0.556 . . . . 0.0 110.572 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -102.04 129.18 48.28 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 -179.732 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.415 ' OH ' ' HB3' ' A' ' 26' ' ' LEU . 79.2 m-85 -107.77 128.41 54.56 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.689 179.812 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.82 130.68 44.05 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.203 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 26.0 t -130.46 131.06 65.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.732 -179.53 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.41 170.67 33.45 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.423 178.479 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.416 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 1.4 pt20 -86.5 123.99 32.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.56 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.662 ' SG ' ' HA3' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -131.94 169.04 16.86 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.747 0.308 . . . . 0.0 111.314 -178.279 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.481 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -153.41 166.42 32.71 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.003 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . . . . . . . . . 6.0 m95 -74.44 115.56 14.12 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 123.176 0.298 . . . . 0.0 110.238 -179.949 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.55 -25.05 3.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.016 0.436 . . . . 0.0 110.853 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -151.49 174.43 13.4 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.813 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.93 99.29 0.33 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.957 0.408 . . . . 0.0 111.318 -179.63 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.7 17.25 68.57 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.333 179.864 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.465 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 4.7 t -128.64 119.85 51.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.108 0.48 . . . . 0.0 111.08 179.94 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 mp -114.68 154.6 28.15 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.568 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -140.03 130.73 25.79 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.726 -179.472 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.755 ' SG ' ' H3 ' ' A' ' 114' ' ' FLN . 6.4 m -102.46 166.25 10.65 Favored 'General case' 0 CA--C 1.518 -0.268 0 O-C-N 123.359 0.412 . . . . 0.0 110.457 -179.625 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.584 HD21 ' HB2' ' A' ' 51' ' ' ASP . 8.4 p-10 -91.98 138.05 24.89 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-O 121.423 0.63 . . . . 0.0 111.597 -179.501 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HG3' ' CD1' ' A' ' 76' ' ' PHE . 40.9 Cg_endo -94.95 8.93 1.91 Allowed 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.041 2.494 . . . . 0.0 112.147 179.083 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.44 -26.39 17.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.037 -178.994 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.584 ' HB2' HD21 ' A' ' 48' ' ' ASN . 14.5 m-20 -131.51 8.91 4.63 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.608 -179.936 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 8.0 p90 -60.2 149.5 32.82 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.664 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.1 m -137.0 109.52 7.42 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.97 0.414 . . . . 0.0 110.979 -179.609 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.4 m -83.37 121.19 26.82 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.611 178.616 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.2 p -113.1 129.37 68.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.068 0.461 . . . . 0.0 111.148 -179.409 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 23.8 m -90.39 126.75 35.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.434 179.788 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.03 127.18 30.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.996 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.01 177.63 6.21 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.566 -179.861 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.48 -10.31 50.39 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.222 0.452 . . . . 0.0 112.222 -179.121 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -88.29 -9.08 54.01 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.806 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.21 32.33 31.99 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 115.377 -0.828 . . . . 0.0 111.912 179.945 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.97 155.21 36.01 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.901 0.381 . . . . 0.0 111.171 -179.146 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -146.03 105.45 3.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.686 178.969 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 2.1 m -113.88 126.3 55.02 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.569 -179.809 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 t -146.13 167.81 22.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.553 -179.947 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.431 ' HB3' ' CG1' ' A' ' 18' ' ' VAL . 6.2 m -126.67 134.59 50.68 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.131 -179.835 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.79 140.41 50.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.944 0.402 . . . . 0.0 111.609 -178.995 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.9 m -101.81 105.23 16.06 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.647 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.62 119.56 31.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.348 0.594 . . . . 0.0 111.746 -178.905 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -95.62 173.71 7.35 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.205 178.945 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -81.68 -43.5 18.41 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.284 179.749 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.4 m -128.65 138.59 52.25 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.786 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.548 ' CD2' ' HB3' ' A' ' 48' ' ' ASN . 48.2 p90 -152.78 174.93 13.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 111.798 -178.925 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -96.01 123.8 39.76 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 178.99 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -81.42 125.97 7.16 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.766 -179.11 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.427 ' CD1' ' HG3' ' A' ' 49' ' ' PRO . 7.0 m-85 -126.41 151.03 48.23 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 120.706 0.289 . . . . 0.0 110.262 -179.528 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.465 ' HA ' ' H5 ' ' A' ' 114' ' ' FLN . 63.8 mt -92.15 -176.25 4.32 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.066 -0.515 . . . . 0.0 109.874 179.449 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.04 -32.35 50.9 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.841 0.353 . . . . 0.0 111.062 -178.835 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -74.29 -26.17 60.03 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.226 -179.903 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 125.83 -23.67 5.88 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.339 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 87.5 m -61.05 134.92 57.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 0.0 110.762 179.641 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -94.52 142.99 26.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.243 179.949 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 8.5 t-105 -96.45 -48.81 5.41 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -179.96 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 162.62 -177.81 38.6 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.867 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.2 m -74.57 124.48 26.72 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.934 0.397 . . . . 0.0 110.655 179.646 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.481 HG11 ' HB3' ' A' ' 38' ' ' ALA . 22.0 t -108.9 123.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.568 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -110.28 135.32 51.2 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.978 -179.636 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.28 43.34 2.35 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.9 0.381 . . . . 0.0 111.586 -179.582 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.8 m -89.53 -41.51 11.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.003 0.43 . . . . 0.0 110.425 178.887 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.26 -14.66 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.264 0.554 . . . . 0.0 110.136 179.43 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.96 -178.33 3.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.753 179.837 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 110' ' ' ILE . . . -112.51 144.49 41.9 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.961 0.41 . . . . 0.0 110.98 -179.578 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.05 164.25 11.73 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.114 179.736 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.2 160.46 38.31 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.899 0.381 . . . . 0.0 110.728 179.307 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 18.1 t -86.79 118.59 33.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.425 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.662 ' HA3' ' SG ' ' A' ' 37' ' ' CYS . . . -96.88 120.53 6.72 Favored Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.369 -179.593 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.22 127.28 35.45 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.816 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 74.6 m -149.53 153.05 36.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.53 179.571 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -81.42 -150.98 0.08 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.36 -0.76 47.33 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.815 0.34 . . . . 0.0 111.651 -179.623 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.63 -45.47 2.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.291 -179.862 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 140.93 24.47 0.24 Allowed Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.851 179.857 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 50.7 m-80 -126.44 -174.2 3.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.783 0.325 . . . . 0.0 110.613 -179.635 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 130.63 -153.8 20.4 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.988 179.853 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.63 146.75 89.44 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.383 2.055 . . . . 0.0 111.354 179.651 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -68.08 147.47 52.3 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.963 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.423 ' HA3' " H4'" ' A' ' 114' ' ' FLN . . . -71.32 148.93 44.79 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.414 -179.466 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 63.8 t -118.23 129.64 74.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.622 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.36 144.47 26.38 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.103 0.478 . . . . 0.0 111.193 -179.534 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.411 ' O ' ' HB1' ' A' ' 92' ' ' ALA . 47.3 pt -126.24 173.25 12.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.68 179.726 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.4 m -149.02 146.36 27.73 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 -179.892 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 13' ' ' LEU . 75.6 m-85 -94.45 147.16 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.576 0.227 . . . . 0.0 110.973 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 11.3 p30 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.507 -0.759 . . . . 0.0 110.377 -179.833 . . . . . . . . 0 0 . 1 . 058 nuclear nobuild full ' A' A ' 114' ' ' FLN . . . . . 0.755 ' H3 ' ' SG ' ' A' ' 47' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_